<?xml version='1.0' encoding='utf-8'?>
<graphml xmlns="http://graphml.graphdrawing.org/xmlns" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://graphml.graphdrawing.org/xmlns http://graphml.graphdrawing.org/xmlns/1.0/graphml.xsd"><key id="d34" for="edge" attr.name="targetDomainId" attr.type="string"/>
<key id="d33" for="edge" attr.name="sourceDomainId" attr.type="string"/>
<key id="d32" for="edge" attr.name="targetId" attr.type="string"/>
<key id="d31" for="edge" attr.name="sourceId" attr.type="string"/>
<key id="d30" for="edge" attr.name="evidenceTypes" attr.type="string"/>
<key id="d29" for="edge" attr.name="type" attr.type="string"/>
<key id="d28" for="edge" attr.name="memberTwo" attr.type="string"/>
<key id="d27" for="edge" attr.name="memberOne" attr.type="string"/>
<key id="d26" for="edge" attr.name="node2" attr.type="string"/>
<key id="d25" for="edge" attr.name="node1" attr.type="string"/>
<key id="d24" for="edge" attr.name="idTwo" attr.type="string"/>
<key id="d23" for="edge" attr.name="idOne" attr.type="string"/>
<key id="d22" for="node" attr.name="sequences" attr.type="string"/>
<key id="d21" for="node" attr.name="_cls" attr.type="string"/>
<key id="d20" for="node" attr.name="indication" attr.type="string"/>
<key id="d19" for="node" attr.name="smiles" attr.type="string"/>
<key id="d18" for="node" attr.name="inchi" attr.type="string"/>
<key id="d17" for="node" attr.name="allDatasets" attr.type="string"/>
<key id="d16" for="node" attr.name="primaryDataset" attr.type="string"/>
<key id="d15" for="node" attr.name="casNumber" attr.type="string"/>
<key id="d14" for="node" attr.name="molecularFormula" attr.type="string"/>
<key id="d13" for="node" attr.name="iupacName" attr.type="string"/>
<key id="d12" for="node" attr.name="drugCategories" attr.type="string"/>
<key id="d11" for="node" attr.name="drugGroups" attr.type="string"/>
<key id="d10" for="node" attr.name="type" attr.type="string"/>
<key id="d9" for="node" attr.name="description" attr.type="string"/>
<key id="d8" for="node" attr.name="synonyms" attr.type="string"/>
<key id="d7" for="node" attr.name="mapLocation" attr.type="string"/>
<key id="d6" for="node" attr.name="chromosome" attr.type="string"/>
<key id="d5" for="node" attr.name="geneType" attr.type="string"/>
<key id="d4" for="node" attr.name="symbols" attr.type="string"/>
<key id="d3" for="node" attr.name="approvedSymbol" attr.type="string"/>
<key id="d2" for="node" attr.name="domainIds" attr.type="string"/>
<key id="d1" for="node" attr.name="primaryDomainId" attr.type="string"/>
<key id="d0" for="node" attr.name="displayName" attr.type="string"/>
<graph edgedefault="undirected"><node id="entrez.238">
  <data key="d0">ALK</data>
  <data key="d1">entrez.238</data>
  <data key="d2">[entrez.238]</data>
  <data key="d3">ALK</data>
  <data key="d4">[CD246, NBLST3]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">2</data>
  <data key="d7">2p23.2-p23.1</data>
  <data key="d8">[ALK tyrosine kinase receptor, CD246 antigen, anaplastic lymphoma receptor tyrosine kinase, mutant anaplastic lymphoma kinase]</data>
  <data key="d9">ALK receptor tyrosine kinase</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.867">
  <data key="d0">CBL</data>
  <data key="d1">entrez.867</data>
  <data key="d2">[entrez.867]</data>
  <data key="d3">CBL</data>
  <data key="d4">[C-CBL, CBL2, FRA11B, NSLL, RNF55]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">11</data>
  <data key="d7">11q23.3</data>
  <data key="d8">[E3 ubiquitin-protein ligase CBL, Cas-Br-M (murine) ecotropic retroviral transforming sequence, Cbl proto-oncogene, E3 ubiquitin protein ligase, RING finger protein 55, RING-type E3 ubiquitin transferase CBL, casitas B-lineage lymphoma proto-oncogene, fragile site, folic acid type, rare, fra(11)(q23.3), oncogene CBL2, proto-oncogene c-Cbl, signal transduction protein CBL]</data>
  <data key="d9">Cbl proto-oncogene</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.4067">
  <data key="d0">LYN</data>
  <data key="d1">entrez.4067</data>
  <data key="d2">[entrez.4067]</data>
  <data key="d3">LYN</data>
  <data key="d4">[JTK8, p53Lyn, p56Lyn]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">8</data>
  <data key="d7">8q12.1</data>
  <data key="d8">[tyrosine-protein kinase Lyn, lck/Yes-related novel protein tyrosine kinase, v-yes-1 Yamaguchi sarcoma viral related oncogene homolog]</data>
  <data key="d9">LYN proto-oncogene, Src family tyrosine kinase</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.8651">
  <data key="d0">SOCS1</data>
  <data key="d1">entrez.8651</data>
  <data key="d2">[entrez.8651]</data>
  <data key="d3">SOCS1</data>
  <data key="d4">[CIS1, CISH1, JAB, SOCS-1, SSI-1, SSI1, TIP-3, TIP3]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">16</data>
  <data key="d7">16p13.13</data>
  <data key="d8">[suppressor of cytokine signaling 1, JAK binding protein, STAT induced SH3 protein 1, STAT-induced STAT inhibitor 1, Tec-interacting protein 3, cytokine-inducible SH2 protein 1]</data>
  <data key="d9">suppressor of cytokine signaling 1</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.4233">
  <data key="d0">MET</data>
  <data key="d1">entrez.4233</data>
  <data key="d2">[entrez.4233]</data>
  <data key="d3">MET</data>
  <data key="d4">[AUTS9, DFNB97, HGFR, RCCP2, c-Met]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">7</data>
  <data key="d7">7q31.2</data>
  <data key="d8">[hepatocyte growth factor receptor, HGF receptor, HGF/SF receptor, SF receptor, proto-oncogene c-Met, scatter factor receptor, tyrosine-protein kinase Met]</data>
  <data key="d9">MET proto-oncogene, receptor tyrosine kinase</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.3932">
  <data key="d0">LCK</data>
  <data key="d1">entrez.3932</data>
  <data key="d2">[entrez.3932]</data>
  <data key="d3">LCK</data>
  <data key="d4">[IMD22, LSK, YT16, p56lck, pp58lck]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">1</data>
  <data key="d7">1p35.2</data>
  <data key="d8">[tyrosine-protein kinase Lck, T-lymphocyte specific protein tyrosine kinase p56lck, leukocyte C-terminal Src kinase, lymphocyte cell-specific protein-tyrosine kinase, p56(LSTRA) protein-tyrosine kinase, proto-oncogene tyrosine-protein kinase LCK, t cell-specific protein-tyrosine kinase]</data>
  <data key="d9">LCK proto-oncogene, Src family tyrosine kinase</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.3717">
  <data key="d0">JAK2</data>
  <data key="d1">entrez.3717</data>
  <data key="d2">[entrez.3717]</data>
  <data key="d3">JAK2</data>
  <data key="d4">[JTK10, THCYT3]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">9</data>
  <data key="d7">9p24.1</data>
  <data key="d8">[tyrosine-protein kinase JAK2, JAK-2, Janus kinase 2 (a protein tyrosine kinase)]</data>
  <data key="d9">Janus kinase 2</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.3716">
  <data key="d0">JAK1</data>
  <data key="d1">entrez.3716</data>
  <data key="d2">[entrez.3716]</data>
  <data key="d3">JAK1</data>
  <data key="d4">[JAK1A, JAK1B, JTK3]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">1</data>
  <data key="d7">1p31.3</data>
  <data key="d8">[tyrosine-protein kinase JAK1]</data>
  <data key="d9">Janus kinase 1</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.3815">
  <data key="d0">KIT</data>
  <data key="d1">entrez.3815</data>
  <data key="d2">[entrez.3815]</data>
  <data key="d3">KIT</data>
  <data key="d4">[C-Kit, CD117, MASTC, PBT, SCFR]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">4</data>
  <data key="d7">4q12</data>
  <data key="d8">[mast/stem cell growth factor receptor Kit, c-Kit protooncogene, p145 c-kit, piebald trait protein, proto-oncogene c-Kit, proto-oncogene tyrosine-protein kinase Kit, soluble KIT variant 1, tyrosine-protein kinase Kit, v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog, v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene-like protein]</data>
  <data key="d9">KIT proto-oncogene, receptor tyrosine kinase</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.7409">
  <data key="d0">VAV1</data>
  <data key="d1">entrez.7409</data>
  <data key="d2">[entrez.7409]</data>
  <data key="d3">VAV1</data>
  <data key="d4">[VAV]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">19</data>
  <data key="d7">19p13.3</data>
  <data key="d8">[proto-oncogene vav, vav 1 guanine nucleotide exchange factor, vav 1 oncogene]</data>
  <data key="d9">vav guanine nucleotide exchange factor 1</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.3667">
  <data key="d0">IRS1</data>
  <data key="d1">entrez.3667</data>
  <data key="d2">[entrez.3667]</data>
  <data key="d3">IRS1</data>
  <data key="d4">[HIRS-1]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">2</data>
  <data key="d7">2q36.3</data>
  <data key="d8">[insulin receptor substrate 1, IRS-1]</data>
  <data key="d9">insulin receptor substrate 1</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.3326">
  <data key="d0">HSP90AB1</data>
  <data key="d1">entrez.3326</data>
  <data key="d2">[entrez.3326]</data>
  <data key="d3">HSP90AB1</data>
  <data key="d4">[D6S182, HSP84, HSP90B, HSPC2, HSPCB]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">6</data>
  <data key="d7">6p21.1</data>
  <data key="d8">[heat shock protein HSP 90-beta, HSP90-beta, heat shock 84 kDa, heat shock 90kD protein 1, beta, heat shock protein 90 kDa, heat shock protein 90kDa alpha (cytosolic), class B member 1, heat shock protein 90kDa alpha family class B member 1]</data>
  <data key="d9">heat shock protein 90 alpha family class B member 1</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.3320">
  <data key="d0">HSP90AA1</data>
  <data key="d1">entrez.3320</data>
  <data key="d2">[entrez.3320]</data>
  <data key="d3">HSP90AA1</data>
  <data key="d4">[EL52, HEL-S-65p, HSP86, HSP89A, HSP90A, HSP90N, HSPC1, HSPCA, HSPCAL1, HSPCAL4, HSPN, Hsp103, Hsp89, Hsp90, LAP-2, LAP2]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">14</data>
  <data key="d7">14q32.31</data>
  <data key="d8">[heat shock protein HSP 90-alpha, HSP 86, LPS-associated protein 2, epididymis luminal secretory protein 52, epididymis secretory sperm binding protein Li 65p, heat shock 86 kDa, heat shock 90kD protein 1, alpha, heat shock 90kD protein 1, alpha-like 4, heat shock 90kD protein, alpha-like 4, heat shock 90kDa protein 1, alpha, heat shock protein 90kDa alpha (cytosolic), class A member 1, heat shock protein 90kDa alpha family class A member 1, lipopolysaccharide-associated protein 2, renal carcinoma antigen NY-REN-38]</data>
  <data key="d9">heat shock protein 90 alpha family class A member 1</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.3480">
  <data key="d0">IGF1R</data>
  <data key="d1">entrez.3480</data>
  <data key="d2">[entrez.3480]</data>
  <data key="d3">IGF1R</data>
  <data key="d4">[CD221, IGFIR, IGFR, JTK13]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">15</data>
  <data key="d7">15q26.3</data>
  <data key="d8">[insulin-like growth factor 1 receptor, IGF-I receptor, soluble IGF1R variant 1, soluble IGF1R variant 2]</data>
  <data key="d9">insulin like growth factor 1 receptor</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.2885">
  <data key="d0">GRB2</data>
  <data key="d1">entrez.2885</data>
  <data key="d2">[entrez.2885]</data>
  <data key="d3">GRB2</data>
  <data key="d4">[ASH, EGFRBP-GRB2, Grb3-3, MST084, MSTP084, NCKAP2]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">17</data>
  <data key="d7">17q25.1</data>
  <data key="d8">[growth factor receptor-bound protein 2, HT027, SH2/SH3 adapter GRB2, abundant SRC homology, epidermal growth factor receptor-binding protein GRB2, epididymis secretory sperm binding protein, growth factor receptor-bound protein 3, protein Ash]</data>
  <data key="d9">growth factor receptor bound protein 2</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.2534">
  <data key="d0">FYN</data>
  <data key="d1">entrez.2534</data>
  <data key="d2">[entrez.2534]</data>
  <data key="d3">FYN</data>
  <data key="d4">[SLK, SYN, p59-FYN]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">6</data>
  <data key="d7">6q21</data>
  <data key="d8">[tyrosine-protein kinase Fyn, FYN oncogene related to SRC, FGR, YES, OKT3-induced calcium influx regulator, c-syn protooncogene, proto-oncogene Syn, proto-oncogene c-Fyn, src-like kinase, src/yes-related novel, tyrosine kinase p59fyn(T)]</data>
  <data key="d9">FYN proto-oncogene, Src family tyrosine kinase</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.2549">
  <data key="d0">GAB1</data>
  <data key="d1">entrez.2549</data>
  <data key="d2">[entrez.2549]</data>
  <data key="d3">GAB1</data>
  <data key="d4">[DFNB26]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">4</data>
  <data key="d7">4q31.21</data>
  <data key="d8">[GRB2-associated-binding protein 1, GRB2-associated binder 1, deafness, autosomal recessive 26, growth factor receptor bound protein 2-associated protein 1, symbol withdrawn, see GAB1]</data>
  <data key="d9">GRB2 associated binding protein 1</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.6714">
  <data key="d0">SRC</data>
  <data key="d1">entrez.6714</data>
  <data key="d2">[entrez.6714]</data>
  <data key="d3">SRC</data>
  <data key="d4">[ASV, SRC1, THC6, c-SRC, p60-Src]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">20</data>
  <data key="d7">20q11.23</data>
  <data key="d8">[proto-oncogene tyrosine-protein kinase Src, proto-oncogene c-Src, protooncogene SRC, Rous sarcoma, tyrosine kinase pp60c-src, tyrosine-protein kinase SRC-1, v-src avian sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog]</data>
  <data key="d9">SRC proto-oncogene, non-receptor tyrosine kinase</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.6464">
  <data key="d0">SHC1</data>
  <data key="d1">entrez.6464</data>
  <data key="d2">[entrez.6464]</data>
  <data key="d3">SHC1</data>
  <data key="d4">[SHC, SHCA]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">1</data>
  <data key="d7">1q21.3</data>
  <data key="d8">[SHC-transforming protein 1, SH2 domain protein C1, SHC (Src homology 2 domain containing) transforming protein 1, SHC-transforming protein 3, SHC-transforming protein A]</data>
  <data key="d9">SHC adaptor protein 1</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.2185">
  <data key="d0">PTK2B</data>
  <data key="d1">entrez.2185</data>
  <data key="d2">[entrez.2185]</data>
  <data key="d3">PTK2B</data>
  <data key="d4">[CADTK, CAKB, FADK2, FAK2, PKB, PTK, PYK2, RAFTK]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">8</data>
  <data key="d7">8p21.2</data>
  <data key="d8">[protein-tyrosine kinase 2-beta, CAK-beta, FADK 2, PTK2B protein tyrosine kinase 2 beta, calcium-dependent tyrosine kinase, calcium-regulated non-receptor proline-rich tyrosine kinase, cell adhesion kinase beta, focal adhesion kinase 2, proline-rich tyrosine kinase 2, protein kinase B, related adhesion focal tyrosine kinase]</data>
  <data key="d9">protein tyrosine kinase 2 beta</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.2057">
  <data key="d0">EPOR</data>
  <data key="d1">entrez.2057</data>
  <data key="d2">[entrez.2057]</data>
  <data key="d3">EPOR</data>
  <data key="d4">[EPO-R]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">19</data>
  <data key="d7">19p13.2</data>
  <data key="d8">[erythropoietin receptor]</data>
  <data key="d9">erythropoietin receptor</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.2064">
  <data key="d0">ERBB2</data>
  <data key="d1">entrez.2064</data>
  <data key="d2">[entrez.2064]</data>
  <data key="d3">ERBB2</data>
  <data key="d4">[CD340, HER-2, HER-2/neu, HER2, MLN 19, NEU, NGL, TKR1]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">17</data>
  <data key="d7">17q12</data>
  <data key="d8">[receptor tyrosine-protein kinase erbB-2, c-erb B2/neu protein, herstatin, human epidermal growth factor receptor 2, metastatic lymph node gene 19 protein, neuro/glioblastoma derived oncogene homolog, neuroblastoma/glioblastoma derived oncogene homolog, p185erbB2, proto-oncogene Neu, proto-oncogene c-ErbB-2, tyrosine kinase-type cell surface receptor HER2, v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2, v-erb-b2 avian erythroblastic leukemia viral oncoprotein 2, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog]</data>
  <data key="d9">erb-b2 receptor tyrosine kinase 2</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.6774">
  <data key="d0">STAT3</data>
  <data key="d1">entrez.6774</data>
  <data key="d2">[entrez.6774]</data>
  <data key="d3">STAT3</data>
  <data key="d4">[ADMIO, ADMIO1, APRF, HIES]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">17</data>
  <data key="d7">17q21.2</data>
  <data key="d8">[signal transducer and activator of transcription 3, DNA-binding protein APRF, acute-phase response factor]</data>
  <data key="d9">signal transducer and activator of transcription 3</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.6850">
  <data key="d0">SYK</data>
  <data key="d1">entrez.6850</data>
  <data key="d2">[entrez.6850]</data>
  <data key="d3">SYK</data>
  <data key="d4">[p72-Syk]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">9</data>
  <data key="d7">9q22.2</data>
  <data key="d8">[tyrosine-protein kinase SYK, spleen tyrosine kinase]</data>
  <data key="d9">spleen associated tyrosine kinase</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.1439">
  <data key="d0">CSF2RB</data>
  <data key="d1">entrez.1439</data>
  <data key="d2">[entrez.1439]</data>
  <data key="d3">CSF2RB</data>
  <data key="d4">[CD131, CDw131, IL3RB, IL5RB, SMDP5, betaGMR]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">22</data>
  <data key="d7">22q12.3</data>
  <data key="d8">[cytokine receptor common subunit beta, GM-CSF/IL-3/IL-5 receptor common beta subunit, GM-CSF/IL-3/IL-5 receptor common beta-chain, beta common cytokine receptor, beta-GM-CSF receptor, colony stimulating factor 2 receptor beta common subunit, colony stimulating factor 2 receptor, beta, low-affinity (granulocyte-macrophage), colony-stimulating factor-2 receptor, beta, low-affinity, interleukin 3 receptor/granulocyte-macrophage colony stimulating factor 3 receptor, beta (high affinity)]</data>
  <data key="d9">colony stimulating factor 2 receptor subunit beta</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.1956">
  <data key="d0">EGFR</data>
  <data key="d1">entrez.1956</data>
  <data key="d2">[entrez.1956]</data>
  <data key="d3">EGFR</data>
  <data key="d4">[ERBB, ERBB1, HER1, NISBD2, PIG61, mENA]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">7</data>
  <data key="d7">7p11.2</data>
  <data key="d8">[epidermal growth factor receptor, avian erythroblastic leukemia viral (v-erb-b) oncogene homolog, cell growth inhibiting protein 40, cell proliferation-inducing protein 61, epidermal growth factor receptor tyrosine kinase domain, erb-b2 receptor tyrosine kinase 1, proto-oncogene c-ErbB-1, receptor tyrosine-protein kinase erbB-1]</data>
  <data key="d9">epidermal growth factor receptor</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.5296">
  <data key="d0">PIK3R2</data>
  <data key="d1">entrez.5296</data>
  <data key="d2">[entrez.5296]</data>
  <data key="d3">PIK3R2</data>
  <data key="d4">[MPPH, MPPH1, P85B, p85, p85-BETA]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">19</data>
  <data key="d7">19p13.11</data>
  <data key="d8">[phosphatidylinositol 3-kinase regulatory subunit beta, PI3-kinase subunit p85-beta, PI3K regulatory subunit beta, phosphatidylinositol 3-kinase 85 kDa regulatory subunit beta, phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 2 (p85 beta), phosphoinositide-3-kinase regulatory subunit beta, phosphoinositide-3-kinase, regulatory subunit 2 (beta), ptdIns-3-kinase regulatory subunit p85-beta]</data>
  <data key="d9">phosphoinositide-3-kinase regulatory subunit 2</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.5295">
  <data key="d0">PIK3R1</data>
  <data key="d1">entrez.5295</data>
  <data key="d2">[entrez.5295]</data>
  <data key="d3">PIK3R1</data>
  <data key="d4">[AGM7, GRB1, IMD36, p85, p85-ALPHA]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">5</data>
  <data key="d7">5q13.1</data>
  <data key="d8">[phosphatidylinositol 3-kinase regulatory subunit alpha, PI3-kinase subunit p85-alpha, PI3K regulatory subunit alpha, phosphatidylinositol 3-kinase 85 kDa regulatory subunit alpha, phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 1 (p85 alpha), phosphatidylinositol 3-kinase-associated p-85 alpha, phosphoinositide-3-kinase regulatory subunit alpha, phosphoinositide-3-kinase, regulatory subunit 1 (alpha), ptdIns-3-kinase regulatory subunit alpha]</data>
  <data key="d9">phosphoinositide-3-kinase regulatory subunit 1</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.5336">
  <data key="d0">PLCG2</data>
  <data key="d1">entrez.5336</data>
  <data key="d2">[entrez.5336]</data>
  <data key="d3">PLCG2</data>
  <data key="d4">[APLAID, FCAS3, PLC-IV, PLC-gamma-2]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">16</data>
  <data key="d7">16q23.3</data>
  <data key="d8">[1-phosphatidylinositol 4, 5-bisphosphate phosphodiesterase gamma-2, phosphoinositide phospholipase C-gamma-2, phospholipase C, gamma 2 (phosphatidylinositol-specific), phospholipase C-IV]</data>
  <data key="d9">phospholipase C gamma 2</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.5335">
  <data key="d0">PLCG1</data>
  <data key="d1">entrez.5335</data>
  <data key="d2">[entrez.5335]</data>
  <data key="d3">PLCG1</data>
  <data key="d4">[NCKAP3, PLC-II, PLC1, PLC148, PLCgamma1]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">20</data>
  <data key="d7">20q12</data>
  <data key="d8">[1-phosphatidylinositol 4, 5-bisphosphate phosphodiesterase gamma-1, 1-phosphatidyl-D-myo-inositol-4, 5-bisphosphate, PLC-148, PLC-gamma-1, inositoltrisphosphohydrolase, monophosphatidylinositol phosphodiesterase, phosphatidylinositol phospholipase C, phosphoinositidase C, phosphoinositide phospholipase C, phosphoinositide phospholipase C-gamma-1, phospholipase C, gamma 1 (formerly subtype 148), phospholipase C-148, phospholipase C-II, triphosphoinositide phosphodiesterase]</data>
  <data key="d9">phospholipase C gamma 1</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.5159">
  <data key="d0">PDGFRB</data>
  <data key="d1">entrez.5159</data>
  <data key="d2">[entrez.5159]</data>
  <data key="d3">PDGFRB</data>
  <data key="d4">[CD140B, IBGC4, IMF1, JTK12, KOGS, PDGFR, PDGFR-1, PDGFR1, PENTT]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">5</data>
  <data key="d7">5q32</data>
  <data key="d8">[platelet-derived growth factor receptor beta, Activated tyrosine kinase PDGFRB, CD140 antigen-like family member B, NDEL1-PDGFRB, PDGF-R-beta, PDGFR-beta, beta-type platelet-derived growth factor receptor, platelet-derived growth factor receptor 1, platelet-derived growth factor receptor, beta polypeptide]</data>
  <data key="d9">platelet derived growth factor receptor beta</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.5921">
  <data key="d0">RASA1</data>
  <data key="d1">entrez.5921</data>
  <data key="d2">[entrez.5921]</data>
  <data key="d3">RASA1</data>
  <data key="d4">[CM-AVM, CMAVM, CMAVM1, GAP, PKWS, RASA, RASGAP, p120, p120GAP, p120RASGAP]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">5</data>
  <data key="d7">5q14.3</data>
  <data key="d8">[ras GTPase-activating protein 1, RAS p21 protein activator (GTPase activating protein) 1, p120 RAS GTPase activating protein, triphosphatase-activating protein]</data>
  <data key="d9">RAS p21 protein activator 1</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.5781">
  <data key="d0">PTPN11</data>
  <data key="d1">entrez.5781</data>
  <data key="d2">[entrez.5781]</data>
  <data key="d3">PTPN11</data>
  <data key="d4">[BPTP3, CFC, JMML, METCDS, NS1, PTP-1D, PTP2C, SH-PTP2, SH-PTP3, SHP2]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">12</data>
  <data key="d7">12q24.13</data>
  <data key="d8">[tyrosine-protein phosphatase non-receptor type 11, protein-tyrosine phosphatase 1D, protein-tyrosine phosphatase 2C]</data>
  <data key="d9">protein tyrosine phosphatase non-receptor type 11</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.5777">
  <data key="d0">PTPN6</data>
  <data key="d1">entrez.5777</data>
  <data key="d2">[entrez.5777]</data>
  <data key="d3">PTPN6</data>
  <data key="d4">[HCP, HCPH, HPTP1C, PTP-1C, SH-PTP1, SHP-1, SHP-1L, SHP1]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">12</data>
  <data key="d7">12p13.31</data>
  <data key="d8">[tyrosine-protein phosphatase non-receptor type 6, hematopoietic cell phosphatase, hematopoietic cell protein-tyrosine phosphatase, protein-tyrosine phosphatase 1C, protein-tyrosine phosphatase SHP-1]</data>
  <data key="d9">protein tyrosine phosphatase non-receptor type 6</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.5747">
  <data key="d0">PTK2</data>
  <data key="d1">entrez.5747</data>
  <data key="d2">[entrez.5747]</data>
  <data key="d3">PTK2</data>
  <data key="d4">[FADK, FAK, FAK1, FRNK, PPP1R71, p125FAK, pp125FAK]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">8</data>
  <data key="d7">8q24.3</data>
  <data key="d8">[focal adhesion kinase 1, FADK 1, FAK-related non-kinase polypeptide, PTK2 protein tyrosine kinase 2, focal adhesion kinase isoform FAK-Del33, focal adhesion kinase-related nonkinase, protein phosphatase 1 regulatory subunit 71]</data>
  <data key="d9">protein tyrosine kinase 2</data>
  <data key="d10">gene</data>
</node>
<node id="drugbank.DB02010">
  <data key="d0">Staurosporine</data>
  <data key="d1">drugbank.DB02010</data>
  <data key="d2">[drugbank.DB02010, drugbank.EXPT02970, drugbank.EXPT02972]</data>
  <data key="d11">[experimental]</data>
  <data key="d12">[Alkaloids, Carbazoles, Enzyme Inhibitors, Indole Alkaloids, Indoles, P-glycoprotein/ABCB1 Inhibitors]</data>
  <data key="d13">(2S,3R,4R,6R)-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.1²,⁶.0⁷,²⁸.0⁸,¹³.0¹⁵,¹⁹.0²⁰,²⁷.0²¹,²⁶]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-16-one</data>
  <data key="d14">C28H26N4O3</data>
  <data key="d15">62996-74-1</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C28H26N4O3/c1-28-26(34-3)17(29-2)12-20(35-28)31-18-10-6-4-8-14(18)22-23-16(13-30-27(23)33)21-15-9-5-7-11-19(15)32(28)25(21)24(22)31/h4-11,17,20,26,29H,12-13H2,1-3H3,(H,30,33)/t17-,20-,26-,28+/m1/s1</data>
  <data key="d19">[H][C@]1(C[C@@]2([H])O[C@](C)(N3C4=CC=CC=C4C4=C5CNC(=O)C5=C5C6=CC=CC=C6N2C5=C34)[C@]1([H])OC)NC</data>
  <data key="d20"></data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[]</data>
  <data key="d9">An indolocarbazole that is a potent protein kinase C inhibitor which enhances cAMP-mediated responses in human neuroblastoma cells. (Biochem Biophys Res Commun 1995;214(3):1114-20)</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB05944">
  <data key="d0">Varlitinib</data>
  <data key="d1">drugbank.DB05944</data>
  <data key="d2">[drugbank.DB05944, drugbank.DB12723]</data>
  <data key="d11">[investigational]</data>
  <data key="d12">[Sulfur Compounds]</data>
  <data key="d13">N4-{3-chloro-4-[(1,3-thiazol-2-yl)methoxy]phenyl}-N6-[(4R)-4-methyl-4,5-dihydro-1,3-oxazol-2-yl]quinazoline-4,6-diamine</data>
  <data key="d14">C22H19ClN6O2S</data>
  <data key="d15">845272-21-1</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C22H19ClN6O2S/c1-13-10-31-22(27-13)29-14-2-4-18-16(8-14)21(26-12-25-18)28-15-3-5-19(17(23)9-15)30-11-20-24-6-7-32-20/h2-9,12-13H,10-11H2,1H3,(H,27,29)(H,25,26,28)/t13-/m1/s1</data>
  <data key="d19">C[C@@H]1COC(NC2=CC=C3N=CN=C(NC4=CC=C(OCC5=NC=CS5)C(Cl)=C4)C3=C2)=N1</data>
  <data key="d20">Investigated for use/treatment in cancer/tumors (unspecified).</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[]</data>
  <data key="d9">Varlitinib is an oral, selective, reversible, small molecule tyrosine kinase inhibitor of both ErbB-2 (Her-2/neu) and EGFR. Over-expression of ErbB-2 and EGFR receptors in tumors is predictive of poor prognosis in cancer patients. Varlitinib has shown significant anti-tumor activity in preclinical models of human breast, lung, and epidermal carcinoma tumors.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB03023">
  <data key="d0">1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine</data>
  <data key="d1">drugbank.DB03023</data>
  <data key="d2">[drugbank.DB03023, drugbank.EXPT02634]</data>
  <data key="d11">[experimental]</data>
  <data key="d12">[]</data>
  <data key="d13">4-amino-1-tert-butyl-3-(4-chlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-2-ium</data>
  <data key="d14">C15H17ClN5</data>
  <data key="d15"></data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C15H16ClN5/c1-15(2,3)21-14-11(13(17)18-8-19-14)12(20-21)9-4-6-10(16)7-5-9/h4-8H,1-3H3,(H2,17,18,19)/p+1</data>
  <data key="d19">CC(C)(C)N1[NH+]=C(C2=C1N=CN=C2N)C1=CC=C(Cl)C=C1</data>
  <data key="d20"></data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04395">
  <data key="d0">Phosphoaminophosphonic Acid-Adenylate Ester</data>
  <data key="d1">drugbank.DB04395</data>
  <data key="d2">[drugbank.DB04395, drugbank.EXPT00524]</data>
  <data key="d11">[experimental]</data>
  <data key="d12">[]</data>
  <data key="d13">({[({[(2S,3R,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy](hydroxy)phosphoryl}amino)phosphonic acid</data>
  <data key="d14">C10H17N6O12P3</data>
  <data key="d15"></data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C10H17N6O12P3/c11-8-5-9(13-2-12-8)16(3-14-5)10-7(18)6(17)4(27-10)1-26-31(24,25)28-30(22,23)15-29(19,20)21/h2-4,6-7,10,17-18H,1H2,(H,24,25)(H2,11,12,13)(H4,15,19,20,21,22,23)/t4-,6-,7+,10+/m0/s1</data>
  <data key="d19">NC1=NC=NC2=C1N=CN2[C@@H]1O[C@@H](CO[P@](O)(=O)O[P@@](O)(=O)NP(O)(O)=O)[C@H](O)[C@H]1O</data>
  <data key="d20"></data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[]</data>
  <data key="d9">5&amp;#39;-Adenylic acid, monoanhydride with imidodiphosphoric acid. An analog of ATP, in which the oxygen atom bridging the beta to the gamma phosphate is replaced by a nitrogen atom. It is a potent competitive inhibitor of soluble and membrane-bound mitochondrial ATPase and also inhibits ATP-dependent reactions of oxidative phosphorylation. [PubChem]</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB03166">
  <data key="d0">Acetic acid</data>
  <data key="d1">drugbank.DB03166</data>
  <data key="d2">[drugbank.DB03166, drugbank.EXPT00423, drugbank.DB04184]</data>
  <data key="d11">[approved]</data>
  <data key="d12">[Acetates, Acids, Acyclic, Anti-Infective Agents, Compounds used in a research, industrial, or household setting, Fatty Acids, Fatty Acids, Volatile, Genito Urinary System and Sex Hormones, Gynecological Antiinfectives and Antiseptics, Indicators and Reagents, Laboratory Chemicals, Lipids, Organic Acids, Otologicals, Sensory Organs]</data>
  <data key="d13">acetic acid</data>
  <data key="d14">C2H4O2</data>
  <data key="d15">64-19-7</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C2H4O2/c1-2(3)4/h1H3,(H,3,4)</data>
  <data key="d19">CC(O)=O</data>
  <data key="d20">Used to treat infections in the ear canal.</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[Acetic acid, glacial, Aceticum acidum, acide acétique, ácido acético, Essigsäure, Ethanoat, Ethanoate, Ethanoic acid, Ethoic acid, Ethylic acid, Glacial acetic acid, HOAc, Methanecarboxylic acid, Vinegar]</data>
  <data key="d9">Acetic acid is a product of the oxidation of ethanol and of the destructive distillation of wood. It is used locally, occasionally internally, as a counterirritant and also as a reagent. (Stedman, 26th ed) Acetic acid otic (for the ear) is an antibiotic that treats infections caused by bacteria or fungus.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB13050">
  <data key="d0">Tirilazad</data>
  <data key="d1">drugbank.DB13050</data>
  <data key="d2">[drugbank.DB13050]</data>
  <data key="d11">[investigational]</data>
  <data key="d12">[Antioxidants, Central Nervous System Agents, Compounds used in a research, industrial, or household setting, Nervous System, Neuroprotective Agents, Pregnanes, Protective Agents, Steroids]</data>
  <data key="d13">(2S,10S,11S,13R,14S,15S)-14-(2-{4-[2,6-bis(pyrrolidin-1-yl)pyrimidin-4-yl]piperazin-1-yl}acetyl)-2,13,15-trimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-1(17),3,6-trien-5-one</data>
  <data key="d14">C38H52N6O2</data>
  <data key="d15">110101-66-1</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C38H52N6O2/c1-26-22-31-29-9-8-27-23-28(45)10-12-37(27,2)30(29)11-13-38(31,3)35(26)32(46)25-41-18-20-43(21-19-41)34-24-33(42-14-4-5-15-42)39-36(40-34)44-16-6-7-17-44/h10-12,23-24,26,29,31,35H,4-9,13-22,25H2,1-3H3/t26-,29-,31+,35-,37+,38+/m1/s1</data>
  <data key="d19">C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)C3=CC[C@]2(C)[C@H]1C(=O)CN1CCN(CC1)C1=CC(=NC(=N1)N1CCCC1)N1CCCC1</data>
  <data key="d20"></data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[]</data>
  <data key="d9">Tirilazad has been used in trials studying the treatment of Spinal Cord Injury.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01074">
  <data key="d0">Perhexiline</data>
  <data key="d1">drugbank.DB01074</data>
  <data key="d2">[drugbank.DB01074, drugbank.APRD00107]</data>
  <data key="d11">[approved, investigational]</data>
  <data key="d12">[Agents causing hyperkalemia, Antiarrhythmic agents, Bradycardia-Causing Agents, Calcium Channel Blockers, Cardiovascular Agents, Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (moderate), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Membrane Transport Modulators, Non-Selective Calcium Channel Blockers, Piperidines, Potential QTc-Prolonging Agents, QTc Prolonging Agents, Vasodilating Agents]</data>
  <data key="d13">2-(2,2-dicyclohexylethyl)piperidine</data>
  <data key="d14">C19H35N</data>
  <data key="d15">6621-47-2</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C19H35N/c1-3-9-16(10-4-1)19(17-11-5-2-6-12-17)15-18-13-7-8-14-20-18/h16-20H,1-15H2</data>
  <data key="d19">C(C(C1CCCCC1)C1CCCCC1)C1CCCCN1</data>
  <data key="d20">For the management of severe angina pectoris.</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[Perhexilene, Perhexilina, Perhexiline, Perhexilinum]</data>
  <data key="d9">Perhexiline is a coronary vasodilator used especially for angina of effort. It may cause neuropathy and hepatitis.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB13089">
  <data key="d0">Enoxolone</data>
  <data key="d1">drugbank.DB13089</data>
  <data key="d2">[drugbank.DB13089]</data>
  <data key="d11">[investigational]</data>
  <data key="d12">[Anti-Inflammatory Agents, Cicatrizants, Dermatologicals, Pentacyclic Triterpenes, Preparations for Treatment of Wounds and Ulcers, Terpenes, Triterpenes]</data>
  <data key="d13">(2S,4aS,6aS,6bR,8aR,10S,12aS,12bR,14bR)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-2-carboxylic acid</data>
  <data key="d14">C30H46O4</data>
  <data key="d15">471-53-4</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C30H46O4/c1-25(2)21-8-11-30(7)23(28(21,5)10-9-22(25)32)20(31)16-18-19-17-27(4,24(33)34)13-12-26(19,3)14-15-29(18,30)6/h16,19,21-23,32H,8-15,17H2,1-7H3,(H,33,34)/t19-,21-,22-,23+,26+,27-,28-,29+,30+/m0/s1</data>
  <data key="d19">[H][C@@]12C[C@](C)(CC[C@]1(C)CC[C@]1(C)C2=CC(=O)[C@]2([H])[C@@]3(C)CC[C@H](O)C(C)(C)[C@]3([H])CC[C@@]12C)C(O)=O</data>
  <data key="d20"></data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[Enoxolona, Glycyrrhetic Acid]</data>
  <data key="d9">Enoxolone (glycyrrhetic acid) has been investigated for the basic science of Apparent Mineralocorticoid Excess (AME).</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01064">
  <data key="d0">Isoprenaline</data>
  <data key="d1">drugbank.DB01064</data>
  <data key="d2">[drugbank.DB01064, drugbank.APRD00182]</data>
  <data key="d11">[approved, investigational]</data>
  <data key="d12">[Adrenergic Agents, Adrenergic Agonists, Adrenergic and Dopaminergic Agents, Adrenergic beta-2 Receptor Agonists, Adrenergic beta-Agonists, Adrenergics for Systemic Use, Adrenergics, Inhalants, Agents producing tachycardia, Agents that produce hypertension, Alcohols, Amines, Amino Alcohols, Anti-Asthmatic Agents, Autonomic Agents, Biogenic Amines, Biogenic Monoamines, Bronchodilator Agents, Cardiac Stimulants Excl. Cardiac Glycosides, Cardiac Therapy, Cardiotonic Agents, Cardiovascular Agents, Catecholamines, Compounds used in a research, industrial, or household setting, Drugs for Obstructive Airway Diseases, Ethanolamines, Neurotransmitter Agents, Non-selective Beta-adrenergic Agonists, Peripheral Nervous System Agents, Protective Agents, Respiratory System Agents, Sympathomimetics]</data>
  <data key="d13">4-{1-hydroxy-2-[(propan-2-yl)amino]ethyl}benzene-1,2-diol</data>
  <data key="d14">C11H17NO3</data>
  <data key="d15">7683-59-2</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C11H17NO3/c1-7(2)12-6-11(15)8-3-4-9(13)10(14)5-8/h3-5,7,11-15H,6H2,1-2H3</data>
  <data key="d19">CC(C)NCC(O)C1=CC(O)=C(O)C=C1</data>
  <data key="d20">For the treatment of mild or transient episodes of heart block that do not require electric shock or pacemaker therapy also used in management of asthma and chronic bronchitis</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[(±)-isoprenaline, (±)-isoproterenol, 1-(3, 4-dihydroxyphenyl)-2-(isopropylamino)ethanol, 1-(3, 4-dihydroxyphenyl)-2-isopropylaminoethanol, 3, 4-dihydroxy-α-[(isopropylamino)methyl]benzyl alcohol, Isoprenalina, Isoprénaline, Isoprenaline, Isoprenalinum, Isopropyl noradrenaline, Isoproterenol, N-isopropyl-β-dihydroxyphenyl-β-hydroxyethylamine, N-Isopropylnoradrenaline, N-Isopropylnorepinephrine, α-(isopropylaminomethyl)protocatechuyl alcohol]</data>
  <data key="d9">Isopropyl analog of epinephrine; beta-sympathomimetic that acts on the heart, bronchi, skeletal muscle, alimentary tract, etc. It is used mainly as bronchodilator and heart stimulant.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04988">
  <data key="d0">IGN311</data>
  <data key="d1">drugbank.DB04988</data>
  <data key="d2">[drugbank.DB04988]</data>
  <data key="d11">[investigational]</data>
  <data key="d12">[Amino Acids, Peptides, and Proteins, Antibodies, Blood Proteins, Globulins, Immunoglobulins, Immunoproteins, Proteins, Serum Globulins]</data>
  <data key="d13">NA</data>
  <data key="d14">NA</data>
  <data key="d15"></data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">NA</data>
  <data key="d19">NA</data>
  <data key="d20">Intended for the treatment of various forms of cancer.</data>
  <data key="d21">BiotechDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[]</data>
  <data key="d9">IGN311 is a humanized monoclonal antibody (mab) against the Lewis Y carbohydrate antigen, a blood-group-related oligosaccharide.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01196">
  <data key="d0">Estramustine</data>
  <data key="d1">drugbank.DB01196</data>
  <data key="d2">[drugbank.DB01196, drugbank.APRD00625]</data>
  <data key="d11">[approved, investigational]</data>
  <data key="d12">[Alkylating Activity, Alkylating Drugs, Antineoplastic Agents, Antineoplastic Agents, Alkylating, Antineoplastic Agents, Hormonal, Antineoplastic and Immunomodulating Agents, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Estradiol, Estradiol Congeners, Estranes, Estrenes, Gonadal Hormones, Gonadal Steroid Hormones, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Hydrocarbons, Halogenated, Immunosuppressive Agents, Mustard Compounds, Nitrogen Mustard Compounds, Noxae, P-glycoprotein/ABCB1 Inhibitors, Steroids, Toxic Actions]</data>
  <data key="d13">(1S,10R,11S,14S,15S)-14-hydroxy-15-methyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-2,4,6-trien-5-yl N,N-bis(2-chloroethyl)carbamate</data>
  <data key="d14">C23H31Cl2NO3</data>
  <data key="d15">2998-57-4</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C23H31Cl2NO3/c1-23-9-8-18-17-5-3-16(29-22(28)26(12-10-24)13-11-25)14-15(17)2-4-19(18)20(23)6-7-21(23)27/h3,5,14,18-21,27H,2,4,6-13H2,1H3/t18-,19-,20+,21+,23+/m1/s1</data>
  <data key="d19">[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(OC(=O)N(CCCl)CCCl)C=C3CC[C@@]21[H]</data>
  <data key="d20">For the palliative treatment of patients with metastatic and/or progressive carcinoma of the prostate</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[17β-Estradiol 3-(bis(2-chloroethyl)carbamate), Estradiol 3-(N, N-bis(2-chloroethyl)carbamate), Estramustina, Estramustine, Estramustinum]</data>
  <data key="d9">A nitrogen mustard linked to estradiol, usually as phosphate; used to treat prostatic neoplasms; also has radiation protective properties.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01110">
  <data key="d0">Miconazole</data>
  <data key="d1">drugbank.DB01110</data>
  <data key="d2">[drugbank.DB01110, drugbank.APRD01115]</data>
  <data key="d11">[approved, investigational, vet_approved]</data>
  <data key="d12">[14-alpha Demethylase Inhibitors, Alimentary Tract and Metabolism, Anti-Infective Agents, Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents, Antifungal Agents, Antifungal Agents (Vaginal), Antifungals for Dermatological Use, Antifungals for Topical Use, Antiinfectives and Antiseptics for Local Oral Treatment, Antiinfectives for Systemic Use, Antimycotics for Systemic Use, Azole Antifungals, Chemically-Induced Disorders, Cytochrome P-450 CYP2A6 Inhibitors, Cytochrome P-450 CYP2A6 Inhibitors (strong), Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2B6 Inhibitors (strength unknown), Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 Inhibitors (strong), Cytochrome P-450 CYP2C19 inhibitors (unknown strength), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (moderate), Cytochrome P-450 CYP2C9 Inhibitors (strong), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (strong), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (moderate), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Dermatologicals, Enzyme Inhibitors, Genito Urinary System and Sex Hormones, Gynecological Antiinfectives and Antiseptics, Hormone Antagonists, Hormones, Hormone Substitutes, and Hormone Antagonists, Imidazole and Triazole Derivatives, Imidazole Derivatives, Imidazoles, Intestinal Antiinfectives, Otologicals, P-glycoprotein/ABCB1 Inhibitors, Sensory Organs, Steroid Synthesis Inhibitors, Stomatological Preparations, Vaginal Creams, Foams, and Jellies]</data>
  <data key="d13">1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole</data>
  <data key="d14">C18H14Cl4N2O</data>
  <data key="d15">22916-47-8</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C18H14Cl4N2O/c19-13-2-1-12(16(21)7-13)10-25-18(9-24-6-5-23-11-24)15-4-3-14(20)8-17(15)22/h1-8,11,18H,9-10H2</data>
  <data key="d19">ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1</data>
  <data key="d20">For topical application in the treatment of tinea pedis (athlete&amp;rsquo;s foot), tinea cruris, and tinea corporis caused by &lt;i&gt;Trichophyton rubrum&lt;/i&gt;, &lt;i&gt;Trichophyton mentagrophytes&lt;/i&gt;, and &lt;i&gt;Epidermophyton floccosum&lt;/i&gt;, in the treatment of cutaneous candidiasis (moniliasis), and in the treatment of tinea versicolor.</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[1-(2, 4-Dichloro-beta-((2, 4-dichlorobenzyl)oxy)phenethyl)imidazole, 1-[2-(2, 4-Dichloro-benzyloxy)-2-(2, 4-dichloro-phenyl)-ethyl]-1H-imidazole, Miconazol, Miconazole]</data>
  <data key="d9">An imidazole antifungal agent that is used topically and by intravenous infusion.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01118">
  <data key="d0">Amiodarone</data>
  <data key="d1">drugbank.DB01118</data>
  <data key="d2">[drugbank.DB01118, drugbank.APRD00288]</data>
  <data key="d11">[approved, investigational]</data>
  <data key="d12">[Agents causing hyperkalemia, Agents Causing Muscle Toxicity, Agents that reduce seizure threshold, alpha-Galactosidase, antagonists &amp; inhibitors, Antiarrhythmic agents, Antiarrhythmics, Class III, Benzofurans, Bradycardia-Causing Agents, BSEP/ABCB11 Substrates, BSEP/ABCB11 Substrates with Narrow Therapeutic Index, Calcium Channel Blockers, Cardiac Therapy, Cardiovascular Agents, Chemically-Induced Disorders, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (unknown strength), Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2A6 Inhibitors, Cytochrome P-450 CYP2A6 Inhibitors (moderate), Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (unknown strength), Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (moderate), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strong), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (moderate), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A5 Inhibitors, Cytochrome P-450 CYP3A5 Inhibitors (strength unknown), Cytochrome P-450 CYP3A7 Inhibitors, Cytochrome P-450 CYP3A7 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Cytochrome P450 1A2 Inhibitors, Cytochrome P450 2C9 Inhibitors, Cytochrome P450 2D6 Inhibitors, Cytochrome P450 3A4 Inhibitors, Enzyme Inhibitors, Highest Risk QTc-Prolonging Agents, Hypotensive Agents, Membrane Transport Modulators, Narrow Therapeutic Index Drugs, OCT2 Inhibitors, P-glycoprotein/ABCB1 Inducers, P-glycoprotein/ABCB1 Inhibitors, Potassium Channel Blockers, QTc Prolonging Agents, Sodium Channel Blockers, Vasodilating Agents]</data>
  <data key="d13">{2-[4-(2-butyl-1-benzofuran-3-carbonyl)-2,6-diiodophenoxy]ethyl}diethylamine</data>
  <data key="d14">C25H29I2NO3</data>
  <data key="d15">1951-25-3</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C25H29I2NO3/c1-4-7-11-22-23(18-10-8-9-12-21(18)31-22)24(29)17-15-19(26)25(20(27)16-17)30-14-13-28(5-2)6-3/h8-10,12,15-16H,4-7,11,13-14H2,1-3H3</data>
  <data key="d19">CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2</data>
  <data key="d20">Intravenously, for initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia in patients refractory to other therapy. Orally, for the treatment of life-threatening recurrent ventricular arrhythmias such as recurrent ventricular fibrillation and recurrent hemodynamically unstable ventricular tachycardia.</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[2-Butyl-3-(3, 5-diiodo-4-(2-diethylaminoethoxy)benzoyl)benzofuran, 2-Butyl-3-benzofuranyl 4-(2-(diethylamino)ethoxy)-3, 5-diiodophenyl ketone, 2-n-Butyl-3', 5'-diiodo-4'-N-diethylaminoethoxy-3-benzoylbenzofuran, Amiodarona, Amiodarone, Amiodaronum]</data>
  <data key="d9">An antianginal and antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting Na,K-activated myocardial adenosine triphosphatase. There is a resulting decrease in heart rate and in vascular resistance.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01127">
  <data key="d0">Econazole</data>
  <data key="d1">drugbank.DB01127</data>
  <data key="d2">[drugbank.DB01127, drugbank.APRD00943]</data>
  <data key="d11">[approved]</data>
  <data key="d12">[14-alpha Demethylase Inhibitors, Anti-Infective Agents, Antifungal Agents, Antifungal Agents (Vaginal), Antifungals for Dermatological Use, Antifungals for Topical Use, Azole Antifungals, Chemically-Induced Disorders, Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Inhibitors (strong), Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strong), Cytochrome P-450 Enzyme Inhibitors, Dermatologicals, Enzyme Inhibitors, Genito Urinary System and Sex Hormones, Gynecological Antiinfectives and Antiseptics, Hormone Antagonists, Hormones, Hormone Substitutes, and Hormone Antagonists, Imidazole and Triazole Derivatives, Imidazole Derivatives, Imidazoles, P-glycoprotein/ABCB1 Inhibitors, Steroid Synthesis Inhibitors]</data>
  <data key="d13">1-{2-[(4-chlorophenyl)methoxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole</data>
  <data key="d14">C18H15Cl3N2O</data>
  <data key="d15">27220-47-9</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C18H15Cl3N2O/c19-14-3-1-13(2-4-14)11-24-18(10-23-8-7-22-12-23)16-6-5-15(20)9-17(16)21/h1-9,12,18H,10-11H2</data>
  <data key="d19">ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1</data>
  <data key="d20">For topical application in the treatment of tinea pedis, tinea cruris, and tinea corporis caused by &lt;i&gt;Trichophyton rubrum&lt;/i&gt;, &lt;i&gt;Trichophyton mentagrophytes&lt;/i&gt;, &lt;i&gt;Trichophyton tonsurans&lt;/i&gt;, &lt;i&gt;Microsporum canis&lt;/i&gt;, &lt;i&gt;Microsporum audouini&lt;/i&gt;, &lt;i&gt;Microsporum gypseum&lt;/i&gt;, and &lt;i&gt;Epidermophyton floccosum&lt;/i&gt;, in the treatment of cutaneous candidiasis, and in the treatment of tinea versicolor.</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[(+-)-Econazole, Econazol, Econazole]</data>
  <data key="d9">A broad spectrum antimycotic with some action against Gram positive bacteria. It is used topically in dermatomycoses also orally and parenterally.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04716">
  <data key="d0">2-(1,1-DIMETHYLETHYL)9-FLUORO-3,6-DIHYDRO-7H-BENZ[H]-IMIDAZ[4,5-F]ISOQUINOLIN-7-ONE</data>
  <data key="d1">drugbank.DB04716</data>
  <data key="d2">[drugbank.DB04716]</data>
  <data key="d11">[experimental]</data>
  <data key="d12">[]</data>
  <data key="d13">4-tert-butyl-15-fluoro-3,5,10-triazatetracyclo[11.4.0.0²,⁶.0⁷,¹²]heptadeca-1,3,6,8,12,14,16-heptaen-11-one</data>
  <data key="d14">C18H16FN3O</data>
  <data key="d15"></data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C18H16FN3O/c1-18(2,3)17-21-14-10-5-4-9(19)8-12(10)13-11(15(14)22-17)6-7-20-16(13)23/h4-8H,1-3H3,(H,20,23)(H,21,22)</data>
  <data key="d19">CC(C)(C)C1=NC2=C3C=CC(F)=CC3=C3C(=O)NC=CC3=C2N1</data>
  <data key="d20"></data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04868">
  <data key="d0">Nilotinib</data>
  <data key="d1">drugbank.DB04868</data>
  <data key="d2">[drugbank.DB04868]</data>
  <data key="d11">[approved, investigational]</data>
  <data key="d12">[Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, BCRP/ABCG2 Inhibitors, BCRP/ABCG2 Substrates, Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 CYP2B6 Inducers (strength unknown), Cytochrome P-450 CYP2C8 Inducers, Cytochrome P-450 CYP2C8 Inducers (strength unknown), Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (moderate), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (moderate), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Inhibitors (strong), Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strong), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Highest Risk QTc-Prolonging Agents, Hyperglycemia-Associated Agents, Immunosuppressive Agents, Kinase Inhibitor, Myelosuppressive Agents, OATP1B1/SLCO1B1 Inhibitors, P-glycoprotein/ABCB1 Inhibitors, P-glycoprotein/ABCB1 Substrates, Protein Kinase Inhibitors, QTc Prolonging Agents, Tyrosine Kinase Inhibitors, UGT1A1 Inhibitors]</data>
  <data key="d13">4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}benzamide</data>
  <data key="d14">C28H22F3N7O</data>
  <data key="d15">641571-10-0</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C28H22F3N7O/c1-17-5-6-19(10-25(17)37-27-33-9-7-24(36-27)20-4-3-8-32-14-20)26(39)35-22-11-21(28(29,30)31)12-23(13-22)38-15-18(2)34-16-38/h3-16H,1-2H3,(H,35,39)(H,33,36,37)</data>
  <data key="d19">CC1=CN(C=N1)C1=CC(NC(=O)C2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)=CC(=C1)C(F)(F)F</data>
  <data key="d20">For the potential treatment of various leukemias, including chronic myeloid leukemia (CML).</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[Nilotinib, Nilotinibum]</data>
  <data key="d9">Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec), another tyrosine kinase inhibitor used as a first-line treatment for CML.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04813">
  <data key="d0">Bithionol</data>
  <data key="d1">drugbank.DB04813</data>
  <data key="d2">[drugbank.DB04813]</data>
  <data key="d11">[approved, withdrawn]</data>
  <data key="d12">[Anthelmintics, Anti-Acne Preparations, Anti-Acne Preparations for Topical Use, Anti-Infective Agents, Anti-Infective Agents, Local, Antiparasitic Agents, Antiparasitic Products, Insecticides and Repellents, Antiplatyhelmintic Agents, Antitrematodals, Benzene Derivatives, Dermatologicals, Phenols, Preparations Containing Sulfur]</data>
  <data key="d13">2,4-dichloro-6-[(3,5-dichloro-2-hydroxyphenyl)sulfanyl]phenol</data>
  <data key="d14">C12H6Cl4O2S</data>
  <data key="d15">97-18-7</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C12H6Cl4O2S/c13-5-1-7(15)11(17)9(3-5)19-10-4-6(14)2-8(16)12(10)18/h1-4,17-18H</data>
  <data key="d19">OC1=C(SC2=C(O)C(Cl)=CC(Cl)=C2)C=C(Cl)C=C1Cl</data>
  <data key="d20"></data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[2-Hydroxy-3, 5-dichlorophenyl sulfide, 2-Hydroxy-3, 5-dichlorophenyl sulphide, 2, 2'-Dihydroxy-3, 3', 5, 5'-tetrachlorodiphenyl sulfide, 2, 2'-Dihydroxy-3, 3', 5, 5'-tetrachlorodiphenylsulfide, 2, 2'-sulfanediylbis(4, 6-dichlorophenol), 2, 2'-Thiobis(4, 6-dichlorophenol), Bis(3, 5-dichloro-2-hydroxyphenyl) sulfide, Bithionol, Bithionol sulfide, Bithionolate, Bithionolum, Bitionol]</data>
  <data key="d9">Bithionol, formerly marketed as an active ingredient in various topical drug products, was shown to be a potent photosensitizer with the potential to cause serious skin disorders. Approvals of the NDA's for bithionol drug products were withdrawn on October 24, 1967 (see the Federal Register of October 31, 1967 (32 FR 15046)).</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00190">
  <data key="d0">Carbidopa</data>
  <data key="d1">drugbank.DB00190</data>
  <data key="d2">[drugbank.DB00190, drugbank.APRD00160]</data>
  <data key="d11">[approved]</data>
  <data key="d12">[Amines, Anti-Dyskinesia Agents, Anti-Parkinson Drugs, Aromatic Amino Acid Decarboxylase Inhibitors, Biogenic Amines, Biogenic Monoamines, Catecholamines, Central Nervous System Agents, Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Hydrazines]</data>
  <data key="d13">(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid</data>
  <data key="d14">C10H14N2O4</data>
  <data key="d15">28860-95-9</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C10H14N2O4/c1-10(12-11,9(15)16)5-6-2-3-7(13)8(14)4-6/h2-4,12-14H,5,11H2,1H3,(H,15,16)/t10-/m0/s1</data>
  <data key="d19">C[C@@](CC1=CC(O)=C(O)C=C1)(NN)C(O)=O</data>
  <data key="d20">Carbidopa is indicated with [levodopa] for the treatment of symptoms of idiopathic Parkinson disease, postencephalitic parkinsonism and symptomatic parkinsonism followed by carbon monoxide or manganese intoxication.[FDA label]\n\nThe combination therapy is administered for the reduction of [levodopa]-driven nausea and vomiting.[FDA label]\n\nThe product of carbidopa should be used in patients where the combination therapy of carbidopa/[levodopa] provide less than the adequate daily dosage.[FDA label]\n\nAs well carbidopa can be used in patients where the dosages of carbidopa and [levodopa] require individual titration.[FDA label]</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[(-)-L-alpha-Hydrazino-3, 4-dihydroxy-alpha-methylhydrocinnamic acid monohydrate, (S)-(−)-carbidopa, (S)-carbidopa, (αS)-α-hydrazino-3, 4-dihydroxy-α-methylbenzenepropanoic acid, Carbidopa, Carbidopa (anhydrous), Carbidopa anhydrous, Carbidopum, L-3-(3, 4-dihydroxyphenyl)-2-methyl-2-hydrazinopropionic acid, L-α-methyldopahydrazine]</data>
  <data key="d9">Carbidopa presents a chemical denomination of N-amino-alpha-methyl-3-hydroxy-L-tyrosine monohydrate. It potently inhibits aromatic amino acid decarboxylase (DDC) and due to its chemical properties, it does not cross the blood-brain barrier. Due to its activity, carbidopa is always administered concomitantly with [levodopa]. An individual formulation containing solely carbidopa was generated to treat nausea in patients where the combination therapy [levodopa]/carbidopa is not efficient reducing nausea.[T394] \n\nThe first approved product by the FDA containing only carbidopa was developed by Amerigens Pharmaceuticals Ltd and approved on 2014.[L5110] On the other hand, the combination treatment of carbidopa/levodopa was originally developed by Watson Labs but the historical information by the FDA brings back to the approval of this combination therapy developed by Mayne Pharma in 1992.[L5113]</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB12147">
  <data key="d0">Erdafitinib</data>
  <data key="d1">drugbank.DB12147</data>
  <data key="d2">[drugbank.DB12147]</data>
  <data key="d11">[approved, investigational]</data>
  <data key="d12">[Antineoplastic Agents, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), OCT2 Inhibitors, P-glycoprotein/ABCB1 Inhibitors, P-glycoprotein/ABCB1 Substrates, Receptors, Fibroblast Growth Factor, antagonists &amp; inhibitors, Tumor Suppressor Proteins, Tyrosine Kinase Inhibitors]</data>
  <data key="d13">N-(3,5-dimethoxyphenyl)-3-(1-methyl-1H-pyrazol-4-yl)-N-{2-[(propan-2-yl)amino]ethyl}quinoxalin-6-amine</data>
  <data key="d14">C25H30N6O2</data>
  <data key="d15">1346242-81-6</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C25H30N6O2/c1-17(2)26-8-9-31(20-10-21(32-4)13-22(11-20)33-5)19-6-7-23-24(12-19)29-25(15-27-23)18-14-28-30(3)16-18/h6-7,10-17,26H,8-9H2,1-5H3</data>
  <data key="d19">COC1=CC(=CC(OC)=C1)N(CCNC(C)C)C1=CC=C2N=CC(=NC2=C1)C1=CN(C)N=C1</data>
  <data key="d20">Erdafitinib is a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor [FDA Label][A177109, A177112, A177115] that is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has:\ni) susceptible FGFR3 or FGFR2 genetic alterations and has [FDA Label],\nii) progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy [FDA Label].\n\nThe selection of patients for the treatment of locally advanced or metastatic urothelial carcinoma with erdafitinib should be based on the presence of susceptible FGFR genetic alterations in tumor specimens as detected by an FDA-approved companion diagnostic like the FDA approved therascreen FGFR RGQ RT-PCR Kit as developed by QIAGEN [FDA Label].\n\nThis above indication is approved under accelerated approval by the US FDA based on tumor response rate [FDA Label]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials [FDA Label].</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[Erdafitinib]</data>
  <data key="d9">In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for patients with locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations, that has progressed during or following platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy [L5956, L5959]. At the same time, the FDA also approved the therascreen FGFR RGQ RT-PCR Kit (Qiagen) for utilization as a companion diagnostic with erdafitinib for selecting patients for the indicated therapy [L5956, L5959].\n\nErdafitinib's innovation lies in the fact that it is the first personalized treatment targeting susceptible FGFR genetic alterations for patients with metastatic bladder cancer, which demonstrates the design of erdafitinib in developing more personalized and precision medicines with the capacity to target cancer treatment to a patient's specific genetic mutation [L5956, L5959]. Considering urothelial cancer is statistically the fourth most common kind of cancer in the world [F4372], the introduction of erdafitinib offers a welcome new option in the ever-expanding therapeutic tool kit to treat such prevalent medical conditions.\n\nNevertheless, although erdafitinib was granted Breakthrough Therapy designation and Accelerated Approval from the FDA so as to allow the agency to focus on and expedite the approval process for a medication indicated for a serious condition that fills an unmet medical need using clinical trial data that is believed to predict a genuine clinical benefit for patients with the given condition, such designations mean further ongoing clinical trials are necessary to confirm the clinical benefit of erdafitinib going forward [L5956, L5959].</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00257">
  <data key="d0">Clotrimazole</data>
  <data key="d1">drugbank.DB00257</data>
  <data key="d2">[drugbank.DB00257, drugbank.APRD00244]</data>
  <data key="d11">[approved, vet_approved]</data>
  <data key="d12">[Anti-Infective Agents, Anti-Infective Agents, Local, Antifungal Agents, Antifungal Agents (Vaginal), Antifungals for Dermatological Use, Antifungals for Topical Use, Antiinfectives and Antiseptics for Local Oral Treatment, Azole Antifungals, BSEP/ABCB11 Inhibitors, BSEP/ABCB11 Substrates, Cytochrome P-450 CYP2A6 Inhibitors, Cytochrome P-450 CYP2A6 Inhibitors (strong), Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 CYP2B6 Inducers (strength unknown), Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2B6 Inhibitors (strong), Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (moderate), Cytochrome P-450 CYP2C8 Inhibitors (strong), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (moderate), Cytochrome P-450 CYP2C9 Inhibitors (strong), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (moderate), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (moderate), Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Inducers (strong), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Inhibitors (strong), Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A7 Inducers, Cytochrome P-450 CYP3A7 Inducers (strong), Cytochrome P-450 CYP3A7 Inducers (weak), Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Dermatologicals, Enzyme Inhibitors, Gynecological Antiinfectives and Antiseptics, Hormone Antagonists, Hormones, Hormone Substitutes, and Hormone Antagonists, Imidazole and Triazole Derivatives, Imidazole Derivatives, Imidazoles, OATP1B1/SLCO1B1 Inhibitors, OATP1B1/SLCO1B1 Substrates, OATP1B3 inducers, P-glycoprotein/ABCB1 Inducers, P-glycoprotein/ABCB1 Inhibitors, P-glycoprotein/ABCB1 Substrates, Steroid Synthesis Inhibitors, Stomatological Preparations]</data>
  <data key="d13">1-[(2-chlorophenyl)diphenylmethyl]-1H-imidazole</data>
  <data key="d14">C22H17ClN2</data>
  <data key="d15">23593-75-1</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C22H17ClN2/c23-21-14-8-7-13-20(21)22(25-16-15-24-17-25,18-9-3-1-4-10-18)19-11-5-2-6-12-19/h1-17H</data>
  <data key="d19">ClC1=CC=CC=C1C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1</data>
  <data key="d20">**Topical preparations**\n\nClotrimazole topical cream is indicated for the topical treatment of the following dermal infections [F3088], [F3121]:\n\nTinea pedis, tinea cruris, and tinea corporis due to _Trichophyton rubrum_, _Trichophyton mentagrophytes_, _Epidermophyton floccosum_\n\nCandidiasis due to _Candida albicans_\n\nTinea versicolor due to _Malassezia furfur_\n\nDiaper rash infected by _Candida albicans_\n\n\nIn some preparations, clotrimazole may be combined with betamethasone dipropionate, a corticosteroid [F3121]. \n\n**Oral preparations**\n\nThe oral troche preparation is indicated for the local treatment of oropharyngeal candidiasis [FDA label].  It is also indicated as a prophylactic drug to reduce the incidence of oropharyngeal candidiasis in patients immunocompromised by conditions such as chemotherapy, radiotherapy, or steroid therapy utilized in the treatment of leukemia, solid tumors, or renal transplantation [FDA label]. Troche preparations are not indicated for the treatment of any systemic mycoses [FDA label].</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[1-((2-Chlorophenyl)diphenylmethyl)-1H-imidazole, 1-(o-Chloro-α, α-diphenylbenzyl)imidazole, 1-(o-Chlorotrityl)imidazole, 1-(α-(2-Chlorophenyl)benzhydryl)imidazole, Clotrimazol, Clotrimazole, Clotrimazolum]</data>
  <data key="d9">This drug is a broad spectrum antimycotic or antifungal agent. Clotrimazole's antimycotic properties were discovered in the late 1960s [A174094]. Clotrimazole falls under the _imidazole_ category of _azole_ antifungals, possessing broad-spectrum antimycotic activity [A174094].  It is available in various preparations, including creams, pessaries, and troche formulations (slowly dissolving tablets).  As well as its antifungal activity, clotrimazole has become a drug of interest in treating several other diseases such as sickle cell disease, malaria and some cancers [A174094].  The minimal side effect profile of this drug and its uncomplicated metabolic profile have led it to gain widespread acceptance for the treatment of mycotic outbreaks such as vaginal yeast infections as well as athlete's foot [A174097].</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00255">
  <data key="d0">Diethylstilbestrol</data>
  <data key="d1">drugbank.DB00255</data>
  <data key="d2">[drugbank.DB00255, drugbank.APRD00920, drugbank.EXPT01164]</data>
  <data key="d11">[approved, investigational]</data>
  <data key="d12">[Adrenal Cortex Hormones, Antineoplastic Agents, Hormonal, Antineoplastic and Immunomodulating Agents, BCRP/ABCG2 Inhibitors, Benzene Derivatives, Benzylidene Compounds, BSEP/ABCB11 Substrates, Carcinogens, COMT Substrates, Contraceptive Agents, Female, Contraceptive Agents, Male, Contraceptives, Postcoital, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strength unknown), Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (strong), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Endocrine Therapy, Estrogen Contraceptives, Estrogens, Estrogens, Non-Steroidal, Genito Urinary System and Sex Hormones, Hormonal Contraceptives for Systemic Use, Hormones, Hormones and Related Agents, Hormones, Hormone Substitutes, and Hormone Antagonists, Noxae, OATP1B1/SLCO1B1 Inhibitors, P-glycoprotein/ABCB1 Substrates, Sex Hormones and Modulators of the Genital System, Stilbenes, Synthetic Estrogens, Plain, Toxic Actions]</data>
  <data key="d13">4-[(3E)-4-(4-hydroxyphenyl)hex-3-en-3-yl]phenol</data>
  <data key="d14">C18H20O2</data>
  <data key="d15">56-53-1</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C18H20O2/c1-3-17(13-5-9-15(19)10-6-13)18(4-2)14-7-11-16(20)12-8-14/h5-12,19-20H,3-4H2,1-2H3/b18-17+</data>
  <data key="d19">CC\C(=C(\CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1</data>
  <data key="d20">Used in the treatment of prostate cancer. Previously used in the prevention of miscarriage or premature delivery in pregnant women prone to miscarriage or premature delivery.</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[(E)-3, 4-bis(4-hydroxyphenyl)-3-hexene, (E)-4, 4'-(1, 2-diethyl-1, 2-ethenediyl)bisphenol, 4, 4'-dihydroxy-α, β-diethylstilbene, DES, Diethylstilbestrol, Diéthylstilbestrol, Diethylstilbestrolum, Dietilestilbestrol, Stilboestrol, trans-4, 4'-(1, 2-diethyl-1, 2-ethenediyl)bisphenol, trans-Diethylstilbesterol, trans-Diethylstilbestrol, trans-Diethylstilboesterol, α, α'-diethyl-(E)-4, 4'-stilbenediol]</data>
  <data key="d9">A synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal disorders. It was also used formerly as a growth promoter in animals. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), diethylstilbestrol has been listed as a known carcinogen. (Merck, 11th ed)</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB12267">
  <data key="d0">Brigatinib</data>
  <data key="d1">drugbank.DB12267</data>
  <data key="d2">[drugbank.DB12267]</data>
  <data key="d11">[approved, investigational]</data>
  <data key="d12">[Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, BCRP/ABCG2 Inhibitors, BCRP/ABCG2 Substrates, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P450 3A Inducers, Kinase Inhibitor, MATE 1 Inhibitors, MATE 2 Inhibitors, MATE inhibitors, Protein Kinase Inhibitors, Tyrosine Kinase Inhibitors]</data>
  <data key="d13">5-chloro-N4-[2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}pyrimidine-2,4-diamine</data>
  <data key="d14">C29H39ClN7O2P</data>
  <data key="d15">1197953-54-0</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C29H39ClN7O2P/c1-35-15-17-37(18-16-35)21-11-13-36(14-12-21)22-9-10-24(26(19-22)39-2)33-29-31-20-23(30)28(34-29)32-25-7-5-6-8-27(25)40(3,4)38/h5-10,19-21H,11-18H2,1-4H3,(H2,31,32,33,34)</data>
  <data key="d19">COC1=CC(=CC=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2P(C)(C)=O)=N1)N1CCC(CC1)N1CCN(C)CC1</data>
  <data key="d20">The anaplastic lymphoma kinase positive, metastatic non-small cell lung cancer (ALK+ NSCLC), represents only 3-5% of the NSCLC cancer cases, but the ALK mutation, overexpression and presence in several oncogenic fusion proteins in solid and hematologic tumors have pointed out the importance as well as its potential as a cancer therapy target.[A31311] The ALK-related cases of NSCLC are associated with the presence of the fusion gene EML4-ALK which fused the ALK protein with the echinoderm microtubule-associated protein like-4 whose original function is the correct formation of microtubules.[A31313] The presence of the aberrant fusion protein results in abnormal signaling that provokes increased cell growth, proliferation and survival.[A31316] Crizotinib is indicated for the treatment of such cases but the presence of ALK kinase domain mutations confer resistance to the treatment. Thus, brigatinib is indicated for the treatment of patients with ALK+ NSCLC with intolerance to Crizotinib.[A31314]</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[Brigatinib]</data>
  <data key="d9">Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type.[A31311] It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a pivotal player in the transformation of susceptible lung parenchyma.[A31313] Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and FDA-approved on April 28, 2017.[L1026]</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00220">
  <data key="d0">Nelfinavir</data>
  <data key="d1">drugbank.DB00220</data>
  <data key="d2">[drugbank.DB00220, drugbank.APRD00003]</data>
  <data key="d11">[approved]</data>
  <data key="d12">[Anti-HIV Agents, Anti-Infective Agents, Anti-Retroviral Agents, Antiinfectives for Systemic Use, Antiviral Agents, Antivirals for Systemic Use, BCRP/ABCG2 Inhibitors, BSEP/ABCB11 Substrates, Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2B6 Inhibitors (strength unknown), Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (unknown strength), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (moderate), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Inhibitors (strong), Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strong), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A5 Inhibitors, Cytochrome P-450 CYP3A5 Inhibitors (strong), Cytochrome P-450 CYP3A7 Inhibitors, Cytochrome P-450 CYP3A7 Inhibitors (strong), Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P450 3A Inhibitors, Direct Acting Antivirals, Enzyme Inhibitors, HIV Protease Inhibitors, Hyperglycemia-Associated Agents, Isoquinolines, OATP1B1/SLCO1B1 Inhibitors, OATP1B3 inhibitors, OCT1 inhibitors, P-glycoprotein/ABCB1 Inducers, P-glycoprotein/ABCB1 Inhibitors, P-glycoprotein/ABCB1 Substrates, Potential QTc-Prolonging Agents, Protease Inhibitors, QTc Prolonging Agents, UGT1A1 Inducers]</data>
  <data key="d13">(3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylphenyl)formamido]-4-(phenylsulfanyl)butyl]-decahydroisoquinoline-3-carboxamide</data>
  <data key="d14">C32H45N3O4S</data>
  <data key="d15">159989-64-7</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C32H45N3O4S/c1-21-25(15-10-16-28(21)36)30(38)33-26(20-40-24-13-6-5-7-14-24)29(37)19-35-18-23-12-9-8-11-22(23)17-27(35)31(39)34-32(2,3)4/h5-7,10,13-16,22-23,26-27,29,36-37H,8-9,11-12,17-20H2,1-4H3,(H,33,38)(H,34,39)/t22-,23+,26-,27-,29+/m0/s1</data>
  <data key="d19">[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C</data>
  <data key="d20">Used in combination with other antiviral drugs in the treatment of HIV in both adults and children.</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[Nelfinavir]</data>
  <data key="d9">Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00317">
  <data key="d0">Gefitinib</data>
  <data key="d1">drugbank.DB00317</data>
  <data key="d2">[drugbank.DB00317, drugbank.APRD00997, drugbank.DB07998]</data>
  <data key="d11">[approved, investigational]</data>
  <data key="d12">[Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, BCRP/ABCG2 Inhibitors, BCRP/ABCG2 Substrates, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (unknown strength), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (weak), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Enzyme Inhibitors, Kinase Inhibitor, P-glycoprotein/ABCB1 Inhibitors, P-glycoprotein/ABCB1 Substrates, Protein Kinase Inhibitors, Receptor, Epidermal Growth Factor, antagonists &amp; inhibitors, Tyrosine Kinase Inhibitors]</data>
  <data key="d13">N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine</data>
  <data key="d14">C22H24ClFN4O3</data>
  <data key="d15">184475-35-2</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)</data>
  <data key="d19">COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1</data>
  <data key="d20">For the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docetaxel chemotherapies.</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline, Gefitinib, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamine]</data>
  <data key="d9">Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01268">
  <data key="d0">Sunitinib</data>
  <data key="d1">drugbank.DB01268</data>
  <data key="d2">[drugbank.DB01268, drugbank.DB07417]</data>
  <data key="d11">[approved, investigational]</data>
  <data key="d12">[Angiogenesis Inhibitors, Angiogenesis Modulating Agents, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, BCRP/ABCG2 Inhibitors, Blood Glucose Lowering Agents, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inhibitors, Growth Inhibitors, Growth Substances, Hypoglycemia-Associated Agents, Immunosuppressive Agents, Kinase Inhibitor, P-glycoprotein/ABCB1 Inhibitors, P-glycoprotein/ABCB1 Substrates, Potential QTc-Prolonging Agents, Protein Kinase Inhibitors, QTc Prolonging Agents, Tyrosine Kinase Inhibitors]</data>
  <data key="d13">N-[2-(diethylamino)ethyl]-5-{[(3Z)-5-fluoro-2-oxo-2,3-dihydro-1H-indol-3-ylidene]methyl}-2,4-dimethyl-1H-pyrrole-3-carboxamide</data>
  <data key="d14">C22H27FN4O2</data>
  <data key="d15">557795-19-4</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12-</data>
  <data key="d19">CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C</data>
  <data key="d20">For the treatment of advanced renal cell carcinoma as well as the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate.</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[Sunitinib, Sunitinibum]</data>
  <data key="d9">Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01229">
  <data key="d0">Paclitaxel</data>
  <data key="d1">drugbank.DB01229</data>
  <data key="d2">[drugbank.DB01229, drugbank.APRD00259, drugbank.DB05261, drugbank.DB05927, drugbank.DB05526, drugbank.DB05281]</data>
  <data key="d11">[approved, vet_approved]</data>
  <data key="d12">[Agents Causing Muscle Toxicity, Albumins, Amino Acids, Peptides, and Proteins, Antimitotic Agents, Antineoplastic Agents, Antineoplastic Agents, Phytogenic, Antineoplastic and Immunomodulating Agents, BCRP/ABCG2 Substrates, BSEP/ABCB11 Inhibitors, BSEP/ABCB11 Substrates, BSEP/ABCB11 Substrates with Narrow Therapeutic Index, Cardiotoxic antineoplastic agents, Cyclodecanes, Cycloparaffins, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 CYP3A7 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Enzyme Inducers, Diterpenes, Hypotensive Agents, Immunosuppressive Agents, Microtubule Inhibition, Microtubule Inhibitors, Mitosis Modulators, Myelosuppressive Agents, Narrow Therapeutic Index Drugs, Neurotoxic agents, OATP1B3 substrates, P-glycoprotein/ABCB1 Inhibitors, P-glycoprotein/ABCB1 Substrates, P-glycoprotein/ABCB1 Substrates with narrow therapeutic index, Proteins, Taxane Derivatives, Taxoids, Terpenes, Tubulin Modulators]</data>
  <data key="d13">(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-bis(acetyloxy)-1,9-dihydroxy-15-{[(2R,3S)-2-hydroxy-3-phenyl-3-(phenylformamido)propanoyl]oxy}-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0³,¹⁰.0⁴,⁷]heptadec-13-en-2-yl benzoate</data>
  <data key="d14">C47H51NO14</data>
  <data key="d15">33069-62-4</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C47H51NO14/c1-25-31(60-43(56)36(52)35(28-16-10-7-11-17-28)48-41(54)29-18-12-8-13-19-29)23-47(57)40(61-42(55)30-20-14-9-15-21-30)38-45(6,32(51)22-33-46(38,24-58-33)62-27(3)50)39(53)37(59-26(2)49)34(25)44(47,4)5/h7-21,31-33,35-38,40,51-52,57H,22-24H2,1-6H3,(H,48,54)/t31-,32-,33+,35-,36+,37+,38-,40-,45+,46-,47+/m0/s1</data>
  <data key="d19">[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C</data>
  <data key="d20">Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[(2aR-(2aalpha, 4beta, 4abeta, 6beta, 9alpha(alpha R*, betaS*), 11alpha, 12alpha, 12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6, 12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4, 11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7, 11-methano-1H-cyclodeca(3, 4)benz(1, 2-b)oxet-9-yl ester, 5beta, 20-Epoxy-1, 2-alpha, 4, 7beta, 10beta, 13alpha-hexahydroxytax-11-en-9-one 4, 10-diacetate 2-benzoate 13-ester with (2R, 3S)-N-benzoyl-3-phenylisoserine, Paclitaxel, Taxol A]</data>
  <data key="d9">Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01248">
  <data key="d0">Docetaxel</data>
  <data key="d1">drugbank.DB01248</data>
  <data key="d2">[drugbank.DB01248, drugbank.APRD00932]</data>
  <data key="d11">[approved, investigational]</data>
  <data key="d12">[Agents Causing Muscle Toxicity, Antimitotic Agents, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, BCRP/ABCG2 Substrates, Cardiotoxic antineoplastic agents, Cyclodecanes, Cycloparaffins, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inhibitors, Diterpenes, Immunosuppressive Agents, Microtubule Inhibition, Microtubule Inhibitors, Mitosis Modulators, Myelosuppressive Agents, OATP1B3 substrates, P-glycoprotein/ABCB1 Substrates, Taxane Derivatives, Taxoids, Terpenes, Tubulin Modulators]</data>
  <data key="d13">(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-(acetyloxy)-15-{[(2R,3S)-3-{[(tert-butoxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoyl]oxy}-1,9,12-trihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0³,¹⁰.0⁴,⁷]heptadec-13-en-2-yl benzoate</data>
  <data key="d14">C43H53NO14</data>
  <data key="d15">114977-28-5</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,52)/t26-,27-,28+,30-,31+,32+,33-,35-,41+,42-,43+/m0/s1</data>
  <data key="d19">[H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1</data>
  <data key="d20">For the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Also used as a single agent in the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. It is also used in combination with prednisone, in the treatment of patients with androgen independent (hormone refractory) metastatic prostate cancer. Furthermore, docetaxel has uses in the treatment of gastric adenocarinoma and head and neck cancer.</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[Docetaxel, Docetaxel anhydrous, N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel, N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol, TXL]</data>
  <data key="d9">Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel reversibly binds to tubulin with high affinity in a 1:1 stoichiometric ratio</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01259">
  <data key="d0">Lapatinib</data>
  <data key="d1">drugbank.DB01259</data>
  <data key="d2">[drugbank.DB01259, drugbank.DB02584]</data>
  <data key="d11">[approved, investigational]</data>
  <data key="d12">[Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strength unknown), Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (weak), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 Enzyme Inhibitors, Enzyme Inhibitors, Kinase Inhibitor, P-glycoprotein/ABCB1 Inhibitors, Potential QTc-Prolonging Agents, Protein Kinase Inhibitors, QTc Prolonging Agents, Tyrosine Kinase Inhibitors]</data>
  <data key="d13">N-{3-chloro-4-[(3-fluorophenyl)methoxy]phenyl}-6-(5-{[(2-methanesulfonylethyl)amino]methyl}furan-2-yl)quinazolin-4-amine</data>
  <data key="d14">C29H26ClFN4O4S</data>
  <data key="d15">231277-92-2</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)</data>
  <data key="d19">CS(=O)(=O)CCNCC1=CC=C(O1)C1=CC2=C(C=C1)N=CN=C2NC1=CC(Cl)=C(OCC2=CC(F)=CC=C2)C=C1</data>
  <data key="d20">Indicated in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress the human epidermal receptor type 2 (HER2) protein and who have received prior therapy including an anthracycline, a taxane, and trastuzuma.</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[Lapatinib, N-(3-chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine]</data>
  <data key="d9">Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug Capecitabine. Lapatinib is human epidermal growth factor receptor type 2 (HER2/ERBB2) and epidermal growth factor receptor (HER1/EGFR/ERBB1) tyrosine kinases inhibitor. It binds to the intracellular phosphorylation domain to prevent receptor autophosphorylation upon ligand binding.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01254">
  <data key="d0">Dasatinib</data>
  <data key="d1">drugbank.DB01254</data>
  <data key="d2">[drugbank.DB01254]</data>
  <data key="d11">[approved, investigational]</data>
  <data key="d12">[Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, BCRP/ABCG2 Inhibitors, BCRP/ABCG2 Substrates, CYP3A Substrates (Sensitive), Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (weak), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P450 3A4 Inhibitors, Enzyme Inhibitors, Immunosuppressive Agents, Kinase Inhibitor, Myelosuppressive Agents, P-glycoprotein/ABCB1 Inhibitors, P-glycoprotein/ABCB1 Substrates, Potential QTc-Prolonging Agents, Protein Kinase Inhibitors, Pyrimidines, QTc Prolonging Agents, Sulfur Compounds, Thiazoles, Tyrosine Kinase Inhibitors]</data>
  <data key="d13">N-(2-chloro-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide</data>
  <data key="d14">C22H26ClN7O2S</data>
  <data key="d15">302962-49-8</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)</data>
  <data key="d19">CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1</data>
  <data key="d20">For the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia with resistance or intolerance to prior therapy. Also indicated for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy.</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[anh. dasatinib, Anhydrous dasatinib, BMS dasatinib, Dasatinib, Dasatinib (anh.), dasatinib (anhydrous), Dasatinib anhydrous, Dasatinibum, N-(2-CHLORO-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1, 3-thiazole-5-carboxamide]</data>
  <data key="d9">Dasatinib is an oral dual BCR/ABL and Src family tyrosine kinase inhibitor approved for use in patients with chronic myelogenous leukemia (CML). The main targets of Dasatinib, are BCRABL, SRC, Ephrins and GFR.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01204">
  <data key="d0">Mitoxantrone</data>
  <data key="d1">drugbank.DB01204</data>
  <data key="d2">[drugbank.DB01204, drugbank.APRD00371]</data>
  <data key="d11">[approved, investigational]</data>
  <data key="d12">[Analgesics, Anthracenes, Anthracyclines and Related Substances, Anthraquinones, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, BCRP/ABCG2 Substrates, Cardiotoxic antineoplastic agents, Central Nervous System Agents, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Cytotoxic Antibiotics and Related Substances, Enzyme Inhibitors, Immunosuppressive Agents, Myelosuppressive Agents, P-glycoprotein/ABCB1 Inducers, P-glycoprotein/ABCB1 Inhibitors, P-glycoprotein/ABCB1 Substrates, Peripheral Nervous System Agents, Quinones, Sensory System Agents, Topoisomerase II Inhibitors, Topoisomerase Inhibitors]</data>
  <data key="d13">1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)-9,10-dihydroanthracene-9,10-dione</data>
  <data key="d14">C22H28N4O6</data>
  <data key="d15">65271-80-9</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C22H28N4O6/c27-11-9-23-5-7-25-13-1-2-14(26-8-6-24-10-12-28)18-17(13)21(31)19-15(29)3-4-16(30)20(19)22(18)32/h1-4,23-30H,5-12H2</data>
  <data key="d19">OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C1=C(C(O)=CC=C1O)C2=O</data>
  <data key="d20">For the treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[1, 4-Bis(2-(2-hydroxyethylamino)ethyl)amino)-5, 8-dihydroxyanthraquinone, Mitoxantrona, Mitoxantrone, Mitoxantronum]</data>
  <data key="d9">An anthracenedione-derived antineoplastic agent.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00061">
  <data key="d0">Pegademase</data>
  <data key="d1">drugbank.DB00061</data>
  <data key="d2">[drugbank.DB00061, drugbank.BTD00100, drugbank.BIOD00100]</data>
  <data key="d11">[approved]</data>
  <data key="d12">[Adjuvants, Immunologic, Aminohydrolases, Antineoplastic and Immunomodulating Agents, Bovine Intestinal Adenosine Deaminase, Drug Carriers, Enzymes, Enzymes and Coenzymes, Hydrolases, Nucleoside Deaminases, Pegylated agents, Severe Combined Immunodeficiency]</data>
  <data key="d13">NA</data>
  <data key="d14">NA</data>
  <data key="d15">130167-68-9</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">NA</data>
  <data key="d19">NA</data>
  <data key="d20">For treatment of adenosine deaminase deficiency</data>
  <data key="d21">BiotechDrug</data>
  <data key="d22">[&gt;9d159a6f-1ccf-41fe-8a27-1f05c60afae1 DB00061 sequence\nMAQTPAFNKPKVELHVHLDGAIKPETILYYGRKRGIALPADTPEELQNIIGMDKPLSLPEFLAKFDYYMPAIAGCREAVKRIAYEFVEMKAKDGVVYVEVRYSPHLLANSKVEPIPWNQAEGDLTPDEVVSLVNQGLQEGERDFGVKVRSILCCMRHQPSWSSEVVELCKKYREQTVVAIDLAGDETIEGSSLFPGHVKAYAEAVKSGVHRTVHAGEVGSANVVKEAVDTLKTERLGHGYHTLEDATLYNRLRQENMHFEVCPWSSYLTGAWKPDTEHPVVRFKNDQVNYSLNTDDPLIFKSTLDTDYQMTKNEMGFTEEEFKRLNINAAKSSFLPEDEKKELLDLLYKAYGMPSPASAEQCL]</data>
  <data key="d8">[(monomethoxypolyethylene glycol succinimidyl) 11-17-adenosine deaminase, PEG-adenosine deaminase, pegADA, Pegademase, Pegademase bovine]</data>
  <data key="d9">Bovine adenosine deaminase derived from bovine intestine that has been extensively pegylated for extended serum half life.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00072">
  <data key="d0">Trastuzumab</data>
  <data key="d1">drugbank.DB00072</data>
  <data key="d2">[drugbank.DB00072, drugbank.BTD00098, drugbank.BIOD00098]</data>
  <data key="d11">[approved, investigational]</data>
  <data key="d12">[Amino Acids, Peptides, and Proteins, Antibodies, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Blood Proteins, Cardiotoxic antineoplastic agents, Globulins, HER2 Receptor Antagonist, HER2/Neu/cerbB2 Antagonists, Immunoglobulins, Immunoproteins, Immunosuppressive Agents, Proteins, Serum Globulins]</data>
  <data key="d13">NA</data>
  <data key="d14">NA</data>
  <data key="d15">180288-69-1</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">NA</data>
  <data key="d19">NA</data>
  <data key="d20">Indicated for treatment of early stage HER2-positive breast cancer, or metastatic breast cancer that substantially overexpress HER2. The intravenous powder for solution, OGIVRI, is approved in Canada for early breast cancer, metastatic breast cancer, and gastric cancer, provided these cancers overexpress HER2[L6214].</data>
  <data key="d21">BiotechDrug</data>
  <data key="d22">[&gt;d2c4d7dc-f340-42c0-8b94-b2b08c03f797 Anti-HER2 Light chain (1 and 2)\nDIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC, &gt;126b0eba-a94d-4b58-8a68-0358b90a1bca Anti-HER2 Heavy chain (1 and 2)\nEVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK]</data>
  <data key="d8">[RHUMAB HER2, trastuzumab-anns, trastuzumab-dkst, trastuzumab-dttb, trastuzumab-pkrb, trastuzumab-qyyp]</data>
  <data key="d9">Produced in CHO cell cultures, trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody [A40276] that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein (HER2) [FDA label]. It is used as a treatment of human epidermal growth factor receptor (HER)-2+ metastatic breast cancer, where there is a proven amplification of the HER-2 oncogene or over-expression of the HER-2 protein in tumours. It is suggested that the overexpression or gene amplification of HER2 has been found in about 20–30% of breast cancers and elevated activation of HER2 triggers multiple downstream pathways leading to abnormal proliferation of cancer cells [A121]. Trastuzumab binds to HER2 and suppresses cancer cells growth, proliferation, and survival directly and indirectly [A121].\n\nIn December 2017, FDA approved Ogivri (trastuzumab-dkst) as a biosimilar to Herceptin (trastuzumab) for the treatment of patients with breast or metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma) whose tumors overexpress the HER2 gene (HER2+). It displays biosimilar properties as Herceptin according to clinical data. While Ogivri is the first biosimilar approved in the U.S. for the treatment of breast cancer or stomach cancer, it is the second biosimilar approved in the U.S. for the treatment of cancer. Herzuma (trastuzumab-pkrb) is a biosimilar drug approved in December 2018 for the treatment of HER2-overexpressing breast cancer. KANJINTI (trastuzumab-anns) is another biosimilar approved by the FDA in June 2019.[L6715]</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB12010">
  <data key="d0">Fostamatinib</data>
  <data key="d1">drugbank.DB12010</data>
  <data key="d2">[drugbank.DB12010]</data>
  <data key="d11">[approved, investigational]</data>
  <data key="d12">[BCRP/ABCG2 Inhibitors, Blood and Blood Forming Organs, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Hemostatics, Phosphodiesterase 5 Inhibitors, Tyrosine Kinase Inhibitors, UGT1A1 Inhibitors, UGT1A9 Substrates, Vasodilating Agents]</data>
  <data key="d13">{[6-({5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl}amino)-2,2-dimethyl-3-oxo-2H,3H,4H-pyrido[3,2-b][1,4]oxazin-4-yl]methoxy}phosphonic acid</data>
  <data key="d14">C23H26FN6O9P</data>
  <data key="d15">901119-35-5</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C23H26FN6O9P/c1-23(2)21(31)30(11-38-40(32,33)34)20-14(39-23)6-7-17(28-20)27-19-13(24)10-25-22(29-19)26-12-8-15(35-3)18(37-5)16(9-12)36-4/h6-10H,11H2,1-5H3,(H2,32,33,34)(H2,25,26,27,28,29)</data>
  <data key="d19">COC1=CC(NC2=NC=C(F)C(NC3=NC4=C(OC(C)(C)C(=O)N4COP(O)(O)=O)C=C3)=N2)=CC(OC)=C1OC</data>
  <data key="d20">Fostamatinib is indicated for use in the treatment of chronic immune thrombocytopenia (ITP) in patients who have had insufficient response to previous therapy [FDA Label].</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[Fostamatinib]</data>
  <data key="d9">Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018 under the trade name Tavalisse for use in ITP [L2644,FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA [L2644].</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00027">
  <data key="d0">Gramicidin D</data>
  <data key="d1">drugbank.DB00027</data>
  <data key="d2">[drugbank.DB00027, drugbank.BTD00036, drugbank.BIOD00036]</data>
  <data key="d11">[approved]</data>
  <data key="d12">[Amino Acids, Peptides, and Proteins, Anti-Bacterial Agents, Anti-Infective Agents, Anti-Infective Agents, Local, Membrane Proteins, P-glycoprotein/ABCB1 Inhibitors, P-glycoprotein/ABCB1 Substrates, Peptides, Peptides, Cyclic, Pore Forming Cytotoxic Proteins, Proteins, Throat Preparations, Tyrothricin]</data>
  <data key="d13">(2R)-N-[(1S)-1-{[(1R)-1-{[(1S)-1-{[(1R)-1-{[(1S)-1-{[(1R)-1-{[(1S)-1-{[(1R)-1-{[(1S)-1-{[(1R)-1-{[(1S)-1-[(2-hydroxyethyl)carbamoyl]-2-(1H-indol-3-yl)ethyl]carbamoyl}-3-methylbutyl]carbamoyl}-2-(1H-indol-3-yl)ethyl]carbamoyl}-3-methylbutyl]carbamoyl}-2-(1H-indol-3-yl)ethyl]carbamoyl}-3-methylbutyl]carbamoyl}-2-(1H-indol-3-yl)ethyl]carbamoyl}-2-methylpropyl]carbamoyl}-2-methylpropyl]carbamoyl}-2-methylpropyl]carbamoyl}ethyl]-2-{2-[(2S)-2-formamido-3-methylbutanamido]acetamido}-4-methylpentanamide</data>
  <data key="d14">C96H135N19O16</data>
  <data key="d15">1405-97-6</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C96H135N19O16/c1-50(2)36-71(105-79(118)48-102-93(128)80(54(9)10)103-49-117)86(121)104-58(17)84(119)113-82(56(13)14)95(130)115-83(57(15)16)96(131)114-81(55(11)12)94(129)112-78(43-62-47-101-70-33-25-21-29-66(62)70)92(127)108-74(39-53(7)8)89(124)111-77(42-61-46-100-69-32-24-20-28-65(61)69)91(126)107-73(38-52(5)6)88(123)110-76(41-60-45-99-68-31-23-19-27-64(60)68)90(125)106-72(37-51(3)4)87(122)109-75(85(120)97-34-35-116)40-59-44-98-67-30-22-18-26-63(59)67/h18-33,44-47,49-58,71-78,80-83,98-101,116H,34-43,48H2,1-17H3,(H,97,120)(H,102,128)(H,103,117)(H,104,121)(H,105,118)(H,106,125)(H,107,126)(H,108,127)(H,109,122)(H,110,123)(H,111,124)(H,112,129)(H,113,119)(H,114,131)(H,115,130)/t58-,71+,72+,73+,74+,75-,76-,77-,78-,80-,81+,82+,83-/m0/s1</data>
  <data key="d19">CC(C)C[C@@H](NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)NCCO</data>
  <data key="d20">For treatment of skin lesions, surface wounds and eye infections.</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[Bacillus brevis gramicidin D, Gramicidin, Gramicidin A, Gramicidin B, Gramicidin C, Gramicidina, Gramicidine]</data>
  <data key="d9">Gramcidin D is a heterogeneous mixture of three antibiotic compounds, gramicidins A, B and C, making up 80%, 6%, and 14% respectively all of which are obtained from the soil bacterial species Bacillus brevis and called collectively gramicidin D. Gramcidins are 15 residue peptides with alternating D and L amino acids, which assemble inside of the hydrophobic interior of the cellular lipid bilayer to form a β-helix. Active against most Gram-positive bacteria and some Gram-negative organisms, Gramicidin D is used primarily as a topical antibiotic and is also found in Polysporin ophthalmic solution.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00030">
  <data key="d0">Insulin Human</data>
  <data key="d1">drugbank.DB00030</data>
  <data key="d2">[drugbank.DB00030, drugbank.BTD00105, drugbank.BIOD00105, drugbank.DB01383, drugbank.DB05278, drugbank.DB05215, drugbank.DB05283, drugbank.DB08914]</data>
  <data key="d11">[approved, investigational]</data>
  <data key="d12">[Alimentary Tract and Metabolism, Amino Acids, Peptides, and Proteins, Blood Glucose Lowering Agents, Drugs Used in Diabetes, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Hypoglycemia-Associated Agents, Insulin, Insulin, Long-Acting, Insulins and Analogues, Insulins and Analogues for Inhalation, Insulins and Analogues for Injection, Fast-Acting, Insulins and Analogues for Injection, Intermediate- or Long-Acting Combined With Fast-Acting, Insulins and Analogues for Injection, Intermediate-Acting, Pancreatic Hormones, Peptide Hormones, Peptides]</data>
  <data key="d13">NA</data>
  <data key="d14">NA</data>
  <data key="d15">11061-68-0</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">NA</data>
  <data key="d19">NA</data>
  <data key="d20">Human insulin is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.</data>
  <data key="d21">BiotechDrug</data>
  <data key="d22">[&gt;52037387-cbc6-4ec5-bcde-8a67bcd1c863 A chain\nGIVEQCCTSICSLYQLENYCN, &gt;af6ac1b6-1378-4147-b4d5-eb9761dee316 B chain\nFVNQHLCGSHLVEALYLVCGERGFFYTPKT]</data>
  <data key="d8">[High molecular weight insulin human, Human insulin, human insulin (rDNA), Insulin (human), Insulin human [rDNA origin], Insulin Human Regular, Insulin human regular (rDNA), Insulin human, rDNA origin, Insulin recombinant human, Insulin recombinant purified human, Insulin regular, Insulin, human, Insulina regular, Regular Insulin, human]</data>
  <data key="d9">Human Insulin, also known as Regular Insulin, is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Human insulin is produced by recombinant DNA technology and is identical to endogenously produced insulin. Typically prescribed for the management of diabetes mellitus, insulin is a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle. Absorption of glucose into cells allows for its transformation into glycogen or fat for storage. Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis among many other functions.\n\nInsulin is an important treatment in the management of Type 1 Diabetes (T1D) which is caused by an autoimmune reaction that destroys the beta cells of the pancreas, resulting in the body not being able to produce or synthesize the insulin needed to manage circulating blood sugar levels. As a result, people with T1D rely primarily on exogenous forms of insulin to lower glucose levels in the blood. Insulin is also used in the treatment of Type 2 Diabetes (T2D), another form of diabetes mellitus that is a slowly progressing metabolic disorder caused by a combination of genetic and lifestyle factors that promote chronically elevated blood sugar levels. Without treatment or improvement in non-pharmacological measures such as diet and exercise to lower blood glucose, high blood sugar eventually causes cellular resistance to endogenous insulin, and in the long term, damage to pancreatic islet cells. Insulin is typically prescribed later in the course of T2D, after trying several oral medications such as [DB00331], [DB01120], or [DB01261] have been tried, when sufficient damage has been caused to pancreatic cells that the body is no longer able to produce insulin on its own. \n\nMarketed as the brand name product Humulin R or Novolin R, human insulin begins to exert its effects within 30 minutes of subcutaneous administration, while peak levels occur 3-4 hours after administration. Due to its quick onset of action, human insulin is considered "bolus insulin" as it provides high levels of insulin in a short period of time to mimic the release of endogenous insulin from the pancreas after meals. Bolus insulin is often combined with once daily, long-acting "basal insulin" such as [DB01307], [DB09564], and [DB00047] to provide low concentrations of background insulin that can keep blood sugar stable between meals or overnight. Use of basal and bolus insulin together is intended to mimic the pancreas' production of endogenous insulin, with a goal of avoiding any periods of hypoglycemia.\n\nHuman insulin is also available in an inhalable form, intended to be used as a bolus meal-time insulin. Exubera was the first inhaled insulin available on the market and was developed by Inhale Therapeutics (later named Nektar Therapeutics). Unfortunately, limited uptake by physicians and patients, poor sales, bulky packaging, and concerns over the possible impact on lung cancer development resulted in Exubera products being withdrawn from the US markets [A176005]. Exubera was followed by Afrezza, a monomeric inhaled insulin developed by Mannkind Corporation, which received FDA approval in 2016. While still available in the US, Afrezza has had similar concerns associated with its use, and had an FDA "black box" warning added to it to warn about use in patients with chronic lung disease. Afrezza does not currently have Health Canada or European Medicines Agency approval for marketing in Canada or the EU. \n\nHuman Insulin is a 51 residue peptide hormone produced by recombinant DNA technology by inserting the human insulin gene into Escherichia coli bacteria or Saccharomyces cerevisiae. The structure is identical to native human insulin, with two amino acid chains covalently linked by disulfide bonds. \n\nHuman insulin is also available in an intermediate-acting form as NPH (Neutral Protamine Hagedorn) as the marketed products Novolin N and Humulin N. NPH insulin is provided as a crystalline suspension of insulin with protamine and zinc, resulting in an onset of action in 1 to 3 hours, duration of action up to 24 hours, and peak action from 6 to 8 hours. Due to the added crystals, NPH insulin is typically cloudy when compared to other forms of insulin and has a neutral pH.\n\nWithout an adequate supply of insulin to promote absorption of glucose from the bloodstream, blood sugar levels can climb to dangerously high levels and can result in symptoms such as fatigue, headache, blurred vision, and increased thirst. If left untreated, the body starts to break down fat, instead of glucose, for energy which results in a build-up of ketone acids in the blood and a syndrome called ketoacidosis, which is a life-threatening medical emergency. In the long term, elevated blood sugar levels increase the risk of heart attack, stroke, and diabetic neuropathy.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00002">
  <data key="d0">Cetuximab</data>
  <data key="d1">drugbank.DB00002</data>
  <data key="d2">[drugbank.DB00002, drugbank.BTD00071, drugbank.BIOD00071]</data>
  <data key="d11">[approved]</data>
  <data key="d12">[Amino Acids, Peptides, and Proteins, Antibodies, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Blood Proteins, Epidermal Growth Factor Receptor Antagonist, Globulins, HER1 Antagonists, Immunoglobulins, Immunoproteins, Proteins, Serum Globulins]</data>
  <data key="d13">NA</data>
  <data key="d14">NA</data>
  <data key="d15">205923-56-4</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">NA</data>
  <data key="d19">NA</data>
  <data key="d20">Cetuximab, used in combination with irinotecan, is indicated for the treatment of EGFR-expressing, metastatic colorectal carcinoma in patients who are refractory to irinotecan-based chemotherapy. Cetuximab administered as a single agent is indicated for the treatment of EGFR-expressing, metastatic colorectal carcinoma in patients who are intolerant to irinotecan-based chemotherapy.</data>
  <data key="d21">BiotechDrug</data>
  <data key="d22">[&gt;7b1efb8c-b431-473c-823e-2bb678a0927c Cetuximab heavy chain\nQVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK, &gt;03bc8baf-b1b1-439f-a7c7-9112b615249e Cetuximab light chain\nDILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC]</data>
  <data key="d8">[Cetuximab, Cétuximab, Cetuximabum, Immunoglobulin G 1 (human-mouse monoclonal C 225 gamma 1 - chain anti-human epidermal growt factor receptor), disulfide wit human-mouse monoclonal C 225 kappa - chain, dimer]</data>
  <data key="d9">Cetuximab is an epidermal growth factor receptor binding FAB. Cetuximab is composed of the Fv (variable; antigen-binding) regions of the 225 murine EGFr monoclonal antibody specific for the N-terminal portion of human EGFr with human IgG1 heavy and kappa light chain constant (framework) regions. Cetuximab is marketed under the brand Erbitux® by Eli Lilly and Company. In the United States, a regimen of cetuximab costs approximately $30,790 for an eight-week course.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00679">
  <data key="d0">Thioridazine</data>
  <data key="d1">drugbank.DB00679</data>
  <data key="d2">[drugbank.DB00679, drugbank.APRD00596]</data>
  <data key="d11">[approved, withdrawn]</data>
  <data key="d12">[Adrenergic alpha-1 Receptor Antagonists, Adrenergic alpha-Antagonists, Adrenergic Antagonists, Agents that produce hypertension, Antidepressive Agents, Antipsychotic Agents, Antipsychotic Agents (First Generation [Typical]), Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strong), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Dopamine Agents, Dopamine Antagonists, Dopamine D2 Receptor Antagonists, Highest Risk QTc-Prolonging Agents, Hypotensive Agents, Nervous System, Neurotoxic agents, Neurotransmitter Agents, Phenothiazines, Phenothiazines With Piperidine Structure, Psycholeptics, Psychotropic Drugs, QTc Prolonging Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 5-HT2 Receptor Antagonists, Serotonin Agents, Serotonin Receptor Antagonists, Sulfur Compounds, Tranquilizing Agents]</data>
  <data key="d13">10-[2-(1-methylpiperidin-2-yl)ethyl]-2-(methylsulfanyl)-10H-phenothiazine</data>
  <data key="d14">C21H26N2S2</data>
  <data key="d15">50-52-2</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C21H26N2S2/c1-22-13-6-5-7-16(22)12-14-23-18-8-3-4-9-20(18)25-21-11-10-17(24-2)15-19(21)23/h3-4,8-11,15-16H,5-7,12-14H2,1-2H3</data>
  <data key="d19">CSC1=CC2=C(SC3=CC=CC=C3N2CCC2CCCCN2C)C=C1</data>
  <data key="d20">For the treatment of schizophrenia and generalized anxiety disorder.</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[10-[2-(1-methyl-2-piperidyl)ethyl]-2-methylsulfanyl-phenothiazine, 2-Methylmercapto-10-(2-(N-methyl-2-piperidyl)ethyl)phenothiazine, 3-Methylmercapto-N-(2'-(N-methyl-2-piperidyl)ethyl)phenothiazine, Thioridazin, Thioridazine, Thioridazinum, Tioridazina]</data>
  <data key="d9">A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p618).\n\nThioridazine was withdrawn worldwide in 2005 due to it's association with cardiac arrythmias.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00675">
  <data key="d0">Tamoxifen</data>
  <data key="d1">drugbank.DB00675</data>
  <data key="d2">[drugbank.DB00675, drugbank.APRD00123]</data>
  <data key="d11">[approved]</data>
  <data key="d12">[Anti-Estrogens, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Antineoplastic and Immunomodulating Agents, BCRP/ABCG2 Substrates, Benzene Derivatives, Benzylidene Compounds, BSEP/ABCB11 Inhibitors, Cardiotoxic antineoplastic agents, Cytochrome P-450 CYP2A6 Substrates, Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2B6 Inhibitors (moderate), Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (moderate), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Endocrine Therapy, Estrogen Agonist/Antagonist, Estrogen Antagonists, Estrogen Receptor Modulators, Hormone Antagonists, Hormone Antagonists and Related Agents, Hormones, Hormone Substitutes, and Hormone Antagonists, P-glycoprotein/ABCB1 Inducers, P-glycoprotein/ABCB1 Inhibitors, P-glycoprotein/ABCB1 Substrates, Potential QTc-Prolonging Agents, QTc Prolonging Agents, Selective Estrogen Receptor Modulators, Stilbenes, Thyroxine-binding globulin inducers]</data>
  <data key="d13">(2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}ethyl)dimethylamine</data>
  <data key="d14">C26H29NO</data>
  <data key="d15">10540-29-1</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C26H29NO/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3/h5-18H,4,19-20H2,1-3H3/b26-25-</data>
  <data key="d19">CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1</data>
  <data key="d20">Tamoxifen is indicated for the treatment of metastatic breast cancer in women and men and ductal carcinoma in Situ.</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[(Z)-2-(4-(1, 2-Diphenyl-1-butenyl)phenoxy)-N, N-dimethylethanamine, (Z)-2-(para-(1, 2-Diphenyl-1-butenyl)phenoxy)-N, N-dimethylamine, 1-p-beta-Dimethylaminoethoxyphenyl-trans-1, 2-diphenylbut-1-ene, 1-para-beta-Dimethylaminoethoxyphenyl-trans-1, 2-diphenylbut-1-ene, Tamoxifen, Tamoxifène, Tamoxifene, Tamoxifeno, Tamoxifenum, trans-Tamoxifen]</data>
  <data key="d9">One of the selective estrogen receptor modulators (SERM) with tissue-specific activities for the treatment and prevention of estrogen receptor positive breast cancer. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the endometrium.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00619">
  <data key="d0">Imatinib</data>
  <data key="d1">drugbank.DB00619</data>
  <data key="d2">[drugbank.DB00619, drugbank.APRD01028, drugbank.EXPT02967, drugbank.DB03261]</data>
  <data key="d11">[approved]</data>
  <data key="d12">[Acids, Carbocyclic, Amides, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, BCRP/ABCG2 Inhibitors, BCRP/ABCG2 Substrates, Benzamides and benzamide derivatives, Benzene Derivatives, Benzoates, BSEP/ABCB11 Substrates, Cardiotoxic antineoplastic agents, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (moderate), Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (weak), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (moderate), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A5 Inhibitors, Cytochrome P-450 CYP3A5 Inhibitors (strength unknown), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Inhibitors, Cytochrome P-450 CYP3A7 Inhibitors (strength unknown), Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inhibitors, Enzyme Inhibitors, Highest Risk QTc-Prolonging Agents, Immunosuppressive Agents, Kinase Inhibitor, Miscellaneous Therapeutic Agents, Myelosuppressive Agents, OCT1 substrates, OCT2 Inhibitors, P-glycoprotein/ABCB1 Inhibitors, P-glycoprotein/ABCB1 Substrates, Piperazines, Protein Kinase Inhibitors, Pyrimidines, QTc Prolonging Agents, Tyrosine Kinase Inhibitors]</data>
  <data key="d13">N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)-4-[(4-methylpiperazin-1-yl)methyl]benzamide</data>
  <data key="d14">C29H31N7O</data>
  <data key="d15">152459-95-5</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34)</data>
  <data key="d19">CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1</data>
  <data key="d20">For the treatment of Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML), Ph+ acute lymphoblastic leukaemia, myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome and/or chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans, and malignant gastrointestinal stromal tumors (GIST).</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[Imatinib, Imatinibum, α-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-toluidide]</data>
  <data key="d9">Imatinib is a small molecule kinase inhibitor used to treat certain types of cancer. It is currently marketed by Novartis as Gleevec (USA) or Glivec (Europe/Australia) as its mesylate salt, imatinib mesilate (INN). It is occasionally referred to as CGP57148B or STI571 (especially in older publications). It is used in treating chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies.\n\nIt is the first member of a new class of agents that act by inhibiting particular tyrosine kinase enzymes, instead of non-specifically inhibiting rapidly dividing cells.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00626">
  <data key="d0">Bacitracin</data>
  <data key="d1">drugbank.DB00626</data>
  <data key="d2">[drugbank.DB00626, drugbank.APRD00816]</data>
  <data key="d11">[approved, vet_approved]</data>
  <data key="d12">[Acids, Carbocyclic, Amino Acids, Peptides, and Proteins, Anti-Bacterial Agents, Anti-Infective Agents, Anti-Infective Agents, Local, Antibacterials for Systemic Use, Antibiotics for Topical Use, Antiinfectives for Systemic Use, Bacitracins, Benzene Derivatives, Benzoates, Decreased Cell Wall Synthesis &amp; Repair, Dermatologicals, Hydroxy Acids, Hydroxybenzoates, Nephrotoxic agents, Peptides, Peptides, Cyclic, Phenols, Throat Preparations]</data>
  <data key="d13">(4R)-4-[(2S)-2-{[(4R)-2-[(1S,2S)-1-amino-2-methylbutyl]-4,5-dihydro-1,3-thiazol-4-yl]formamido}-4-methylpentanamido]-4-{[(1S,2S)-1-{[(3S,6R,9S,12R,15S,18R,21S)-18-(3-aminopropyl)-12-benzyl-15-[(2S)-butan-2-yl]-3-(carbamoylmethyl)-6-(carboxymethyl)-9-[(1H-imidazol-4-yl)methyl]-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptaazacyclopentacosan-21-yl]carbamoyl}-2-methylbutyl]carbamoyl}butanoic acid</data>
  <data key="d14">C66H103N17O16S</data>
  <data key="d15">1405-87-4</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C66H103N17O16S/c1-9-35(6)52(69)66-81-48(32-100-66)63(97)76-43(26-34(4)5)59(93)74-42(22-23-50(85)86)58(92)83-53(36(7)10-2)64(98)75-40-20-15-16-25-71-55(89)46(29-49(68)84)78-62(96)47(30-51(87)88)79-61(95)45(28-39-31-70-33-72-39)77-60(94)44(27-38-18-13-12-14-19-38)80-65(99)54(37(8)11-3)82-57(91)41(21-17-24-67)73-56(40)90/h12-14,18-19,31,33-37,40-48,52-54H,9-11,15-17,20-30,32,67,69H2,1-8H3,(H2,68,84)(H,70,72)(H,71,89)(H,73,90)(H,74,93)(H,75,98)(H,76,97)(H,77,94)(H,78,96)(H,79,95)(H,80,99)(H,82,91)(H,83,92)(H,85,86)(H,87,88)/t35-,36-,37-,40-,41+,42+,43-,44+,45-,46-,47+,48-,52-,53-,54-/m0/s1</data>
  <data key="d19">CC[C@H](C)[C@H](N)C1=N[C@@H](CS1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H]1CCCCNC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC(O)=O)NC(=O)[C@H](CC2=CNC=N2)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@@H](CCCN)NC1=O)[C@@H](C)CC</data>
  <data key="d20">For the treatment of infants with pneumonia and empyema caused by staphylococci shown to be susceptible to the drug. Also used in ointment form for topical treatment of a variety of localized skin and eye infections, as well as for the prevention of wound infections. Used against gram positive bacteria. Bacitracin is also used as an inhibitor of proteases and other enzymes. \nHowever, specific activity of bactracin's inhibition of protein disulfide isomerase has been called into question.</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[Bacitracin, Bacitracin A, Bacitracina]</data>
  <data key="d9">Bacitracin is a mixture of related cyclic polypeptides produced by organisms of the licheniformis group of Bacillus subtilis var Tracy. Its unique name derives from the fact that the bacillus producing it was first isolated in 1943 from a knee scrape from a girl named Margaret Tracy. It is synthesized via the activity of nonribosomal peptide synthetases (NRPSs). As a toxic and difficult-to-use antibiotic, bacitracin doesn't work well orally. However, it is very effective topically.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00623">
  <data key="d0">Fluphenazine</data>
  <data key="d1">drugbank.DB00623</data>
  <data key="d2">[drugbank.DB00623, drugbank.APRD00633]</data>
  <data key="d11">[approved]</data>
  <data key="d12">[Agents that reduce seizure threshold, Antipsychotic Agents, Antipsychotic Agents (First Generation [Typical]), Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (weak), Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Delayed-Action Preparations, Dopamine Agents, Dopamine Antagonists, Dopamine D2 Receptor Antagonists, Nervous System, Neurotoxic agents, Neurotransmitter Agents, P-glycoprotein/ABCB1 Inhibitors, Phenothiazines, Phenothiazines With Piperazine Structure, Prodrugs, Psycholeptics, Psychotropic Drugs, Sulfur Compounds, Tranquilizing Agents]</data>
  <data key="d13">2-(4-{3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl}piperazin-1-yl)ethan-1-ol</data>
  <data key="d14">C22H26F3N3OS</data>
  <data key="d15">69-23-8</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C22H26F3N3OS/c23-22(24,25)17-6-7-21-19(16-17)28(18-4-1-2-5-20(18)30-21)9-3-8-26-10-12-27(13-11-26)14-15-29/h1-2,4-7,16,29H,3,8-15H2</data>
  <data key="d19">OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1</data>
  <data key="d20">For management of manifestations of psychotic disorders.</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[1-(2-hydroxyethyl)-4-(3-(trifluoromethyl-10-phenothiazinyl)propyl)-piperazine, 10-(3-(2-hydroxyethyl)piperazinopropyl)-2-(trifluoromethyl)phenothiazine, 10-(3'-(4''-(β-hydroxyethyl)-1''-piperazinyl)-propyl)-3-trifluoromethylphenothiazine, 2-(4-(3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl)-1-piperazinyl)ethanol, 2-(trifluoromethyl)-10-(3-(1-(β-hydroxyethyl)-4-piperazinyl)propyl)phenothiazine, 4-(3-(-trifluoromethyl-10-phenothiazyl)-propyl)-1-piperazineethanol, 4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)-1-piperazineethanol, 4-(3-(2-trifluoromethyl-10-phenothiazyl)-propyl)-1-piperazineethanol, Flufenazina, Fluorfenazine, Fluorophenazine, Fluorphenazine, Fluphenazin, Fluphénazine, Fluphenazine, Fluphenazinum, Triflumethazine]</data>
  <data key="d9">A phenothiazine used in the treatment of psychoses. Its properties and uses are generally similar to those of chlorpromazine.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00637">
  <data key="d0">Astemizole</data>
  <data key="d1">drugbank.DB00637</data>
  <data key="d2">[drugbank.DB00637, drugbank.APRD00585]</data>
  <data key="d11">[approved, withdrawn]</data>
  <data key="d12">[Anti-Allergic Agents, Antihistamines for Systemic Use, Benzimidazoles, BSEP/ABCB11 Substrates, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inhibitors, Highest Risk QTc-Prolonging Agents, Histamine Agents, Histamine Antagonists, Histamine H1 Antagonists, Histamine H1 Antagonists, Non-Sedating, Neurotransmitter Agents, P-glycoprotein/ABCB1 Inhibitors, QTc Prolonging Agents]</data>
  <data key="d13">1-[(4-fluorophenyl)methyl]-N-{1-[2-(4-methoxyphenyl)ethyl]piperidin-4-yl}-1H-1,3-benzodiazol-2-amine</data>
  <data key="d14">C28H31FN4O</data>
  <data key="d15">68844-77-9</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C28H31FN4O/c1-34-25-12-8-21(9-13-25)14-17-32-18-15-24(16-19-32)30-28-31-26-4-2-3-5-27(26)33(28)20-22-6-10-23(29)11-7-22/h2-13,24H,14-20H2,1H3,(H,30,31)</data>
  <data key="d19">COC1=CC=C(CCN2CCC(CC2)NC2=NC3=CC=CC=C3N2CC2=CC=C(F)C=C2)C=C1</data>
  <data key="d20">Astemizole was indicated for use in the relieving allergy symptoms, particularly rhinitis and conjunctivitis. It has been withdrawn from the market however due to concerns of arrhythmias.</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[1-(p-Fluorobenzyl)-2-((1-(2-(p-methoxyphenyl)ethyl)piperid-4-yl)amino)benzimidazole, 1-(p-Fluorobenzyl)-2-((1-(p-methoxyphenethyl)-4-piperidyl)amino)benzimidazole, Astemizol, Astémizole, Astemizole, Astemizolum]</data>
  <data key="d9">Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when  when taken with CYP inhibitors or grapefruit juice.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01962">
  <data key="d0">Phosphonotyrosine</data>
  <data key="d1">drugbank.DB01962</data>
  <data key="d2">[drugbank.DB01962, drugbank.EXPT02687]</data>
  <data key="d11">[experimental]</data>
  <data key="d12">[]</data>
  <data key="d13">(2S)-2-amino-3-[4-(phosphonooxy)phenyl]propanoic acid</data>
  <data key="d14">C9H12NO6P</data>
  <data key="d15">21820-51-9</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C9H12NO6P/c10-8(9(11)12)5-6-1-3-7(4-2-6)16-17(13,14)15/h1-4,8H,5,10H2,(H,11,12)(H2,13,14,15)/t8-/m0/s1</data>
  <data key="d19">N[C@@H](CC1=CC=C(OP(O)(O)=O)C=C1)C(O)=O</data>
  <data key="d20"></data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[]</data>
  <data key="d9">An amino acid that occurs in endogenous proteins. Tyrosine phosphorylation and dephosphorylation plays a role in cellular signal transduction and possibly in cell growth control and carcinogenesis. [PubChem]</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB13919">
  <data key="d0">Candesartan</data>
  <data key="d1">drugbank.DB13919</data>
  <data key="d2">[drugbank.DB13919]</data>
  <data key="d11">[experimental]</data>
  <data key="d12">[Agents Acting on the Renin-Angiotensin System, Agents causing hyperkalemia, Angiotensin 2 Receptor Blocker, Angiotensin II receptor blockers (ARBs) and calcium channel blockers, Angiotensin II receptor blockers (ARBs) and diuretics, Angiotensin II receptor blockers (ARBs), plain, Angiotensin II Type 2 Receptor Blockers, Angiotensin Receptor Antagonists, Antihypertensive Agents, Cardiovascular Agents, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strength unknown), Cytochrome P-450 CYP2C8 Inhibitors (weak), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (weak), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 Enzyme Inhibitors, OATP1B1/SLCO1B1 Inhibitors, P-glycoprotein/ABCB1 Inhibitors, UGT1A3 substrates]</data>
  <data key="d13">2-ethoxy-1-{[2'-(1H-1,2,3,4-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl}-1H-1,3-benzodiazole-7-carboxylic acid</data>
  <data key="d14">C24H20N6O3</data>
  <data key="d15">139481-59-7</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C24H20N6O3/c1-2-33-24-25-20-9-5-8-19(23(31)32)21(20)30(24)14-15-10-12-16(13-11-15)17-6-3-4-7-18(17)22-26-28-29-27-22/h3-13H,2,14H2,1H3,(H,31,32)(H,26,27,28,29)</data>
  <data key="d19">CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1</data>
  <data key="d20"></data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[2-ethoxy-1-(p-(o-1H-tetrazol-5-ylphenyl)benzyl)-7-benzimidazolecarboxylic acid]</data>
  <data key="d9">Candesartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension. It is available as a prodrug in the form of [Candesartan cilexetil].</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB09079">
  <data key="d0">Nintedanib</data>
  <data key="d1">drugbank.DB09079</data>
  <data key="d2">[drugbank.DB09079]</data>
  <data key="d11">[approved]</data>
  <data key="d12">[Antifibrotic Agents, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Enzyme Inhibitors, Kinase Inhibitor, P-glycoprotein/ABCB1 Substrates, Protein Kinase Inhibitors, Tyrosine Kinase Inhibitors]</data>
  <data key="d13">methyl (3Z)-3-[({4-[N-methyl-2-(4-methylpiperazin-1-yl)acetamido]phenyl}amino)(phenyl)methylidene]-2-oxo-2,3-dihydro-1H-indole-6-carboxylate</data>
  <data key="d14">C31H33N5O4</data>
  <data key="d15">656247-17-5</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C31H33N5O4/c1-34-15-17-36(18-16-34)20-27(37)35(2)24-12-10-23(11-13-24)32-29(21-7-5-4-6-8-21)28-25-14-9-22(31(39)40-3)19-26(25)33-30(28)38/h4-14,19,32H,15-18,20H2,1-3H3,(H,33,38)/b29-28-</data>
  <data key="d19">COC(=O)C1=CC=C2C(NC(=O)\C2=C(/NC2=CC=C(C=C2)N(C)C(=O)CN2CCN(C)CC2)C2=CC=CC=C2)=C1</data>
  <data key="d20">Nintedanib is indicated for the treatment of idiopathic pulmonary fibrosis (IPF).</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[methyl (3Z)-3-[(4-{methyl[(4-methylpiperazin-1-yl)acetyl]amino}anilino)(phenyl)methylidene]-2-oxo-2, 3-dihydro-1H-indole-6-carboxylate, Nintedanib]</data>
  <data key="d9">Nintedanib is a drug indicated for the treatment of idiopathic pulmonary fibrosis (IPF) that targets multiple receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases (nRTKs). Nintedanib inhibits the following RTKs: platelet-derived growth factor receptor (PDGFR) α and β, fibroblast growth factor receptor (FGFR) 1-3, vascular endothelial growth factor receptor (VEGFR) 1-3, and Fms-like tyrosine kinase-3 (FLT3). Among them, FGFR, PDGFR, and VEGFR have been implicated in IPF pathogenesis. Nintedanib binds competitively to the adenosine triphosphate (ATP) binding pocket of these receptors and blocks the intracellular signaling which is crucial for the proliferation, migration, and transformation of fibroblasts representing essential mechanisms of the IPF pathology. In addition, nintedanib inhibits the following nRTKs: Lck, Lyn and Src kinases. The contribution of FLT3 and nRTK inhibition to IPF efficacy is unknown.\n\nIdiopathic pulmonary fibrosis (IPF) is a progressive and ultimately fatal lung disease characterized by a progressive loss of lung function with worsening dyspnoea and cough. Development is thought to be instigated by repetitive lung injury (such as by cigarette smoke, industrial dusts, gastrooesophageal reflux and viral infection) leading to destruction of epithelial alveolar cells. Subsequent dysregulation of the repair process results in the proliferation/migration of fibroblasts and their differentiation into myofibroblasts, abnormal extracellular matrix deposition and excessive collagen accumulation in the lung interstitium and alveolar space, leading to progressive fibrosis and stiffening of the lungs. Vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF) and platelet-derived growth factor (PDGF) mediate various processes, including fibrogenesis and angiogenesis, and are implicated in the pathogenesis of IPF. By blocking substrate binding and downstream signalling cascades, nintedanib interferes with processes active in fibrosis such as fibroblast proliferation, migration and differentiation, and the secretion of extracellular matrix.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB09078">
  <data key="d0">Lenvatinib</data>
  <data key="d1">drugbank.DB09078</data>
  <data key="d2">[drugbank.DB09078]</data>
  <data key="d11">[approved, investigational]</data>
  <data key="d12">[Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, BCRP/ABCG2 Substrates, Benzene Derivatives, BSEP/ABCB11 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (unknown strength), Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2B6 Inhibitors (strength unknown), Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (unknown strength), Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (moderate), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (weak), Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (weak), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Enzyme Inhibitors, Kinase Inhibitor, Moderate Risk QTc-Prolonging Agents, OAT1/SLC22A6 inhibitors, OAT3/SLC22A8 Inhibitors, OATP1B1/SLCO1B1 Inhibitors, OCT2 Inhibitors, P-glycoprotein/ABCB1 Substrates, Protein Kinase Inhibitors, QTc Prolonging Agents, Receptor Tyrosine Kinase Inhibitors, Tyrosine Kinase Inhibitors, Urea]</data>
  <data key="d13">4-{3-chloro-4-[(cyclopropyl-C-hydroxycarbonimidoyl)amino]phenoxy}-7-methoxyquinoline-6-carboximidic acid</data>
  <data key="d14">C21H19ClN4O4</data>
  <data key="d15">417716-92-8</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C21H19ClN4O4/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28)</data>
  <data key="d19">COC1=C(C=C2C(OC3=CC(Cl)=C(NC(O)=NC4CC4)C=C3)=CC=NC2=C1)C(O)=N</data>
  <data key="d20">Lenvatinib is indicated for the treatment of following conditions.\n\n- Treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer.\n\n- Treatment of advanced renal cell carcinoma (RCC) in combination with everolimus following one prior antiangiogenic therapy.\n\n- First-line treatment of unresectable hepatocellular carcinoma (HCC).</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxyquinoline-6-carboxamide, Lenvatinib]</data>
  <data key="d9">Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET. These receptor tyrosine kinases (RTKs) located in the cell membrane play a central role in the activation of signal transduction pathways involved in the normal regulation of cellular processes, such as cell proliferation, migration, apoptosis and differentiation, and in pathogenic angiogenesis, lymphogenesis, tumour growth and cancer progression. In particular, VEGF has been identified as a crucial regulator of both physiologic and pathologic angiogenesis and increased expression of VEGF is associated with a poor prognosis in many types of cancers.\n\nLenvatinib is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer. Most patients with thyroid cancer have a very good prognosis with treatment (98% 5 year survival rate) involving surgery and hormone therapy. However, for patients with RAI-refractory thyroid cancer, treatment options are limited and the prognosis is poor, leading to a push for the development of more targeted therapies such as lenvatinib.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00696">
  <data key="d0">Ergotamine</data>
  <data key="d1">drugbank.DB00696</data>
  <data key="d2">[drugbank.DB00696, drugbank.APRD00677]</data>
  <data key="d11">[approved]</data>
  <data key="d12">[Adrenergic Agents, Adrenergic alpha-1 Receptor Antagonists, Adrenergic alpha-Antagonists, Adrenergic Antagonists, Agents that produce hypertension, Alkaloids, Analgesics, Analgesics, Non-Narcotic, Antidepressive Agents, Antimigraine Preparations, Cardiovascular Agents, Central Nervous System Agents, Central Nervous System Depressants, CYP3A Substrates (Sensitive), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Inhibitors (strong), Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Inhibitors (strong), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Enzyme Inhibitors, Ergot Alkaloids and Derivatives, Ergotamine Derivative, Ergotamines, Narrow Therapeutic Index Drugs, Nervous System, Neurotransmitter Agents, P-glycoprotein/ABCB1 Inhibitors, Peripheral Nervous System Agents, Reproductive Control Agents, Sensory System Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 5-HT1 Receptor Agonists, Serotonin 5-HT2 Receptor Agonists, Serotonin Agents, Serotonin Modulators, Serotonin Receptor Agonists, Sympatholytic (Adrenergic Blocking) Agents, Uterotonic agents, Vasoconstrictor Agents]</data>
  <data key="d13">(4R,7R)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.0^{2,6}]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(16),2,9,12,14-pentaene-4-carboxamide</data>
  <data key="d14">C33H35N5O5</data>
  <data key="d15">113-15-5</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C33H35N5O5/c1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)20(17-34-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30(40)37-13-7-12-27(37)33(38,42)43-32/h3-6,8-11,15,17,21,25-27,34,42H,7,12-14,16,18H2,1-2H3,(H,35,39)/t21-,25-,26+,27+,32-,33+/m1/s1</data>
  <data key="d19">[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)C4=C3)O[C@@]21O</data>
  <data key="d20">For use as therapy to abort or prevent vascular headache, e.g., migraine, migraine variants, or so called "histaminic cephalalgia".</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[(5'α)-12'-hydroxy-2'-methyl-5'-(phenylmethyl)ergotoman-3', 6', 18-trione, 12'-Hydroxy-2'-methyl-5'alpha-(phenylmethyl)ergotaman-3', 6', 18-trione, 12'-hydroxy-2'-methyl-5'α-(phenylmethyl)ergotaman-3', 6', 18-trione, Ergotamin, Ergotamina, Ergotamine, Ergotaminum]</data>
  <data key="d9">A vasoconstrictor found in ergot of Central Europe. It is an alpha-1 selective adrenergic agonist and is commonly used in the treatment of migraine disorders.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB09053">
  <data key="d0">Ibrutinib</data>
  <data key="d1">drugbank.DB09053</data>
  <data key="d2">[drugbank.DB09053]</data>
  <data key="d11">[approved]</data>
  <data key="d12">[Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, CYP3A Substrates (Sensitive), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A5 Substrates, Immunosuppressive Agents, Kinase Inhibitor, Myelosuppressive Agents, Protein Kinase Inhibitors, Tyrosine Kinase Inhibitors]</data>
  <data key="d13">1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one</data>
  <data key="d14">C25H24N6O2</data>
  <data key="d15">936563-96-1</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1</data>
  <data key="d19">NC1=NC=NC2=C1C(=NN2[C@@H]1CCCN(C1)C(=O)C=C)C1=CC=C(OC2=CC=CC=C2)C=C1</data>
  <data key="d20">Ibrutinib acquired an accelerated approval for the treatment of mantle cell lymphoma who have received at least one prior therapy.[FDA label] Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma that develops in the outer edge of a lymph node. MCL is usually diagnosed at late stages and it is easily spread into bone marrow, spleen, liver and gastrointestinal tract.[L1929]\n\nIbrutinib is indicated for the treatment of chronic lymphocytic leukemia (CLL) who have at least one prior therapy.[FDA label] CLL is a type of cancer caused by an overproduction of lymphocytes by the bone marrow. Some of the symptoms include swollen lymph nodes and tiredness.[L1931]\n\nIbrutinib is indicated for the treatment of chronic lymphocytic leukemia (CLL) with 17p deletion.[FDA label] CLL with 17p is a type of leukemia in which a deletion in 17p disrupts the tumor suppressor p53 by deleting one allele of the TP53 gene. The remaining allele is mainly inactivated and thus, this type of leukemia is unresponsive to p53-dependent treatments.[A32305]\n\nIbrutinib is indicated for the treatment of patients with Waldenstrom's Macroglobulinemia (WM).[FDA label] WM, also called lymphoplasmacytic lymphoma, is a type of non-Hodgkin lymphoma in which the cancer cells make large amounts of macroglobulin. The macroglobulin is a monoclonal protein that corresponds to the type of IgM antibodies and the unrestricted formation of this protein causes typical symptoms such as excessive bleeding and effects in vision and nervous system.[L1934]</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[1-[(3R)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3, 4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one, Ibrutinib]</data>
  <data key="d9">Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and it presents a very promising activity in B cell malignancies.[A32299] Ibrutinib was developed by Pharmacyclics Inc and in November 2013 was FDA-approved for the treatment of mantle cell lymphoma. Later, in February 2014, ibrutinib was approved for the treatment of chronic lymphocytic leukemia and it is also indicated for the treatment of patients with Waldenström's Macroglobulinemia.[L1926] Ibrutinib has also been approved by the EMA for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma.[A32299] Ibrutinib was approved for use in chronic graft versus host disease in August 2017 [L937].</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB09063">
  <data key="d0">Ceritinib</data>
  <data key="d1">drugbank.DB09063</data>
  <data key="d2">[drugbank.DB09063]</data>
  <data key="d11">[approved]</data>
  <data key="d12">[Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Bradycardia-Causing Agents, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (weak), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Cytochrome P450 2C9 Inhibitors, Cytochrome P450 3A Inhibitors, Enzyme Inhibitors, Hyperglycemia-Associated Agents, Kinase Inhibitor, Moderate Risk QTc-Prolonging Agents, P-glycoprotein/ABCB1 Substrates, Protein Kinase Inhibitors, QTc Prolonging Agents, Receptor Protein-Tyrosine Kinases, antagonists &amp; inhibitors, Sulfur Compounds, Tyrosine Kinase Inhibitors]</data>
  <data key="d13">5-chloro-N2-[5-methyl-4-(piperidin-4-yl)-2-(propan-2-yloxy)phenyl]-N4-[2-(propane-2-sulfonyl)phenyl]pyrimidine-2,4-diamine</data>
  <data key="d14">C28H36ClN5O3S</data>
  <data key="d15">1032900-25-6</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C28H36ClN5O3S/c1-17(2)37-25-15-21(20-10-12-30-13-11-20)19(5)14-24(25)33-28-31-16-22(29)27(34-28)32-23-8-6-7-9-26(23)38(35,36)18(3)4/h6-9,14-18,20,30H,10-13H2,1-5H3,(H2,31,32,33,34)</data>
  <data key="d19">CC(C)OC1=C(NC2=NC=C(Cl)C(N2)=NC2=CC=CC=C2S(=O)(=O)C(C)C)C=C(C)C(=C1)C1CCNCC1</data>
  <data key="d20">Ceritinib is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This indication is approved under accelerated approval based on tumor response rate and duration of response. An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[Ceritinib, céritinib, N-{2-[(5-chloro-2-{[2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl]amino}pyrimidin-4-yl)amino]phenyl}propane-2-sulfonamide]</data>
  <data key="d9">Ceritinib is used for the treatment of adults with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) following failure (secondary to resistance or intolerance) of prior crizotinib therapy. About 4% of patients with NSCLC have a chromosomal rearrangement that generates a fusion gene between EML4 (echinoderm microtubule-associated protein-like 4) and ALK (anaplastic lymphoma kinase), which results in constitutive kinase activity that contributes to carcinogenesis and seems to drive the malignant phenotype. Ceritinib exerts its therapeutic effect by inhibiting autophosphorylation of ALK, ALK-mediated phosphorylation of the downstream signaling protein STAT3, and proliferation of ALK-dependent cancer cells. Following treatment with crizotinib (a first-generation ALK inhibitor), most tumours develop drug resistance due to mutations in key "gatekeeper" residues of the enzyme. This occurrence led to development of novel second-generation ALK inhibitors such as ceritinib to overcome crizotinib resistance. The FDA approved ceritinib in April 2014 due to a surprisingly high response rate (56%) towards crizotinib-resistant tumours and has designated it with orphan drug status.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB09115">
  <data key="d0">Diiodohydroxyquinoline</data>
  <data key="d1">drugbank.DB09115</data>
  <data key="d2">[drugbank.DB09115]</data>
  <data key="d11">[approved]</data>
  <data key="d12">[Amebicides, Anti-Infective Agents, Antiparasitic Agents, Antiprotozoals, Genito Urinary System and Sex Hormones, Gynecological Antiinfectives and Antiseptics, Hydroxyquinolines, Oxyquinoline, Quinoline Derivatives, Quinolines]</data>
  <data key="d13">5,7-diiodoquinolin-8-ol</data>
  <data key="d14">C9H5I2NO</data>
  <data key="d15">83-73-8</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C9H5I2NO/c10-6-4-7(11)9(13)8-5(6)2-1-3-12-8/h1-4,13H</data>
  <data key="d19">OC1=C2N=CC=CC2=C(I)C=C1I</data>
  <data key="d20">Used in the treatment of amoebiasis.</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[Diiodohydroxyquin, Diiodohydroxyquinoline, Iodoquinol, Ioquin]</data>
  <data key="d9">Diiodohydroxyquinoline, also known as uidoquinol, is a quinoline derivative that can be used in the treatment of amoebiasis. The exact mechanism of action is unknown. Iodoquinol is not currently available in any FDA-approved products.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB09129">
  <data key="d0">Chromic chloride</data>
  <data key="d1">drugbank.DB09129</data>
  <data key="d2">[drugbank.DB09129]</data>
  <data key="d11">[approved]</data>
  <data key="d12">[Acids, Acids, Noncarboxylic, Anions, Antioxidants, Chlorine Compounds, Compounds used in a research, industrial, or household setting, Drugs that are Mainly Renally Excreted, Electrolytes, Hydrochloric Acid, Ions, Minerals, Protective Agents, Replacement Preparations]</data>
  <data key="d13">chromium(3+) ion trichloride</data>
  <data key="d14">Cl3Cr</data>
  <data key="d15">10025-73-7</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/3ClH.Cr/h3*1H;/q;;;+3/p-3</data>
  <data key="d19">[Cl-].[Cl-].[Cl-].[Cr+3]</data>
  <data key="d20">For use as a supplement to intravenous solutions given for total parenteral nutrition (TPN).</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[anhydrous chromium(III) chloride, Chromium chloride, Chromium trichloride, chromium(3+) trichloride, Chromium(III) chloride, Puratronic chromium chloride, Trichlorochromium]</data>
  <data key="d9">Chromic chloride, for injection, is a sterile, nonpyrogenic solution intended for use as an additive to solutions for Total Parenteral Nutrition (TPN).</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00783">
  <data key="d0">Estradiol</data>
  <data key="d1">drugbank.DB00783</data>
  <data key="d2">[drugbank.DB00783, drugbank.APRD00311]</data>
  <data key="d11">[approved, investigational, vet_approved]</data>
  <data key="d12">[Adrenal Cortex Hormones, Androgens and Estrogens, Antiandrogens and Estrogens, BCRP/ABCG2 Inducers, BCRP/ABCG2 Inhibitors, Contraceptive Agents, Female, Contraceptives, Oral, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (unknown strength), Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Drugs that are Mainly Renally Excreted, Estradiol Congeners, Estranes, Estrenes, Estrogen Contraceptives, Estrogens, Genito Urinary System and Sex Hormones, Gonadal Hormones, Gonadal Steroid Hormones, Hormonal Contraceptives for Systemic Use, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Hyperglycemia-Associated Agents, Intravaginal Contraceptives, Natural and Semisynthetic Estrogens, Plain, OAT3/SLC22A8 Substrates, OATP1B1/SLCO1B1 Inhibitors, OCT1 inhibitors, OCT2 Inhibitors, P-glycoprotein/ABCB1 Substrates, Progestogens and Estrogens, Sequential Preparations, Sex Hormones and Modulators of the Genital System, Steroids, UGT1A1 Substrates]</data>
  <data key="d13">(1S,10R,11S,14S,15S)-15-methyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-2(7),3,5-triene-5,14-diol</data>
  <data key="d14">C18H24O2</data>
  <data key="d15">50-28-2</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C18H24O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-17,19-20H,2,4,6-9H2,1H3/t14-,15-,16+,17+,18+/m1/s1</data>
  <data key="d19">[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3</data>
  <data key="d20">Estradiol is indicated for the treatment of moderate to severe vasomotor symptoms and vulvar and vaginal atrophy due to menopause, for the treatment of hypoestrogenism due to hypogonadism, castration, or primary ovarian failure, and for the prevention of post-menopausal osteoarthritis. It is also used for the treatment of breast cancer (for palliation only) in appropriately selected women and men with metastatic disease, and for the treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only).</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[(17β)-estra-1, 3, 5(10)-triene-3, 17-diol, 17beta oestradiol, 17β-estra-1, 3, 5(10)-triene-3, 17-diol, 17β-estradiol, 17β-oestradiol, beta-Estradiol, cis-Estradiol, Estradiol, Estradiol-17beta, Estradiolum]</data>
  <data key="d9">Estradiol (also known as E2 or 17β-estradiol) is a naturally occurring hormone that circulates endogenously within the human body. It is the most potent form of mammalian estrogenic steroids and acts as the major female sex hormone. As such, estradiol plays an essential role in the regulation of the menstrual cycle, in the development of puberty and secondary female sex characteristics, as well as in ageing and several hormonally-mediated disease states. Estrogen mediates its effects across the body through potent agonism of the Estrogen Receptor (ER), which is located in various tissues including in the breasts, uterus, ovaries, skin, prostate, bone, fat, and brain. Estradiol binds to both subtypes of the Estrogen Receptor: Estrogen Receptor Alpha (ERα) and Estrogen Receptor Beta (ERβ). Estradiol also acts as a potent agonist of G Protein-coupled Estrogen Receptor (GPER), which has recently been recognized as a major mediator of estradiol's rapid cellular effects [A31620]. \n\nEstradiol is commercially available in several hormone therapy products for managing conditions associated with reduced estrogen production such as menopausal and peri-menopausal symptoms as well as hypoestrogenism. It is also used in transgender hormone therapy, as a component of oral contraceptive pills for preventing pregnancy (most commonly as [DB00977], a synthetic form of estradiol), and is sometimes used for the palliative treatment of some hormone-sensitive cancers like breast and prostate cancer. Estradiol is available in a number of formulations including oral, transdermal, and injectable. \n\nThe primary source of estrogen in normally cycling adult women is the ovarian follicle, which secretes 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle. However, after menopause, most endogenous estrogen is produced by conversion of androstenedione, secreted by the adrenal cortex, to estrone by peripheral tissues. Thus, estrone and the sulphate conjugated form, estrone sulphate, are the most abundant circulating estrogens in postmenopausal women [FDA Label]. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol at the receptor level. Because of the difference in potency between estradiol and estrone, menopause (and a change in primary hormone from estradiol to estrone) is associated with a number of symptoms associated with this reduction in potency and in estrogenic effects. These include hot flashes, vaginal dryness, mood changes, irregular menses, chills, and sleeping problems.\n\nWhen used for oral or IM administration, estradiol is commonly synthesized as a pro-drug ester (such as [DB13952], [DB13953], [DB13954], [DB13955], and [DB13956]). It is commonly produced with an ester side-chain as endogenous estradiol has very low oral bioavailability on its own (2-10%). First-pass metabolism by the gut and the liver quickly degrades the estradiol molecule before it gets a chance to enter the systemic circulation and exert its estrogenic effects [A12102]. Esterification of estradiol aims to improve absorption after oral administration (such as with Estradiol valerate) or to sustain release from intramuscular depot injections (such as with Estradiol Cypionate) through improved lipophilicity [T84]. Following absorption, the esters are cleaved, resulting in the release of endogenous estradiol, or 17β-estradiol. \n\nRecommendations for treatment of menopausal symptoms changed drastically following the release of results and early termination of the Women's Health Initiative (WHI) studies in 2002 as a number of concerns were raised regarding the use of estrogen [A31626]. Specifically, the combined estrogen–progestin arm was discontinued after approximately five years of follow up due to a statistically significant increase in invasive breast cancer and in cardiovascular events [A31627]. Following extensive critique of the WHI results in the years following its release, Hormone Replacement Therapy (HRT) is now recommended to be used only for a short period (for 3-5 years post-menopause) in low doses, and in women without a history of breast cancer or at increased risk of cardiovascular or thromboembolic disease [A31628]. Notably, use of estrogen for menopausal symptoms should always be accompanied by a progestin component due to estrogen's effects on the endometrium; in women with an intact uterus, unopposed estrogen has been shown to promote the growth of the endometrium which can lead to endometrial hyperplasia and possibly cancer in the long-term. \n\n[DB00977] (EE) is a synthetic form of estradiol commonly used as the estrogenic component of most combination Oral Contraceptive Pills (OCPs). Ethinyl Estradiol differs from Estradiol in that it has improved biovailability and greater resistance to metabolism, making it more suitable for oral administration.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00756">
  <data key="d0">Hexachlorophene</data>
  <data key="d1">drugbank.DB00756</data>
  <data key="d2">[drugbank.DB00756, drugbank.APRD00722]</data>
  <data key="d11">[approved, withdrawn]</data>
  <data key="d12">[Anti-Infective Agents, Anti-Infective Agents, Local, Antiseptics and Disinfectants, Benzene Derivatives, Chlorobenzenes, Chlorophenols, Dermatologicals, Hydrocarbons, Chlorinated, Hydrocarbons, Halogenated, Phenol and Derivatives, Phenols]</data>
  <data key="d13">3,4,6-trichloro-2-[(2,3,5-trichloro-6-hydroxyphenyl)methyl]phenol</data>
  <data key="d14">C13H6Cl6O2</data>
  <data key="d15">70-30-4</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C13H6Cl6O2/c14-6-2-8(16)12(20)4(10(6)18)1-5-11(19)7(15)3-9(17)13(5)21/h2-3,20-21H,1H2</data>
  <data key="d19">OC1=C(CC2=C(O)C(Cl)=CC(Cl)=C2Cl)C(Cl)=C(Cl)C=C1Cl</data>
  <data key="d20">For use as a surgical scrub and a bacteriostatic skin cleanser. It may also be used to control an outbreak of gram-positive infection where other infection control procedures have been unsuccessful.</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[2, 2'-dihydroxy-3, 3', 5, 5', 6, 6'-hexachlorodiphenylmethane, 2, 2'-dihydroxy-3, 5, 6, 3', 5', 6'-hexachlorodiphenylmethane, 2, 2'-methanediylbis(3, 4, 6-trichlorophenol), 2, 2'-methylenebis(3, 4, 6-trichlorophenol), 2, 2', 3, 3', 5, 5'-hexachloro-6, 6'-dihydroxydiphenylmethane, bis(2-hydroxy-3, 5, 6-trichlorophenyl)methane, bis(3, 5, 6-trichloro-2-hydroxyphenyl)methane, hexachlorophène, Hexachlorophene, Hexachlorophenum, Hexaclorofeno]</data>
  <data key="d9">A chlorinated bisphenol antiseptic with a bacteriostatic action against Gram-positive organisms, but much less effective against Gram-negative organisms. It is mainly used in soaps and creams and is an ingredient of various preparations used for skin disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p797)</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB12742">
  <data key="d0">Amuvatinib</data>
  <data key="d1">drugbank.DB12742</data>
  <data key="d2">[drugbank.DB12742, drugbank.DB05216]</data>
  <data key="d11">[investigational]</data>
  <data key="d12">[]</data>
  <data key="d13">N-[(2H-1,3-benzodioxol-5-yl)methyl]-4-{8-oxa-3,5-diazatricyclo[7.4.0.0^{2,7}]trideca-1(9),2(7),3,5,10,12-hexaen-6-yl}piperazine-1-carbothioamide</data>
  <data key="d14">C23H21N5O3S</data>
  <data key="d15">850879-09-3</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C23H21N5O3S/c32-23(24-12-15-5-6-18-19(11-15)30-14-29-18)28-9-7-27(8-10-28)22-21-20(25-13-26-22)16-3-1-2-4-17(16)31-21/h1-6,11,13H,7-10,12,14H2,(H,24,32)</data>
  <data key="d19">S=C(NCC1=CC=C2OCOC2=C1)N1CCN(CC1)C1=NC=NC2=C1OC1=C2C=CC=C1</data>
  <data key="d20">Amuvatinib is a selective multi-targeted tyrosine kinase inhibitor that suppresses c-MET, c-RET and the mutant forms of c-KIT, PDGFR and FLT3. Amuvatinib also suppresses Rad51 protein, a critical component of double-stranded DNA repair in cancer cells.</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[]</data>
  <data key="d9">Amuvatinib has been used in trials studying the treatment of Solid Tumors and Small Cell Lung Carcinoma. Amuvatinib is an oral, selective multi-targeted tyrosine kinase inhibitor that suppresses c-MET, c-RET and the mutant forms of c-KIT, PDGFR and FLT3. Amuvatinib also suppresses Rad51 protein, a critical component of double-stranded DNA repair in cancer cells.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00398">
  <data key="d0">Sorafenib</data>
  <data key="d1">drugbank.DB00398</data>
  <data key="d2">[drugbank.DB00398, drugbank.APRD01304, drugbank.DB07438]</data>
  <data key="d11">[approved, investigational]</data>
  <data key="d12">[Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, BCRP/ABCG2 Inhibitors, BCRP/ABCG2 Substrates, Benzene Derivatives, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2B6 Inhibitors (moderate), Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (unknown strength), Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strength unknown), Cytochrome P-450 CYP2C8 Inhibitors (strong), Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strong), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inhibitors, Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Immunosuppressive Agents, Kinase Inhibitor, Miscellaneous Therapeutic Agents, Myelosuppressive Agents, Nicotinic Acids, OATP1B1/SLCO1B1 Inhibitors, P-glycoprotein/ABCB1 Inhibitors, P-glycoprotein/ABCB1 Substrates, Potential QTc-Prolonging Agents, Protein Kinase Inhibitors, Pyridines, QTc Prolonging Agents, raf Kinases, Receptors, Vascular Endothelial Growth Factor, Tyrosine Kinase Inhibitors, UGT1A1 Inhibitors, UGT1A9 Inhibitors, UGT1A9 Substrates, Urea]</data>
  <data key="d13">4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide</data>
  <data key="d14">C21H16ClF3N4O3</data>
  <data key="d15">284461-73-0</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)</data>
  <data key="d19">CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1</data>
  <data key="d20">Sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide, N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea, Sorafénib, Sorafenib, Sorafenibum]</data>
  <data key="d9">Sorafenib (rINN), marketed as Nexavar by Bayer, is a drug approved for the treatment of advanced renal cell carcinoma (primary kidney cancer). It has also received "Fast Track" designation by the FDA for the treatment of advanced hepatocellular carcinoma (primary liver cancer), and has since performed well in Phase III trials.\nSorafenib is a small molecular inhibitor of Raf kinase, PDGF (platelet-derived growth factor), VEGF receptor 2 &amp; 3 kinases and c Kit the receptor for Stem cell factor. A growing number of drugs target most of these pathways. The originality of Sorafenib lays in its simultaneous targeting of the Raf/Mek/Erk pathway.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00342">
  <data key="d0">Terfenadine</data>
  <data key="d1">drugbank.DB00342</data>
  <data key="d2">[drugbank.DB00342, drugbank.APRD00606]</data>
  <data key="d11">[approved, withdrawn]</data>
  <data key="d12">[Anticholinergic Agents, Antihistamines for Systemic Use, Benzene Derivatives, Benzhydryl Compounds, BSEP/ABCB11 Substrates, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (moderate), Cytochrome P-450 CYP2D6 Inhibitors (weak), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Inhibitors (strong), Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strong), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Highest Risk QTc-Prolonging Agents, Histamine Agents, Histamine Antagonists, Histamine H1 Antagonists, Histamine H1 Antagonists, Non-Sedating, Muscarinic Antagonists, Neurotransmitter Agents, P-glycoprotein/ABCB1 Inhibitors, P-glycoprotein/ABCB1 Substrates, Piperidines, QTc Prolonging Agents]</data>
  <data key="d13">1-(4-tert-butylphenyl)-4-[4-(hydroxydiphenylmethyl)piperidin-1-yl]butan-1-ol</data>
  <data key="d14">C32H41NO2</data>
  <data key="d15">50679-08-8</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C32H41NO2/c1-31(2,3)26-18-16-25(17-19-26)30(34)15-10-22-33-23-20-29(21-24-33)32(35,27-11-6-4-7-12-27)28-13-8-5-9-14-28/h4-9,11-14,16-19,29-30,34-35H,10,15,20-24H2,1-3H3</data>
  <data key="d19">CC(C)(C)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1</data>
  <data key="d20">For the treatment of allergic rhinitis, hay fever, and allergic skin disorders.</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[(RS)-1-(4-tert-butylphenyl)-4-{4-[hydroxy(diphenyl)methyl]piperidin-1-yl}-butan-1-ol, Terfenadin, Terfenadina, Terfénadine, Terfenadine, Terfenadinum]</data>
  <data key="d9">In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00406">
  <data key="d0">Gentian violet cation</data>
  <data key="d1">drugbank.DB00406</data>
  <data key="d2">[drugbank.DB00406, drugbank.APRD00998]</data>
  <data key="d11">[approved]</data>
  <data key="d12">[Amines, Aniline Compounds, Anti-Infective Agents, Anti-Infective Agents, Local, Antifungals for Dermatological Use, Antifungals for Topical Use, Dermatologicals, Genito Urinary System and Sex Hormones, Gynecological Antiinfectives and Antiseptics, Miscellaneous Antifungals]</data>
  <data key="d13">4-{bis[4-(dimethylamino)phenyl]methylidene}-N,N-dimethylcyclohexa-2,5-dien-1-iminium</data>
  <data key="d14">C25H30N3</data>
  <data key="d15">7438-46-2</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C25H30N3/c1-26(2)22-13-7-19(8-14-22)25(20-9-15-23(16-10-20)27(3)4)21-11-17-24(18-12-21)28(5)6/h7-18H,1-6H3/q+1</data>
  <data key="d19">CN(C)C1=CC=C(C=C1)C(C1=CC=C(C=C1)N(C)C)=C1C=CC(C=C1)=[N+](C)C</data>
  <data key="d20">For the treatment of bacterial and fungal infections inside the mouth (thrush) and skin, also for the prevention of transmission of Chagas' disease (as a blood additive).</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[Crystal Violet, Crystal violet carbocation, Crystal violet ion(1), Crystal violet(1+), Gentian violet carbocation, Gentian violet cation, Gentian violet(1+), Methylrosaniline, Methylrosanilinium]</data>
  <data key="d9">A dye that is a mixture of violet rosanilinis with antibacterial, antifungal, and anthelmintic properties.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00471">
  <data key="d0">Montelukast</data>
  <data key="d1">drugbank.DB00471</data>
  <data key="d2">[drugbank.DB00471, drugbank.APRD00434]</data>
  <data key="d11">[approved]</data>
  <data key="d12">[Acids, Acyclic, Agents Causing Muscle Toxicity, Agents to Treat Airway Disease, Anti-Asthmatic Agents, Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP2A6 Substrates, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Drugs for Obstructive Airway Diseases, Fatty Acids, Fatty Acids, Volatile, Hormone Antagonists, Hormones, Hormone Substitutes, and Hormone Antagonists, Leukotriene Antagonists, Leukotriene Modifiers, Lipids, Respiratory System Agents]</data>
  <data key="d13">2-[1-({[(1R)-1-{3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl}-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]sulfanyl}methyl)cyclopropyl]acetic acid</data>
  <data key="d14">C35H36ClNO3S</data>
  <data key="d15">158966-92-8</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C35H36ClNO3S/c1-34(2,40)30-9-4-3-7-25(30)13-17-32(41-23-35(18-19-35)22-33(38)39)27-8-5-6-24(20-27)10-15-29-16-12-26-11-14-28(36)21-31(26)37-29/h3-12,14-16,20-21,32,40H,13,17-19,22-23H2,1-2H3,(H,38,39)/b15-10+/t32-/m1/s1</data>
  <data key="d19">OC(=O)CC1(CC1)CS[C@H](CCC1=CC=CC=C1C(O)(C)C)C1=CC=CC(\C=C\C2=NC3=C(C=CC(Cl)=C3)C=C2)=C1</data>
  <data key="d20">Montelukast is indicated for:\n\n(a) the prophylaxis and chronic treatment of asthma in adults and pediatric patients who are 12 months of age and older[L6301], although other regional health authorities specifically note this indication for adults and adolescents who are 15 years and older[L6304,L6307] and also include indications for preventing day and night-time symptoms, and the treatment of acetylsalicylic acid-sensitive asthma[L6304];\n\n(b) the prevention of exercise-induced bronchoconstriction (EIB) in patients who are 6 years of age and older[L6301], although other regional health authorities specifically note this indication for adults and adolescents who are 15 years and older[L6304,L6307]; and\n\n(c) the relief of symptoms of seasonal allergic rhinitis in patients 2 years of age and older and perennial allergic rhinitis in patients 6 months of age and older[L6301], although other regional health authorities specifically note the relief of seasonal allergic rhinitis symptoms for adults and adolescents who are 15 years and older[L6304,L6307].\n\nFurthermore, some formulations like chewable montelukast tablets may also be specifically indicated by particular regulatory bodies for the prophylaxis and chronic treatment of asthma, including the prevention of day and night-time symptoms, the treatment of acetylsalicylic acid based asthma, and the prevention of exercise-induced bronchoconstriction in adult and pediatric patients aged 2 and older[L6328], between the ages 2 and 5[L6325], or between the ages of 6 and 14 years.[L6331]\n\nMoreover, when employed for such indications montelukast is considered effective as monotherapy or when combined with other medications indicated for the maintenance treatment of chronic asthma.[L6304,L6328] For instance, montelukast and inhaled corticosteroids can be used concomitantly to demonstrate additive effects to control asthma or to decrease the necessary inhaled corticosteroid dose while still maintaining clinical stability.[L6304,L6328]\n\nAdditionally, in patients who continue to experience asthma symptoms, montelukast can also be combined with an 'as required' short-acting beta-agonist, an inhaled corticosteroid, or inhaled corticosteroid paired with a long-acting beta-agonist.[L6304,L6328]</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[(R-(E))-1-(((1-(3-(2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid, 1-[[[(1 R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl] phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]sulfanyl]methyl]cyclopropaneacetic acid, Montelukast, Montélukast, Montelukastum]</data>
  <data key="d9">Montelukast was first approved for clinical use by the US FDA in 1998 as Merck's brand name Singulair.[L6301] The medication is a member of the leukotriene receptor antagonist (LTRA) category of drugs.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] Although capable of demonstrating effectiveness, the use of such LTRAs like montelukast is typically in addition to or complementary with the use of inhaled corticosteroids or other agents in asthma step therapy.[A178645] Regardless, in 2008-2009, there were FDA-led investigations into the possibility of montelukast to elicit neuropsychiatric effects like agitation, hallucinations, suicidal behaviour, and others in individuals who used the medication.[A178651] And although these kinds of effects are currently included in the official prescribing information for montelukast,[L6301,L6304,L6307,L6310,L6325,L6328,L6331] the drug still sees extensive use worldwide via millions of prescriptions annually and has since become available as a generic and as a brand name product.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00477">
  <data key="d0">Chlorpromazine</data>
  <data key="d1">drugbank.DB00477</data>
  <data key="d2">[drugbank.DB00477, drugbank.APRD00482]</data>
  <data key="d11">[approved, investigational, vet_approved]</data>
  <data key="d12">[Adrenergic alpha-1 Receptor Antagonists, Adrenergic alpha-Antagonists, Adrenergic Antagonists, Agents producing tachycardia, Agents that produce hypertension, Agents that reduce seizure threshold, Anticholinergic Agents, Antidepressive Agents, Antiemetics, Antipsychotic Agents, Antipsychotic Agents (First Generation [Typical]), Autonomic Agents, BSEP/ABCB11 Inhibitors, Central Nervous System Agents, Central Nervous System Depressants, Cholinesterase Inhibitors, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (moderate), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Dopamine Agents, Dopamine Antagonists, Dopamine D2 Receptor Antagonists, Drugs that are Mainly Renally Excreted, Gastrointestinal Agents, Histamine Antagonists, Histamine H1 Antagonists, Hyperglycemia-Associated Agents, Hypotensive Agents, Moderate Risk QTc-Prolonging Agents, Muscarinic Antagonists, Nervous System, Neurotoxic agents, Neurotransmitter Agents, P-glycoprotein/ABCB1 Inhibitors, P-glycoprotein/ABCB1 Substrates, Peripheral Nervous System Agents, Phenothiazines, Phenothiazines With Aliphatic Side-Chain, Psycholeptics, Psychotropic Drugs, QTc Prolonging Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 5-HT1 Receptor Antagonists, Serotonin 5-HT2 Receptor Antagonists, Serotonin Agents, Serotonin Receptor Antagonists, Sulfur Compounds, Tranquilizing Agents]</data>
  <data key="d13">[3-(2-chloro-10H-phenothiazin-10-yl)propyl]dimethylamine</data>
  <data key="d14">C17H19ClN2S</data>
  <data key="d15">50-53-3</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C17H19ClN2S/c1-19(2)10-5-11-20-14-6-3-4-7-16(14)21-17-9-8-13(18)12-15(17)20/h3-4,6-9,12H,5,10-11H2,1-2H3</data>
  <data key="d19">CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2</data>
  <data key="d20">For the treatment of schizophrenia; to control nausea and vomiting; for relief of restlessness and apprehension before surgery; for acute intermittent porphyria; as an adjunct in the treatment of tetanus; to control the manifestations of the manic type of manic-depressive illness; for relief of intractable hiccups; for the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance.</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[3-(2-chloro-10H-phenothiazin-10-yl)-N, N-dimethyl-1-propanamine, 3-(2-chlorophenothiazin-10-yl)-N, N-dimethyl-propan-1-amine, Chlorpromazine, Chlorpromazinum, Clorpromazina, CPZ, N-(3-dimethylaminopropyl)-3-chlorophenothiazine]</data>
  <data key="d9">The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB11125">
  <data key="d0">Benzethonium</data>
  <data key="d1">drugbank.DB11125</data>
  <data key="d2">[drugbank.DB11125]</data>
  <data key="d11">[approved]</data>
  <data key="d12">[Amines, Ammonium Compounds, Anti-Infective Agents, Anti-Infective Agents, Local, Antiseptics and Disinfectants, Benzylammonium Compounds, Dermatologicals, Miscellaneous Local Anti-infectives, Nitrogen Compounds, Onium Compounds, Quaternary Ammonium Compounds, Throat Preparations]</data>
  <data key="d13">benzyldimethyl(2-{2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy}ethyl)azanium</data>
  <data key="d14">C27H42NO2</data>
  <data key="d15">10172-60-8</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C27H42NO2/c1-26(2,3)22-27(4,5)24-13-15-25(16-14-24)30-20-19-29-18-17-28(6,7)21-23-11-9-8-10-12-23/h8-16H,17-22H2,1-7H3/q+1</data>
  <data key="d19">CC(C)(C)CC(C)(C)C1=CC=C(OCCOCC[N+](C)(C)CC2=CC=CC=C2)C=C1</data>
  <data key="d20">Indicated as an antiseptic agent. No therapeutic indications for clinical use.</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[]</data>
  <data key="d9">Benzethonium is a synthetic quaternary ammonium salt with surfactant, antiseptic, and broad spectrum antimicrobial properties. Its salt form, benzethonium chloride, is primarily used as a skin disinfectant at concentrations of 0.1-0.2 %, which are safe and effective concentrations for the compound specified by the U.S. Food and Drug Administration (FDA). It is additionally found in cosmetics and toiletries such as mouthwashes and anti-itch ointments. It is shown to be effective in mediating its antimicrobial action against bacteria, fungi, mold and viruses. There is evidence that benzethonium acts as a spermatocide but may cause vaginal irritation [A32304]. Benzethonium was identified as a novel cancer-specific compound by cell-based small-molecule screen [A32298].</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00530">
  <data key="d0">Erlotinib</data>
  <data key="d1">drugbank.DB00530</data>
  <data key="d2">[drugbank.DB00530, drugbank.APRD00951]</data>
  <data key="d11">[approved, investigational]</data>
  <data key="d12">[Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, BCRP/ABCG2 Inhibitors, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strong), Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 Enzyme Inhibitors, Enzyme Inhibitors, Highest Risk QTc-Prolonging Agents, Kinase Inhibitor, P-glycoprotein/ABCB1 Inhibitors, P-glycoprotein/ABCB1 Substrates, Protein Kinase Inhibitors, QTc Prolonging Agents, Quinazolines, Tyrosine Kinase Inhibitors, UGT1A1 Inhibitors]</data>
  <data key="d13">N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine</data>
  <data key="d14">C22H23N3O4</data>
  <data key="d15">183321-74-6</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)</data>
  <data key="d19">COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2</data>
  <data key="d20">Erlotinib is indicated for:\n\n- The treatment of metastatic non-small cell lung cancer (NSCLC) with tumors showing epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations [FDA label]. \n\n- In combination with first-line treatment for patients diagnosed with locally advanced, unresectable or metastatic pancreatic cancer [FDA label].\n\nThe safety and efficacy of erlotinib have not been established for patients with NSCLC whose tumors show other EGFR mutations. Additionally it is not recommended for use in combination with platinum-based chemotherapy. [FDA label]</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[[6, 7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine, Erlotinib]</data>
  <data key="d9">Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor. Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and other myeloproliferative disorders.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00549">
  <data key="d0">Zafirlukast</data>
  <data key="d1">drugbank.DB00549</data>
  <data key="d2">[drugbank.DB00549, drugbank.APRD00377]</data>
  <data key="d11">[approved, investigational]</data>
  <data key="d12">[Agents to Treat Airway Disease, Anti-Asthmatic Agents, Benzene Derivatives, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (strong), Cytochrome P-450 CYP1A2 Inhibitors (unknown strength), Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 Inhibitors (strong), Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strong), Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (weak), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Cytochrome P450 2C9 Inhibitors, Drugs for Obstructive Airway Diseases, Hormone Antagonists, Hormones, Hormone Substitutes, and Hormone Antagonists, Leukotriene Antagonists, Leukotriene Modifiers, Respiratory System Agents, Sulfones, Sulfur Compounds, Toluene]</data>
  <data key="d13">cyclopentyl N-[3-({2-methoxy-4-[(2-methylbenzenesulfonyl)carbamoyl]phenyl}methyl)-1-methyl-1H-indol-5-yl]carbamate</data>
  <data key="d14">C31H33N3O6S</data>
  <data key="d15">107753-78-6</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C31H33N3O6S/c1-20-8-4-7-11-29(20)41(37,38)33-30(35)22-13-12-21(28(17-22)39-3)16-23-19-34(2)27-15-14-24(18-26(23)27)32-31(36)40-25-9-5-6-10-25/h4,7-8,11-15,17-19,25H,5-6,9-10,16H2,1-3H3,(H,32,36)(H,33,35)</data>
  <data key="d19">COC1=CC(=CC=C1CC1=CN(C)C2=C1C=C(NC(=O)OC1CCCC1)C=C2)C(=O)NS(=O)(=O)C1=CC=CC=C1C</data>
  <data key="d20">For the prophylaxis and chronic treatment of asthma.</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[4-(5-cyclopentyloxycarbonylamino-1-methyl-1H-indol-3-ylmethyl)-3-methoxy-N-o-tolylsulfonylbenzamide, cyclopentyl 3-(2-methoxy-4-((o-tolylsulfonyl)carbamoyl)benzyl)-1-methylindole-5-carbamate, Zafirlukast]</data>
  <data key="d9">Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), which is usually taken just once daily.\n\nZafirlukast blocks the action of the cysteinyl leukotrienes on the CysLT1 receptors, thus reducing constriction of the airways, build-up of mucus in the lungs and inflammation of the breathing passages.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00515">
  <data key="d0">Cisplatin</data>
  <data key="d1">drugbank.DB00515</data>
  <data key="d2">[drugbank.DB00515, drugbank.APRD00359]</data>
  <data key="d11">[approved]</data>
  <data key="d12">[Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, BCRP/ABCG2 Substrates, Cardiotoxic antineoplastic agents, Chlorine Compounds, Cholinesterase Inhibitors, Compounds used in a research, industrial, or household setting, Cross-Linking Reagents, Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2B6 Inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Drugs that are Mainly Renally Excreted, Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index, Immunosuppressive Agents, Indicators and Reagents, Laboratory Chemicals, Myelosuppressive Agents, Nephrotoxic agents, Nitrogen Compounds, OCT2 Inhibitors, OCT2 Substrates, OCT2 substrates with narrow therapeutic index, P-glycoprotein/ABCB1 Substrates, Platinum Compounds, Radiation-Sensitizing Agents]</data>
  <data key="d13">NA</data>
  <data key="d14">Cl2H6N2Pt</data>
  <data key="d15">15663-27-1</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/2ClH.2H3N.Pt/h2*1H;2*1H3;/q;;;;+2/p-2</data>
  <data key="d19">[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]</data>
  <data key="d20">For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[CDDP, Cis-DDP, cis-diamminedichloroplatinum(II), Cisplatin, cisplatino]</data>
  <data key="d9">Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB11742">
  <data key="d0">Ebastine</data>
  <data key="d1">drugbank.DB11742</data>
  <data key="d2">[drugbank.DB11742]</data>
  <data key="d11">[approved, investigational]</data>
  <data key="d12">[Antihistamines for Systemic Use, CYP3A Substrates (Sensitive), Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Histamine Agents, Histamine Antagonists, Histamine H1 Antagonists, Ketones, Neurotransmitter Agents, Potential QTc-Prolonging Agents, QTc Prolonging Agents]</data>
  <data key="d13">1-(4-tert-butylphenyl)-4-[4-(diphenylmethoxy)piperidin-1-yl]butan-1-one</data>
  <data key="d14">C32H39NO2</data>
  <data key="d15">90729-43-4</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C32H39NO2/c1-32(2,3)28-18-16-25(17-19-28)30(34)15-10-22-33-23-20-29(21-24-33)35-31(26-11-6-4-7-12-26)27-13-8-5-9-14-27/h4-9,11-14,16-19,29,31H,10,15,20-24H2,1-3H3</data>
  <data key="d19">CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1</data>
  <data key="d20"></data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[Ebastina]</data>
  <data key="d9">Ebastine is under investigation for the treatment of Irritable Bowel Syndrome (IBS). Ebastine has been investigated for the treatment of Urticaria.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB11828">
  <data key="d0">Neratinib</data>
  <data key="d1">drugbank.DB11828</data>
  <data key="d2">[drugbank.DB11828]</data>
  <data key="d11">[approved, investigational]</data>
  <data key="d12">[Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Kinase Inhibitor, Kinase Inhibitors, P-glycoprotein/ABCB1 Inhibitors, Protein Kinase Inhibitors, Tyrosine Kinase Inhibitors]</data>
  <data key="d13">(2E)-N-[4-({3-chloro-4-[(pyridin-2-yl)methoxy]phenyl}amino)-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide</data>
  <data key="d14">C30H29ClN6O3</data>
  <data key="d15">698387-09-6</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C30H29ClN6O3/c1-4-39-28-16-25-23(15-26(28)36-29(38)9-7-13-37(2)3)30(20(17-32)18-34-25)35-21-10-11-27(24(31)14-21)40-19-22-8-5-6-12-33-22/h5-12,14-16,18H,4,13,19H2,1-3H3,(H,34,35)(H,36,38)/b9-7+</data>
  <data key="d19">CCOC1=C(NC(=O)\C=C\CN(C)C)C=C2C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C(C=NC2=C1)C#N</data>
  <data key="d20">For use as an extended adjuvant treatment in adult patients with early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy [FDA Label].</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[Neratinib]</data>
  <data key="d9">Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib is currently under investigation for use in many other forms of cancer.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB11829">
  <data key="d0">Ruboxistaurin</data>
  <data key="d1">drugbank.DB11829</data>
  <data key="d2">[drugbank.DB11829]</data>
  <data key="d11">[investigational]</data>
  <data key="d12">[Acids, Acyclic, Dicarboxylic Acids, Enzyme Inhibitors, Imides, Maleates, Protein Kinase C, antagonists &amp; inhibitors]</data>
  <data key="d13">(18S)-18-[(dimethylamino)methyl]-3-hydroxy-17-oxa-4,14,21-triazahexacyclo[19.6.1.1⁷,¹⁴.0²,⁶.0⁸,¹³.0²²,²⁷]nonacosa-1(28),2(6),3,7(29),8,10,12,22,24,26-decaen-5-one</data>
  <data key="d14">C28H28N4O3</data>
  <data key="d15">169939-94-0</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C28H28N4O3/c1-30(2)15-18-11-12-31-16-21(19-7-3-5-9-23(19)31)25-26(28(34)29-27(25)33)22-17-32(13-14-35-18)24-10-6-4-8-20(22)24/h3-10,16-18H,11-15H2,1-2H3,(H,29,33,34)/t18-/m0/s1</data>
  <data key="d19">[H][C@@]1(CN(C)C)CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)N=C2O)C2=CN(CCO1)C1=CC=CC=C21</data>
  <data key="d20"></data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[]</data>
  <data key="d9">Ruboxistaurin has been investigated for the basic science of Type 2 Diabetes Mellitus and Type 1 Diabetes Mellitus.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB11800">
  <data key="d0">Tivozanib</data>
  <data key="d1">drugbank.DB11800</data>
  <data key="d2">[drugbank.DB11800]</data>
  <data key="d11">[investigational]</data>
  <data key="d12">[Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Benzene Derivatives, Protein Kinase Inhibitors, Receptors, Vascular Endothelial Growth Factor, antagonists &amp; inhibitors, Urea]</data>
  <data key="d13">N'-{2-chloro-4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N-(5-methyl-2,3-dihydro-1,2-oxazol-3-ylidene)carbamimidic acid</data>
  <data key="d14">C22H19ClN4O5</data>
  <data key="d15">475108-18-0</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C22H19ClN4O5/c1-12-8-21(27-32-12)26-22(28)25-16-5-4-13(9-15(16)23)31-18-6-7-24-17-11-20(30-3)19(29-2)10-14(17)18/h4-11H,1-3H3,(H2,25,26,27,28)</data>
  <data key="d19">COC1=C(OC)C=C2C(OC3=CC(Cl)=C(C=C3)N=C(O)N=C3NOC(C)=C3)=CC=NC2=C1</data>
  <data key="d20"></data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[]</data>
  <data key="d9">Tivozanib has been used in trials studying the treatment and basic science of Solid Tumors, Glioblastoma, Ovarian Cancer, Prostate Cancer, and Stage IV Disease, among others.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB11817">
  <data key="d0">Baricitinib</data>
  <data key="d1">drugbank.DB11817</data>
  <data key="d2">[drugbank.DB11817]</data>
  <data key="d11">[approved, investigational]</data>
  <data key="d12">[Amides, Antineoplastic and Immunomodulating Agents, Azetines, BCRP/ABCG2 Inhibitors, BCRP/ABCG2 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Drugs that are Mainly Renally Excreted, Immunosuppressive Agents, Janus Kinase Inhibitor, Janus Kinase Inhibitors, MATE 2 Inhibitors, MATE 2 Substrates, MATE 2 Substrates with a Narrow Therapeutic Index, MATE inhibitors, MATE substrates, OAT1/SLC22A6 inhibitors, OAT3/SLC22A8 Inhibitors, OAT3/SLC22A8 Substrates, OATP1B3 inhibitors, OCT2 Inhibitors, P-glycoprotein/ABCB1 Substrates, Selective Immunosuppressants, Sulfones, Sulfur Compounds]</data>
  <data key="d13">2-[1-(ethanesulfonyl)-3-(4-{7H-pyrrolo[2,3-d]pyrimidin-4-yl}-1H-pyrazol-1-yl)azetidin-3-yl]acetonitrile</data>
  <data key="d14">C16H17N7O2S</data>
  <data key="d15">1187594-09-7</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C16H17N7O2S/c1-2-26(24,25)22-9-16(10-22,4-5-17)23-8-12(7-21-23)14-13-3-6-18-15(13)20-11-19-14/h3,6-8,11H,2,4,9-10H2,1H3,(H,18,19,20)</data>
  <data key="d19">CCS(=O)(=O)N1CC(CC#N)(C1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1</data>
  <data key="d20">Indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs as monotherapy or in combination with methotrexate.</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[Baricitinib]</data>
  <data key="d9">Baricitinib is a selective and reversible Janus kinase 1 (JAK1) and 2 (JAK2) inhibitor. Janus kinases belong to the tyrosine protein kinase family and play an important role in the proinflammatory pathway signalling that is frequently over-activated in autoimmune disorders such as rheumatoid arthritis. By blocking the actions of JAK1/2, baricitinib disrupts the activation of downstream signalling molecules and proinflammatory mediators. \n\nRheumatoid arthritis is a progressive autoimmune disease commonly associated with discomfort, diasability, and joint damage. Throughout disease progression, the disease may further lead to joint erosions and deformities, causing premature mortality, functional impairment, and reduced quality of life [A31386]. While there are several disease modifying antirheumatic drugs (DMARDs) available for treatment, patients often experience inadequate threapeutic resposes to these drugs. In animal models of inflammatory arthritis, baricitinib was shown to have significant anti-inflammatory effects, but also led to preservation of cartilage and bone, with no detectable suppression of humoral immunity or adverse hematologic effects [A31382].\n\nIn the EU, baricitinib was approved in February of 2017 as a second-line orally administered treatment for moderate to severe active rheumatoid arthritis in adults, either as a monotherapy or when combined with methotrexate. It is marketed under the trade name Olumiant.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB09221">
  <data key="d0">Polaprezinc</data>
  <data key="d1">drugbank.DB09221</data>
  <data key="d2">[drugbank.DB09221]</data>
  <data key="d11">[experimental]</data>
  <data key="d12">[Amino Acids, Peptides, and Proteins, Anti-Ulcer Agents, Dipeptides, Gastrointestinal Agents, Metal cations, Metal divalent cations, Nerve Tissue Proteins, Neuropeptides, Oligopeptides, Peptides, Proteins, Zinc Compounds]</data>
  <data key="d13">zinc(2+) ion (2S)-2-[(3-aminopropanoyl)azanidyl]-3-(1H-imidazol-5-yl)propanoate</data>
  <data key="d14">C9H12N4O3Zn</data>
  <data key="d15">107667-60-7</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C9H14N4O3.Zn/c10-2-1-8(14)13-7(9(15)16)3-6-4-11-5-12-6;/h4-5,7H,1-3,10H2,(H3,11,12,13,14,15,16);/q;+2/p-2/t7-;/m0./s1</data>
  <data key="d19">[Zn++].[H][C@@](CC1=CN=CN1)([N-]C(=O)CCN)C([O-])=O</data>
  <data key="d20">Peptic ulcer disease, dyspepsia [L1308].</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[beta-alanyl-l-histidinato zinc, Zinc L-carnosine]</data>
  <data key="d9">Polaprezinc is a chelated form of zinc and L-carnosine. It is a zinc-related medicine approved for the first time in Japan, which has been clinically used to treat gastric ulcers [L1307, L1208].  It was determined that polaprezinc may be effective in pressure ulcer treatment [A31856]. A study in 2013 showed that CO-administration of polaprezinc may be effective against small intestine mucosal injury associated with long-term aspirin therapy [A7840].</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00882">
  <data key="d0">Clomifene</data>
  <data key="d1">drugbank.DB00882</data>
  <data key="d2">[drugbank.DB00882, drugbank.APRD00880]</data>
  <data key="d11">[approved, investigational]</data>
  <data key="d12">[Benzene Derivatives, Benzylidene Compounds, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (unknown strength), Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Estrogen Agonist-antagonists, Estrogen Agonist/Antagonist, Estrogen Antagonists, Estrogen Receptor Modulators, Fertility Agents, Fertility Agents, Female, Genito Urinary System and Sex Hormones, Hormone Antagonists, Hormones, Hormone Substitutes, and Hormone Antagonists, Ovulation Stimulants, Synthetic, P-glycoprotein/ABCB1 Substrates, Reproductive Control Agents, Selective Estrogen Receptor Modulators, Sex Hormones and Modulators of the Genital System, Stilbenes]</data>
  <data key="d13">{2-[4-(2-chloro-1,2-diphenylethenyl)phenoxy]ethyl}diethylamine</data>
  <data key="d14">C26H28ClNO</data>
  <data key="d15">911-45-5</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C26H28ClNO/c1-3-28(4-2)19-20-29-24-17-15-22(16-18-24)25(21-11-7-5-8-12-21)26(27)23-13-9-6-10-14-23/h5-18H,3-4,19-20H2,1-2H3</data>
  <data key="d19">CCN(CC)CCOC1=CC=C(C=C1)C(=C(Cl)C1=CC=CC=C1)C1=CC=CC=C1</data>
  <data key="d20">Used mainly in female infertility due to anovulation (e.g. due to polycystic ovary syndrome) to induce ovulation.</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[2-(4-(2-chloro-1, 2-diphenylethenyl)phenoxy)-N, N-diethylethanamine, 2-(p-(2-chloro-1, 2-diphenylvinyl)phenoxy)triethylamine, 2-(p-(β-chloro-α-phenylstyryl)phenoxy)triethylamine, Clomifene, Clomifeno, Clomifenum, Clomiphene]</data>
  <data key="d9">A triphenyl ethylene stilbene derivative which is an estrogen agonist or antagonist depending on the target tissue.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00834">
  <data key="d0">Mifepristone</data>
  <data key="d1">drugbank.DB00834</data>
  <data key="d2">[drugbank.DB00834, drugbank.APRD00432]</data>
  <data key="d11">[approved, investigational]</data>
  <data key="d12">[Abortifacient Agents, Abortifacient Agents, Steroidal, Adrenal Cortex Hormones, Blood Glucose Lowering Agents, BSEP/ABCB11 Substrates, Contraceptive Agents, Female, Contraceptives, Oral, Contraceptives, Oral, Synthetic, Contraceptives, Postcoital, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (moderate), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (moderate), Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (moderate), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Inhibitors, Cytochrome P-450 CYP3A7 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Estranes, Estrenes, Genito Urinary System and Sex Hormones, Highest Risk QTc-Prolonging Agents, Hormonal Contraceptives for Systemic Use, Hormone Antagonists, Hormones, Hormone Substitutes, and Hormone Antagonists, Hypoglycemia-Associated Agents, Luteolytic Agents, Menstruation-Inducing Agents, OATP1B1/SLCO1B1 Inhibitors, OATP1B3 inhibitors, P-glycoprotein/ABCB1 Inducers, P-glycoprotein/ABCB1 Inhibitors, Progestational Hormone Receptor Antagonists, Progesterone Receptor Modulators, Progestin Antagonist, QTc Prolonging Agents, Reproductive Control Agents, Sex Hormones and Modulators of the Genital System, Steroids]</data>
  <data key="d13">(1S,3aS,3bS,10R,11aS)-10-[4-(dimethylamino)phenyl]-1-hydroxy-11a-methyl-1-(prop-1-yn-1-yl)-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,10H,11H,11aH-cyclopenta[a]phenanthren-7-one</data>
  <data key="d14">C29H35NO2</data>
  <data key="d15">84371-65-3</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C29H35NO2/c1-5-15-29(32)16-14-26-24-12-8-20-17-22(31)11-13-23(20)27(24)25(18-28(26,29)2)19-6-9-21(10-7-19)30(3)4/h6-7,9-10,17,24-26,32H,8,11-14,16,18H2,1-4H3/t24-,25+,26-,28-,29-/m0/s1</data>
  <data key="d19">[H][C@@]12CC[C@@](O)(C#CC)[C@@]1(C)C[C@H](C1=CC=C(C=C1)N(C)C)C1=C3CCC(=O)C=C3CC[C@@]21[H]</data>
  <data key="d20">For the medical termination of intrauterine pregnancy through 49 days' pregnancy. Also indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and are not candidates for surgery or have had unsuccessful surgery.</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[Mifepriston, Mifepristona, Mifépristone, Mifepristone, Mifepristonum]</data>
  <data key="d9">Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary cushing syndrome. The two marketed forms of mifepristone are Mifeprex® (mifepristone 200mg) and Korlym™ (mifepristone 300mg). Currently under investigation for use in psychotic depression (phase 3 trials).</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00841">
  <data key="d0">Dobutamine</data>
  <data key="d1">drugbank.DB00841</data>
  <data key="d2">[drugbank.DB00841, drugbank.APRD00122]</data>
  <data key="d11">[approved]</data>
  <data key="d12">[Adrenergic Agents, Adrenergic Agonists, Adrenergic alpha-1 Receptor Agonists, Adrenergic alpha-Agonists, Adrenergic and Dopaminergic Agents, Adrenergic beta-1 Receptor Agonists, Adrenergic beta-2 Receptor Agonists, Adrenergic beta-Agonists, Agents producing tachycardia, Agents that produce hypertension, Amines, Autonomic Agents, Biogenic Amines, Biogenic Monoamines, Cardiac Stimulants Excl. Cardiac Glycosides, Cardiac Therapy, Cardiotonic Agents, Cardiovascular Agents, Catecholamines, Compounds used in a research, industrial, or household setting, COMT Substrates, Drugs that are Mainly Renally Excreted, Ethylamines, Neurotransmitter Agents, Peripheral Nervous System Agents, Phenethylamines, Protective Agents, Selective Beta 1-adrenergic Agonists, Sympathomimetic (Adrenergic) Agents, Sympathomimetics]</data>
  <data key="d13">4-(2-{[4-(4-hydroxyphenyl)butan-2-yl]amino}ethyl)benzene-1,2-diol</data>
  <data key="d14">C18H23NO3</data>
  <data key="d15">34368-04-2</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C18H23NO3/c1-13(2-3-14-4-7-16(20)8-5-14)19-11-10-15-6-9-17(21)18(22)12-15/h4-9,12-13,19-22H,2-3,10-11H2,1H3</data>
  <data key="d19">CC(CCC1=CC=C(O)C=C1)NCCC1=CC(O)=C(O)C=C1</data>
  <data key="d20">Indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures.</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[(±)-4-(2-((3-(p-hydroxyphenyl)-1-methylpropyl)amino)ethyl)pyrocatechol, 3, 4-dihydroxy-N-[3-(4-hydroxyphenyl)-1-methylpropyl]-β-phenylethylamine, 4-{2-[3-(4-Hydroxy-phenyl)-1-methyl-propylamino]-ethyl}-benzene-1, 2-diol, DL-dobutamine, Dobutamin, Dobutamina, Dobutamine, Dobutaminum, rac-dobutamine, racemic-dobutamine]</data>
  <data key="d9">A beta-1 agonist catecholamine that has cardiac stimulant action without evoking vasoconstriction or tachycardia. It is proposed as a cardiotonic after myocardial infarction or open heart surgery.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00803">
  <data key="d0">Colistin</data>
  <data key="d1">drugbank.DB00803</data>
  <data key="d2">[drugbank.DB00803, drugbank.APRD00886]</data>
  <data key="d11">[approved]</data>
  <data key="d12">[Agents that produce neuromuscular block (indirect), Alimentary Tract and Metabolism, Amino Acids, Peptides, and Proteins, Aminoglycoside Antibacterials, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents, Antiinfectives for Systemic Use, Antimicrobial Cationic Peptides, Intestinal Antiinfectives, Lipids, Lipopeptides, Membrane Proteins, Nephrotoxic agents, Peptides, Peptides, Cyclic, Polymyxins, Pore Forming Cytotoxic Proteins, Proteins]</data>
  <data key="d13">N-[(1S)-3-amino-1-{[(1S,2R)-1-{[(1S)-3-amino-1-{[(6R,9S,12R,18S,21S)-6,9,18-tris(2-aminoethyl)-2,5,8,11,14,17,20-heptahydroxy-3-[(1R)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-1,4,7,10,13,16,19-heptaazacyclotricosa-1,4,7,10,13,16,19-heptaen-21-yl]-C-hydroxycarbonimidoyl}propyl]-C-hydroxycarbonimidoyl}-2-hydroxypropyl]-C-hydroxycarbonimidoyl}propyl]-5-methylheptanimidic acid</data>
  <data key="d14">C52H98N16O13</data>
  <data key="d15">1066-17-7</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C52H98N16O13/c1-9-29(6)11-10-12-40(71)59-32(13-19-53)47(76)68-42(31(8)70)52(81)64-35(16-22-56)44(73)63-37-18-24-58-51(80)41(30(7)69)67-48(77)36(17-23-57)61-43(72)33(14-20-54)62-49(78)38(25-27(2)3)66-50(79)39(26-28(4)5)65-45(74)34(15-21-55)60-46(37)75/h27-39,41-42,69-70H,9-26,53-57H2,1-8H3,(H,58,80)(H,59,71)(H,60,75)(H,61,72)(H,62,78)(H,63,73)(H,64,81)(H,65,74)(H,66,79)(H,67,77)(H,68,76)/t29?,30-,31-,32+,33+,34+,35+,36-,37+,38-,39?,41?,42+/m1/s1</data>
  <data key="d19">[H]C(C)(CC)CCCC(O)=N[C@@]([H])(CCN)C(O)=N[C@]([H])(C(O)=N[C@@]([H])(CCN)C(O)=N[C@@]1([H])CCN=C(O)C([H])(N=C(O)[C@@]([H])(CCN)N=C(O)[C@]([H])(CCN)N=C(O)[C@@]([H])(CC(C)C)N=C(O)C([H])(CC(C)C)N=C(O)[C@]([H])(CCN)N=C1O)[C@@]([H])(C)O)[C@@]([H])(C)O</data>
  <data key="d20">For the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli, particularly &lt;i&gt;Pseudomonas aeruginosa&lt;/i&gt;.</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[Colistin, Colistina, Colistine, Colistinum, Polymyxin E]</data>
  <data key="d9">Cyclic polypeptide antibiotic from Bacillus colistinus. It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes. Colistin is less toxic than Polymyxin B, but otherwise similar; the methanesulfonate is used orally.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB09276">
  <data key="d0">Sodium aurothiomalate</data>
  <data key="d1">drugbank.DB09276</data>
  <data key="d2">[drugbank.DB09276]</data>
  <data key="d11">[approved, investigational]</data>
  <data key="d12">[Acids, Acyclic, Antiinflammatory and Antirheumatic Products, Antirheumatic Agents, Dicarboxylic Acids, Drugs that are Mainly Renally Excreted, Gold Compounds, Gold Preparations, Hydroxy Acids, Malates, Musculo-Skeletal System, Organogold Compounds, Organometallic Compounds, Specific Antirheumatic Agents, Sulfhydryl Compounds, Sulfur Compounds, Thiomalates, UGT1A1 Inhibitors]</data>
  <data key="d13">sodium 2-(auriosulfanyl)-3-carboxypropanoate</data>
  <data key="d14">C4H4AuNaO4S</data>
  <data key="d15">12244-57-4</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C4H6O4S.Au.Na/c5-3(6)1-2(9)4(7)8;;/h2,9H,1H2,(H,5,6)(H,7,8);;/q;2*+1/p-2</data>
  <data key="d19">[Na+].OC(=O)CC(S[Au])C([O-])=O</data>
  <data key="d20">A disease-modifying antirheumatic drug (DMARD) indicated for the symptomatic treatment of arthritis.</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[Aurotiomalato sodico, Gold sodium thiomalate, Natrii aurothiomalas, Sodium aurothiomalate]</data>
  <data key="d9">Sodium aurothiomalate is a gold compound that is used for its immunosuppressive anti-rheumatic effects. Gold Sodium Thiomalate is supplied as a solution for intramuscular injection containing 50 mg of Gold Sodium Thiomalate per mL. It is most effective in active progressive rheumatoid arthritis and of little or no value in the presence of extensive deformities or in the treatment of other forms of arthritis.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB09372">
  <data key="d0">Tannic acid</data>
  <data key="d1">drugbank.DB09372</data>
  <data key="d2">[drugbank.DB09372]</data>
  <data key="d11">[approved]</data>
  <data key="d12">[Biomedical and Dental Materials, Biopolymers, Compounds used in a research, industrial, or household setting, Macromolecular Substances, Polymers]</data>
  <data key="d13">(2R,3R,4S,5R)-4,5,6-tris[3,4-dihydroxy-5-(3,4,5-trihydroxybenzoyloxy)benzoyloxy]-2-{[3,4-dihydroxy-5-(3,4,5-trihydroxybenzoyloxy)benzoyloxy]methyl}oxan-3-yl 3,4-dihydroxy-5-(3,4,5-trihydroxybenzoyloxy)benzoate</data>
  <data key="d14">C76H52O46</data>
  <data key="d15">1401-55-4</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C76H52O46/c77-32-1-22(2-33(78)53(32)92)67(103)113-47-16-27(11-42(87)58(47)97)66(102)112-21-52-63(119-72(108)28-12-43(88)59(98)48(17-28)114-68(104)23-3-34(79)54(93)35(80)4-23)64(120-73(109)29-13-44(89)60(99)49(18-29)115-69(105)24-5-36(81)55(94)37(82)6-24)65(121-74(110)30-14-45(90)61(100)50(19-30)116-70(106)25-7-38(83)56(95)39(84)8-25)76(118-52)122-75(111)31-15-46(91)62(101)51(20-31)117-71(107)26-9-40(85)57(96)41(86)10-26/h1-20,52,63-65,76-101H,21H2/t52-,63-,64+,65-,76?/m1/s1</data>
  <data key="d19">OC1=CC(=CC(O)=C1O)C(=O)OC1=C(O)C(O)=CC(=C1)C(=O)OC[C@H]1OC(OC(=O)C2=CC(OC(=O)C3=CC(O)=C(O)C(O)=C3)=C(O)C(O)=C2)[C@H](OC(=O)C2=CC(OC(=O)C3=CC(O)=C(O)C(O)=C3)=C(O)C(O)=C2)[C@@H](OC(=O)C2=CC(OC(=O)C3=CC(O)=C(O)C(O)=C3)=C(O)C(O)=C2)[C@@H]1OC(=O)C1=CC(OC(=O)C2=CC(O)=C(O)C(O)=C2)=C(O)C(O)=C1</data>
  <data key="d20">Tannic acid is indicated for cold sores, fever blisters, diaper rash, minor burn or sunburn and prickly heat.\nVaginally, tannic acid is used as a douche for leukorrhea. It has been also indicated for sore throat, inflamed tonsils, spongy or receding gums, and acute dermatitis.</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[ácido tánico, Gallotannic acid, Gallotannin]</data>
  <data key="d9">Tannic acid is a polyphenolic compound. It is a type of the commercially available tannins. It acts as a weak acid. Tannic acid is found in the nutgalls formed by insects on twigs of certain oak trees (Quercus infectoria and other Quercus species). It is removed and used as medicine. In the old days it was used as antidote against different poisons. \nNowadays, tannic acid is applied topically for the treatment of cold sores, diaper rash, fever blisters and poison ivy. Tannic acid is also taken by mouth and applied directly for bleeding, chronic diarrhea, dysentery, bloody urine, painful joints, persistent coughs, and cancer.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08059">
  <data key="d0">Wortmannin</data>
  <data key="d1">drugbank.DB08059</data>
  <data key="d2">[drugbank.DB08059]</data>
  <data key="d11">[experimental]</data>
  <data key="d12">[Androstanes, Androstenes, Anti-Infective Agents, Antidepressive Agents, Antifungal Agents, Central Nervous System Depressants, Enzyme Inhibitors, Hormone Antagonists, Hormones, Hormone Substitutes, and Hormone Antagonists, Immunologic Factors, Immunosuppressive Agents, Insulin Antagonists, Mycotoxins, Neurotransmitter Agents, Phosphatidylinositol 3-Kinases, antagonists &amp; inhibitors, Phosphodiesterase Inhibitors, Protein Kinase Inhibitors, Radiation-Sensitizing Agents, Serotonin Agents, Serotonin Receptor Antagonists, Steroids]</data>
  <data key="d13">(1R,3R,5S,9R,18S)-18-(methoxymethyl)-1,5-dimethyl-6,11,16-trioxo-13,17-dioxapentacyclo[10.6.1.0^{2,10}.0^{5,9}.0^{15,19}]nonadeca-2(10),12(19),14-trien-3-yl acetate</data>
  <data key="d14">C23H24O8</data>
  <data key="d15">19545-26-7</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C23H24O8/c1-10(24)30-13-7-22(2)12(5-6-14(22)25)16-18(13)23(3)15(9-28-4)31-21(27)11-8-29-20(17(11)23)19(16)26/h8,12-13,15H,5-7,9H2,1-4H3/t12-,13+,15+,22-,23-/m0/s1</data>
  <data key="d19">[H][C@@]12CCC(=O)[C@@]1(C)C[C@@H](OC(C)=O)C1=C2C(=O)C2=C3C(=CO2)C(=O)O[C@H](COC)[C@]13C</data>
  <data key="d20"></data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[Wartmannin]</data>
  <data key="d9">Wortmannin is a steroid metabolite of _Penicillium funiculosum_ and _Talaromyces wortmannii_ fungi. This drug acts as a nonspecific, covalent inhibitor of phosphoinositide 3-kinase enzymes (PI3Ks).</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00970">
  <data key="d0">Dactinomycin</data>
  <data key="d1">drugbank.DB00970</data>
  <data key="d2">[drugbank.DB00970, drugbank.APRD00124]</data>
  <data key="d11">[approved, investigational]</data>
  <data key="d12">[Actinomycin, Actinomycines, Amino Acids, Peptides, and Proteins, Anti-Infective Agents, Antibiotics, Antineoplastic, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, BCRP/ABCG2 Substrates, Cytotoxic Antibiotics and Related Substances, Enzyme Inhibitors, Immunosuppressive Agents, Myelosuppressive Agents, Nucleic Acid Synthesis Inhibitors, P-glycoprotein/ABCB1 Inhibitors, P-glycoprotein/ABCB1 Substrates, Peptides, Peptides, Cyclic, Protein Synthesis Inhibitors]</data>
  <data key="d13">N1,N9-bis[(6S,9R,10S,13R,18aS)-2,5,9-trimethyl-1,4,7,11,14-pentaoxo-6,13-bis(propan-2-yl)-hexadecahydro-1H-pyrrolo[2,1-i]1-oxa-4,7,10,13-tetraazacyclohexadecan-10-yl]-2-amino-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide</data>
  <data key="d14">C62H86N12O16</data>
  <data key="d15">50-76-0</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C62H86N12O16/c1-27(2)42-59(84)73-23-17-19-36(73)57(82)69(13)25-38(75)71(15)48(29(5)6)61(86)88-33(11)44(55(80)65-42)67-53(78)35-22-21-31(9)51-46(35)64-47-40(41(63)50(77)32(10)52(47)90-51)54(79)68-45-34(12)89-62(87)49(30(7)8)72(16)39(76)26-70(14)58(83)37-20-18-24-74(37)60(85)43(28(3)4)66-56(45)81/h21-22,27-30,33-34,36-37,42-45,48-49H,17-20,23-26,63H2,1-16H3,(H,65,80)(H,66,81)(H,67,78)(H,68,79)/t33-,34-,36+,37+,42-,43-,44+,45+,48+,49+/m1/s1</data>
  <data key="d19">[H][C@@]12CCCN1C(=O)[C@H](NC(=O)[C@@H](NC(=O)C1=C3N=C4C(OC3=C(C)C=C1)=C(C)C(=O)C(N)=C4C(=O)N[C@H]1[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@]3([H])CCCN3C(=O)[C@H](NC1=O)C(C)C)[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C2=O)C(C)C</data>
  <data key="d20">For the treatment of Wilms' tumor, childhood rhabdomyosarcoma, Ewing's sarcoma and metastatic, nonseminomatous testicular cancer as part of a combination chemotherapy and/or multi-modality treatment regimen</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[2-amino-N, N'-bis(hexadecahydro-2, 5, 9-trimethyl-6, 13-bis(1-methylethyl)-1, 4, 7, 11, 14-pentaoxo-1H-pyrrolo(2, 1-i)(1, 4, 7, 10, 13)oxatetra-azacyclohexadecin-10-yl)-4, 6-dimethyl-3-oxo-3H-phenoxazine-1, 9-dicarboxamide, ActD, Actinomycin C1, Actinomycin D, Actinomycin IV, Dactinomicina, Dactinomycin, Dactinomycine, Dactinomycinum, Meractinomycin]</data>
  <data key="d9">A compound composed of a two cyclic peptides attached to a phenoxazine that is derived from streptomyces parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00988">
  <data key="d0">Dopamine</data>
  <data key="d1">drugbank.DB00988</data>
  <data key="d2">[drugbank.DB00988, drugbank.APRD00085]</data>
  <data key="d11">[approved]</data>
  <data key="d12">[Adrenergic and Dopaminergic Agents, Agents producing tachycardia, Agents that produce hypertension, Amines, Autonomic Agents, Biogenic Amines, Biogenic Monoamines, Cardiac Stimulants Excl. Cardiac Glycosides, Cardiac Therapy, Cardiotonic Agents, Cardiovascular Agents, Catecholamines, Compounds used in a research, industrial, or household setting, COMT Substrates, Dopamine Agents, Drugs that are Mainly Renally Excreted, Monoamine Oxidase A Substrates, Neurotransmitter Agents, OCT1 substrates, OCT2 Inhibitors, OCT2 Substrates, OCT2 substrates with narrow therapeutic index, Peripheral Nervous System Agents, Protective Agents, Selective Beta 1-adrenergic Agonists, Sympathomimetics]</data>
  <data key="d13">4-(2-aminoethyl)benzene-1,2-diol</data>
  <data key="d14">C8H11NO2</data>
  <data key="d15">51-61-6</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C8H11NO2/c9-4-3-6-1-2-7(10)8(11)5-6/h1-2,5,10-11H,3-4,9H2</data>
  <data key="d19">NCCC1=CC(O)=C(O)C=C1</data>
  <data key="d20">For the correction of hemodynamic imbalances present in the shock syndrome due to myocardial infarction, trauma, endotoxic septicemia, open-heart surgery, renal failure, and chronic cardiac decompensation as in congestive failure</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[2-(3, 4-dihydroxyphenyl)ethylamine, 3-Hydroxytyramine, 3, 4-Dihydroxyphenethylamine, 4-(2-aminoethyl)-1, 2-benzenediol, 4-(2-Aminoethyl)benzene-1, 2-diol, 4-(2-aminoethyl)catechol, 4-(2-aminoethyl)pyrocatechol, Dopamina, Dopamine, Dopaminum, Oxytyramine]</data>
  <data key="d9">One of the catecholamine neurotransmitters in the brain.  It is derived from tyrosine and is the precursor to norepinephrine and epinephrine. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (receptors, dopamine) mediate its action.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00997">
  <data key="d0">Doxorubicin</data>
  <data key="d1">drugbank.DB00997</data>
  <data key="d2">[drugbank.DB00997, drugbank.APRD00185, drugbank.DB05331, drugbank.DB05847]</data>
  <data key="d11">[approved, investigational]</data>
  <data key="d12">[Anthracycline Topoisomerase Inhibitor, Anthracyclines, Anthracyclines and Related Substances, Antibiotics, Antineoplastic, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, BCRP/ABCG2 Substrates, BSEP/ABCB11 Substrates, Carbohydrates, Cardiotoxic antineoplastic agents, Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2B6 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Cytotoxic Antibiotics and Related Substances, Daunorubicin, Enzyme Inhibitors, Glycosides, Immunosuppressive Agents, Myelosuppressive Agents, Naphthacenes, P-glycoprotein/ABCB1 Inducers, P-glycoprotein/ABCB1 Inhibitors, P-glycoprotein/ABCB1 Substrates, Topoisomerase II Inhibitors, Topoisomerase Inhibitors]</data>
  <data key="d13">(8S,10S)-10-{[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy}-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-5,7,8,9,10,12-hexahydrotetracene-5,12-dione</data>
  <data key="d14">C27H29NO11</data>
  <data key="d15">23214-92-8</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C27H29NO11/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3/t10-,13-,15-,17-,22+,27-/m0/s1</data>
  <data key="d19">COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O</data>
  <data key="d20">Doxorubicin is used to produce regression in disseminated neoplastic conditions like acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms’ tumor, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, ovarian carcinoma, transitional cell bladder carcinoma, thyroid carcinoma, gastric carcinoma, Hodgkin’s disease, malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types. Doxorubicin is also indicated for use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer.</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[(1S, 3S)-3-glycoloyl-3, 5, 12-trihydroxy-10-methoxy-6, 11-dioxo-1, 2, 3, 4, 6, 11-hexahydrotetracen-1-yl 3-amino-2, 3, 6-trideoxy-α-L-lyxo-hexopyranoside, (8S-cis)-10-((3-amino-2, 3, 6-trideoxy-α-L-lyxo-hexopyranosyl)oxy)-7, 8, 9, 10-tetrahydro-6, 8, 11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5, 12-naphthacenedione, 14-hydroxydaunomycin, 14-hydroxydaunorubicine, Doxorubicin, Doxorubicina, Doxorubicine, Doxorubicinum, Hydroxydaunorubicin]</data>
  <data key="d9">Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00968">
  <data key="d0">Methyldopa</data>
  <data key="d1">drugbank.DB00968</data>
  <data key="d2">[drugbank.DB00968, drugbank.APRD01106]</data>
  <data key="d11">[approved]</data>
  <data key="d12">[Adrenergic Agents, Adrenergic Agonists, Adrenergic alpha-2 Receptor Agonists, Adrenergic alpha-Agonists, Agents Causing Muscle Toxicity, Amines, Amino Acids, Amino Acids, Aromatic, Amino Acids, Cyclic, Amino Acids, Essential, Amino Acids, Peptides, and Proteins, Antihypertensive Agents, Autonomic Agents, Biogenic Amines, Biogenic Monoamines, Bradycardia-Causing Agents, Cardiovascular Agents, Catecholamines, Central alpha-2 Adrenergic Agonist, Central Alpha-agonists, COMT Substrates, Dihydroxyphenylalanine, Drugs that are Mainly Renally Excreted, Hypotensive Agents, Neurotransmitter Agents, Peripheral Nervous System Agents, Phenylalanine, Sympatholytics, Tyrosine]</data>
  <data key="d13">(2S)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid</data>
  <data key="d14">C10H13NO4</data>
  <data key="d15">555-30-6</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C10H13NO4/c1-10(11,9(14)15)5-6-2-3-7(12)8(13)4-6/h2-4,12-13H,5,11H2,1H3,(H,14,15)/t10-/m0/s1</data>
  <data key="d19">C[C@](N)(CC1=CC=C(O)C(O)=C1)C(O)=O</data>
  <data key="d20">For use in the treatment of hypertension.</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[(S)-(-)-alpha-Methyldopa, 3-Hydroxy-alpha-methyl-L-tyrosine, Alpha medopa, alpha-Methyl dopa, alpha-methyl-L-dopa, Alphamethyldopa, AMD, Anhydrous methyldopa, L-alpha-Methyldopa, L-Methyl Dopa, Methyl dopa, Methyldopa, Methyldopa anhydrous, metildopa, α-Methyl dopa, α-methyl-L-dopa]</data>
  <data key="d9">An alpha-2 adrenergic agonist that has both central and peripheral nervous system effects. Its primary clinical use is as an antihypertensive agent. [PubChem]</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06021">
  <data key="d0">AV-412</data>
  <data key="d1">drugbank.DB06021</data>
  <data key="d2">[drugbank.DB06021]</data>
  <data key="d11">[investigational]</data>
  <data key="d12">[Receptor, Epidermal Growth Factor, antagonists &amp; inhibitors, Receptor, ErbB-2, antagonists &amp; inhibitors]</data>
  <data key="d13">bis(4-methylbenzene-1-sulfonic acid); N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[3-methyl-3-(4-methylpiperazin-1-yl)but-1-yn-1-yl]quinazolin-6-yl}prop-2-enamide</data>
  <data key="d14">C41H44ClFN6O7S2</data>
  <data key="d15">451493-31-5</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C27H28ClFN6O.2C7H8O3S/c1-5-25(36)33-23-16-20-24(30-17-31-26(20)32-19-6-7-22(29)21(28)15-19)14-18(23)8-9-27(2,3)35-12-10-34(4)11-13-35;2*1-6-2-4-7(5-3-6)11(8,9)10/h5-7,14-17H,1,10-13H2,2-4H3,(H,33,36)(H,30,31,32);2*2-5H,1H3,(H,8,9,10)</data>
  <data key="d19">CC1=CC=C(C=C1)S(O)(=O)=O.CC1=CC=C(C=C1)S(O)(=O)=O.CN1CCN(CC1)C(C)(C)C#CC1=C(NC(=O)C=C)C=C2C(NC3=CC=C(F)C(Cl)=C3)=NC=NC2=C1</data>
  <data key="d20">Investigated for use/treatment in cancer/tumors (unspecified).</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB10772">
  <data key="d0">Foreskin keratinocyte (neonatal)</data>
  <data key="d1">drugbank.DB10772</data>
  <data key="d2">[drugbank.DB10772]</data>
  <data key="d11">[approved]</data>
  <data key="d12">[Allogeneic Cultured Cell Scaffold]</data>
  <data key="d13">NA</data>
  <data key="d14">NA</data>
  <data key="d15"></data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">NA</data>
  <data key="d19">NA</data>
  <data key="d20">For chronic leg ulcers and diabetic foot [L2439].  \n\nOrcel is indicated for use with standard therapeutic compression for the treatment of non-infected partial and full-thickness skin ulcers due to venous insufficiency of greater than 1 month in duration and which have not effectively responded to conventional ulcer therapy. Orcel is also for use with standard diabetic foot ulcer care for the treatment of full-thickness neuropathic diabetic foot ulcers of greater than 3 weeks in duration which have not effectively responded to conventional ulcer therapy, and which extend through the dermis but without tendon, muscle, capsule or bone involvement [L2459].</data>
  <data key="d21">BiotechDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[foreskin keratinocyte, neonatal]</data>
  <data key="d9">Skin, the largest organ of the human body, plays the main role in protecting the body from mechanical damage. It is composed of epidermal, dermal and hypodermal layers. The barrier function of the skin owed to its avascular epidermal layer, which is made mainly of keratinocytes. The keratinocytes form a stratified epithelium, with growing basal cells at the innermost layer and the keratinized, and mostly impermeable outer stratum corneum layer on the surface [L2452].\n\nForeskin keratinocytes are a form of skin cells that are cultured as a skin cell replacement for wounds, to accelerate wound closure and healing [L2434], [L2460]. \n\nThe defining moment in skin culture was in 1975 when Rheinwald and Green successfully grew human keratinocytes on lethally irradiated murine fibroblasts. In 1981, O’Conner and his group utilized cultured autologous epithelium to coat burn defects for the first time. To construct a "living" alternative, a dermal substitute based on collagen I gel was created with mesenchymal cells such as fibroblasts. When an epidermal layer was added, this approach became known as "skin equivalent", "composite culture" or "organotypical culture" [L2453].\n\nForeskin keratinocytes are an important ingredient in several skin substitutes [L2460], used for various indications. \nKeratinocytes are derived from neonatal foreskins and used to create a drug called _Apligraf_, a mixture of [DB10770] and keratinocytes. A gel made of bovine collagen is used as the matrix for cell growth and differentiation. Apligraf has been useful in the treatment of venous leg ulcers and diabetic foot ulcers, by increasing rates of wound healing and decreasing the time required for closure of wounds [L2452].\n\nOrcel, another skin substitute,  is similar to Apligraf since it contains both fibroblasts and keratinocytes derived from neonatal foreskin, but in addition, utilizes a type I collagen sponge as its matrix. It is used for grafting onto partial-thickness wounds, where it offers a favorable matrix for host cell migration [L2452].</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08901">
  <data key="d0">Ponatinib</data>
  <data key="d1">drugbank.DB08901</data>
  <data key="d2">[drugbank.DB08901, drugbank.DB06300]</data>
  <data key="d11">[approved, investigational]</data>
  <data key="d12">[Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, BCRP/ABCG2 Inhibitors, BCRP/ABCG2 Substrates, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strength unknown), Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 Enzyme Inhibitors, Enzyme Inhibitors, Immunosuppressive Agents, Kinase Inhibitor, Myelosuppressive Agents, P-glycoprotein/ABCB1 Inhibitors, P-glycoprotein/ABCB1 Substrates, Protein Kinase Inhibitors, Tyrosine Kinase Inhibitors]</data>
  <data key="d13">3-(2-{imidazo[1,2-b]pyridazin-3-yl}ethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide</data>
  <data key="d14">C29H27F3N6O</data>
  <data key="d15">943319-70-8</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C29H27F3N6O/c1-20-5-6-22(16-21(20)8-10-25-18-33-27-4-3-11-34-38(25)27)28(39)35-24-9-7-23(26(17-24)29(30,31)32)19-37-14-12-36(2)13-15-37/h3-7,9,11,16-18H,12-15,19H2,1-2H3,(H,35,39)</data>
  <data key="d19">CN1CCN(CC2=CC=C(NC(=O)C3=CC(C#CC4=CN=C5C=CC=NN45)=C(C)C=C3)C=C2C(F)(F)F)CC1</data>
  <data key="d20">Ponatinib is indicated for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy.</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[Ponatinib, Ponatinibum]</data>
  <data key="d9">Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08916">
  <data key="d0">Afatinib</data>
  <data key="d1">drugbank.DB08916</data>
  <data key="d2">[drugbank.DB08916]</data>
  <data key="d11">[approved]</data>
  <data key="d12">[Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, BCRP/ABCG2 Inhibitors, BCRP/ABCG2 Substrates, Kinase Inhibitor, P-glycoprotein/ABCB1 Inhibitors, P-glycoprotein/ABCB1 Substrates, Protein Kinase Inhibitors, Tyrosine Kinase Inhibitors]</data>
  <data key="d13">(2E)-N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[(3S)-oxolan-3-yloxy]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide</data>
  <data key="d14">C24H25ClFN5O3</data>
  <data key="d15">850140-72-6</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C24H25ClFN5O3/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29)/b4-3+/t16-/m0/s1</data>
  <data key="d19">CN(C)C\C=C\C(=O)NC1=C(O[C@H]2CCOC2)C=C2N=CN=C(NC3=CC(Cl)=C(F)C=C3)C2=C1</data>
  <data key="d20">Afatinib is a kinase inhibitor indicated as monotherapy [L2937] for the first-line [FDA Label] treatment of (a) Epidermal Growth Factor Receptor (EGFR) TKI (tyrosine kinase inhibitor)-naive adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumours have non-resistant EGFR mutations as detected by an FDA-approved test [FDA Label], and (b) adult patients with locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy [FDA Label, L2937].\n\nRecently, as of January 2018, the US FDA approved a supplemental New Drug Application for Boehringer Ingelheim's Gilotrif (afatinib) for the first line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test [L2939]. The new label includes data on three additional EGFR mutations: L861Q, G719X and S768I [L2939].</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[Afatinib, Afatinibum]</data>
  <data key="d9">Afatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available as Boehringer Ingelheim's brand name Gilotrif [FDA Label]. For oral use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test [L2939]. Gilotrif (afatinib) is the first FDA-approved oncology product from Boehringer Ingelheim [L2939].</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07662">
  <data key="d0">N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE</data>
  <data key="d1">drugbank.DB07662</data>
  <data key="d2">[drugbank.DB07662]</data>
  <data key="d11">[experimental]</data>
  <data key="d12">[]</data>
  <data key="d13">N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}prop-2-enamide</data>
  <data key="d14">C17H13BrN4O</data>
  <data key="d15"></data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C17H13BrN4O/c1-2-16(23)21-13-6-7-15-14(9-13)17(20-10-19-15)22-12-5-3-4-11(18)8-12/h2-10H,1H2,(H,21,23)(H,19,20,22)</data>
  <data key="d19">BrC1=CC=CC(NC2=C3C=C(NC(=O)C=C)C=CC3=NC=N2)=C1</data>
  <data key="d20"></data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06486">
  <data key="d0">Enzastaurin</data>
  <data key="d1">drugbank.DB06486</data>
  <data key="d2">[drugbank.DB06486]</data>
  <data key="d11">[investigational]</data>
  <data key="d12">[]</data>
  <data key="d13">3-(1-methyl-1H-indol-3-yl)-4-(1-{1-[(pyridin-2-yl)methyl]piperidin-4-yl}-1H-indol-3-yl)-2,5-dihydro-1H-pyrrole-2,5-dione</data>
  <data key="d14">C32H29N5O2</data>
  <data key="d15">170364-57-5</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C32H29N5O2/c1-35-19-25(23-9-2-4-11-27(23)35)29-30(32(39)34-31(29)38)26-20-37(28-12-5-3-10-24(26)28)22-13-16-36(17-14-22)18-21-8-6-7-15-33-21/h2-12,15,19-20,22H,13-14,16-18H2,1H3,(H,34,38,39)</data>
  <data key="d19">CN1C=C(C2=CC=CC=C12)C1=C(C(=O)NC1=O)C1=CN(C2CCN(CC3=CC=CC=N3)CC2)C2=CC=CC=C12</data>
  <data key="d20">Investigated for use/treatment in brain cancer, lymphoma (non-hodgkin's), and lung cancer.</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[]</data>
  <data key="d9">Enzastaurin, an investigational, targeted, oral agent, will be evaluated at more than 100 sites worldwide for the treatment of relapsed glioblastoma multiforme (GBM), an aggressive and malignant form of brain cancer.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB05184">
  <data key="d0">XL228</data>
  <data key="d1">drugbank.DB05184</data>
  <data key="d2">[drugbank.DB05184]</data>
  <data key="d11">[investigational]</data>
  <data key="d12">[]</data>
  <data key="d13">NA</data>
  <data key="d14">NA</data>
  <data key="d15"></data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">NA</data>
  <data key="d19">NA</data>
  <data key="d20">Investigated for use/treatment in leukemia (lymphoid) and leukemia (myeloid).</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[]</data>
  <data key="d9">XL228 is a novel anticancer compound designed to inhibit the insulin-like growth factor type-1 receptor (IGF1R), Src and Abl tyrosine kinases – targets that play crucial roles in cancer cell proliferation, survival and metastasis.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB05146">
  <data key="d0">XL820</data>
  <data key="d1">drugbank.DB05146</data>
  <data key="d2">[drugbank.DB05146]</data>
  <data key="d11">[investigational]</data>
  <data key="d12">[]</data>
  <data key="d13">NA</data>
  <data key="d14">NA</data>
  <data key="d15"></data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">NA</data>
  <data key="d19">NA</data>
  <data key="d20">Investigated for use/treatment in solid tumors.</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[]</data>
  <data key="d9">XL820 is investigated for use/treatment in solid tumors. XL820 is a solid. The proteins that XL820 inhibit include platelet-derived growth factor receptor beta (PDGFR), mast/stem cell growth factor receptor KIT, vascular endothelial growth factor receptor 2, and platelet-derived growth factor receptor alpha, clinically validated targets implicated in a variety of human cancers. XL820 exhibits dose-dependent growth inhibition in models of breast carcinoma, gliomas and leukemia.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08865">
  <data key="d0">Crizotinib</data>
  <data key="d1">drugbank.DB08865</data>
  <data key="d2">[drugbank.DB08865, drugbank.DB08700]</data>
  <data key="d11">[approved]</data>
  <data key="d12">[Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Bradycardia-Causing Agents, Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2B6 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (moderate), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A5 Inhibitors, Cytochrome P-450 CYP3A5 Inhibitors (strength unknown), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P450 3A Inhibitors, Enzyme Inhibitors, Kinase Inhibitor, Moderate Risk QTc-Prolonging Agents, OCT2 Inhibitors, Organic Cation Transporter 1 Inhibitors, P-glycoprotein/ABCB1 Inhibitors, P-glycoprotein/ABCB1 Substrates, Protein Kinase Inhibitors, QTc Prolonging Agents, Receptor Tyrosine Kinase Inhibitors, Tyrosine Kinase Inhibitors]</data>
  <data key="d13">3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]pyridin-2-amine</data>
  <data key="d14">C21H22Cl2FN5O</data>
  <data key="d15">877399-52-5</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C21H22Cl2FN5O/c1-12(19-16(22)2-3-17(24)20(19)23)30-18-8-13(9-27-21(18)25)14-10-28-29(11-14)15-4-6-26-7-5-15/h2-3,8-12,15,26H,4-7H2,1H3,(H2,25,27)/t12-/m1/s1</data>
  <data key="d19">C[C@@H](OC1=CC(=CN=C1N)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl</data>
  <data key="d20">Crizotinib is used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic-lymphoma kinase (ALK)-positive as detected by a FDA-approved test.</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[(R)-crizotinib, Crizotinib, Crizotinibum]</data>
  <data key="d9">Crizotinib an inhibitor of receptor tyrosine kinase for the treatment of non-small cell lung cancer (NSCLC). Verification of the presence of ALK fusion gene is done by Abbott Molecular's Vysis ALK Break Apart FISH Probe Kit. This verification is used to select for patients suitable for treatment. FDA approved in August 26, 2011.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08877">
  <data key="d0">Ruxolitinib</data>
  <data key="d1">drugbank.DB08877</data>
  <data key="d2">[drugbank.DB08877, drugbank.DB06164]</data>
  <data key="d11">[approved]</data>
  <data key="d12">[Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Drugs that are Mainly Renally Excreted, Immunosuppressive Agents, Janus Kinases, antagonists &amp; inhibitors, Kinase Inhibitor, Myelosuppressive Agents, Protein Kinase Inhibitors, Tyrosine Kinase Inhibitors]</data>
  <data key="d13">(3R)-3-cyclopentyl-3-(4-{7H-pyrrolo[2,3-d]pyrimidin-4-yl}-1H-pyrazol-1-yl)propanenitrile</data>
  <data key="d14">C17H18N6</data>
  <data key="d15">941678-49-5</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)/t15-/m1/s1</data>
  <data key="d19">N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1</data>
  <data key="d20">Treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera (post-PV) myelofibrosis and post-essential thrombocythemia (post-ET) myelofibrosis. [Lexicomp] Myeolofibrosis is the proliferation of abnormal bone marrow stem cells which cause fibrosis (the excessive formation of connective tissue).</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[Ruxolitinib]</data>
  <data key="d9">Ruxolitinib is a janus-associated kinase inhibitor indicated to treat bone marrow cancer, specifically intermediate or high-risk myelofibrosis. FDA approved on November 16, 2011.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08896">
  <data key="d0">Regorafenib</data>
  <data key="d1">drugbank.DB08896</data>
  <data key="d2">[drugbank.DB08896]</data>
  <data key="d11">[approved]</data>
  <data key="d12">[Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, BCRP/ABCG2 Inhibitors, Benzene Derivatives, Bradycardia-Causing Agents, Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2B6 Inhibitors (strength unknown), Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Kinase Inhibitor, P-glycoprotein/ABCB1 Inhibitors, P-glycoprotein/ABCB1 Substrates, Protein Kinase Inhibitors, Tyrosine Kinase Inhibitors, UGT1A1 Inhibitors, UGT1A9 Inhibitors, UGT1A9 Substrates, Urea]</data>
  <data key="d13">4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide</data>
  <data key="d14">C21H15ClF4N4O3</data>
  <data key="d15">755037-03-7</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C21H15ClF4N4O3/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26/h2-10H,1H3,(H,27,31)(H2,29,30,32)</data>
  <data key="d19">CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1</data>
  <data key="d20">Regorafenib is indicated for the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy. Regorafenib is also indicated for the treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[Regorafenib, Régorafénib, Regorafenibum]</data>
  <data key="d9">Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer and advanced gastrointestinal stromal tumours. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April, 2017.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08895">
  <data key="d0">Tofacitinib</data>
  <data key="d1">drugbank.DB08895</data>
  <data key="d2">[drugbank.DB08895, drugbank.DB08183]</data>
  <data key="d11">[approved, investigational]</data>
  <data key="d12">[Antineoplastic and Immunomodulating Agents, Antirheumatic Agents, Biologics for Rheumatoid Arthritis Treatment, Bradycardia-Causing Agents, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Disease-modifying Antirheumatic Agents, Enzyme Inhibitors, Immunosuppressive Agents, Janus Kinase 3, antagonists &amp; inhibitors, Janus Kinase Inhibitor, Janus Kinase Inhibitors, Myelosuppressive Agents, Protein Kinase Inhibitors, Selective Immunosuppressants]</data>
  <data key="d13">3-[(3R,4R)-4-methyl-3-[methyl({7H-pyrrolo[2,3-d]pyrimidin-4-yl})amino]piperidin-1-yl]-3-oxopropanenitrile</data>
  <data key="d14">C16H20N6O</data>
  <data key="d15">477600-75-2</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C16H20N6O/c1-11-5-8-22(14(23)3-6-17)9-13(11)21(2)16-12-4-7-18-15(12)19-10-20-16/h4,7,10-11,13H,3,5,8-9H2,1-2H3,(H,18,19,20)/t11-,13+/m1/s1</data>
  <data key="d19">[H][C@@]1(C)CCN(C[C@]1([H])N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N</data>
  <data key="d20">For the treatment of moderate to severe rheumatoid arthritis which is resistant or intolerant to methotrexate therapy. It may also be used as an adjunct to methotrexate therapy, or other non-biologic disease-modifying antirheumatic drugs (DMARDS), when methotrexate alone is not sufficient.  \n\nTofacitinib has also been investigated as a preventative therapy for kidney transplant rejections, and as a treatment for psoriasis, ulcerative colitis, and ankylosing spondylitis. \n\nIt is not to be initiated in patients with a history of chronic or recurrent infections, or in the presence of active infection, even if localized, due to reports of serious and sometimes fatal infections (commonly pneumonia, herpes zoster and urinary tract infections). Use of tofacitinib is also discouraged in those who have been, or are likely to be, exposed to TB. An increased likelihood of exposure may be encountered by traveling to certain areas. In addition, tofacitinib is not to be used in patients with severe hepatic impairment, or low hemoglobin (less than 9g/dL). Cautioned is advised when using tofacitinib in patients at risk of gastrointestinal perforation, and in the elderly who are more susceptible to infection.</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[Tasocitinib, Tofacitinib, Tofacitinibum]</data>
  <data key="d9">Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant to methotrexate. \nBesides rheumatoid arthritis, tofacitinib has also been studied in clinical trials for the prevention of organ transplant rejection, and is currently under investigation for the treatment of psoriasis. Known adverse effects include nausea and headache as well as more serious immunologic and hematological adverse effects. Tofacitinib is marketed under the brand name Xeljanz by Pfizer.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04216">
  <data key="d0">Quercetin</data>
  <data key="d1">drugbank.DB04216</data>
  <data key="d2">[drugbank.DB04216, drugbank.EXPT02732]</data>
  <data key="d11">[experimental, investigational]</data>
  <data key="d12">[Antioxidants, BCRP/ABCG2 Inhibitors, Benzopyrans, Chromones, Compounds used in a research, industrial, or household setting, COMT Inhibitors, COMT Substrates, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Flavonoids, Flavonols, OATP1B1/SLCO1B1 Inhibitors, P-glycoprotein/ABCB1 Inhibitors, Protective Agents, Pyrans]</data>
  <data key="d13">2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one</data>
  <data key="d14">C15H10O7</data>
  <data key="d15">117-39-5</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C15H10O7/c16-7-4-10(19)12-11(5-7)22-15(14(21)13(12)20)6-1-2-8(17)9(18)3-6/h1-5,16-19,21H</data>
  <data key="d19">OC1=CC2=C(C(O)=C1)C(=O)C(O)=C(O2)C1=CC=C(O)C(O)=C1</data>
  <data key="d20"></data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[2-(3, 4-dihydroxyphenyl)-3, 5, 7-trihydroxy-4H-1-benzopyran-4-one, 3, 3', 4', 5, 7-pentahydroxyflavone, 3, 5, 7, 3', 4'-Pentahydroxyflavone, Sophoretin, Xanthaurine]</data>
  <data key="d9">Quercetin is a flavonol widely distributed in plants. It is an antioxidant, like many other phenolic heterocyclic compounds. Glycosylated forms include RUTIN and quercetrin.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06803">
  <data key="d0">Niclosamide</data>
  <data key="d1">drugbank.DB06803</data>
  <data key="d2">[drugbank.DB06803]</data>
  <data key="d11">[approved, investigational, vet_approved]</data>
  <data key="d12">[Agrochemicals, Amides, Anilides, Anthelmintics, Anti-Infective Agents, Anticestodal Agents, Anticestodals, Antinematodal Agents, Antiparasitic Agents, Antiparasitic Products, Insecticides and Repellents, Antiplatyhelmintic Agents, Compounds used in a research, industrial, or household setting, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (unknown strength), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 Enzyme Inhibitors, Molluscacides, Pesticides, Salicylamides, Salicylanilides, Salicylic Acid Derivatives, Toxic Actions]</data>
  <data key="d13">5-chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxybenzamide</data>
  <data key="d14">C13H8Cl2N2O4</data>
  <data key="d15">50-65-7</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C13H8Cl2N2O4/c14-7-1-4-12(18)9(5-7)13(19)16-11-3-2-8(17(20)21)6-10(11)15/h1-6,18H,(H,16,19)</data>
  <data key="d19">OC1=C(C=C(Cl)C=C1)C(=O)NC1=C(Cl)C=C(C=C1)[N+]([O-])=O</data>
  <data key="d20">For the treatment of tapeworm and intestinal fluke infections: Taenia saginata (Beef Tapeworm), Taenia solium (Pork Tapeworm), Diphyllobothrium latum (Fish Tapeworm), Fasciolopsis buski (large intestinal fluke). Niclosamide is also used as a molluscicide in the control of schistosomiasis.</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[]</data>
  <data key="d9">Niclosamide is used for the treatment of most tapeworm infections. Helminths (worms) are multicellular organisms that infect very large numbers of humans and cause a broad range of diseases. Over 1 billion people are infected with intestinal nematodes, and many millions are infected with filarial nematodes, flukes, and tapeworms. They are an even greater problem in domestic animals.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB05210">
  <data key="d0">SF1126</data>
  <data key="d1">drugbank.DB05210</data>
  <data key="d2">[drugbank.DB05210]</data>
  <data key="d11">[investigational]</data>
  <data key="d12">[Amino Acids, Peptides, and Proteins, Benzopyrans, Peptides, Pyrans]</data>
  <data key="d13">NA</data>
  <data key="d14">NA</data>
  <data key="d15"></data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">NA</data>
  <data key="d19">NA</data>
  <data key="d20">For the treatment of various forms of cancer.</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[]</data>
  <data key="d9">SF1126 is an integrin-targeted PI3 kinase inhibitor.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB05294">
  <data key="d0">Vandetanib</data>
  <data key="d1">drugbank.DB05294</data>
  <data key="d2">[drugbank.DB05294, drugbank.DB08764]</data>
  <data key="d11">[approved]</data>
  <data key="d12">[Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, BCRP/ABCG2 Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Highest Risk QTc-Prolonging Agents, Kinase Inhibitor, OCT2 Inhibitors, P-glycoprotein/ABCB1 Inhibitors, Protein Kinase Inhibitors, QTc Prolonging Agents, Tyrosine Kinase Inhibitors]</data>
  <data key="d13">N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine</data>
  <data key="d14">C22H24BrFN4O2</data>
  <data key="d15">443913-73-3</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C22H24BrFN4O2/c1-28-7-5-14(6-8-28)12-30-21-11-19-16(10-20(21)29-2)22(26-13-25-19)27-18-4-3-15(23)9-17(18)24/h3-4,9-11,13-14H,5-8,12H2,1-2H3,(H,25,26,27)</data>
  <data key="d19">COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1</data>
  <data key="d20">Vandetanib is currently approved as an alternative to local therapies for both unresectable and disseminated disease. Because Vandetanib can prolong the Q-T interval, it is contraindicated for use in patients with serious cardiac complications such as congenital long QT syndrome and uncompensated heart failure.</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-4-quinazolinamine, N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine, Vandetanib]</data>
  <data key="d9">Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types.\n\nOn April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06595">
  <data key="d0">Midostaurin</data>
  <data key="d1">drugbank.DB06595</data>
  <data key="d2">[drugbank.DB06595]</data>
  <data key="d11">[approved, investigational]</data>
  <data key="d12">[Alkaloids, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Carbazoles, Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP1A2 Inducers (unknown strength), Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (strong), Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 CYP2B6 Inducers (strength unknown), Cytochrome P-450 CYP2C19 Inducers, Cytochrome P-450 CYP2C19 Inducers (unknown strength), Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 Inhibitors (weak), Cytochrome P-450 CYP2C8 Inducers, Cytochrome P-450 CYP2C8 Inducers (strength unknown), Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Inducers, Cytochrome P-450 CYP2C9 Inducers (strength unknown), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strong), Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (strong), Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Inducers (strong), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Inhibitors (strong), Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Inducers (strong), Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strong), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A5 Inducers, Cytochrome P-450 CYP3A5 Inducers (strength unknown), Cytochrome P-450 CYP3A7 Inducers, Cytochrome P-450 CYP3A7 Inducers (strength unknown), Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Enzyme Inhibitors, Indole Alkaloids, Indoles, Kinase Inhibitor, Protein Kinase C, antagonists &amp; inhibitors, Protein Kinase Inhibitors, Receptor Tyrosine Kinase Inhibitors, Tyrosine Kinase Inhibitors]</data>
  <data key="d13">N-[(2S,3R,4R,6R)-3-methoxy-2-methyl-16-oxo-29-oxa-1,7,17-triazaoctacyclo[12.12.2.1^{2,6}.0^{7,28}.0^{8,13}.0^{15,19}.0^{20,27}.0^{21,26}]nonacosa-8(13),9,11,14(28),15(19),20(27),21(26),22,24-nonaen-4-yl]-N-methylbenzamide</data>
  <data key="d14">C35H30N4O4</data>
  <data key="d15">120685-11-2</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C35H30N4O4/c1-35-32(42-3)25(37(2)34(41)19-11-5-4-6-12-19)17-26(43-35)38-23-15-9-7-13-20(23)28-29-22(18-36-33(29)40)27-21-14-8-10-16-24(21)39(35)31(27)30(28)38/h4-16,25-26,32H,17-18H2,1-3H3,(H,36,40)/t25-,26-,32-,35+/m1/s1</data>
  <data key="d19">CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O)N(C)C(=O)C1=CC=CC=C1</data>
  <data key="d20">Investigated for use/treatment in adult patients with high-risk acute myeloid leukemia (AML) who are FLT3 mutation-positive, agressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL).</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[4'-N-benzoylstaurosporine, Midostaurin]</data>
  <data key="d9">Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hematopoietic tumors [A19108]. It was approved on April 28, 2017 and has shown to increase the overall survival rate in patients with AML as an adjunct therapy along with chemotherapeutic agents.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06589">
  <data key="d0">Pazopanib</data>
  <data key="d1">drugbank.DB06589</data>
  <data key="d2">[drugbank.DB06589]</data>
  <data key="d11">[approved]</data>
  <data key="d12">[Amides, Angiogenesis Inhibitors, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, BCRP/ABCG2 Substrates, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (weak), Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (weak), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (weak), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Cytochrome P450 3A4 Inhibitors, Immunosuppressive Agents, Kinase Inhibitor, Moderate Risk QTc-Prolonging Agents, OATP1B1/SLCO1B1 Inhibitors, P-glycoprotein/ABCB1 Substrates, Protein Kinase Inhibitors, QTc Prolonging Agents, Receptors, Vascular Endothelial Growth Factor, antagonists &amp; inhibitors, Sulfones, Sulfur Compounds, Tyrosine Kinase Inhibitors, UGT1A1 Inhibitors]</data>
  <data key="d13">5-({4-[(2,3-dimethyl-2H-indazol-6-yl)(methyl)amino]pyrimidin-2-yl}amino)-2-methylbenzene-1-sulfonamide</data>
  <data key="d14">C21H23N7O2S</data>
  <data key="d15">444731-52-6</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C21H23N7O2S/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25)</data>
  <data key="d19">CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1</data>
  <data key="d20">Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy)</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[Pazopanib, Pazopanibum]</data>
  <data key="d9">Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06616">
  <data key="d0">Bosutinib</data>
  <data key="d1">drugbank.DB06616</data>
  <data key="d2">[drugbank.DB06616]</data>
  <data key="d11">[approved]</data>
  <data key="d12">[Amines, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Immunosuppressive Agents, Kinase Inhibitor, Myelosuppressive Agents, P-glycoprotein/ABCB1 Inhibitors, P-glycoprotein/ABCB1 Substrates, Protein Kinase Inhibitors, Tyrosine Kinase Inhibitors]</data>
  <data key="d13">4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile</data>
  <data key="d14">C26H29Cl2N5O3</data>
  <data key="d15">380843-75-4</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C26H29Cl2N5O3/c1-32-6-8-33(9-7-32)5-4-10-36-25-13-21-18(11-24(25)35-3)26(17(15-29)16-30-21)31-22-14-23(34-2)20(28)12-19(22)27/h11-14,16H,4-10H2,1-3H3,(H,30,31)</data>
  <data key="d19">COC1=CC(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C(Cl)C=C1Cl</data>
  <data key="d20">Treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy in adult patients.</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[4-((2, 4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-3-quinolinecarbonitrile, Bosutinib]</data>
  <data key="d9">Bosutinib is a Bcr-Abl kinase inhibitor for the treatment of Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML). Compared to other tyrosine kinase inhibitors, it has a more favourable hematologic toxicity profile. FDA approved on September 4, 2012.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06626">
  <data key="d0">Axitinib</data>
  <data key="d1">drugbank.DB06626</data>
  <data key="d2">[drugbank.DB06626]</data>
  <data key="d11">[approved, investigational]</data>
  <data key="d12">[Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A5 Substrates, Enzyme Inhibitors, Kinase Inhibitor, OATP1B1/SLCO1B1 Inhibitors, OATP1B1/SLCO1B1 Substrates, P-glycoprotein/ABCB1 Substrates, Protein Kinase Inhibitors, Pyrazoles, Receptor Tyrosine Kinase Inhibitors, Tyrosine Kinase Inhibitors, UGT1A1 Substrates]</data>
  <data key="d13">N-methyl-2-({3-[(E)-2-(pyridin-2-yl)ethenyl]-1H-indazol-6-yl}sulfanyl)benzamide</data>
  <data key="d14">C22H18N4OS</data>
  <data key="d15">319460-85-0</data>
  <data key="d16">DrugBank</data>
  <data key="d17">[DrugBank]</data>
  <data key="d18">InChI=1S/C22H18N4OS/c1-23-22(27)18-7-2-3-8-21(18)28-16-10-11-17-19(25-26-20(17)14-16)12-9-15-6-4-5-13-24-15/h2-14H,1H3,(H,23,27)(H,25,26)/b12-9+</data>
  <data key="d19">CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1</data>
  <data key="d20">Used in kidney cell cancer and investigated for use/treatment in pancreatic and thyroid cancer.</data>
  <data key="d21">SmallMoleculeDrug</data>
  <data key="d22">[]</data>
  <data key="d8">[Axitinib, Axitinibum]</data>
  <data key="d9">Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3).[L6676] Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times higher than that of the first generation VEGFR inhibitors.[L6676] Axitinib is an indazole derivative.[A179398] It is most commonly marketed under the name Inlyta® and is available in oral formulations.</data>
  <data key="d10">drug</data>
</node>
<edge source="entrez.238" target="entrez.238">
  <data key="d23">1256</data>
  <data key="d24">1256</data>
  <data key="d25">ALK</data>
  <data key="d26">ALK</data>
  <data key="d27">entrez.238</data>
  <data key="d28">entrez.238</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp]</data>
</edge>
<edge source="entrez.238" target="entrez.8651">
  <data key="d23">1256</data>
  <data key="d24">12108</data>
  <data key="d25">ALK</data>
  <data key="d26">SOCS1</data>
  <data key="d27">entrez.238</data>
  <data key="d28">entrez.8651</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.238" target="entrez.3717">
  <data key="d23">1256</data>
  <data key="d24">19949</data>
  <data key="d25">ALK</data>
  <data key="d26">JAK2</data>
  <data key="d27">entrez.238</data>
  <data key="d28">entrez.3717</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.238" target="entrez.3667">
  <data key="d23">1256</data>
  <data key="d24">29133</data>
  <data key="d25">ALK</data>
  <data key="d26">IRS1</data>
  <data key="d27">entrez.238</data>
  <data key="d28">entrez.3667</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.238" target="entrez.3326">
  <data key="d23">1256</data>
  <data key="d24">29825</data>
  <data key="d25">ALK</data>
  <data key="d26">HSP90AB1</data>
  <data key="d27">entrez.238</data>
  <data key="d28">entrez.3326</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.238" target="entrez.3320">
  <data key="d23">1256</data>
  <data key="d24">29837</data>
  <data key="d25">ALK</data>
  <data key="d26">HSP90AA1</data>
  <data key="d27">entrez.238</data>
  <data key="d28">entrez.3320</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.238" target="entrez.2885">
  <data key="d23">1256</data>
  <data key="d24">33176</data>
  <data key="d25">ALK</data>
  <data key="d26">GRB2</data>
  <data key="d27">entrez.238</data>
  <data key="d28">entrez.2885</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.238" target="entrez.6714">
  <data key="d23">1256</data>
  <data key="d24">40792</data>
  <data key="d25">ALK</data>
  <data key="d26">SRC</data>
  <data key="d27">entrez.238</data>
  <data key="d28">entrez.6714</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.238" target="entrez.6464">
  <data key="d23">1256</data>
  <data key="d24">41187</data>
  <data key="d25">ALK</data>
  <data key="d26">SHC1</data>
  <data key="d27">entrez.238</data>
  <data key="d28">entrez.6464</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.238" target="entrez.6774">
  <data key="d23">1256</data>
  <data key="d24">46674</data>
  <data key="d25">ALK</data>
  <data key="d26">STAT3</data>
  <data key="d27">entrez.238</data>
  <data key="d28">entrez.6774</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.238" target="entrez.5295">
  <data key="d23">1256</data>
  <data key="d24">54155</data>
  <data key="d25">ALK</data>
  <data key="d26">PIK3R1</data>
  <data key="d27">entrez.238</data>
  <data key="d28">entrez.5295</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.238" target="entrez.5335">
  <data key="d23">1256</data>
  <data key="d24">54399</data>
  <data key="d25">ALK</data>
  <data key="d26">PLCG1</data>
  <data key="d27">entrez.238</data>
  <data key="d28">entrez.5335</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.867" target="entrez.867">
  <data key="d23">3963</data>
  <data key="d24">3963</data>
  <data key="d25">CBL</data>
  <data key="d26">CBL</data>
  <data key="d27">entrez.867</data>
  <data key="d28">entrez.867</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.867" target="entrez.4067">
  <data key="d23">3963</data>
  <data key="d24">8458</data>
  <data key="d25">CBL</data>
  <data key="d26">LYN</data>
  <data key="d27">entrez.867</data>
  <data key="d28">entrez.4067</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.867" target="entrez.4233">
  <data key="d23">3963</data>
  <data key="d24">16661</data>
  <data key="d25">CBL</data>
  <data key="d26">MET</data>
  <data key="d27">entrez.867</data>
  <data key="d28">entrez.4233</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.867" target="entrez.3932">
  <data key="d23">3963</data>
  <data key="d24">19210</data>
  <data key="d25">CBL</data>
  <data key="d26">LCK</data>
  <data key="d27">entrez.867</data>
  <data key="d28">entrez.3932</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.867" target="entrez.3815">
  <data key="d23">3963</data>
  <data key="d24">20223</data>
  <data key="d25">CBL</data>
  <data key="d26">KIT</data>
  <data key="d27">entrez.867</data>
  <data key="d28">entrez.3815</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.867" target="entrez.7409">
  <data key="d23">3963</data>
  <data key="d24">26172</data>
  <data key="d25">CBL</data>
  <data key="d26">VAV1</data>
  <data key="d27">entrez.867</data>
  <data key="d28">entrez.7409</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.867" target="entrez.3667">
  <data key="d23">3963</data>
  <data key="d24">29133</data>
  <data key="d25">CBL</data>
  <data key="d26">IRS1</data>
  <data key="d27">entrez.867</data>
  <data key="d28">entrez.3667</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.867" target="entrez.3480">
  <data key="d23">3963</data>
  <data key="d24">30249</data>
  <data key="d25">CBL</data>
  <data key="d26">IGF1R</data>
  <data key="d27">entrez.867</data>
  <data key="d28">entrez.3480</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.867" target="entrez.2885">
  <data key="d23">3963</data>
  <data key="d24">33176</data>
  <data key="d25">CBL</data>
  <data key="d26">GRB2</data>
  <data key="d27">entrez.867</data>
  <data key="d28">entrez.2885</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.867" target="entrez.2534">
  <data key="d23">3963</data>
  <data key="d24">35619</data>
  <data key="d25">CBL</data>
  <data key="d26">FYN</data>
  <data key="d27">entrez.867</data>
  <data key="d28">entrez.2534</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.867" target="entrez.6714">
  <data key="d23">3963</data>
  <data key="d24">40792</data>
  <data key="d25">CBL</data>
  <data key="d26">SRC</data>
  <data key="d27">entrez.867</data>
  <data key="d28">entrez.6714</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.867" target="entrez.6464">
  <data key="d23">3963</data>
  <data key="d24">41187</data>
  <data key="d25">CBL</data>
  <data key="d26">SHC1</data>
  <data key="d27">entrez.867</data>
  <data key="d28">entrez.6464</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.867" target="entrez.2185">
  <data key="d23">3963</data>
  <data key="d24">43995</data>
  <data key="d25">CBL</data>
  <data key="d26">PTK2B</data>
  <data key="d27">entrez.867</data>
  <data key="d28">entrez.2185</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.867" target="entrez.2057">
  <data key="d23">3963</data>
  <data key="d24">45200</data>
  <data key="d25">CBL</data>
  <data key="d26">EPOR</data>
  <data key="d27">entrez.867</data>
  <data key="d28">entrez.2057</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.867" target="entrez.2064">
  <data key="d23">3963</data>
  <data key="d24">45336</data>
  <data key="d25">CBL</data>
  <data key="d26">ERBB2</data>
  <data key="d27">entrez.867</data>
  <data key="d28">entrez.2064</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.867" target="entrez.6774">
  <data key="d23">3963</data>
  <data key="d24">46674</data>
  <data key="d25">CBL</data>
  <data key="d26">STAT3</data>
  <data key="d27">entrez.867</data>
  <data key="d28">entrez.6774</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.867" target="entrez.6850">
  <data key="d23">3963</data>
  <data key="d24">46818</data>
  <data key="d25">CBL</data>
  <data key="d26">SYK</data>
  <data key="d27">entrez.867</data>
  <data key="d28">entrez.6850</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.867" target="entrez.1956">
  <data key="d23">3963</data>
  <data key="d24">53145</data>
  <data key="d25">CBL</data>
  <data key="d26">EGFR</data>
  <data key="d27">entrez.867</data>
  <data key="d28">entrez.1956</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.867" target="entrez.5296">
  <data key="d23">3963</data>
  <data key="d24">54153</data>
  <data key="d25">CBL</data>
  <data key="d26">PIK3R2</data>
  <data key="d27">entrez.867</data>
  <data key="d28">entrez.5296</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.867" target="entrez.5295">
  <data key="d23">3963</data>
  <data key="d24">54155</data>
  <data key="d25">CBL</data>
  <data key="d26">PIK3R1</data>
  <data key="d27">entrez.867</data>
  <data key="d28">entrez.5295</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.867" target="entrez.5335">
  <data key="d23">3963</data>
  <data key="d24">54399</data>
  <data key="d25">CBL</data>
  <data key="d26">PLCG1</data>
  <data key="d27">entrez.867</data>
  <data key="d28">entrez.5335</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.867" target="entrez.5159">
  <data key="d23">3963</data>
  <data key="d24">55411</data>
  <data key="d25">CBL</data>
  <data key="d26">PDGFRB</data>
  <data key="d27">entrez.867</data>
  <data key="d28">entrez.5159</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.867" target="entrez.5781">
  <data key="d23">3963</data>
  <data key="d24">59850</data>
  <data key="d25">CBL</data>
  <data key="d26">PTPN11</data>
  <data key="d27">entrez.867</data>
  <data key="d28">entrez.5781</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.867" target="entrez.5777">
  <data key="d23">3963</data>
  <data key="d24">59857</data>
  <data key="d25">CBL</data>
  <data key="d26">PTPN6</data>
  <data key="d27">entrez.867</data>
  <data key="d28">entrez.5777</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.867" target="entrez.5747">
  <data key="d23">3963</data>
  <data key="d24">59937</data>
  <data key="d25">CBL</data>
  <data key="d26">PTK2</data>
  <data key="d27">entrez.867</data>
  <data key="d28">entrez.5747</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.4067" target="entrez.4067">
  <data key="d23">8458</data>
  <data key="d24">8458</data>
  <data key="d25">LYN</data>
  <data key="d26">LYN</data>
  <data key="d27">entrez.4067</data>
  <data key="d28">entrez.4067</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.4067" target="entrez.4233">
  <data key="d23">8458</data>
  <data key="d24">16661</data>
  <data key="d25">LYN</data>
  <data key="d26">MET</data>
  <data key="d27">entrez.4067</data>
  <data key="d28">entrez.4233</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.4067" target="entrez.3932">
  <data key="d23">8458</data>
  <data key="d24">19210</data>
  <data key="d25">LYN</data>
  <data key="d26">LCK</data>
  <data key="d27">entrez.4067</data>
  <data key="d28">entrez.3932</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.4067" target="entrez.3717">
  <data key="d23">8458</data>
  <data key="d24">19949</data>
  <data key="d25">LYN</data>
  <data key="d26">JAK2</data>
  <data key="d27">entrez.4067</data>
  <data key="d28">entrez.3717</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.4067" target="entrez.3815">
  <data key="d23">8458</data>
  <data key="d24">20223</data>
  <data key="d25">LYN</data>
  <data key="d26">KIT</data>
  <data key="d27">entrez.4067</data>
  <data key="d28">entrez.3815</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.4067" target="entrez.3326">
  <data key="d23">8458</data>
  <data key="d24">29825</data>
  <data key="d25">LYN</data>
  <data key="d26">HSP90AB1</data>
  <data key="d27">entrez.4067</data>
  <data key="d28">entrez.3326</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp]</data>
</edge>
<edge source="entrez.4067" target="entrez.3320">
  <data key="d23">8458</data>
  <data key="d24">29837</data>
  <data key="d25">LYN</data>
  <data key="d26">HSP90AA1</data>
  <data key="d27">entrez.4067</data>
  <data key="d28">entrez.3320</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.4067" target="entrez.2549">
  <data key="d23">8458</data>
  <data key="d24">35713</data>
  <data key="d25">LYN</data>
  <data key="d26">GAB1</data>
  <data key="d27">entrez.4067</data>
  <data key="d28">entrez.2549</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.4067" target="entrez.6714">
  <data key="d23">8458</data>
  <data key="d24">40792</data>
  <data key="d25">LYN</data>
  <data key="d26">SRC</data>
  <data key="d27">entrez.4067</data>
  <data key="d28">entrez.6714</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.4067" target="entrez.6464">
  <data key="d23">8458</data>
  <data key="d24">41187</data>
  <data key="d25">LYN</data>
  <data key="d26">SHC1</data>
  <data key="d27">entrez.4067</data>
  <data key="d28">entrez.6464</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.4067" target="entrez.2185">
  <data key="d23">8458</data>
  <data key="d24">43995</data>
  <data key="d25">LYN</data>
  <data key="d26">PTK2B</data>
  <data key="d27">entrez.4067</data>
  <data key="d28">entrez.2185</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.4067" target="entrez.2057">
  <data key="d23">8458</data>
  <data key="d24">45200</data>
  <data key="d25">LYN</data>
  <data key="d26">EPOR</data>
  <data key="d27">entrez.4067</data>
  <data key="d28">entrez.2057</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.4067" target="entrez.6774">
  <data key="d23">8458</data>
  <data key="d24">46674</data>
  <data key="d25">LYN</data>
  <data key="d26">STAT3</data>
  <data key="d27">entrez.4067</data>
  <data key="d28">entrez.6774</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.4067" target="entrez.6850">
  <data key="d23">8458</data>
  <data key="d24">46818</data>
  <data key="d25">LYN</data>
  <data key="d26">SYK</data>
  <data key="d27">entrez.4067</data>
  <data key="d28">entrez.6850</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.4067" target="entrez.1439">
  <data key="d23">8458</data>
  <data key="d24">49319</data>
  <data key="d25">LYN</data>
  <data key="d26">CSF2RB</data>
  <data key="d27">entrez.4067</data>
  <data key="d28">entrez.1439</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.4067" target="entrez.1956">
  <data key="d23">8458</data>
  <data key="d24">53145</data>
  <data key="d25">LYN</data>
  <data key="d26">EGFR</data>
  <data key="d27">entrez.4067</data>
  <data key="d28">entrez.1956</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.4067" target="entrez.5295">
  <data key="d23">8458</data>
  <data key="d24">54155</data>
  <data key="d25">LYN</data>
  <data key="d26">PIK3R1</data>
  <data key="d27">entrez.4067</data>
  <data key="d28">entrez.5295</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.4067" target="entrez.5336">
  <data key="d23">8458</data>
  <data key="d24">54398</data>
  <data key="d25">LYN</data>
  <data key="d26">PLCG2</data>
  <data key="d27">entrez.4067</data>
  <data key="d28">entrez.5336</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.4067" target="entrez.5335">
  <data key="d23">8458</data>
  <data key="d24">54399</data>
  <data key="d25">LYN</data>
  <data key="d26">PLCG1</data>
  <data key="d27">entrez.4067</data>
  <data key="d28">entrez.5335</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.4067" target="entrez.5921">
  <data key="d23">8458</data>
  <data key="d24">58816</data>
  <data key="d25">LYN</data>
  <data key="d26">RASA1</data>
  <data key="d27">entrez.4067</data>
  <data key="d28">entrez.5921</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.4067" target="entrez.5777">
  <data key="d23">8458</data>
  <data key="d24">59857</data>
  <data key="d25">LYN</data>
  <data key="d26">PTPN6</data>
  <data key="d27">entrez.4067</data>
  <data key="d28">entrez.5777</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.4067" target="entrez.5747">
  <data key="d23">8458</data>
  <data key="d24">59937</data>
  <data key="d25">LYN</data>
  <data key="d26">PTK2</data>
  <data key="d27">entrez.4067</data>
  <data key="d28">entrez.5747</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.4067" target="drugbank.DB03023">
  <data key="d31">930</data>
  <data key="d32">8458</data>
  <data key="d25">1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine</data>
  <data key="d26">LYN</data>
  <data key="d33">drugbank.DB03023</data>
  <data key="d34">entrez.4067</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.4067" target="drugbank.DB04868">
  <data key="d31">3359</data>
  <data key="d32">8458</data>
  <data key="d25">Nilotinib</data>
  <data key="d26">LYN</data>
  <data key="d33">drugbank.DB04868</data>
  <data key="d34">entrez.4067</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.4067" target="drugbank.DB00317">
  <data key="d31">4668</data>
  <data key="d32">8458</data>
  <data key="d25">Gefitinib</data>
  <data key="d26">LYN</data>
  <data key="d33">drugbank.DB00317</data>
  <data key="d34">entrez.4067</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.4067" target="drugbank.DB01268">
  <data key="d31">4894</data>
  <data key="d32">8458</data>
  <data key="d25">Sunitinib</data>
  <data key="d26">LYN</data>
  <data key="d33">drugbank.DB01268</data>
  <data key="d34">entrez.4067</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.4067" target="drugbank.DB01254">
  <data key="d31">5149</data>
  <data key="d32">8458</data>
  <data key="d25">Dasatinib</data>
  <data key="d26">LYN</data>
  <data key="d33">drugbank.DB01254</data>
  <data key="d34">entrez.4067</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.4067" target="drugbank.DB12010">
  <data key="d31">5608</data>
  <data key="d32">8458</data>
  <data key="d25">Fostamatinib</data>
  <data key="d26">LYN</data>
  <data key="d33">drugbank.DB12010</data>
  <data key="d34">entrez.4067</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.4067" target="drugbank.DB00619">
  <data key="d31">6404</data>
  <data key="d32">8458</data>
  <data key="d25">Imatinib</data>
  <data key="d26">LYN</data>
  <data key="d33">drugbank.DB00619</data>
  <data key="d34">entrez.4067</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.4067" target="drugbank.DB09079">
  <data key="d31">6627</data>
  <data key="d32">8458</data>
  <data key="d25">Nintedanib</data>
  <data key="d26">LYN</data>
  <data key="d33">drugbank.DB09079</data>
  <data key="d34">entrez.4067</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.4067" target="drugbank.DB09053">
  <data key="d31">6731</data>
  <data key="d32">8458</data>
  <data key="d25">Ibrutinib</data>
  <data key="d26">LYN</data>
  <data key="d33">drugbank.DB09053</data>
  <data key="d34">entrez.4067</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.4067" target="drugbank.DB09063">
  <data key="d31">6756</data>
  <data key="d32">8458</data>
  <data key="d25">Ceritinib</data>
  <data key="d26">LYN</data>
  <data key="d33">drugbank.DB09063</data>
  <data key="d34">entrez.4067</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.4067" target="drugbank.DB00398">
  <data key="d31">7170</data>
  <data key="d32">8458</data>
  <data key="d25">Sorafenib</data>
  <data key="d26">LYN</data>
  <data key="d33">drugbank.DB00398</data>
  <data key="d34">entrez.4067</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.4067" target="drugbank.DB00530">
  <data key="d31">7910</data>
  <data key="d32">8458</data>
  <data key="d25">Erlotinib</data>
  <data key="d26">LYN</data>
  <data key="d33">drugbank.DB00530</data>
  <data key="d34">entrez.4067</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.8651" target="entrez.4233">
  <data key="d23">12108</data>
  <data key="d24">16661</data>
  <data key="d25">SOCS1</data>
  <data key="d26">MET</data>
  <data key="d27">entrez.8651</data>
  <data key="d28">entrez.4233</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.8651" target="entrez.3932">
  <data key="d23">12108</data>
  <data key="d24">19210</data>
  <data key="d25">SOCS1</data>
  <data key="d26">LCK</data>
  <data key="d27">entrez.8651</data>
  <data key="d28">entrez.3932</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.8651" target="entrez.3717">
  <data key="d23">12108</data>
  <data key="d24">19949</data>
  <data key="d25">SOCS1</data>
  <data key="d26">JAK2</data>
  <data key="d27">entrez.8651</data>
  <data key="d28">entrez.3717</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.8651" target="entrez.3716">
  <data key="d23">12108</data>
  <data key="d24">19952</data>
  <data key="d25">SOCS1</data>
  <data key="d26">JAK1</data>
  <data key="d27">entrez.8651</data>
  <data key="d28">entrez.3716</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.8651" target="entrez.3815">
  <data key="d23">12108</data>
  <data key="d24">20223</data>
  <data key="d25">SOCS1</data>
  <data key="d26">KIT</data>
  <data key="d27">entrez.8651</data>
  <data key="d28">entrez.3815</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.8651" target="entrez.7409">
  <data key="d23">12108</data>
  <data key="d24">26172</data>
  <data key="d25">SOCS1</data>
  <data key="d26">VAV1</data>
  <data key="d27">entrez.8651</data>
  <data key="d28">entrez.7409</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.8651" target="entrez.3667">
  <data key="d23">12108</data>
  <data key="d24">29133</data>
  <data key="d25">SOCS1</data>
  <data key="d26">IRS1</data>
  <data key="d27">entrez.8651</data>
  <data key="d28">entrez.3667</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.8651" target="entrez.3480">
  <data key="d23">12108</data>
  <data key="d24">30249</data>
  <data key="d25">SOCS1</data>
  <data key="d26">IGF1R</data>
  <data key="d27">entrez.8651</data>
  <data key="d28">entrez.3480</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.8651" target="entrez.2885">
  <data key="d23">12108</data>
  <data key="d24">33176</data>
  <data key="d25">SOCS1</data>
  <data key="d26">GRB2</data>
  <data key="d27">entrez.8651</data>
  <data key="d28">entrez.2885</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.8651" target="entrez.2534">
  <data key="d23">12108</data>
  <data key="d24">35619</data>
  <data key="d25">SOCS1</data>
  <data key="d26">FYN</data>
  <data key="d27">entrez.8651</data>
  <data key="d28">entrez.2534</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.8651" target="entrez.2064">
  <data key="d23">12108</data>
  <data key="d24">45336</data>
  <data key="d25">SOCS1</data>
  <data key="d26">ERBB2</data>
  <data key="d27">entrez.8651</data>
  <data key="d28">entrez.2064</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.8651" target="entrez.1439">
  <data key="d23">12108</data>
  <data key="d24">49319</data>
  <data key="d25">SOCS1</data>
  <data key="d26">CSF2RB</data>
  <data key="d27">entrez.8651</data>
  <data key="d28">entrez.1439</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.8651" target="entrez.1956">
  <data key="d23">12108</data>
  <data key="d24">53145</data>
  <data key="d25">SOCS1</data>
  <data key="d26">EGFR</data>
  <data key="d27">entrez.8651</data>
  <data key="d28">entrez.1956</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.8651" target="entrez.5296">
  <data key="d23">12108</data>
  <data key="d24">54153</data>
  <data key="d25">SOCS1</data>
  <data key="d26">PIK3R2</data>
  <data key="d27">entrez.8651</data>
  <data key="d28">entrez.5296</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.8651" target="entrez.5295">
  <data key="d23">12108</data>
  <data key="d24">54155</data>
  <data key="d25">SOCS1</data>
  <data key="d26">PIK3R1</data>
  <data key="d27">entrez.8651</data>
  <data key="d28">entrez.5295</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.8651" target="entrez.5159">
  <data key="d23">12108</data>
  <data key="d24">55411</data>
  <data key="d25">SOCS1</data>
  <data key="d26">PDGFRB</data>
  <data key="d27">entrez.8651</data>
  <data key="d28">entrez.5159</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.8651" target="entrez.5921">
  <data key="d23">12108</data>
  <data key="d24">58816</data>
  <data key="d25">SOCS1</data>
  <data key="d26">RASA1</data>
  <data key="d27">entrez.8651</data>
  <data key="d28">entrez.5921</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.8651" target="entrez.5781">
  <data key="d23">12108</data>
  <data key="d24">59850</data>
  <data key="d25">SOCS1</data>
  <data key="d26">PTPN11</data>
  <data key="d27">entrez.8651</data>
  <data key="d28">entrez.5781</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.4233" target="entrez.4233">
  <data key="d23">16661</data>
  <data key="d24">16661</data>
  <data key="d25">MET</data>
  <data key="d26">MET</data>
  <data key="d27">entrez.4233</data>
  <data key="d28">entrez.4233</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp]</data>
</edge>
<edge source="entrez.4233" target="entrez.3932">
  <data key="d23">16661</data>
  <data key="d24">19210</data>
  <data key="d25">MET</data>
  <data key="d26">LCK</data>
  <data key="d27">entrez.4233</data>
  <data key="d28">entrez.3932</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.4233" target="entrez.7409">
  <data key="d23">16661</data>
  <data key="d24">26172</data>
  <data key="d25">MET</data>
  <data key="d26">VAV1</data>
  <data key="d27">entrez.4233</data>
  <data key="d28">entrez.7409</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.4233" target="entrez.3326">
  <data key="d23">16661</data>
  <data key="d24">29825</data>
  <data key="d25">MET</data>
  <data key="d26">HSP90AB1</data>
  <data key="d27">entrez.4233</data>
  <data key="d28">entrez.3326</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp]</data>
</edge>
<edge source="entrez.4233" target="entrez.3320">
  <data key="d23">16661</data>
  <data key="d24">29837</data>
  <data key="d25">MET</data>
  <data key="d26">HSP90AA1</data>
  <data key="d27">entrez.4233</data>
  <data key="d28">entrez.3320</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.4233" target="entrez.2885">
  <data key="d23">16661</data>
  <data key="d24">33176</data>
  <data key="d25">MET</data>
  <data key="d26">GRB2</data>
  <data key="d27">entrez.4233</data>
  <data key="d28">entrez.2885</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.4233" target="entrez.2549">
  <data key="d23">16661</data>
  <data key="d24">35713</data>
  <data key="d25">MET</data>
  <data key="d26">GAB1</data>
  <data key="d27">entrez.4233</data>
  <data key="d28">entrez.2549</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.4233" target="entrez.6714">
  <data key="d23">16661</data>
  <data key="d24">40792</data>
  <data key="d25">MET</data>
  <data key="d26">SRC</data>
  <data key="d27">entrez.4233</data>
  <data key="d28">entrez.6714</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.4233" target="entrez.6464">
  <data key="d23">16661</data>
  <data key="d24">41187</data>
  <data key="d25">MET</data>
  <data key="d26">SHC1</data>
  <data key="d27">entrez.4233</data>
  <data key="d28">entrez.6464</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.4233" target="entrez.6774">
  <data key="d23">16661</data>
  <data key="d24">46674</data>
  <data key="d25">MET</data>
  <data key="d26">STAT3</data>
  <data key="d27">entrez.4233</data>
  <data key="d28">entrez.6774</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.4233" target="entrez.6850">
  <data key="d23">16661</data>
  <data key="d24">46818</data>
  <data key="d25">MET</data>
  <data key="d26">SYK</data>
  <data key="d27">entrez.4233</data>
  <data key="d28">entrez.6850</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.4233" target="entrez.1956">
  <data key="d23">16661</data>
  <data key="d24">53145</data>
  <data key="d25">MET</data>
  <data key="d26">EGFR</data>
  <data key="d27">entrez.4233</data>
  <data key="d28">entrez.1956</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.4233" target="entrez.5296">
  <data key="d23">16661</data>
  <data key="d24">54153</data>
  <data key="d25">MET</data>
  <data key="d26">PIK3R2</data>
  <data key="d27">entrez.4233</data>
  <data key="d28">entrez.5296</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.4233" target="entrez.5295">
  <data key="d23">16661</data>
  <data key="d24">54155</data>
  <data key="d25">MET</data>
  <data key="d26">PIK3R1</data>
  <data key="d27">entrez.4233</data>
  <data key="d28">entrez.5295</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.4233" target="entrez.5336">
  <data key="d23">16661</data>
  <data key="d24">54398</data>
  <data key="d25">MET</data>
  <data key="d26">PLCG2</data>
  <data key="d27">entrez.4233</data>
  <data key="d28">entrez.5336</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.4233" target="entrez.5335">
  <data key="d23">16661</data>
  <data key="d24">54399</data>
  <data key="d25">MET</data>
  <data key="d26">PLCG1</data>
  <data key="d27">entrez.4233</data>
  <data key="d28">entrez.5335</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.4233" target="entrez.5921">
  <data key="d23">16661</data>
  <data key="d24">58816</data>
  <data key="d25">MET</data>
  <data key="d26">RASA1</data>
  <data key="d27">entrez.4233</data>
  <data key="d28">entrez.5921</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.4233" target="entrez.5781">
  <data key="d23">16661</data>
  <data key="d24">59850</data>
  <data key="d25">MET</data>
  <data key="d26">PTPN11</data>
  <data key="d27">entrez.4233</data>
  <data key="d28">entrez.5781</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.4233" target="drugbank.DB12267">
  <data key="d31">4340</data>
  <data key="d32">16661</data>
  <data key="d25">Brigatinib</data>
  <data key="d26">MET</data>
  <data key="d33">drugbank.DB12267</data>
  <data key="d34">entrez.4233</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.4233" target="drugbank.DB00317">
  <data key="d31">4668</data>
  <data key="d32">16661</data>
  <data key="d25">Gefitinib</data>
  <data key="d26">MET</data>
  <data key="d33">drugbank.DB00317</data>
  <data key="d34">entrez.4233</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.4233" target="drugbank.DB01268">
  <data key="d31">4894</data>
  <data key="d32">16661</data>
  <data key="d25">Sunitinib</data>
  <data key="d26">MET</data>
  <data key="d33">drugbank.DB01268</data>
  <data key="d34">entrez.4233</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.4233" target="drugbank.DB12010">
  <data key="d31">5608</data>
  <data key="d32">16661</data>
  <data key="d25">Fostamatinib</data>
  <data key="d26">MET</data>
  <data key="d33">drugbank.DB12010</data>
  <data key="d34">entrez.4233</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.4233" target="drugbank.DB09079">
  <data key="d31">6627</data>
  <data key="d32">16661</data>
  <data key="d25">Nintedanib</data>
  <data key="d26">MET</data>
  <data key="d33">drugbank.DB09079</data>
  <data key="d34">entrez.4233</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.4233" target="drugbank.DB09063">
  <data key="d31">6756</data>
  <data key="d32">16661</data>
  <data key="d25">Ceritinib</data>
  <data key="d26">MET</data>
  <data key="d33">drugbank.DB09063</data>
  <data key="d34">entrez.4233</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.4233" target="drugbank.DB12742">
  <data key="d31">7003</data>
  <data key="d32">16661</data>
  <data key="d25">Amuvatinib</data>
  <data key="d26">MET</data>
  <data key="d33">drugbank.DB12742</data>
  <data key="d34">entrez.4233</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.4233" target="drugbank.DB00530">
  <data key="d31">7910</data>
  <data key="d32">16661</data>
  <data key="d25">Erlotinib</data>
  <data key="d26">MET</data>
  <data key="d33">drugbank.DB00530</data>
  <data key="d34">entrez.4233</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.4233" target="drugbank.DB11828">
  <data key="d31">8787</data>
  <data key="d32">16661</data>
  <data key="d25">Neratinib</data>
  <data key="d26">MET</data>
  <data key="d33">drugbank.DB11828</data>
  <data key="d34">entrez.4233</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.4233" target="drugbank.DB11800">
  <data key="d31">8890</data>
  <data key="d32">16661</data>
  <data key="d25">Tivozanib</data>
  <data key="d26">MET</data>
  <data key="d33">drugbank.DB11800</data>
  <data key="d34">entrez.4233</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.4233" target="drugbank.DB08916">
  <data key="d31">11245</data>
  <data key="d32">16661</data>
  <data key="d25">Afatinib</data>
  <data key="d26">MET</data>
  <data key="d33">drugbank.DB08916</data>
  <data key="d34">entrez.4233</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.4233" target="drugbank.DB08865">
  <data key="d31">12120</data>
  <data key="d32">16661</data>
  <data key="d25">Crizotinib</data>
  <data key="d26">MET</data>
  <data key="d33">drugbank.DB08865</data>
  <data key="d34">entrez.4233</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.4233" target="drugbank.DB04216">
  <data key="d31">12527</data>
  <data key="d32">16661</data>
  <data key="d25">Quercetin</data>
  <data key="d26">MET</data>
  <data key="d33">drugbank.DB04216</data>
  <data key="d34">entrez.4233</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.4233" target="drugbank.DB05294">
  <data key="d31">12890</data>
  <data key="d32">16661</data>
  <data key="d25">Vandetanib</data>
  <data key="d26">MET</data>
  <data key="d33">drugbank.DB05294</data>
  <data key="d34">entrez.4233</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.4233" target="drugbank.DB06595">
  <data key="d31">12958</data>
  <data key="d32">16661</data>
  <data key="d25">Midostaurin</data>
  <data key="d26">MET</data>
  <data key="d33">drugbank.DB06595</data>
  <data key="d34">entrez.4233</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.4233" target="drugbank.DB06589">
  <data key="d31">12970</data>
  <data key="d32">16661</data>
  <data key="d25">Pazopanib</data>
  <data key="d26">MET</data>
  <data key="d33">drugbank.DB06589</data>
  <data key="d34">entrez.4233</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.4233" target="drugbank.DB06616">
  <data key="d31">13127</data>
  <data key="d32">16661</data>
  <data key="d25">Bosutinib</data>
  <data key="d26">MET</data>
  <data key="d33">drugbank.DB06616</data>
  <data key="d34">entrez.4233</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.4233" target="drugbank.DB06626">
  <data key="d31">13147</data>
  <data key="d32">16661</data>
  <data key="d25">Axitinib</data>
  <data key="d26">MET</data>
  <data key="d33">drugbank.DB06626</data>
  <data key="d34">entrez.4233</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3932" target="entrez.3932">
  <data key="d23">19210</data>
  <data key="d24">19210</data>
  <data key="d25">LCK</data>
  <data key="d26">LCK</data>
  <data key="d27">entrez.3932</data>
  <data key="d28">entrez.3932</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.3932" target="entrez.3815">
  <data key="d23">19210</data>
  <data key="d24">20223</data>
  <data key="d25">LCK</data>
  <data key="d26">KIT</data>
  <data key="d27">entrez.3932</data>
  <data key="d28">entrez.3815</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3932" target="entrez.7409">
  <data key="d23">19210</data>
  <data key="d24">26172</data>
  <data key="d25">LCK</data>
  <data key="d26">VAV1</data>
  <data key="d27">entrez.3932</data>
  <data key="d28">entrez.7409</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3932" target="entrez.3326">
  <data key="d23">19210</data>
  <data key="d24">29825</data>
  <data key="d25">LCK</data>
  <data key="d26">HSP90AB1</data>
  <data key="d27">entrez.3932</data>
  <data key="d28">entrez.3326</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp]</data>
</edge>
<edge source="entrez.3932" target="entrez.3320">
  <data key="d23">19210</data>
  <data key="d24">29837</data>
  <data key="d25">LCK</data>
  <data key="d26">HSP90AA1</data>
  <data key="d27">entrez.3932</data>
  <data key="d28">entrez.3320</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3932" target="entrez.2885">
  <data key="d23">19210</data>
  <data key="d24">33176</data>
  <data key="d25">LCK</data>
  <data key="d26">GRB2</data>
  <data key="d27">entrez.3932</data>
  <data key="d28">entrez.2885</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3932" target="entrez.2549">
  <data key="d23">19210</data>
  <data key="d24">35713</data>
  <data key="d25">LCK</data>
  <data key="d26">GAB1</data>
  <data key="d27">entrez.3932</data>
  <data key="d28">entrez.2549</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3932" target="entrez.6464">
  <data key="d23">19210</data>
  <data key="d24">41187</data>
  <data key="d25">LCK</data>
  <data key="d26">SHC1</data>
  <data key="d27">entrez.3932</data>
  <data key="d28">entrez.6464</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3932" target="entrez.2185">
  <data key="d23">19210</data>
  <data key="d24">43995</data>
  <data key="d25">LCK</data>
  <data key="d26">PTK2B</data>
  <data key="d27">entrez.3932</data>
  <data key="d28">entrez.2185</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3932" target="entrez.2064">
  <data key="d23">19210</data>
  <data key="d24">45336</data>
  <data key="d25">LCK</data>
  <data key="d26">ERBB2</data>
  <data key="d27">entrez.3932</data>
  <data key="d28">entrez.2064</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3932" target="entrez.6774">
  <data key="d23">19210</data>
  <data key="d24">46674</data>
  <data key="d25">LCK</data>
  <data key="d26">STAT3</data>
  <data key="d27">entrez.3932</data>
  <data key="d28">entrez.6774</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3932" target="entrez.6850">
  <data key="d23">19210</data>
  <data key="d24">46818</data>
  <data key="d25">LCK</data>
  <data key="d26">SYK</data>
  <data key="d27">entrez.3932</data>
  <data key="d28">entrez.6850</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3932" target="entrez.1439">
  <data key="d23">19210</data>
  <data key="d24">49319</data>
  <data key="d25">LCK</data>
  <data key="d26">CSF2RB</data>
  <data key="d27">entrez.3932</data>
  <data key="d28">entrez.1439</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3932" target="entrez.5295">
  <data key="d23">19210</data>
  <data key="d24">54155</data>
  <data key="d25">LCK</data>
  <data key="d26">PIK3R1</data>
  <data key="d27">entrez.3932</data>
  <data key="d28">entrez.5295</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.3932" target="entrez.5336">
  <data key="d23">19210</data>
  <data key="d24">54398</data>
  <data key="d25">LCK</data>
  <data key="d26">PLCG2</data>
  <data key="d27">entrez.3932</data>
  <data key="d28">entrez.5336</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3932" target="entrez.5335">
  <data key="d23">19210</data>
  <data key="d24">54399</data>
  <data key="d25">LCK</data>
  <data key="d26">PLCG1</data>
  <data key="d27">entrez.3932</data>
  <data key="d28">entrez.5335</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3932" target="entrez.5921">
  <data key="d23">19210</data>
  <data key="d24">58816</data>
  <data key="d25">LCK</data>
  <data key="d26">RASA1</data>
  <data key="d27">entrez.3932</data>
  <data key="d28">entrez.5921</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3932" target="entrez.5781">
  <data key="d23">19210</data>
  <data key="d24">59850</data>
  <data key="d25">LCK</data>
  <data key="d26">PTPN11</data>
  <data key="d27">entrez.3932</data>
  <data key="d28">entrez.5781</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3932" target="entrez.5777">
  <data key="d23">19210</data>
  <data key="d24">59857</data>
  <data key="d25">LCK</data>
  <data key="d26">PTPN6</data>
  <data key="d27">entrez.3932</data>
  <data key="d28">entrez.5777</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3932" target="entrez.5747">
  <data key="d23">19210</data>
  <data key="d24">59937</data>
  <data key="d25">LCK</data>
  <data key="d26">PTK2</data>
  <data key="d27">entrez.3932</data>
  <data key="d28">entrez.5747</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3932" target="drugbank.DB02010">
  <data key="d31">567</data>
  <data key="d32">19210</data>
  <data key="d25">Staurosporine</data>
  <data key="d26">LCK</data>
  <data key="d33">drugbank.DB02010</data>
  <data key="d34">entrez.3932</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3932" target="drugbank.DB03023">
  <data key="d31">930</data>
  <data key="d32">19210</data>
  <data key="d25">1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine</data>
  <data key="d26">LCK</data>
  <data key="d33">drugbank.DB03023</data>
  <data key="d34">entrez.3932</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3932" target="drugbank.DB04395">
  <data key="d31">1251</data>
  <data key="d32">19210</data>
  <data key="d25">Phosphoaminophosphonic Acid-Adenylate Ester</data>
  <data key="d26">LCK</data>
  <data key="d33">drugbank.DB04395</data>
  <data key="d34">entrez.3932</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3932" target="drugbank.DB03166">
  <data key="d31">1432</data>
  <data key="d32">19210</data>
  <data key="d25">Acetic acid</data>
  <data key="d26">LCK</data>
  <data key="d33">drugbank.DB03166</data>
  <data key="d34">entrez.3932</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3932" target="drugbank.DB13050">
  <data key="d31">1659</data>
  <data key="d32">19210</data>
  <data key="d25">Tirilazad</data>
  <data key="d26">LCK</data>
  <data key="d33">drugbank.DB13050</data>
  <data key="d34">entrez.3932</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3932" target="drugbank.DB04868">
  <data key="d31">3359</data>
  <data key="d32">19210</data>
  <data key="d25">Nilotinib</data>
  <data key="d26">LCK</data>
  <data key="d33">drugbank.DB04868</data>
  <data key="d34">entrez.3932</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3932" target="drugbank.DB04813">
  <data key="d31">3438</data>
  <data key="d32">19210</data>
  <data key="d25">Bithionol</data>
  <data key="d26">LCK</data>
  <data key="d33">drugbank.DB04813</data>
  <data key="d34">entrez.3932</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3932" target="drugbank.DB00190">
  <data key="d31">3567</data>
  <data key="d32">19210</data>
  <data key="d25">Carbidopa</data>
  <data key="d26">LCK</data>
  <data key="d33">drugbank.DB00190</data>
  <data key="d34">entrez.3932</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3932" target="drugbank.DB00220">
  <data key="d31">4422</data>
  <data key="d32">19210</data>
  <data key="d25">Nelfinavir</data>
  <data key="d26">LCK</data>
  <data key="d33">drugbank.DB00220</data>
  <data key="d34">entrez.3932</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3932" target="drugbank.DB00317">
  <data key="d31">4668</data>
  <data key="d32">19210</data>
  <data key="d25">Gefitinib</data>
  <data key="d26">LCK</data>
  <data key="d33">drugbank.DB00317</data>
  <data key="d34">entrez.3932</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3932" target="drugbank.DB01268">
  <data key="d31">4894</data>
  <data key="d32">19210</data>
  <data key="d25">Sunitinib</data>
  <data key="d26">LCK</data>
  <data key="d33">drugbank.DB01268</data>
  <data key="d34">entrez.3932</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3932" target="drugbank.DB01254">
  <data key="d31">5149</data>
  <data key="d32">19210</data>
  <data key="d25">Dasatinib</data>
  <data key="d26">LCK</data>
  <data key="d33">drugbank.DB01254</data>
  <data key="d34">entrez.3932</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3932" target="drugbank.DB12010">
  <data key="d31">5608</data>
  <data key="d32">19210</data>
  <data key="d25">Fostamatinib</data>
  <data key="d26">LCK</data>
  <data key="d33">drugbank.DB12010</data>
  <data key="d34">entrez.3932</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3932" target="drugbank.DB00027">
  <data key="d31">5620</data>
  <data key="d32">19210</data>
  <data key="d25">Gramicidin D</data>
  <data key="d26">LCK</data>
  <data key="d33">drugbank.DB00027</data>
  <data key="d34">entrez.3932</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3932" target="drugbank.DB00030">
  <data key="d31">5641</data>
  <data key="d32">19210</data>
  <data key="d25">Insulin Human</data>
  <data key="d26">LCK</data>
  <data key="d33">drugbank.DB00030</data>
  <data key="d34">entrez.3932</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3932" target="drugbank.DB00675">
  <data key="d31">6319</data>
  <data key="d32">19210</data>
  <data key="d25">Tamoxifen</data>
  <data key="d26">LCK</data>
  <data key="d33">drugbank.DB00675</data>
  <data key="d34">entrez.3932</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3932" target="drugbank.DB00619">
  <data key="d31">6404</data>
  <data key="d32">19210</data>
  <data key="d25">Imatinib</data>
  <data key="d26">LCK</data>
  <data key="d33">drugbank.DB00619</data>
  <data key="d34">entrez.3932</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3932" target="drugbank.DB00626">
  <data key="d31">6437</data>
  <data key="d32">19210</data>
  <data key="d25">Bacitracin</data>
  <data key="d26">LCK</data>
  <data key="d33">drugbank.DB00626</data>
  <data key="d34">entrez.3932</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3932" target="drugbank.DB00637">
  <data key="d31">6473</data>
  <data key="d32">19210</data>
  <data key="d25">Astemizole</data>
  <data key="d26">LCK</data>
  <data key="d33">drugbank.DB00637</data>
  <data key="d34">entrez.3932</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3932" target="drugbank.DB09079">
  <data key="d31">6627</data>
  <data key="d32">19210</data>
  <data key="d25">Nintedanib</data>
  <data key="d26">LCK</data>
  <data key="d33">drugbank.DB09079</data>
  <data key="d34">entrez.3932</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3932" target="drugbank.DB00696">
  <data key="d31">6672</data>
  <data key="d32">19210</data>
  <data key="d25">Ergotamine</data>
  <data key="d26">LCK</data>
  <data key="d33">drugbank.DB00696</data>
  <data key="d34">entrez.3932</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3932" target="drugbank.DB09053">
  <data key="d31">6731</data>
  <data key="d32">19210</data>
  <data key="d25">Ibrutinib</data>
  <data key="d26">LCK</data>
  <data key="d33">drugbank.DB09053</data>
  <data key="d34">entrez.3932</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3932" target="drugbank.DB09063">
  <data key="d31">6756</data>
  <data key="d32">19210</data>
  <data key="d25">Ceritinib</data>
  <data key="d26">LCK</data>
  <data key="d33">drugbank.DB09063</data>
  <data key="d34">entrez.3932</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3932" target="drugbank.DB09115">
  <data key="d31">6783</data>
  <data key="d32">19210</data>
  <data key="d25">Diiodohydroxyquinoline</data>
  <data key="d26">LCK</data>
  <data key="d33">drugbank.DB09115</data>
  <data key="d34">entrez.3932</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3932" target="drugbank.DB00756">
  <data key="d31">6952</data>
  <data key="d32">19210</data>
  <data key="d25">Hexachlorophene</data>
  <data key="d26">LCK</data>
  <data key="d33">drugbank.DB00756</data>
  <data key="d34">entrez.3932</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3932" target="drugbank.DB00398">
  <data key="d31">7170</data>
  <data key="d32">19210</data>
  <data key="d25">Sorafenib</data>
  <data key="d26">LCK</data>
  <data key="d33">drugbank.DB00398</data>
  <data key="d34">entrez.3932</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3932" target="drugbank.DB00530">
  <data key="d31">7910</data>
  <data key="d32">19210</data>
  <data key="d25">Erlotinib</data>
  <data key="d26">LCK</data>
  <data key="d33">drugbank.DB00530</data>
  <data key="d34">entrez.3932</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3932" target="drugbank.DB00515">
  <data key="d31">8119</data>
  <data key="d32">19210</data>
  <data key="d25">Cisplatin</data>
  <data key="d26">LCK</data>
  <data key="d33">drugbank.DB00515</data>
  <data key="d34">entrez.3932</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3932" target="drugbank.DB11828">
  <data key="d31">8787</data>
  <data key="d32">19210</data>
  <data key="d25">Neratinib</data>
  <data key="d26">LCK</data>
  <data key="d33">drugbank.DB11828</data>
  <data key="d34">entrez.3932</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3932" target="drugbank.DB11829">
  <data key="d31">8788</data>
  <data key="d32">19210</data>
  <data key="d25">Ruboxistaurin</data>
  <data key="d26">LCK</data>
  <data key="d33">drugbank.DB11829</data>
  <data key="d34">entrez.3932</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3932" target="drugbank.DB00841">
  <data key="d31">9274</data>
  <data key="d32">19210</data>
  <data key="d25">Dobutamine</data>
  <data key="d26">LCK</data>
  <data key="d33">drugbank.DB00841</data>
  <data key="d34">entrez.3932</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3932" target="drugbank.DB09372">
  <data key="d31">9450</data>
  <data key="d32">19210</data>
  <data key="d25">Tannic acid</data>
  <data key="d26">LCK</data>
  <data key="d33">drugbank.DB09372</data>
  <data key="d34">entrez.3932</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3932" target="drugbank.DB00988">
  <data key="d31">9553</data>
  <data key="d32">19210</data>
  <data key="d25">Dopamine</data>
  <data key="d26">LCK</data>
  <data key="d33">drugbank.DB00988</data>
  <data key="d34">entrez.3932</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3932" target="drugbank.DB00997">
  <data key="d31">9598</data>
  <data key="d32">19210</data>
  <data key="d25">Doxorubicin</data>
  <data key="d26">LCK</data>
  <data key="d33">drugbank.DB00997</data>
  <data key="d34">entrez.3932</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3932" target="drugbank.DB08901">
  <data key="d31">11231</data>
  <data key="d32">19210</data>
  <data key="d25">Ponatinib</data>
  <data key="d26">LCK</data>
  <data key="d33">drugbank.DB08901</data>
  <data key="d34">entrez.3932</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3932" target="drugbank.DB08916">
  <data key="d31">11245</data>
  <data key="d32">19210</data>
  <data key="d25">Afatinib</data>
  <data key="d26">LCK</data>
  <data key="d33">drugbank.DB08916</data>
  <data key="d34">entrez.3932</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3932" target="drugbank.DB08865">
  <data key="d31">12120</data>
  <data key="d32">19210</data>
  <data key="d25">Crizotinib</data>
  <data key="d26">LCK</data>
  <data key="d33">drugbank.DB08865</data>
  <data key="d34">entrez.3932</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3932" target="drugbank.DB08895">
  <data key="d31">12218</data>
  <data key="d32">19210</data>
  <data key="d25">Tofacitinib</data>
  <data key="d26">LCK</data>
  <data key="d33">drugbank.DB08895</data>
  <data key="d34">entrez.3932</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3932" target="drugbank.DB04216">
  <data key="d31">12527</data>
  <data key="d32">19210</data>
  <data key="d25">Quercetin</data>
  <data key="d26">LCK</data>
  <data key="d33">drugbank.DB04216</data>
  <data key="d34">entrez.3932</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3932" target="drugbank.DB05294">
  <data key="d31">12890</data>
  <data key="d32">19210</data>
  <data key="d25">Vandetanib</data>
  <data key="d26">LCK</data>
  <data key="d33">drugbank.DB05294</data>
  <data key="d34">entrez.3932</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3932" target="drugbank.DB06595">
  <data key="d31">12958</data>
  <data key="d32">19210</data>
  <data key="d25">Midostaurin</data>
  <data key="d26">LCK</data>
  <data key="d33">drugbank.DB06595</data>
  <data key="d34">entrez.3932</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3932" target="drugbank.DB06589">
  <data key="d31">12970</data>
  <data key="d32">19210</data>
  <data key="d25">Pazopanib</data>
  <data key="d26">LCK</data>
  <data key="d33">drugbank.DB06589</data>
  <data key="d34">entrez.3932</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3932" target="drugbank.DB06616">
  <data key="d31">13127</data>
  <data key="d32">19210</data>
  <data key="d25">Bosutinib</data>
  <data key="d26">LCK</data>
  <data key="d33">drugbank.DB06616</data>
  <data key="d34">entrez.3932</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3932" target="drugbank.DB06626">
  <data key="d31">13147</data>
  <data key="d32">19210</data>
  <data key="d25">Axitinib</data>
  <data key="d26">LCK</data>
  <data key="d33">drugbank.DB06626</data>
  <data key="d34">entrez.3932</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3717" target="entrez.3717">
  <data key="d23">19949</data>
  <data key="d24">19949</data>
  <data key="d25">JAK2</data>
  <data key="d26">JAK2</data>
  <data key="d27">entrez.3717</data>
  <data key="d28">entrez.3717</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.3717" target="entrez.3716">
  <data key="d23">19949</data>
  <data key="d24">19952</data>
  <data key="d25">JAK2</data>
  <data key="d26">JAK1</data>
  <data key="d27">entrez.3717</data>
  <data key="d28">entrez.3716</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.3717" target="entrez.3815">
  <data key="d23">19949</data>
  <data key="d24">20223</data>
  <data key="d25">JAK2</data>
  <data key="d26">KIT</data>
  <data key="d27">entrez.3717</data>
  <data key="d28">entrez.3815</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.3717" target="entrez.7409">
  <data key="d23">19949</data>
  <data key="d24">26172</data>
  <data key="d25">JAK2</data>
  <data key="d26">VAV1</data>
  <data key="d27">entrez.3717</data>
  <data key="d28">entrez.7409</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3717" target="entrez.3667">
  <data key="d23">19949</data>
  <data key="d24">29133</data>
  <data key="d25">JAK2</data>
  <data key="d26">IRS1</data>
  <data key="d27">entrez.3717</data>
  <data key="d28">entrez.3667</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.3717" target="entrez.3326">
  <data key="d23">19949</data>
  <data key="d24">29825</data>
  <data key="d25">JAK2</data>
  <data key="d26">HSP90AB1</data>
  <data key="d27">entrez.3717</data>
  <data key="d28">entrez.3326</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3717" target="entrez.3320">
  <data key="d23">19949</data>
  <data key="d24">29837</data>
  <data key="d25">JAK2</data>
  <data key="d26">HSP90AA1</data>
  <data key="d27">entrez.3717</data>
  <data key="d28">entrez.3320</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3717" target="entrez.3480">
  <data key="d23">19949</data>
  <data key="d24">30249</data>
  <data key="d25">JAK2</data>
  <data key="d26">IGF1R</data>
  <data key="d27">entrez.3717</data>
  <data key="d28">entrez.3480</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3717" target="entrez.2885">
  <data key="d23">19949</data>
  <data key="d24">33176</data>
  <data key="d25">JAK2</data>
  <data key="d26">GRB2</data>
  <data key="d27">entrez.3717</data>
  <data key="d28">entrez.2885</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.3717" target="entrez.2534">
  <data key="d23">19949</data>
  <data key="d24">35619</data>
  <data key="d25">JAK2</data>
  <data key="d26">FYN</data>
  <data key="d27">entrez.3717</data>
  <data key="d28">entrez.2534</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.3717" target="entrez.6714">
  <data key="d23">19949</data>
  <data key="d24">40792</data>
  <data key="d25">JAK2</data>
  <data key="d26">SRC</data>
  <data key="d27">entrez.3717</data>
  <data key="d28">entrez.6714</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.3717" target="entrez.6464">
  <data key="d23">19949</data>
  <data key="d24">41187</data>
  <data key="d25">JAK2</data>
  <data key="d26">SHC1</data>
  <data key="d27">entrez.3717</data>
  <data key="d28">entrez.6464</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.3717" target="entrez.2185">
  <data key="d23">19949</data>
  <data key="d24">43995</data>
  <data key="d25">JAK2</data>
  <data key="d26">PTK2B</data>
  <data key="d27">entrez.3717</data>
  <data key="d28">entrez.2185</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.3717" target="entrez.2057">
  <data key="d23">19949</data>
  <data key="d24">45200</data>
  <data key="d25">JAK2</data>
  <data key="d26">EPOR</data>
  <data key="d27">entrez.3717</data>
  <data key="d28">entrez.2057</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.3717" target="entrez.2064">
  <data key="d23">19949</data>
  <data key="d24">45336</data>
  <data key="d25">JAK2</data>
  <data key="d26">ERBB2</data>
  <data key="d27">entrez.3717</data>
  <data key="d28">entrez.2064</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3717" target="entrez.6774">
  <data key="d23">19949</data>
  <data key="d24">46674</data>
  <data key="d25">JAK2</data>
  <data key="d26">STAT3</data>
  <data key="d27">entrez.3717</data>
  <data key="d28">entrez.6774</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.3717" target="entrez.1439">
  <data key="d23">19949</data>
  <data key="d24">49319</data>
  <data key="d25">JAK2</data>
  <data key="d26">CSF2RB</data>
  <data key="d27">entrez.3717</data>
  <data key="d28">entrez.1439</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3717" target="entrez.1956">
  <data key="d23">19949</data>
  <data key="d24">53145</data>
  <data key="d25">JAK2</data>
  <data key="d26">EGFR</data>
  <data key="d27">entrez.3717</data>
  <data key="d28">entrez.1956</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.3717" target="entrez.5295">
  <data key="d23">19949</data>
  <data key="d24">54155</data>
  <data key="d25">JAK2</data>
  <data key="d26">PIK3R1</data>
  <data key="d27">entrez.3717</data>
  <data key="d28">entrez.5295</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.3717" target="entrez.5336">
  <data key="d23">19949</data>
  <data key="d24">54398</data>
  <data key="d25">JAK2</data>
  <data key="d26">PLCG2</data>
  <data key="d27">entrez.3717</data>
  <data key="d28">entrez.5336</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3717" target="entrez.5335">
  <data key="d23">19949</data>
  <data key="d24">54399</data>
  <data key="d25">JAK2</data>
  <data key="d26">PLCG1</data>
  <data key="d27">entrez.3717</data>
  <data key="d28">entrez.5335</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3717" target="entrez.5159">
  <data key="d23">19949</data>
  <data key="d24">55411</data>
  <data key="d25">JAK2</data>
  <data key="d26">PDGFRB</data>
  <data key="d27">entrez.3717</data>
  <data key="d28">entrez.5159</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3717" target="entrez.5781">
  <data key="d23">19949</data>
  <data key="d24">59850</data>
  <data key="d25">JAK2</data>
  <data key="d26">PTPN11</data>
  <data key="d27">entrez.3717</data>
  <data key="d28">entrez.5781</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.3717" target="entrez.5777">
  <data key="d23">19949</data>
  <data key="d24">59857</data>
  <data key="d25">JAK2</data>
  <data key="d26">PTPN6</data>
  <data key="d27">entrez.3717</data>
  <data key="d28">entrez.5777</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.3717" target="entrez.5747">
  <data key="d23">19949</data>
  <data key="d24">59937</data>
  <data key="d25">JAK2</data>
  <data key="d26">PTK2</data>
  <data key="d27">entrez.3717</data>
  <data key="d28">entrez.5747</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3717" target="drugbank.DB04716">
  <data key="d31">3084</data>
  <data key="d32">19949</data>
  <data key="d25">2-(1,1-DIMETHYLETHYL)9-FLUORO-3,6-DIHYDRO-7H-BENZ[H]-IMIDAZ[4,5-F]ISOQUINOLIN-7-ONE</data>
  <data key="d26">JAK2</data>
  <data key="d33">drugbank.DB04716</data>
  <data key="d34">entrez.3717</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3717" target="drugbank.DB04868">
  <data key="d31">3359</data>
  <data key="d32">19949</data>
  <data key="d25">Nilotinib</data>
  <data key="d26">JAK2</data>
  <data key="d33">drugbank.DB04868</data>
  <data key="d34">entrez.3717</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3717" target="drugbank.DB01268">
  <data key="d31">4894</data>
  <data key="d32">19949</data>
  <data key="d25">Sunitinib</data>
  <data key="d26">JAK2</data>
  <data key="d33">drugbank.DB01268</data>
  <data key="d34">entrez.3717</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3717" target="drugbank.DB01254">
  <data key="d31">5149</data>
  <data key="d32">19949</data>
  <data key="d25">Dasatinib</data>
  <data key="d26">JAK2</data>
  <data key="d33">drugbank.DB01254</data>
  <data key="d34">entrez.3717</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3717" target="drugbank.DB12010">
  <data key="d31">5608</data>
  <data key="d32">19949</data>
  <data key="d25">Fostamatinib</data>
  <data key="d26">JAK2</data>
  <data key="d33">drugbank.DB12010</data>
  <data key="d34">entrez.3717</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3717" target="drugbank.DB00619">
  <data key="d31">6404</data>
  <data key="d32">19949</data>
  <data key="d25">Imatinib</data>
  <data key="d26">JAK2</data>
  <data key="d33">drugbank.DB00619</data>
  <data key="d34">entrez.3717</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3717" target="drugbank.DB09079">
  <data key="d31">6627</data>
  <data key="d32">19949</data>
  <data key="d25">Nintedanib</data>
  <data key="d26">JAK2</data>
  <data key="d33">drugbank.DB09079</data>
  <data key="d34">entrez.3717</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3717" target="drugbank.DB09063">
  <data key="d31">6756</data>
  <data key="d32">19949</data>
  <data key="d25">Ceritinib</data>
  <data key="d26">JAK2</data>
  <data key="d33">drugbank.DB09063</data>
  <data key="d34">entrez.3717</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3717" target="drugbank.DB00530">
  <data key="d31">7910</data>
  <data key="d32">19949</data>
  <data key="d25">Erlotinib</data>
  <data key="d26">JAK2</data>
  <data key="d33">drugbank.DB00530</data>
  <data key="d34">entrez.3717</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3717" target="drugbank.DB11817">
  <data key="d31">8895</data>
  <data key="d32">19949</data>
  <data key="d25">Baricitinib</data>
  <data key="d26">JAK2</data>
  <data key="d33">drugbank.DB11817</data>
  <data key="d34">entrez.3717</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3717" target="drugbank.DB08865">
  <data key="d31">12120</data>
  <data key="d32">19949</data>
  <data key="d25">Crizotinib</data>
  <data key="d26">JAK2</data>
  <data key="d33">drugbank.DB08865</data>
  <data key="d34">entrez.3717</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3717" target="drugbank.DB08877">
  <data key="d31">12195</data>
  <data key="d32">19949</data>
  <data key="d25">Ruxolitinib</data>
  <data key="d26">JAK2</data>
  <data key="d33">drugbank.DB08877</data>
  <data key="d34">entrez.3717</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3717" target="drugbank.DB08895">
  <data key="d31">12218</data>
  <data key="d32">19949</data>
  <data key="d25">Tofacitinib</data>
  <data key="d26">JAK2</data>
  <data key="d33">drugbank.DB08895</data>
  <data key="d34">entrez.3717</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3717" target="drugbank.DB06803">
  <data key="d31">12674</data>
  <data key="d32">19949</data>
  <data key="d25">Niclosamide</data>
  <data key="d26">JAK2</data>
  <data key="d33">drugbank.DB06803</data>
  <data key="d34">entrez.3717</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3717" target="drugbank.DB06595">
  <data key="d31">12958</data>
  <data key="d32">19949</data>
  <data key="d25">Midostaurin</data>
  <data key="d26">JAK2</data>
  <data key="d33">drugbank.DB06595</data>
  <data key="d34">entrez.3717</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3717" target="drugbank.DB06589">
  <data key="d31">12970</data>
  <data key="d32">19949</data>
  <data key="d25">Pazopanib</data>
  <data key="d26">JAK2</data>
  <data key="d33">drugbank.DB06589</data>
  <data key="d34">entrez.3717</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3717" target="drugbank.DB06616">
  <data key="d31">13127</data>
  <data key="d32">19949</data>
  <data key="d25">Bosutinib</data>
  <data key="d26">JAK2</data>
  <data key="d33">drugbank.DB06616</data>
  <data key="d34">entrez.3717</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3717" target="drugbank.DB06626">
  <data key="d31">13147</data>
  <data key="d32">19949</data>
  <data key="d25">Axitinib</data>
  <data key="d26">JAK2</data>
  <data key="d33">drugbank.DB06626</data>
  <data key="d34">entrez.3717</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3716" target="entrez.3716">
  <data key="d23">19952</data>
  <data key="d24">19952</data>
  <data key="d25">JAK1</data>
  <data key="d26">JAK1</data>
  <data key="d27">entrez.3716</data>
  <data key="d28">entrez.3716</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.3716" target="entrez.3667">
  <data key="d23">19952</data>
  <data key="d24">29133</data>
  <data key="d25">JAK1</data>
  <data key="d26">IRS1</data>
  <data key="d27">entrez.3716</data>
  <data key="d28">entrez.3667</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.3716" target="entrez.3326">
  <data key="d23">19952</data>
  <data key="d24">29825</data>
  <data key="d25">JAK1</data>
  <data key="d26">HSP90AB1</data>
  <data key="d27">entrez.3716</data>
  <data key="d28">entrez.3326</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp]</data>
</edge>
<edge source="entrez.3716" target="entrez.3320">
  <data key="d23">19952</data>
  <data key="d24">29837</data>
  <data key="d25">JAK1</data>
  <data key="d26">HSP90AA1</data>
  <data key="d27">entrez.3716</data>
  <data key="d28">entrez.3320</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3716" target="entrez.3480">
  <data key="d23">19952</data>
  <data key="d24">30249</data>
  <data key="d25">JAK1</data>
  <data key="d26">IGF1R</data>
  <data key="d27">entrez.3716</data>
  <data key="d28">entrez.3480</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3716" target="entrez.2885">
  <data key="d23">19952</data>
  <data key="d24">33176</data>
  <data key="d25">JAK1</data>
  <data key="d26">GRB2</data>
  <data key="d27">entrez.3716</data>
  <data key="d28">entrez.2885</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3716" target="entrez.2534">
  <data key="d23">19952</data>
  <data key="d24">35619</data>
  <data key="d25">JAK1</data>
  <data key="d26">FYN</data>
  <data key="d27">entrez.3716</data>
  <data key="d28">entrez.2534</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3716" target="entrez.2185">
  <data key="d23">19952</data>
  <data key="d24">43995</data>
  <data key="d25">JAK1</data>
  <data key="d26">PTK2B</data>
  <data key="d27">entrez.3716</data>
  <data key="d28">entrez.2185</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.3716" target="entrez.2064">
  <data key="d23">19952</data>
  <data key="d24">45336</data>
  <data key="d25">JAK1</data>
  <data key="d26">ERBB2</data>
  <data key="d27">entrez.3716</data>
  <data key="d28">entrez.2064</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3716" target="entrez.6774">
  <data key="d23">19952</data>
  <data key="d24">46674</data>
  <data key="d25">JAK1</data>
  <data key="d26">STAT3</data>
  <data key="d27">entrez.3716</data>
  <data key="d28">entrez.6774</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3716" target="entrez.6850">
  <data key="d23">19952</data>
  <data key="d24">46818</data>
  <data key="d25">JAK1</data>
  <data key="d26">SYK</data>
  <data key="d27">entrez.3716</data>
  <data key="d28">entrez.6850</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3716" target="entrez.1439">
  <data key="d23">19952</data>
  <data key="d24">49319</data>
  <data key="d25">JAK1</data>
  <data key="d26">CSF2RB</data>
  <data key="d27">entrez.3716</data>
  <data key="d28">entrez.1439</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3716" target="entrez.1956">
  <data key="d23">19952</data>
  <data key="d24">53145</data>
  <data key="d25">JAK1</data>
  <data key="d26">EGFR</data>
  <data key="d27">entrez.3716</data>
  <data key="d28">entrez.1956</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3716" target="entrez.5295">
  <data key="d23">19952</data>
  <data key="d24">54155</data>
  <data key="d25">JAK1</data>
  <data key="d26">PIK3R1</data>
  <data key="d27">entrez.3716</data>
  <data key="d28">entrez.5295</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3716" target="entrez.5336">
  <data key="d23">19952</data>
  <data key="d24">54398</data>
  <data key="d25">JAK1</data>
  <data key="d26">PLCG2</data>
  <data key="d27">entrez.3716</data>
  <data key="d28">entrez.5336</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp]</data>
</edge>
<edge source="entrez.3716" target="entrez.5335">
  <data key="d23">19952</data>
  <data key="d24">54399</data>
  <data key="d25">JAK1</data>
  <data key="d26">PLCG1</data>
  <data key="d27">entrez.3716</data>
  <data key="d28">entrez.5335</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3716" target="entrez.5159">
  <data key="d23">19952</data>
  <data key="d24">55411</data>
  <data key="d25">JAK1</data>
  <data key="d26">PDGFRB</data>
  <data key="d27">entrez.3716</data>
  <data key="d28">entrez.5159</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3716" target="entrez.5781">
  <data key="d23">19952</data>
  <data key="d24">59850</data>
  <data key="d25">JAK1</data>
  <data key="d26">PTPN11</data>
  <data key="d27">entrez.3716</data>
  <data key="d28">entrez.5781</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3716" target="entrez.5777">
  <data key="d23">19952</data>
  <data key="d24">59857</data>
  <data key="d25">JAK1</data>
  <data key="d26">PTPN6</data>
  <data key="d27">entrez.3716</data>
  <data key="d28">entrez.5777</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3716" target="drugbank.DB04716">
  <data key="d31">3084</data>
  <data key="d32">19952</data>
  <data key="d25">2-(1,1-DIMETHYLETHYL)9-FLUORO-3,6-DIHYDRO-7H-BENZ[H]-IMIDAZ[4,5-F]ISOQUINOLIN-7-ONE</data>
  <data key="d26">JAK1</data>
  <data key="d33">drugbank.DB04716</data>
  <data key="d34">entrez.3716</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3716" target="drugbank.DB01268">
  <data key="d31">4894</data>
  <data key="d32">19952</data>
  <data key="d25">Sunitinib</data>
  <data key="d26">JAK1</data>
  <data key="d33">drugbank.DB01268</data>
  <data key="d34">entrez.3716</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3716" target="drugbank.DB12010">
  <data key="d31">5608</data>
  <data key="d32">19952</data>
  <data key="d25">Fostamatinib</data>
  <data key="d26">JAK1</data>
  <data key="d33">drugbank.DB12010</data>
  <data key="d34">entrez.3716</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3716" target="drugbank.DB09079">
  <data key="d31">6627</data>
  <data key="d32">19952</data>
  <data key="d25">Nintedanib</data>
  <data key="d26">JAK1</data>
  <data key="d33">drugbank.DB09079</data>
  <data key="d34">entrez.3716</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3716" target="drugbank.DB09063">
  <data key="d31">6756</data>
  <data key="d32">19952</data>
  <data key="d25">Ceritinib</data>
  <data key="d26">JAK1</data>
  <data key="d33">drugbank.DB09063</data>
  <data key="d34">entrez.3716</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3716" target="drugbank.DB11817">
  <data key="d31">8895</data>
  <data key="d32">19952</data>
  <data key="d25">Baricitinib</data>
  <data key="d26">JAK1</data>
  <data key="d33">drugbank.DB11817</data>
  <data key="d34">entrez.3716</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3716" target="drugbank.DB08865">
  <data key="d31">12120</data>
  <data key="d32">19952</data>
  <data key="d25">Crizotinib</data>
  <data key="d26">JAK1</data>
  <data key="d33">drugbank.DB08865</data>
  <data key="d34">entrez.3716</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3716" target="drugbank.DB08877">
  <data key="d31">12195</data>
  <data key="d32">19952</data>
  <data key="d25">Ruxolitinib</data>
  <data key="d26">JAK1</data>
  <data key="d33">drugbank.DB08877</data>
  <data key="d34">entrez.3716</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3716" target="drugbank.DB08895">
  <data key="d31">12218</data>
  <data key="d32">19952</data>
  <data key="d25">Tofacitinib</data>
  <data key="d26">JAK1</data>
  <data key="d33">drugbank.DB08895</data>
  <data key="d34">entrez.3716</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3716" target="drugbank.DB06595">
  <data key="d31">12958</data>
  <data key="d32">19952</data>
  <data key="d25">Midostaurin</data>
  <data key="d26">JAK1</data>
  <data key="d33">drugbank.DB06595</data>
  <data key="d34">entrez.3716</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3815" target="entrez.3815">
  <data key="d23">20223</data>
  <data key="d24">20223</data>
  <data key="d25">KIT</data>
  <data key="d26">KIT</data>
  <data key="d27">entrez.3815</data>
  <data key="d28">entrez.3815</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3815" target="entrez.2885">
  <data key="d23">20223</data>
  <data key="d24">33176</data>
  <data key="d25">KIT</data>
  <data key="d26">GRB2</data>
  <data key="d27">entrez.3815</data>
  <data key="d28">entrez.2885</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.3815" target="entrez.2534">
  <data key="d23">20223</data>
  <data key="d24">35619</data>
  <data key="d25">KIT</data>
  <data key="d26">FYN</data>
  <data key="d27">entrez.3815</data>
  <data key="d28">entrez.2534</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3815" target="entrez.6714">
  <data key="d23">20223</data>
  <data key="d24">40792</data>
  <data key="d25">KIT</data>
  <data key="d26">SRC</data>
  <data key="d27">entrez.3815</data>
  <data key="d28">entrez.6714</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3815" target="entrez.6464">
  <data key="d23">20223</data>
  <data key="d24">41187</data>
  <data key="d25">KIT</data>
  <data key="d26">SHC1</data>
  <data key="d27">entrez.3815</data>
  <data key="d28">entrez.6464</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3815" target="entrez.2057">
  <data key="d23">20223</data>
  <data key="d24">45200</data>
  <data key="d25">KIT</data>
  <data key="d26">EPOR</data>
  <data key="d27">entrez.3815</data>
  <data key="d28">entrez.2057</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.3815" target="entrez.6850">
  <data key="d23">20223</data>
  <data key="d24">46818</data>
  <data key="d25">KIT</data>
  <data key="d26">SYK</data>
  <data key="d27">entrez.3815</data>
  <data key="d28">entrez.6850</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3815" target="entrez.1439">
  <data key="d23">20223</data>
  <data key="d24">49319</data>
  <data key="d25">KIT</data>
  <data key="d26">CSF2RB</data>
  <data key="d27">entrez.3815</data>
  <data key="d28">entrez.1439</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3815" target="entrez.5296">
  <data key="d23">20223</data>
  <data key="d24">54153</data>
  <data key="d25">KIT</data>
  <data key="d26">PIK3R2</data>
  <data key="d27">entrez.3815</data>
  <data key="d28">entrez.5296</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3815" target="entrez.5295">
  <data key="d23">20223</data>
  <data key="d24">54155</data>
  <data key="d25">KIT</data>
  <data key="d26">PIK3R1</data>
  <data key="d27">entrez.3815</data>
  <data key="d28">entrez.5295</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.3815" target="entrez.5336">
  <data key="d23">20223</data>
  <data key="d24">54398</data>
  <data key="d25">KIT</data>
  <data key="d26">PLCG2</data>
  <data key="d27">entrez.3815</data>
  <data key="d28">entrez.5336</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3815" target="entrez.5335">
  <data key="d23">20223</data>
  <data key="d24">54399</data>
  <data key="d25">KIT</data>
  <data key="d26">PLCG1</data>
  <data key="d27">entrez.3815</data>
  <data key="d28">entrez.5335</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.3815" target="entrez.5921">
  <data key="d23">20223</data>
  <data key="d24">58816</data>
  <data key="d25">KIT</data>
  <data key="d26">RASA1</data>
  <data key="d27">entrez.3815</data>
  <data key="d28">entrez.5921</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3815" target="entrez.5781">
  <data key="d23">20223</data>
  <data key="d24">59850</data>
  <data key="d25">KIT</data>
  <data key="d26">PTPN11</data>
  <data key="d27">entrez.3815</data>
  <data key="d28">entrez.5781</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3815" target="entrez.5777">
  <data key="d23">20223</data>
  <data key="d24">59857</data>
  <data key="d25">KIT</data>
  <data key="d26">PTPN6</data>
  <data key="d27">entrez.3815</data>
  <data key="d28">entrez.5777</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3815" target="drugbank.DB04868">
  <data key="d31">3359</data>
  <data key="d32">20223</data>
  <data key="d25">Nilotinib</data>
  <data key="d26">KIT</data>
  <data key="d33">drugbank.DB04868</data>
  <data key="d34">entrez.3815</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3815" target="drugbank.DB12147">
  <data key="d31">3790</data>
  <data key="d32">20223</data>
  <data key="d25">Erdafitinib</data>
  <data key="d26">KIT</data>
  <data key="d33">drugbank.DB12147</data>
  <data key="d34">entrez.3815</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3815" target="drugbank.DB00317">
  <data key="d31">4668</data>
  <data key="d32">20223</data>
  <data key="d25">Gefitinib</data>
  <data key="d26">KIT</data>
  <data key="d33">drugbank.DB00317</data>
  <data key="d34">entrez.3815</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3815" target="drugbank.DB01268">
  <data key="d31">4894</data>
  <data key="d32">20223</data>
  <data key="d25">Sunitinib</data>
  <data key="d26">KIT</data>
  <data key="d33">drugbank.DB01268</data>
  <data key="d34">entrez.3815</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3815" target="drugbank.DB01254">
  <data key="d31">5149</data>
  <data key="d32">20223</data>
  <data key="d25">Dasatinib</data>
  <data key="d26">KIT</data>
  <data key="d33">drugbank.DB01254</data>
  <data key="d34">entrez.3815</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3815" target="drugbank.DB12010">
  <data key="d31">5608</data>
  <data key="d32">20223</data>
  <data key="d25">Fostamatinib</data>
  <data key="d26">KIT</data>
  <data key="d33">drugbank.DB12010</data>
  <data key="d34">entrez.3815</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3815" target="drugbank.DB00619">
  <data key="d31">6404</data>
  <data key="d32">20223</data>
  <data key="d25">Imatinib</data>
  <data key="d26">KIT</data>
  <data key="d33">drugbank.DB00619</data>
  <data key="d34">entrez.3815</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3815" target="drugbank.DB01962">
  <data key="d31">6486</data>
  <data key="d32">20223</data>
  <data key="d25">Phosphonotyrosine</data>
  <data key="d26">KIT</data>
  <data key="d33">drugbank.DB01962</data>
  <data key="d34">entrez.3815</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3815" target="drugbank.DB09079">
  <data key="d31">6627</data>
  <data key="d32">20223</data>
  <data key="d25">Nintedanib</data>
  <data key="d26">KIT</data>
  <data key="d33">drugbank.DB09079</data>
  <data key="d34">entrez.3815</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3815" target="drugbank.DB09078">
  <data key="d31">6628</data>
  <data key="d32">20223</data>
  <data key="d25">Lenvatinib</data>
  <data key="d26">KIT</data>
  <data key="d33">drugbank.DB09078</data>
  <data key="d34">entrez.3815</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3815" target="drugbank.DB09063">
  <data key="d31">6756</data>
  <data key="d32">20223</data>
  <data key="d25">Ceritinib</data>
  <data key="d26">KIT</data>
  <data key="d33">drugbank.DB09063</data>
  <data key="d34">entrez.3815</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3815" target="drugbank.DB12742">
  <data key="d31">7003</data>
  <data key="d32">20223</data>
  <data key="d25">Amuvatinib</data>
  <data key="d26">KIT</data>
  <data key="d33">drugbank.DB12742</data>
  <data key="d34">entrez.3815</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3815" target="drugbank.DB00398">
  <data key="d31">7170</data>
  <data key="d32">20223</data>
  <data key="d25">Sorafenib</data>
  <data key="d26">KIT</data>
  <data key="d33">drugbank.DB00398</data>
  <data key="d34">entrez.3815</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3815" target="drugbank.DB00530">
  <data key="d31">7910</data>
  <data key="d32">20223</data>
  <data key="d25">Erlotinib</data>
  <data key="d26">KIT</data>
  <data key="d33">drugbank.DB00530</data>
  <data key="d34">entrez.3815</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3815" target="drugbank.DB11829">
  <data key="d31">8788</data>
  <data key="d32">20223</data>
  <data key="d25">Ruboxistaurin</data>
  <data key="d26">KIT</data>
  <data key="d33">drugbank.DB11829</data>
  <data key="d34">entrez.3815</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3815" target="drugbank.DB11800">
  <data key="d31">8890</data>
  <data key="d32">20223</data>
  <data key="d25">Tivozanib</data>
  <data key="d26">KIT</data>
  <data key="d33">drugbank.DB11800</data>
  <data key="d34">entrez.3815</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3815" target="drugbank.DB08901">
  <data key="d31">11231</data>
  <data key="d32">20223</data>
  <data key="d25">Ponatinib</data>
  <data key="d26">KIT</data>
  <data key="d33">drugbank.DB08901</data>
  <data key="d34">entrez.3815</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3815" target="drugbank.DB05146">
  <data key="d31">11711</data>
  <data key="d32">20223</data>
  <data key="d25">XL820</data>
  <data key="d26">KIT</data>
  <data key="d33">drugbank.DB05146</data>
  <data key="d34">entrez.3815</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3815" target="drugbank.DB08865">
  <data key="d31">12120</data>
  <data key="d32">20223</data>
  <data key="d25">Crizotinib</data>
  <data key="d26">KIT</data>
  <data key="d33">drugbank.DB08865</data>
  <data key="d34">entrez.3815</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3815" target="drugbank.DB08877">
  <data key="d31">12195</data>
  <data key="d32">20223</data>
  <data key="d25">Ruxolitinib</data>
  <data key="d26">KIT</data>
  <data key="d33">drugbank.DB08877</data>
  <data key="d34">entrez.3815</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3815" target="drugbank.DB08896">
  <data key="d31">12215</data>
  <data key="d32">20223</data>
  <data key="d25">Regorafenib</data>
  <data key="d26">KIT</data>
  <data key="d33">drugbank.DB08896</data>
  <data key="d34">entrez.3815</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3815" target="drugbank.DB06803">
  <data key="d31">12674</data>
  <data key="d32">20223</data>
  <data key="d25">Niclosamide</data>
  <data key="d26">KIT</data>
  <data key="d33">drugbank.DB06803</data>
  <data key="d34">entrez.3815</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3815" target="drugbank.DB05294">
  <data key="d31">12890</data>
  <data key="d32">20223</data>
  <data key="d25">Vandetanib</data>
  <data key="d26">KIT</data>
  <data key="d33">drugbank.DB05294</data>
  <data key="d34">entrez.3815</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3815" target="drugbank.DB06595">
  <data key="d31">12958</data>
  <data key="d32">20223</data>
  <data key="d25">Midostaurin</data>
  <data key="d26">KIT</data>
  <data key="d33">drugbank.DB06595</data>
  <data key="d34">entrez.3815</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3815" target="drugbank.DB06589">
  <data key="d31">12970</data>
  <data key="d32">20223</data>
  <data key="d25">Pazopanib</data>
  <data key="d26">KIT</data>
  <data key="d33">drugbank.DB06589</data>
  <data key="d34">entrez.3815</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3815" target="drugbank.DB06616">
  <data key="d31">13127</data>
  <data key="d32">20223</data>
  <data key="d25">Bosutinib</data>
  <data key="d26">KIT</data>
  <data key="d33">drugbank.DB06616</data>
  <data key="d34">entrez.3815</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3815" target="drugbank.DB06626">
  <data key="d31">13147</data>
  <data key="d32">20223</data>
  <data key="d25">Axitinib</data>
  <data key="d26">KIT</data>
  <data key="d33">drugbank.DB06626</data>
  <data key="d34">entrez.3815</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.7409" target="entrez.2885">
  <data key="d23">26172</data>
  <data key="d24">33176</data>
  <data key="d25">VAV1</data>
  <data key="d26">GRB2</data>
  <data key="d27">entrez.7409</data>
  <data key="d28">entrez.2885</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.7409" target="entrez.2534">
  <data key="d23">26172</data>
  <data key="d24">35619</data>
  <data key="d25">VAV1</data>
  <data key="d26">FYN</data>
  <data key="d27">entrez.7409</data>
  <data key="d28">entrez.2534</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.7409" target="entrez.2549">
  <data key="d23">26172</data>
  <data key="d24">35713</data>
  <data key="d25">VAV1</data>
  <data key="d26">GAB1</data>
  <data key="d27">entrez.7409</data>
  <data key="d28">entrez.2549</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.7409" target="entrez.6464">
  <data key="d23">26172</data>
  <data key="d24">41187</data>
  <data key="d25">VAV1</data>
  <data key="d26">SHC1</data>
  <data key="d27">entrez.7409</data>
  <data key="d28">entrez.6464</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.7409" target="entrez.2185">
  <data key="d23">26172</data>
  <data key="d24">43995</data>
  <data key="d25">VAV1</data>
  <data key="d26">PTK2B</data>
  <data key="d27">entrez.7409</data>
  <data key="d28">entrez.2185</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.7409" target="entrez.2057">
  <data key="d23">26172</data>
  <data key="d24">45200</data>
  <data key="d25">VAV1</data>
  <data key="d26">EPOR</data>
  <data key="d27">entrez.7409</data>
  <data key="d28">entrez.2057</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.7409" target="entrez.2064">
  <data key="d23">26172</data>
  <data key="d24">45336</data>
  <data key="d25">VAV1</data>
  <data key="d26">ERBB2</data>
  <data key="d27">entrez.7409</data>
  <data key="d28">entrez.2064</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.7409" target="entrez.6850">
  <data key="d23">26172</data>
  <data key="d24">46818</data>
  <data key="d25">VAV1</data>
  <data key="d26">SYK</data>
  <data key="d27">entrez.7409</data>
  <data key="d28">entrez.6850</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.7409" target="entrez.1956">
  <data key="d23">26172</data>
  <data key="d24">53145</data>
  <data key="d25">VAV1</data>
  <data key="d26">EGFR</data>
  <data key="d27">entrez.7409</data>
  <data key="d28">entrez.1956</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.7409" target="entrez.5295">
  <data key="d23">26172</data>
  <data key="d24">54155</data>
  <data key="d25">VAV1</data>
  <data key="d26">PIK3R1</data>
  <data key="d27">entrez.7409</data>
  <data key="d28">entrez.5295</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.7409" target="entrez.5336">
  <data key="d23">26172</data>
  <data key="d24">54398</data>
  <data key="d25">VAV1</data>
  <data key="d26">PLCG2</data>
  <data key="d27">entrez.7409</data>
  <data key="d28">entrez.5336</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.7409" target="entrez.5335">
  <data key="d23">26172</data>
  <data key="d24">54399</data>
  <data key="d25">VAV1</data>
  <data key="d26">PLCG1</data>
  <data key="d27">entrez.7409</data>
  <data key="d28">entrez.5335</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.7409" target="entrez.5159">
  <data key="d23">26172</data>
  <data key="d24">55411</data>
  <data key="d25">VAV1</data>
  <data key="d26">PDGFRB</data>
  <data key="d27">entrez.7409</data>
  <data key="d28">entrez.5159</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.7409" target="entrez.5777">
  <data key="d23">26172</data>
  <data key="d24">59857</data>
  <data key="d25">VAV1</data>
  <data key="d26">PTPN6</data>
  <data key="d27">entrez.7409</data>
  <data key="d28">entrez.5777</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.3667" target="entrez.3667">
  <data key="d23">29133</data>
  <data key="d24">29133</data>
  <data key="d25">IRS1</data>
  <data key="d26">IRS1</data>
  <data key="d27">entrez.3667</data>
  <data key="d28">entrez.3667</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp]</data>
</edge>
<edge source="entrez.3667" target="entrez.3480">
  <data key="d23">29133</data>
  <data key="d24">30249</data>
  <data key="d25">IRS1</data>
  <data key="d26">IGF1R</data>
  <data key="d27">entrez.3667</data>
  <data key="d28">entrez.3480</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.3667" target="entrez.2885">
  <data key="d23">29133</data>
  <data key="d24">33176</data>
  <data key="d25">IRS1</data>
  <data key="d26">GRB2</data>
  <data key="d27">entrez.3667</data>
  <data key="d28">entrez.2885</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3667" target="entrez.2534">
  <data key="d23">29133</data>
  <data key="d24">35619</data>
  <data key="d25">IRS1</data>
  <data key="d26">FYN</data>
  <data key="d27">entrez.3667</data>
  <data key="d28">entrez.2534</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3667" target="entrez.6464">
  <data key="d23">29133</data>
  <data key="d24">41187</data>
  <data key="d25">IRS1</data>
  <data key="d26">SHC1</data>
  <data key="d27">entrez.3667</data>
  <data key="d28">entrez.6464</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3667" target="entrez.2064">
  <data key="d23">29133</data>
  <data key="d24">45336</data>
  <data key="d25">IRS1</data>
  <data key="d26">ERBB2</data>
  <data key="d27">entrez.3667</data>
  <data key="d28">entrez.2064</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3667" target="entrez.1956">
  <data key="d23">29133</data>
  <data key="d24">53145</data>
  <data key="d25">IRS1</data>
  <data key="d26">EGFR</data>
  <data key="d27">entrez.3667</data>
  <data key="d28">entrez.1956</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3667" target="entrez.5296">
  <data key="d23">29133</data>
  <data key="d24">54153</data>
  <data key="d25">IRS1</data>
  <data key="d26">PIK3R2</data>
  <data key="d27">entrez.3667</data>
  <data key="d28">entrez.5296</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3667" target="entrez.5295">
  <data key="d23">29133</data>
  <data key="d24">54155</data>
  <data key="d25">IRS1</data>
  <data key="d26">PIK3R1</data>
  <data key="d27">entrez.3667</data>
  <data key="d28">entrez.5295</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.3667" target="entrez.5336">
  <data key="d23">29133</data>
  <data key="d24">54398</data>
  <data key="d25">IRS1</data>
  <data key="d26">PLCG2</data>
  <data key="d27">entrez.3667</data>
  <data key="d28">entrez.5336</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3667" target="entrez.5781">
  <data key="d23">29133</data>
  <data key="d24">59850</data>
  <data key="d25">IRS1</data>
  <data key="d26">PTPN11</data>
  <data key="d27">entrez.3667</data>
  <data key="d28">entrez.5781</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.3667" target="entrez.5747">
  <data key="d23">29133</data>
  <data key="d24">59937</data>
  <data key="d25">IRS1</data>
  <data key="d26">PTK2</data>
  <data key="d27">entrez.3667</data>
  <data key="d28">entrez.5747</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3326" target="entrez.3326">
  <data key="d23">29825</data>
  <data key="d24">29825</data>
  <data key="d25">HSP90AB1</data>
  <data key="d26">HSP90AB1</data>
  <data key="d27">entrez.3326</data>
  <data key="d28">entrez.3326</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.3326" target="entrez.3320">
  <data key="d23">29825</data>
  <data key="d24">29837</data>
  <data key="d25">HSP90AB1</data>
  <data key="d26">HSP90AA1</data>
  <data key="d27">entrez.3326</data>
  <data key="d28">entrez.3320</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3326" target="entrez.3480">
  <data key="d23">29825</data>
  <data key="d24">30249</data>
  <data key="d25">HSP90AB1</data>
  <data key="d26">IGF1R</data>
  <data key="d27">entrez.3326</data>
  <data key="d28">entrez.3480</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp]</data>
</edge>
<edge source="entrez.3326" target="entrez.2885">
  <data key="d23">29825</data>
  <data key="d24">33176</data>
  <data key="d25">HSP90AB1</data>
  <data key="d26">GRB2</data>
  <data key="d27">entrez.3326</data>
  <data key="d28">entrez.2885</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp]</data>
</edge>
<edge source="entrez.3326" target="entrez.2534">
  <data key="d23">29825</data>
  <data key="d24">35619</data>
  <data key="d25">HSP90AB1</data>
  <data key="d26">FYN</data>
  <data key="d27">entrez.3326</data>
  <data key="d28">entrez.2534</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp]</data>
</edge>
<edge source="entrez.3326" target="entrez.6714">
  <data key="d23">29825</data>
  <data key="d24">40792</data>
  <data key="d25">HSP90AB1</data>
  <data key="d26">SRC</data>
  <data key="d27">entrez.3326</data>
  <data key="d28">entrez.6714</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3326" target="entrez.6464">
  <data key="d23">29825</data>
  <data key="d24">41187</data>
  <data key="d25">HSP90AB1</data>
  <data key="d26">SHC1</data>
  <data key="d27">entrez.3326</data>
  <data key="d28">entrez.6464</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp]</data>
</edge>
<edge source="entrez.3326" target="entrez.2185">
  <data key="d23">29825</data>
  <data key="d24">43995</data>
  <data key="d25">HSP90AB1</data>
  <data key="d26">PTK2B</data>
  <data key="d27">entrez.3326</data>
  <data key="d28">entrez.2185</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp]</data>
</edge>
<edge source="entrez.3326" target="entrez.2064">
  <data key="d23">29825</data>
  <data key="d24">45336</data>
  <data key="d25">HSP90AB1</data>
  <data key="d26">ERBB2</data>
  <data key="d27">entrez.3326</data>
  <data key="d28">entrez.2064</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3326" target="entrez.6774">
  <data key="d23">29825</data>
  <data key="d24">46674</data>
  <data key="d25">HSP90AB1</data>
  <data key="d26">STAT3</data>
  <data key="d27">entrez.3326</data>
  <data key="d28">entrez.6774</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3326" target="entrez.1956">
  <data key="d23">29825</data>
  <data key="d24">53145</data>
  <data key="d25">HSP90AB1</data>
  <data key="d26">EGFR</data>
  <data key="d27">entrez.3326</data>
  <data key="d28">entrez.1956</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3326" target="entrez.5159">
  <data key="d23">29825</data>
  <data key="d24">55411</data>
  <data key="d25">HSP90AB1</data>
  <data key="d26">PDGFRB</data>
  <data key="d27">entrez.3326</data>
  <data key="d28">entrez.5159</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp]</data>
</edge>
<edge source="entrez.3326" target="entrez.5747">
  <data key="d23">29825</data>
  <data key="d24">59937</data>
  <data key="d25">HSP90AB1</data>
  <data key="d26">PTK2</data>
  <data key="d27">entrez.3326</data>
  <data key="d28">entrez.5747</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp]</data>
</edge>
<edge source="entrez.3326" target="drugbank.DB09221">
  <data key="d31">9195</data>
  <data key="d32">29825</data>
  <data key="d25">Polaprezinc</data>
  <data key="d26">HSP90AB1</data>
  <data key="d33">drugbank.DB09221</data>
  <data key="d34">entrez.3326</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3320" target="entrez.3320">
  <data key="d23">29837</data>
  <data key="d24">29837</data>
  <data key="d25">HSP90AA1</data>
  <data key="d26">HSP90AA1</data>
  <data key="d27">entrez.3320</data>
  <data key="d28">entrez.3320</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.3320" target="entrez.3480">
  <data key="d23">29837</data>
  <data key="d24">30249</data>
  <data key="d25">HSP90AA1</data>
  <data key="d26">IGF1R</data>
  <data key="d27">entrez.3320</data>
  <data key="d28">entrez.3480</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp]</data>
</edge>
<edge source="entrez.3320" target="entrez.2885">
  <data key="d23">29837</data>
  <data key="d24">33176</data>
  <data key="d25">HSP90AA1</data>
  <data key="d26">GRB2</data>
  <data key="d27">entrez.3320</data>
  <data key="d28">entrez.2885</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3320" target="entrez.2534">
  <data key="d23">29837</data>
  <data key="d24">35619</data>
  <data key="d25">HSP90AA1</data>
  <data key="d26">FYN</data>
  <data key="d27">entrez.3320</data>
  <data key="d28">entrez.2534</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3320" target="entrez.6714">
  <data key="d23">29837</data>
  <data key="d24">40792</data>
  <data key="d25">HSP90AA1</data>
  <data key="d26">SRC</data>
  <data key="d27">entrez.3320</data>
  <data key="d28">entrez.6714</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3320" target="entrez.6464">
  <data key="d23">29837</data>
  <data key="d24">41187</data>
  <data key="d25">HSP90AA1</data>
  <data key="d26">SHC1</data>
  <data key="d27">entrez.3320</data>
  <data key="d28">entrez.6464</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3320" target="entrez.2185">
  <data key="d23">29837</data>
  <data key="d24">43995</data>
  <data key="d25">HSP90AA1</data>
  <data key="d26">PTK2B</data>
  <data key="d27">entrez.3320</data>
  <data key="d28">entrez.2185</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3320" target="entrez.2064">
  <data key="d23">29837</data>
  <data key="d24">45336</data>
  <data key="d25">HSP90AA1</data>
  <data key="d26">ERBB2</data>
  <data key="d27">entrez.3320</data>
  <data key="d28">entrez.2064</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3320" target="entrez.6774">
  <data key="d23">29837</data>
  <data key="d24">46674</data>
  <data key="d25">HSP90AA1</data>
  <data key="d26">STAT3</data>
  <data key="d27">entrez.3320</data>
  <data key="d28">entrez.6774</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3320" target="entrez.1956">
  <data key="d23">29837</data>
  <data key="d24">53145</data>
  <data key="d25">HSP90AA1</data>
  <data key="d26">EGFR</data>
  <data key="d27">entrez.3320</data>
  <data key="d28">entrez.1956</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3320" target="entrez.5159">
  <data key="d23">29837</data>
  <data key="d24">55411</data>
  <data key="d25">HSP90AA1</data>
  <data key="d26">PDGFRB</data>
  <data key="d27">entrez.3320</data>
  <data key="d28">entrez.5159</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp]</data>
</edge>
<edge source="entrez.3320" target="entrez.5747">
  <data key="d23">29837</data>
  <data key="d24">59937</data>
  <data key="d25">HSP90AA1</data>
  <data key="d26">PTK2</data>
  <data key="d27">entrez.3320</data>
  <data key="d28">entrez.5747</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3320" target="drugbank.DB00342">
  <data key="d31">7283</data>
  <data key="d32">29837</data>
  <data key="d25">Terfenadine</data>
  <data key="d26">HSP90AA1</data>
  <data key="d33">drugbank.DB00342</data>
  <data key="d34">entrez.3320</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3320" target="drugbank.DB09221">
  <data key="d31">9195</data>
  <data key="d32">29837</data>
  <data key="d25">Polaprezinc</data>
  <data key="d26">HSP90AA1</data>
  <data key="d33">drugbank.DB09221</data>
  <data key="d34">entrez.3320</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3320" target="drugbank.DB04216">
  <data key="d31">12527</data>
  <data key="d32">29837</data>
  <data key="d25">Quercetin</data>
  <data key="d26">HSP90AA1</data>
  <data key="d33">drugbank.DB04216</data>
  <data key="d34">entrez.3320</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3480" target="entrez.3480">
  <data key="d23">30249</data>
  <data key="d24">30249</data>
  <data key="d25">IGF1R</data>
  <data key="d26">IGF1R</data>
  <data key="d27">entrez.3480</data>
  <data key="d28">entrez.3480</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp]</data>
</edge>
<edge source="entrez.3480" target="entrez.6714">
  <data key="d23">30249</data>
  <data key="d24">40792</data>
  <data key="d25">IGF1R</data>
  <data key="d26">SRC</data>
  <data key="d27">entrez.3480</data>
  <data key="d28">entrez.6714</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3480" target="entrez.6464">
  <data key="d23">30249</data>
  <data key="d24">41187</data>
  <data key="d25">IGF1R</data>
  <data key="d26">SHC1</data>
  <data key="d27">entrez.3480</data>
  <data key="d28">entrez.6464</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3480" target="entrez.2064">
  <data key="d23">30249</data>
  <data key="d24">45336</data>
  <data key="d25">IGF1R</data>
  <data key="d26">ERBB2</data>
  <data key="d27">entrez.3480</data>
  <data key="d28">entrez.2064</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3480" target="entrez.6774">
  <data key="d23">30249</data>
  <data key="d24">46674</data>
  <data key="d25">IGF1R</data>
  <data key="d26">STAT3</data>
  <data key="d27">entrez.3480</data>
  <data key="d28">entrez.6774</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3480" target="entrez.1956">
  <data key="d23">30249</data>
  <data key="d24">53145</data>
  <data key="d25">IGF1R</data>
  <data key="d26">EGFR</data>
  <data key="d27">entrez.3480</data>
  <data key="d28">entrez.1956</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3480" target="entrez.5296">
  <data key="d23">30249</data>
  <data key="d24">54153</data>
  <data key="d25">IGF1R</data>
  <data key="d26">PIK3R2</data>
  <data key="d27">entrez.3480</data>
  <data key="d28">entrez.5296</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3480" target="entrez.5295">
  <data key="d23">30249</data>
  <data key="d24">54155</data>
  <data key="d25">IGF1R</data>
  <data key="d26">PIK3R1</data>
  <data key="d27">entrez.3480</data>
  <data key="d28">entrez.5295</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3480" target="entrez.5921">
  <data key="d23">30249</data>
  <data key="d24">58816</data>
  <data key="d25">IGF1R</data>
  <data key="d26">RASA1</data>
  <data key="d27">entrez.3480</data>
  <data key="d28">entrez.5921</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3480" target="entrez.5781">
  <data key="d23">30249</data>
  <data key="d24">59850</data>
  <data key="d25">IGF1R</data>
  <data key="d26">PTPN11</data>
  <data key="d27">entrez.3480</data>
  <data key="d28">entrez.5781</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3480" target="entrez.5777">
  <data key="d23">30249</data>
  <data key="d24">59857</data>
  <data key="d25">IGF1R</data>
  <data key="d26">PTPN6</data>
  <data key="d27">entrez.3480</data>
  <data key="d28">entrez.5777</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3480" target="entrez.5747">
  <data key="d23">30249</data>
  <data key="d24">59937</data>
  <data key="d25">IGF1R</data>
  <data key="d26">PTK2</data>
  <data key="d27">entrez.3480</data>
  <data key="d28">entrez.5747</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.3480" target="drugbank.DB04395">
  <data key="d31">1251</data>
  <data key="d32">30249</data>
  <data key="d25">Phosphoaminophosphonic Acid-Adenylate Ester</data>
  <data key="d26">IGF1R</data>
  <data key="d33">drugbank.DB04395</data>
  <data key="d34">entrez.3480</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3480" target="drugbank.DB12267">
  <data key="d31">4340</data>
  <data key="d32">30249</data>
  <data key="d25">Brigatinib</data>
  <data key="d26">IGF1R</data>
  <data key="d33">drugbank.DB12267</data>
  <data key="d34">entrez.3480</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3480" target="drugbank.DB01268">
  <data key="d31">4894</data>
  <data key="d32">30249</data>
  <data key="d25">Sunitinib</data>
  <data key="d26">IGF1R</data>
  <data key="d33">drugbank.DB01268</data>
  <data key="d34">entrez.3480</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3480" target="drugbank.DB00030">
  <data key="d31">5641</data>
  <data key="d32">30249</data>
  <data key="d25">Insulin Human</data>
  <data key="d26">IGF1R</data>
  <data key="d33">drugbank.DB00030</data>
  <data key="d34">entrez.3480</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3480" target="drugbank.DB09079">
  <data key="d31">6627</data>
  <data key="d32">30249</data>
  <data key="d25">Nintedanib</data>
  <data key="d26">IGF1R</data>
  <data key="d33">drugbank.DB09079</data>
  <data key="d34">entrez.3480</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3480" target="drugbank.DB09063">
  <data key="d31">6756</data>
  <data key="d32">30249</data>
  <data key="d25">Ceritinib</data>
  <data key="d26">IGF1R</data>
  <data key="d33">drugbank.DB09063</data>
  <data key="d34">entrez.3480</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3480" target="drugbank.DB05184">
  <data key="d31">11602</data>
  <data key="d32">30249</data>
  <data key="d25">XL228</data>
  <data key="d26">IGF1R</data>
  <data key="d33">drugbank.DB05184</data>
  <data key="d34">entrez.3480</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3480" target="drugbank.DB08865">
  <data key="d31">12120</data>
  <data key="d32">30249</data>
  <data key="d25">Crizotinib</data>
  <data key="d26">IGF1R</data>
  <data key="d33">drugbank.DB08865</data>
  <data key="d34">entrez.3480</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.3480" target="drugbank.DB04216">
  <data key="d31">12527</data>
  <data key="d32">30249</data>
  <data key="d25">Quercetin</data>
  <data key="d26">IGF1R</data>
  <data key="d33">drugbank.DB04216</data>
  <data key="d34">entrez.3480</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2885" target="entrez.2885">
  <data key="d23">33176</data>
  <data key="d24">33176</data>
  <data key="d25">GRB2</data>
  <data key="d26">GRB2</data>
  <data key="d27">entrez.2885</data>
  <data key="d28">entrez.2885</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.2885" target="entrez.2534">
  <data key="d23">33176</data>
  <data key="d24">35619</data>
  <data key="d25">GRB2</data>
  <data key="d26">FYN</data>
  <data key="d27">entrez.2885</data>
  <data key="d28">entrez.2534</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.2885" target="entrez.2549">
  <data key="d23">33176</data>
  <data key="d24">35713</data>
  <data key="d25">GRB2</data>
  <data key="d26">GAB1</data>
  <data key="d27">entrez.2885</data>
  <data key="d28">entrez.2549</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.2885" target="entrez.6714">
  <data key="d23">33176</data>
  <data key="d24">40792</data>
  <data key="d25">GRB2</data>
  <data key="d26">SRC</data>
  <data key="d27">entrez.2885</data>
  <data key="d28">entrez.6714</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.2885" target="entrez.6464">
  <data key="d23">33176</data>
  <data key="d24">41187</data>
  <data key="d25">GRB2</data>
  <data key="d26">SHC1</data>
  <data key="d27">entrez.2885</data>
  <data key="d28">entrez.6464</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.2885" target="entrez.2185">
  <data key="d23">33176</data>
  <data key="d24">43995</data>
  <data key="d25">GRB2</data>
  <data key="d26">PTK2B</data>
  <data key="d27">entrez.2885</data>
  <data key="d28">entrez.2185</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.2885" target="entrez.2057">
  <data key="d23">33176</data>
  <data key="d24">45200</data>
  <data key="d25">GRB2</data>
  <data key="d26">EPOR</data>
  <data key="d27">entrez.2885</data>
  <data key="d28">entrez.2057</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.2885" target="entrez.2064">
  <data key="d23">33176</data>
  <data key="d24">45336</data>
  <data key="d25">GRB2</data>
  <data key="d26">ERBB2</data>
  <data key="d27">entrez.2885</data>
  <data key="d28">entrez.2064</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.2885" target="entrez.6850">
  <data key="d23">33176</data>
  <data key="d24">46818</data>
  <data key="d25">GRB2</data>
  <data key="d26">SYK</data>
  <data key="d27">entrez.2885</data>
  <data key="d28">entrez.6850</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.2885" target="entrez.1956">
  <data key="d23">33176</data>
  <data key="d24">53145</data>
  <data key="d25">GRB2</data>
  <data key="d26">EGFR</data>
  <data key="d27">entrez.2885</data>
  <data key="d28">entrez.1956</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.2885" target="entrez.5296">
  <data key="d23">33176</data>
  <data key="d24">54153</data>
  <data key="d25">GRB2</data>
  <data key="d26">PIK3R2</data>
  <data key="d27">entrez.2885</data>
  <data key="d28">entrez.5296</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.2885" target="entrez.5295">
  <data key="d23">33176</data>
  <data key="d24">54155</data>
  <data key="d25">GRB2</data>
  <data key="d26">PIK3R1</data>
  <data key="d27">entrez.2885</data>
  <data key="d28">entrez.5295</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.2885" target="entrez.5336">
  <data key="d23">33176</data>
  <data key="d24">54398</data>
  <data key="d25">GRB2</data>
  <data key="d26">PLCG2</data>
  <data key="d27">entrez.2885</data>
  <data key="d28">entrez.5336</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.2885" target="entrez.5335">
  <data key="d23">33176</data>
  <data key="d24">54399</data>
  <data key="d25">GRB2</data>
  <data key="d26">PLCG1</data>
  <data key="d27">entrez.2885</data>
  <data key="d28">entrez.5335</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.2885" target="entrez.5159">
  <data key="d23">33176</data>
  <data key="d24">55411</data>
  <data key="d25">GRB2</data>
  <data key="d26">PDGFRB</data>
  <data key="d27">entrez.2885</data>
  <data key="d28">entrez.5159</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.2885" target="entrez.5921">
  <data key="d23">33176</data>
  <data key="d24">58816</data>
  <data key="d25">GRB2</data>
  <data key="d26">RASA1</data>
  <data key="d27">entrez.2885</data>
  <data key="d28">entrez.5921</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.2885" target="entrez.5781">
  <data key="d23">33176</data>
  <data key="d24">59850</data>
  <data key="d25">GRB2</data>
  <data key="d26">PTPN11</data>
  <data key="d27">entrez.2885</data>
  <data key="d28">entrez.5781</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.2885" target="entrez.5777">
  <data key="d23">33176</data>
  <data key="d24">59857</data>
  <data key="d25">GRB2</data>
  <data key="d26">PTPN6</data>
  <data key="d27">entrez.2885</data>
  <data key="d28">entrez.5777</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.2885" target="entrez.5747">
  <data key="d23">33176</data>
  <data key="d24">59937</data>
  <data key="d25">GRB2</data>
  <data key="d26">PTK2</data>
  <data key="d27">entrez.2885</data>
  <data key="d28">entrez.5747</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.2885" target="drugbank.DB00061">
  <data key="d31">5450</data>
  <data key="d32">33176</data>
  <data key="d25">Pegademase</data>
  <data key="d26">GRB2</data>
  <data key="d33">drugbank.DB00061</data>
  <data key="d34">entrez.2885</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2885" target="drugbank.DB00970">
  <data key="d31">9524</data>
  <data key="d32">33176</data>
  <data key="d25">Dactinomycin</data>
  <data key="d26">GRB2</data>
  <data key="d33">drugbank.DB00970</data>
  <data key="d34">entrez.2885</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2534" target="entrez.2534">
  <data key="d23">35619</data>
  <data key="d24">35619</data>
  <data key="d25">FYN</data>
  <data key="d26">FYN</data>
  <data key="d27">entrez.2534</data>
  <data key="d28">entrez.2534</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.2534" target="entrez.6714">
  <data key="d23">35619</data>
  <data key="d24">40792</data>
  <data key="d25">FYN</data>
  <data key="d26">SRC</data>
  <data key="d27">entrez.2534</data>
  <data key="d28">entrez.6714</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.2534" target="entrez.6464">
  <data key="d23">35619</data>
  <data key="d24">41187</data>
  <data key="d25">FYN</data>
  <data key="d26">SHC1</data>
  <data key="d27">entrez.2534</data>
  <data key="d28">entrez.6464</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.2534" target="entrez.2185">
  <data key="d23">35619</data>
  <data key="d24">43995</data>
  <data key="d25">FYN</data>
  <data key="d26">PTK2B</data>
  <data key="d27">entrez.2534</data>
  <data key="d28">entrez.2185</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.2534" target="entrez.2064">
  <data key="d23">35619</data>
  <data key="d24">45336</data>
  <data key="d25">FYN</data>
  <data key="d26">ERBB2</data>
  <data key="d27">entrez.2534</data>
  <data key="d28">entrez.2064</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.2534" target="entrez.6774">
  <data key="d23">35619</data>
  <data key="d24">46674</data>
  <data key="d25">FYN</data>
  <data key="d26">STAT3</data>
  <data key="d27">entrez.2534</data>
  <data key="d28">entrez.6774</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.2534" target="entrez.6850">
  <data key="d23">35619</data>
  <data key="d24">46818</data>
  <data key="d25">FYN</data>
  <data key="d26">SYK</data>
  <data key="d27">entrez.2534</data>
  <data key="d28">entrez.6850</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.2534" target="entrez.1439">
  <data key="d23">35619</data>
  <data key="d24">49319</data>
  <data key="d25">FYN</data>
  <data key="d26">CSF2RB</data>
  <data key="d27">entrez.2534</data>
  <data key="d28">entrez.1439</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.2534" target="entrez.5296">
  <data key="d23">35619</data>
  <data key="d24">54153</data>
  <data key="d25">FYN</data>
  <data key="d26">PIK3R2</data>
  <data key="d27">entrez.2534</data>
  <data key="d28">entrez.5296</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.2534" target="entrez.5295">
  <data key="d23">35619</data>
  <data key="d24">54155</data>
  <data key="d25">FYN</data>
  <data key="d26">PIK3R1</data>
  <data key="d27">entrez.2534</data>
  <data key="d28">entrez.5295</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.2534" target="entrez.5336">
  <data key="d23">35619</data>
  <data key="d24">54398</data>
  <data key="d25">FYN</data>
  <data key="d26">PLCG2</data>
  <data key="d27">entrez.2534</data>
  <data key="d28">entrez.5336</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.2534" target="entrez.5335">
  <data key="d23">35619</data>
  <data key="d24">54399</data>
  <data key="d25">FYN</data>
  <data key="d26">PLCG1</data>
  <data key="d27">entrez.2534</data>
  <data key="d28">entrez.5335</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.2534" target="entrez.5159">
  <data key="d23">35619</data>
  <data key="d24">55411</data>
  <data key="d25">FYN</data>
  <data key="d26">PDGFRB</data>
  <data key="d27">entrez.2534</data>
  <data key="d28">entrez.5159</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.2534" target="entrez.5781">
  <data key="d23">35619</data>
  <data key="d24">59850</data>
  <data key="d25">FYN</data>
  <data key="d26">PTPN11</data>
  <data key="d27">entrez.2534</data>
  <data key="d28">entrez.5781</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.2534" target="entrez.5747">
  <data key="d23">35619</data>
  <data key="d24">59937</data>
  <data key="d25">FYN</data>
  <data key="d26">PTK2</data>
  <data key="d27">entrez.2534</data>
  <data key="d28">entrez.5747</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.2534" target="drugbank.DB03166">
  <data key="d31">1432</data>
  <data key="d32">35619</data>
  <data key="d25">Acetic acid</data>
  <data key="d26">FYN</data>
  <data key="d33">drugbank.DB03166</data>
  <data key="d34">entrez.2534</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2534" target="drugbank.DB13050">
  <data key="d31">1659</data>
  <data key="d32">35619</data>
  <data key="d25">Tirilazad</data>
  <data key="d26">FYN</data>
  <data key="d33">drugbank.DB13050</data>
  <data key="d34">entrez.2534</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2534" target="drugbank.DB01074">
  <data key="d31">1669</data>
  <data key="d32">35619</data>
  <data key="d25">Perhexiline</data>
  <data key="d26">FYN</data>
  <data key="d33">drugbank.DB01074</data>
  <data key="d34">entrez.2534</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2534" target="drugbank.DB01110">
  <data key="d31">2410</data>
  <data key="d32">35619</data>
  <data key="d25">Miconazole</data>
  <data key="d26">FYN</data>
  <data key="d33">drugbank.DB01110</data>
  <data key="d34">entrez.2534</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2534" target="drugbank.DB01118">
  <data key="d31">2440</data>
  <data key="d32">35619</data>
  <data key="d25">Amiodarone</data>
  <data key="d26">FYN</data>
  <data key="d33">drugbank.DB01118</data>
  <data key="d34">entrez.2534</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2534" target="drugbank.DB01127">
  <data key="d31">2486</data>
  <data key="d32">35619</data>
  <data key="d25">Econazole</data>
  <data key="d26">FYN</data>
  <data key="d33">drugbank.DB01127</data>
  <data key="d34">entrez.2534</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2534" target="drugbank.DB04868">
  <data key="d31">3359</data>
  <data key="d32">35619</data>
  <data key="d25">Nilotinib</data>
  <data key="d26">FYN</data>
  <data key="d33">drugbank.DB04868</data>
  <data key="d34">entrez.2534</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2534" target="drugbank.DB00190">
  <data key="d31">3567</data>
  <data key="d32">35619</data>
  <data key="d25">Carbidopa</data>
  <data key="d26">FYN</data>
  <data key="d33">drugbank.DB00190</data>
  <data key="d34">entrez.2534</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2534" target="drugbank.DB00257">
  <data key="d31">4215</data>
  <data key="d32">35619</data>
  <data key="d25">Clotrimazole</data>
  <data key="d26">FYN</data>
  <data key="d33">drugbank.DB00257</data>
  <data key="d34">entrez.2534</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2534" target="drugbank.DB00255">
  <data key="d31">4219</data>
  <data key="d32">35619</data>
  <data key="d25">Diethylstilbestrol</data>
  <data key="d26">FYN</data>
  <data key="d33">drugbank.DB00255</data>
  <data key="d34">entrez.2534</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2534" target="drugbank.DB00220">
  <data key="d31">4422</data>
  <data key="d32">35619</data>
  <data key="d25">Nelfinavir</data>
  <data key="d26">FYN</data>
  <data key="d33">drugbank.DB00220</data>
  <data key="d34">entrez.2534</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2534" target="drugbank.DB01268">
  <data key="d31">4894</data>
  <data key="d32">35619</data>
  <data key="d25">Sunitinib</data>
  <data key="d26">FYN</data>
  <data key="d33">drugbank.DB01268</data>
  <data key="d34">entrez.2534</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2534" target="drugbank.DB01229">
  <data key="d31">4988</data>
  <data key="d32">35619</data>
  <data key="d25">Paclitaxel</data>
  <data key="d26">FYN</data>
  <data key="d33">drugbank.DB01229</data>
  <data key="d34">entrez.2534</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2534" target="drugbank.DB01254">
  <data key="d31">5149</data>
  <data key="d32">35619</data>
  <data key="d25">Dasatinib</data>
  <data key="d26">FYN</data>
  <data key="d33">drugbank.DB01254</data>
  <data key="d34">entrez.2534</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2534" target="drugbank.DB01204">
  <data key="d31">5230</data>
  <data key="d32">35619</data>
  <data key="d25">Mitoxantrone</data>
  <data key="d26">FYN</data>
  <data key="d33">drugbank.DB01204</data>
  <data key="d34">entrez.2534</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2534" target="drugbank.DB12010">
  <data key="d31">5608</data>
  <data key="d32">35619</data>
  <data key="d25">Fostamatinib</data>
  <data key="d26">FYN</data>
  <data key="d33">drugbank.DB12010</data>
  <data key="d34">entrez.2534</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2534" target="drugbank.DB00027">
  <data key="d31">5620</data>
  <data key="d32">35619</data>
  <data key="d25">Gramicidin D</data>
  <data key="d26">FYN</data>
  <data key="d33">drugbank.DB00027</data>
  <data key="d34">entrez.2534</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2534" target="drugbank.DB00679">
  <data key="d31">6312</data>
  <data key="d32">35619</data>
  <data key="d25">Thioridazine</data>
  <data key="d26">FYN</data>
  <data key="d33">drugbank.DB00679</data>
  <data key="d34">entrez.2534</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2534" target="drugbank.DB00675">
  <data key="d31">6319</data>
  <data key="d32">35619</data>
  <data key="d25">Tamoxifen</data>
  <data key="d26">FYN</data>
  <data key="d33">drugbank.DB00675</data>
  <data key="d34">entrez.2534</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2534" target="drugbank.DB00619">
  <data key="d31">6404</data>
  <data key="d32">35619</data>
  <data key="d25">Imatinib</data>
  <data key="d26">FYN</data>
  <data key="d33">drugbank.DB00619</data>
  <data key="d34">entrez.2534</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2534" target="drugbank.DB00623">
  <data key="d31">6443</data>
  <data key="d32">35619</data>
  <data key="d25">Fluphenazine</data>
  <data key="d26">FYN</data>
  <data key="d33">drugbank.DB00623</data>
  <data key="d34">entrez.2534</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2534" target="drugbank.DB00637">
  <data key="d31">6473</data>
  <data key="d32">35619</data>
  <data key="d25">Astemizole</data>
  <data key="d26">FYN</data>
  <data key="d33">drugbank.DB00637</data>
  <data key="d34">entrez.2534</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2534" target="drugbank.DB09079">
  <data key="d31">6627</data>
  <data key="d32">35619</data>
  <data key="d25">Nintedanib</data>
  <data key="d26">FYN</data>
  <data key="d33">drugbank.DB09079</data>
  <data key="d34">entrez.2534</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2534" target="drugbank.DB00696">
  <data key="d31">6672</data>
  <data key="d32">35619</data>
  <data key="d25">Ergotamine</data>
  <data key="d26">FYN</data>
  <data key="d33">drugbank.DB00696</data>
  <data key="d34">entrez.2534</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2534" target="drugbank.DB09053">
  <data key="d31">6731</data>
  <data key="d32">35619</data>
  <data key="d25">Ibrutinib</data>
  <data key="d26">FYN</data>
  <data key="d33">drugbank.DB09053</data>
  <data key="d34">entrez.2534</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2534" target="drugbank.DB09115">
  <data key="d31">6783</data>
  <data key="d32">35619</data>
  <data key="d25">Diiodohydroxyquinoline</data>
  <data key="d26">FYN</data>
  <data key="d33">drugbank.DB09115</data>
  <data key="d34">entrez.2534</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2534" target="drugbank.DB09129">
  <data key="d31">6819</data>
  <data key="d32">35619</data>
  <data key="d25">Chromic chloride</data>
  <data key="d26">FYN</data>
  <data key="d33">drugbank.DB09129</data>
  <data key="d34">entrez.2534</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2534" target="drugbank.DB00783">
  <data key="d31">6820</data>
  <data key="d32">35619</data>
  <data key="d25">Estradiol</data>
  <data key="d26">FYN</data>
  <data key="d33">drugbank.DB00783</data>
  <data key="d34">entrez.2534</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2534" target="drugbank.DB00756">
  <data key="d31">6952</data>
  <data key="d32">35619</data>
  <data key="d25">Hexachlorophene</data>
  <data key="d26">FYN</data>
  <data key="d33">drugbank.DB00756</data>
  <data key="d34">entrez.2534</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2534" target="drugbank.DB00398">
  <data key="d31">7170</data>
  <data key="d32">35619</data>
  <data key="d25">Sorafenib</data>
  <data key="d26">FYN</data>
  <data key="d33">drugbank.DB00398</data>
  <data key="d34">entrez.2534</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2534" target="drugbank.DB00342">
  <data key="d31">7283</data>
  <data key="d32">35619</data>
  <data key="d25">Terfenadine</data>
  <data key="d26">FYN</data>
  <data key="d33">drugbank.DB00342</data>
  <data key="d34">entrez.2534</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2534" target="drugbank.DB00406">
  <data key="d31">7615</data>
  <data key="d32">35619</data>
  <data key="d25">Gentian violet cation</data>
  <data key="d26">FYN</data>
  <data key="d33">drugbank.DB00406</data>
  <data key="d34">entrez.2534</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2534" target="drugbank.DB00471">
  <data key="d31">7787</data>
  <data key="d32">35619</data>
  <data key="d25">Montelukast</data>
  <data key="d26">FYN</data>
  <data key="d33">drugbank.DB00471</data>
  <data key="d34">entrez.2534</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2534" target="drugbank.DB00477">
  <data key="d31">7827</data>
  <data key="d32">35619</data>
  <data key="d25">Chlorpromazine</data>
  <data key="d26">FYN</data>
  <data key="d33">drugbank.DB00477</data>
  <data key="d34">entrez.2534</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2534" target="drugbank.DB11125">
  <data key="d31">7840</data>
  <data key="d32">35619</data>
  <data key="d25">Benzethonium</data>
  <data key="d26">FYN</data>
  <data key="d33">drugbank.DB11125</data>
  <data key="d34">entrez.2534</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2534" target="drugbank.DB00515">
  <data key="d31">8119</data>
  <data key="d32">35619</data>
  <data key="d25">Cisplatin</data>
  <data key="d26">FYN</data>
  <data key="d33">drugbank.DB00515</data>
  <data key="d34">entrez.2534</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2534" target="drugbank.DB11742">
  <data key="d31">8412</data>
  <data key="d32">35619</data>
  <data key="d25">Ebastine</data>
  <data key="d26">FYN</data>
  <data key="d33">drugbank.DB11742</data>
  <data key="d34">entrez.2534</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2534" target="drugbank.DB11828">
  <data key="d31">8787</data>
  <data key="d32">35619</data>
  <data key="d25">Neratinib</data>
  <data key="d26">FYN</data>
  <data key="d33">drugbank.DB11828</data>
  <data key="d34">entrez.2534</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2534" target="drugbank.DB00882">
  <data key="d31">9198</data>
  <data key="d32">35619</data>
  <data key="d25">Clomifene</data>
  <data key="d26">FYN</data>
  <data key="d33">drugbank.DB00882</data>
  <data key="d34">entrez.2534</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2534" target="drugbank.DB00834">
  <data key="d31">9252</data>
  <data key="d32">35619</data>
  <data key="d25">Mifepristone</data>
  <data key="d26">FYN</data>
  <data key="d33">drugbank.DB00834</data>
  <data key="d34">entrez.2534</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2534" target="drugbank.DB00841">
  <data key="d31">9274</data>
  <data key="d32">35619</data>
  <data key="d25">Dobutamine</data>
  <data key="d26">FYN</data>
  <data key="d33">drugbank.DB00841</data>
  <data key="d34">entrez.2534</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2534" target="drugbank.DB00803">
  <data key="d31">9289</data>
  <data key="d32">35619</data>
  <data key="d25">Colistin</data>
  <data key="d26">FYN</data>
  <data key="d33">drugbank.DB00803</data>
  <data key="d34">entrez.2534</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2534" target="drugbank.DB09276">
  <data key="d31">9312</data>
  <data key="d32">35619</data>
  <data key="d25">Sodium aurothiomalate</data>
  <data key="d26">FYN</data>
  <data key="d33">drugbank.DB09276</data>
  <data key="d34">entrez.2534</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2534" target="drugbank.DB09372">
  <data key="d31">9450</data>
  <data key="d32">35619</data>
  <data key="d25">Tannic acid</data>
  <data key="d26">FYN</data>
  <data key="d33">drugbank.DB09372</data>
  <data key="d34">entrez.2534</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2534" target="drugbank.DB00988">
  <data key="d31">9553</data>
  <data key="d32">35619</data>
  <data key="d25">Dopamine</data>
  <data key="d26">FYN</data>
  <data key="d33">drugbank.DB00988</data>
  <data key="d34">entrez.2534</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2534" target="drugbank.DB00997">
  <data key="d31">9598</data>
  <data key="d32">35619</data>
  <data key="d25">Doxorubicin</data>
  <data key="d26">FYN</data>
  <data key="d33">drugbank.DB00997</data>
  <data key="d34">entrez.2534</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2534" target="drugbank.DB00968">
  <data key="d31">9773</data>
  <data key="d32">35619</data>
  <data key="d25">Methyldopa</data>
  <data key="d26">FYN</data>
  <data key="d33">drugbank.DB00968</data>
  <data key="d34">entrez.2534</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2534" target="drugbank.DB08865">
  <data key="d31">12120</data>
  <data key="d32">35619</data>
  <data key="d25">Crizotinib</data>
  <data key="d26">FYN</data>
  <data key="d33">drugbank.DB08865</data>
  <data key="d34">entrez.2534</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2534" target="drugbank.DB08895">
  <data key="d31">12218</data>
  <data key="d32">35619</data>
  <data key="d25">Tofacitinib</data>
  <data key="d26">FYN</data>
  <data key="d33">drugbank.DB08895</data>
  <data key="d34">entrez.2534</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2534" target="drugbank.DB05294">
  <data key="d31">12890</data>
  <data key="d32">35619</data>
  <data key="d25">Vandetanib</data>
  <data key="d26">FYN</data>
  <data key="d33">drugbank.DB05294</data>
  <data key="d34">entrez.2534</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2534" target="drugbank.DB06595">
  <data key="d31">12958</data>
  <data key="d32">35619</data>
  <data key="d25">Midostaurin</data>
  <data key="d26">FYN</data>
  <data key="d33">drugbank.DB06595</data>
  <data key="d34">entrez.2534</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2534" target="drugbank.DB06589">
  <data key="d31">12970</data>
  <data key="d32">35619</data>
  <data key="d25">Pazopanib</data>
  <data key="d26">FYN</data>
  <data key="d33">drugbank.DB06589</data>
  <data key="d34">entrez.2534</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2534" target="drugbank.DB06616">
  <data key="d31">13127</data>
  <data key="d32">35619</data>
  <data key="d25">Bosutinib</data>
  <data key="d26">FYN</data>
  <data key="d33">drugbank.DB06616</data>
  <data key="d34">entrez.2534</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2549" target="entrez.6714">
  <data key="d23">35713</data>
  <data key="d24">40792</data>
  <data key="d25">GAB1</data>
  <data key="d26">SRC</data>
  <data key="d27">entrez.2549</data>
  <data key="d28">entrez.6714</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.2549" target="entrez.6464">
  <data key="d23">35713</data>
  <data key="d24">41187</data>
  <data key="d25">GAB1</data>
  <data key="d26">SHC1</data>
  <data key="d27">entrez.2549</data>
  <data key="d28">entrez.6464</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.2549" target="entrez.2057">
  <data key="d23">35713</data>
  <data key="d24">45200</data>
  <data key="d25">GAB1</data>
  <data key="d26">EPOR</data>
  <data key="d27">entrez.2549</data>
  <data key="d28">entrez.2057</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.2549" target="entrez.6850">
  <data key="d23">35713</data>
  <data key="d24">46818</data>
  <data key="d25">GAB1</data>
  <data key="d26">SYK</data>
  <data key="d27">entrez.2549</data>
  <data key="d28">entrez.6850</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.2549" target="entrez.1956">
  <data key="d23">35713</data>
  <data key="d24">53145</data>
  <data key="d25">GAB1</data>
  <data key="d26">EGFR</data>
  <data key="d27">entrez.2549</data>
  <data key="d28">entrez.1956</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.2549" target="entrez.5296">
  <data key="d23">35713</data>
  <data key="d24">54153</data>
  <data key="d25">GAB1</data>
  <data key="d26">PIK3R2</data>
  <data key="d27">entrez.2549</data>
  <data key="d28">entrez.5296</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.2549" target="entrez.5295">
  <data key="d23">35713</data>
  <data key="d24">54155</data>
  <data key="d25">GAB1</data>
  <data key="d26">PIK3R1</data>
  <data key="d27">entrez.2549</data>
  <data key="d28">entrez.5295</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.2549" target="entrez.5336">
  <data key="d23">35713</data>
  <data key="d24">54398</data>
  <data key="d25">GAB1</data>
  <data key="d26">PLCG2</data>
  <data key="d27">entrez.2549</data>
  <data key="d28">entrez.5336</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.2549" target="entrez.5335">
  <data key="d23">35713</data>
  <data key="d24">54399</data>
  <data key="d25">GAB1</data>
  <data key="d26">PLCG1</data>
  <data key="d27">entrez.2549</data>
  <data key="d28">entrez.5335</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.2549" target="entrez.5159">
  <data key="d23">35713</data>
  <data key="d24">55411</data>
  <data key="d25">GAB1</data>
  <data key="d26">PDGFRB</data>
  <data key="d27">entrez.2549</data>
  <data key="d28">entrez.5159</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.2549" target="entrez.5921">
  <data key="d23">35713</data>
  <data key="d24">58816</data>
  <data key="d25">GAB1</data>
  <data key="d26">RASA1</data>
  <data key="d27">entrez.2549</data>
  <data key="d28">entrez.5921</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.2549" target="entrez.5781">
  <data key="d23">35713</data>
  <data key="d24">59850</data>
  <data key="d25">GAB1</data>
  <data key="d26">PTPN11</data>
  <data key="d27">entrez.2549</data>
  <data key="d28">entrez.5781</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.6714" target="entrez.6714">
  <data key="d23">40792</data>
  <data key="d24">40792</data>
  <data key="d25">SRC</data>
  <data key="d26">SRC</data>
  <data key="d27">entrez.6714</data>
  <data key="d28">entrez.6714</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho]</data>
</edge>
<edge source="entrez.6714" target="entrez.6464">
  <data key="d23">40792</data>
  <data key="d24">41187</data>
  <data key="d25">SRC</data>
  <data key="d26">SHC1</data>
  <data key="d27">entrez.6714</data>
  <data key="d28">entrez.6464</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.6714" target="entrez.2185">
  <data key="d23">40792</data>
  <data key="d24">43995</data>
  <data key="d25">SRC</data>
  <data key="d26">PTK2B</data>
  <data key="d27">entrez.6714</data>
  <data key="d28">entrez.2185</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.6714" target="entrez.2057">
  <data key="d23">40792</data>
  <data key="d24">45200</data>
  <data key="d25">SRC</data>
  <data key="d26">EPOR</data>
  <data key="d27">entrez.6714</data>
  <data key="d28">entrez.2057</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.6714" target="entrez.2064">
  <data key="d23">40792</data>
  <data key="d24">45336</data>
  <data key="d25">SRC</data>
  <data key="d26">ERBB2</data>
  <data key="d27">entrez.6714</data>
  <data key="d28">entrez.2064</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.6714" target="entrez.6774">
  <data key="d23">40792</data>
  <data key="d24">46674</data>
  <data key="d25">SRC</data>
  <data key="d26">STAT3</data>
  <data key="d27">entrez.6714</data>
  <data key="d28">entrez.6774</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.6714" target="entrez.6850">
  <data key="d23">40792</data>
  <data key="d24">46818</data>
  <data key="d25">SRC</data>
  <data key="d26">SYK</data>
  <data key="d27">entrez.6714</data>
  <data key="d28">entrez.6850</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.6714" target="entrez.1956">
  <data key="d23">40792</data>
  <data key="d24">53145</data>
  <data key="d25">SRC</data>
  <data key="d26">EGFR</data>
  <data key="d27">entrez.6714</data>
  <data key="d28">entrez.1956</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.6714" target="entrez.5296">
  <data key="d23">40792</data>
  <data key="d24">54153</data>
  <data key="d25">SRC</data>
  <data key="d26">PIK3R2</data>
  <data key="d27">entrez.6714</data>
  <data key="d28">entrez.5296</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.6714" target="entrez.5295">
  <data key="d23">40792</data>
  <data key="d24">54155</data>
  <data key="d25">SRC</data>
  <data key="d26">PIK3R1</data>
  <data key="d27">entrez.6714</data>
  <data key="d28">entrez.5295</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.6714" target="entrez.5335">
  <data key="d23">40792</data>
  <data key="d24">54399</data>
  <data key="d25">SRC</data>
  <data key="d26">PLCG1</data>
  <data key="d27">entrez.6714</data>
  <data key="d28">entrez.5335</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.6714" target="entrez.5159">
  <data key="d23">40792</data>
  <data key="d24">55411</data>
  <data key="d25">SRC</data>
  <data key="d26">PDGFRB</data>
  <data key="d27">entrez.6714</data>
  <data key="d28">entrez.5159</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.6714" target="entrez.5921">
  <data key="d23">40792</data>
  <data key="d24">58816</data>
  <data key="d25">SRC</data>
  <data key="d26">RASA1</data>
  <data key="d27">entrez.6714</data>
  <data key="d28">entrez.5921</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.6714" target="entrez.5781">
  <data key="d23">40792</data>
  <data key="d24">59850</data>
  <data key="d25">SRC</data>
  <data key="d26">PTPN11</data>
  <data key="d27">entrez.6714</data>
  <data key="d28">entrez.5781</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.6714" target="entrez.5777">
  <data key="d23">40792</data>
  <data key="d24">59857</data>
  <data key="d25">SRC</data>
  <data key="d26">PTPN6</data>
  <data key="d27">entrez.6714</data>
  <data key="d28">entrez.5777</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.6714" target="entrez.5747">
  <data key="d23">40792</data>
  <data key="d24">59937</data>
  <data key="d25">SRC</data>
  <data key="d26">PTK2</data>
  <data key="d27">entrez.6714</data>
  <data key="d28">entrez.5747</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.6714" target="drugbank.DB03023">
  <data key="d31">930</data>
  <data key="d32">40792</data>
  <data key="d25">1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine</data>
  <data key="d26">SRC</data>
  <data key="d33">drugbank.DB03023</data>
  <data key="d34">entrez.6714</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.6714" target="drugbank.DB04868">
  <data key="d31">3359</data>
  <data key="d32">40792</data>
  <data key="d25">Nilotinib</data>
  <data key="d26">SRC</data>
  <data key="d33">drugbank.DB04868</data>
  <data key="d34">entrez.6714</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.6714" target="drugbank.DB00317">
  <data key="d31">4668</data>
  <data key="d32">40792</data>
  <data key="d25">Gefitinib</data>
  <data key="d26">SRC</data>
  <data key="d33">drugbank.DB00317</data>
  <data key="d34">entrez.6714</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.6714" target="drugbank.DB01268">
  <data key="d31">4894</data>
  <data key="d32">40792</data>
  <data key="d25">Sunitinib</data>
  <data key="d26">SRC</data>
  <data key="d33">drugbank.DB01268</data>
  <data key="d34">entrez.6714</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.6714" target="drugbank.DB01254">
  <data key="d31">5149</data>
  <data key="d32">40792</data>
  <data key="d25">Dasatinib</data>
  <data key="d26">SRC</data>
  <data key="d33">drugbank.DB01254</data>
  <data key="d34">entrez.6714</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.6714" target="drugbank.DB12010">
  <data key="d31">5608</data>
  <data key="d32">40792</data>
  <data key="d25">Fostamatinib</data>
  <data key="d26">SRC</data>
  <data key="d33">drugbank.DB12010</data>
  <data key="d34">entrez.6714</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.6714" target="drugbank.DB00619">
  <data key="d31">6404</data>
  <data key="d32">40792</data>
  <data key="d25">Imatinib</data>
  <data key="d26">SRC</data>
  <data key="d33">drugbank.DB00619</data>
  <data key="d34">entrez.6714</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.6714" target="drugbank.DB01962">
  <data key="d31">6486</data>
  <data key="d32">40792</data>
  <data key="d25">Phosphonotyrosine</data>
  <data key="d26">SRC</data>
  <data key="d33">drugbank.DB01962</data>
  <data key="d34">entrez.6714</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.6714" target="drugbank.DB09079">
  <data key="d31">6627</data>
  <data key="d32">40792</data>
  <data key="d25">Nintedanib</data>
  <data key="d26">SRC</data>
  <data key="d33">drugbank.DB09079</data>
  <data key="d34">entrez.6714</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.6714" target="drugbank.DB09053">
  <data key="d31">6731</data>
  <data key="d32">40792</data>
  <data key="d25">Ibrutinib</data>
  <data key="d26">SRC</data>
  <data key="d33">drugbank.DB09053</data>
  <data key="d34">entrez.6714</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.6714" target="drugbank.DB09063">
  <data key="d31">6756</data>
  <data key="d32">40792</data>
  <data key="d25">Ceritinib</data>
  <data key="d26">SRC</data>
  <data key="d33">drugbank.DB09063</data>
  <data key="d34">entrez.6714</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.6714" target="drugbank.DB00398">
  <data key="d31">7170</data>
  <data key="d32">40792</data>
  <data key="d25">Sorafenib</data>
  <data key="d26">SRC</data>
  <data key="d33">drugbank.DB00398</data>
  <data key="d34">entrez.6714</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.6714" target="drugbank.DB00530">
  <data key="d31">7910</data>
  <data key="d32">40792</data>
  <data key="d25">Erlotinib</data>
  <data key="d26">SRC</data>
  <data key="d33">drugbank.DB00530</data>
  <data key="d34">entrez.6714</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.6714" target="drugbank.DB11828">
  <data key="d31">8787</data>
  <data key="d32">40792</data>
  <data key="d25">Neratinib</data>
  <data key="d26">SRC</data>
  <data key="d33">drugbank.DB11828</data>
  <data key="d34">entrez.6714</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.6714" target="drugbank.DB08901">
  <data key="d31">11231</data>
  <data key="d32">40792</data>
  <data key="d25">Ponatinib</data>
  <data key="d26">SRC</data>
  <data key="d33">drugbank.DB08901</data>
  <data key="d34">entrez.6714</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.6714" target="drugbank.DB08916">
  <data key="d31">11245</data>
  <data key="d32">40792</data>
  <data key="d25">Afatinib</data>
  <data key="d26">SRC</data>
  <data key="d33">drugbank.DB08916</data>
  <data key="d34">entrez.6714</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.6714" target="drugbank.DB07662">
  <data key="d31">11376</data>
  <data key="d32">40792</data>
  <data key="d25">N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE</data>
  <data key="d26">SRC</data>
  <data key="d33">drugbank.DB07662</data>
  <data key="d34">entrez.6714</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.6714" target="drugbank.DB05184">
  <data key="d31">11602</data>
  <data key="d32">40792</data>
  <data key="d25">XL228</data>
  <data key="d26">SRC</data>
  <data key="d33">drugbank.DB05184</data>
  <data key="d34">entrez.6714</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.6714" target="drugbank.DB08865">
  <data key="d31">12120</data>
  <data key="d32">40792</data>
  <data key="d25">Crizotinib</data>
  <data key="d26">SRC</data>
  <data key="d33">drugbank.DB08865</data>
  <data key="d34">entrez.6714</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.6714" target="drugbank.DB04216">
  <data key="d31">12527</data>
  <data key="d32">40792</data>
  <data key="d25">Quercetin</data>
  <data key="d26">SRC</data>
  <data key="d33">drugbank.DB04216</data>
  <data key="d34">entrez.6714</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.6714" target="drugbank.DB06803">
  <data key="d31">12674</data>
  <data key="d32">40792</data>
  <data key="d25">Niclosamide</data>
  <data key="d26">SRC</data>
  <data key="d33">drugbank.DB06803</data>
  <data key="d34">entrez.6714</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.6714" target="drugbank.DB05294">
  <data key="d31">12890</data>
  <data key="d32">40792</data>
  <data key="d25">Vandetanib</data>
  <data key="d26">SRC</data>
  <data key="d33">drugbank.DB05294</data>
  <data key="d34">entrez.6714</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.6714" target="drugbank.DB06595">
  <data key="d31">12958</data>
  <data key="d32">40792</data>
  <data key="d25">Midostaurin</data>
  <data key="d26">SRC</data>
  <data key="d33">drugbank.DB06595</data>
  <data key="d34">entrez.6714</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.6714" target="drugbank.DB06589">
  <data key="d31">12970</data>
  <data key="d32">40792</data>
  <data key="d25">Pazopanib</data>
  <data key="d26">SRC</data>
  <data key="d33">drugbank.DB06589</data>
  <data key="d34">entrez.6714</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.6714" target="drugbank.DB06616">
  <data key="d31">13127</data>
  <data key="d32">40792</data>
  <data key="d25">Bosutinib</data>
  <data key="d26">SRC</data>
  <data key="d33">drugbank.DB06616</data>
  <data key="d34">entrez.6714</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.6464" target="entrez.6464">
  <data key="d23">41187</data>
  <data key="d24">41187</data>
  <data key="d25">SHC1</data>
  <data key="d26">SHC1</data>
  <data key="d27">entrez.6464</data>
  <data key="d28">entrez.6464</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.6464" target="entrez.2185">
  <data key="d23">41187</data>
  <data key="d24">43995</data>
  <data key="d25">SHC1</data>
  <data key="d26">PTK2B</data>
  <data key="d27">entrez.6464</data>
  <data key="d28">entrez.2185</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.6464" target="entrez.2057">
  <data key="d23">41187</data>
  <data key="d24">45200</data>
  <data key="d25">SHC1</data>
  <data key="d26">EPOR</data>
  <data key="d27">entrez.6464</data>
  <data key="d28">entrez.2057</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.6464" target="entrez.2064">
  <data key="d23">41187</data>
  <data key="d24">45336</data>
  <data key="d25">SHC1</data>
  <data key="d26">ERBB2</data>
  <data key="d27">entrez.6464</data>
  <data key="d28">entrez.2064</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.6464" target="entrez.6850">
  <data key="d23">41187</data>
  <data key="d24">46818</data>
  <data key="d25">SHC1</data>
  <data key="d26">SYK</data>
  <data key="d27">entrez.6464</data>
  <data key="d28">entrez.6850</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.6464" target="entrez.1439">
  <data key="d23">41187</data>
  <data key="d24">49319</data>
  <data key="d25">SHC1</data>
  <data key="d26">CSF2RB</data>
  <data key="d27">entrez.6464</data>
  <data key="d28">entrez.1439</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.6464" target="entrez.1956">
  <data key="d23">41187</data>
  <data key="d24">53145</data>
  <data key="d25">SHC1</data>
  <data key="d26">EGFR</data>
  <data key="d27">entrez.6464</data>
  <data key="d28">entrez.1956</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.6464" target="entrez.5296">
  <data key="d23">41187</data>
  <data key="d24">54153</data>
  <data key="d25">SHC1</data>
  <data key="d26">PIK3R2</data>
  <data key="d27">entrez.6464</data>
  <data key="d28">entrez.5296</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.6464" target="entrez.5295">
  <data key="d23">41187</data>
  <data key="d24">54155</data>
  <data key="d25">SHC1</data>
  <data key="d26">PIK3R1</data>
  <data key="d27">entrez.6464</data>
  <data key="d28">entrez.5295</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.6464" target="entrez.5336">
  <data key="d23">41187</data>
  <data key="d24">54398</data>
  <data key="d25">SHC1</data>
  <data key="d26">PLCG2</data>
  <data key="d27">entrez.6464</data>
  <data key="d28">entrez.5336</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.6464" target="entrez.5335">
  <data key="d23">41187</data>
  <data key="d24">54399</data>
  <data key="d25">SHC1</data>
  <data key="d26">PLCG1</data>
  <data key="d27">entrez.6464</data>
  <data key="d28">entrez.5335</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.6464" target="entrez.5159">
  <data key="d23">41187</data>
  <data key="d24">55411</data>
  <data key="d25">SHC1</data>
  <data key="d26">PDGFRB</data>
  <data key="d27">entrez.6464</data>
  <data key="d28">entrez.5159</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.6464" target="entrez.5921">
  <data key="d23">41187</data>
  <data key="d24">58816</data>
  <data key="d25">SHC1</data>
  <data key="d26">RASA1</data>
  <data key="d27">entrez.6464</data>
  <data key="d28">entrez.5921</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.6464" target="entrez.5781">
  <data key="d23">41187</data>
  <data key="d24">59850</data>
  <data key="d25">SHC1</data>
  <data key="d26">PTPN11</data>
  <data key="d27">entrez.6464</data>
  <data key="d28">entrez.5781</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.6464" target="entrez.5777">
  <data key="d23">41187</data>
  <data key="d24">59857</data>
  <data key="d25">SHC1</data>
  <data key="d26">PTPN6</data>
  <data key="d27">entrez.6464</data>
  <data key="d28">entrez.5777</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.6464" target="entrez.5747">
  <data key="d23">41187</data>
  <data key="d24">59937</data>
  <data key="d25">SHC1</data>
  <data key="d26">PTK2</data>
  <data key="d27">entrez.6464</data>
  <data key="d28">entrez.5747</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.2185" target="entrez.2185">
  <data key="d23">43995</data>
  <data key="d24">43995</data>
  <data key="d25">PTK2B</data>
  <data key="d26">PTK2B</data>
  <data key="d27">entrez.2185</data>
  <data key="d28">entrez.2185</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp]</data>
</edge>
<edge source="entrez.2185" target="entrez.2064">
  <data key="d23">43995</data>
  <data key="d24">45336</data>
  <data key="d25">PTK2B</data>
  <data key="d26">ERBB2</data>
  <data key="d27">entrez.2185</data>
  <data key="d28">entrez.2064</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.2185" target="entrez.6774">
  <data key="d23">43995</data>
  <data key="d24">46674</data>
  <data key="d25">PTK2B</data>
  <data key="d26">STAT3</data>
  <data key="d27">entrez.2185</data>
  <data key="d28">entrez.6774</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.2185" target="entrez.6850">
  <data key="d23">43995</data>
  <data key="d24">46818</data>
  <data key="d25">PTK2B</data>
  <data key="d26">SYK</data>
  <data key="d27">entrez.2185</data>
  <data key="d28">entrez.6850</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.2185" target="entrez.1956">
  <data key="d23">43995</data>
  <data key="d24">53145</data>
  <data key="d25">PTK2B</data>
  <data key="d26">EGFR</data>
  <data key="d27">entrez.2185</data>
  <data key="d28">entrez.1956</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.2185" target="entrez.5295">
  <data key="d23">43995</data>
  <data key="d24">54155</data>
  <data key="d25">PTK2B</data>
  <data key="d26">PIK3R1</data>
  <data key="d27">entrez.2185</data>
  <data key="d28">entrez.5295</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.2185" target="entrez.5921">
  <data key="d23">43995</data>
  <data key="d24">58816</data>
  <data key="d25">PTK2B</data>
  <data key="d26">RASA1</data>
  <data key="d27">entrez.2185</data>
  <data key="d28">entrez.5921</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.2185" target="entrez.5781">
  <data key="d23">43995</data>
  <data key="d24">59850</data>
  <data key="d25">PTK2B</data>
  <data key="d26">PTPN11</data>
  <data key="d27">entrez.2185</data>
  <data key="d28">entrez.5781</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.2185" target="entrez.5777">
  <data key="d23">43995</data>
  <data key="d24">59857</data>
  <data key="d25">PTK2B</data>
  <data key="d26">PTPN6</data>
  <data key="d27">entrez.2185</data>
  <data key="d28">entrez.5777</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.2185" target="entrez.5747">
  <data key="d23">43995</data>
  <data key="d24">59937</data>
  <data key="d25">PTK2B</data>
  <data key="d26">PTK2</data>
  <data key="d27">entrez.2185</data>
  <data key="d28">entrez.5747</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.2185" target="drugbank.DB01268">
  <data key="d31">4894</data>
  <data key="d32">43995</data>
  <data key="d25">Sunitinib</data>
  <data key="d26">PTK2B</data>
  <data key="d33">drugbank.DB01268</data>
  <data key="d34">entrez.2185</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2185" target="drugbank.DB12010">
  <data key="d31">5608</data>
  <data key="d32">43995</data>
  <data key="d25">Fostamatinib</data>
  <data key="d26">PTK2B</data>
  <data key="d33">drugbank.DB12010</data>
  <data key="d34">entrez.2185</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2185" target="drugbank.DB09079">
  <data key="d31">6627</data>
  <data key="d32">43995</data>
  <data key="d25">Nintedanib</data>
  <data key="d26">PTK2B</data>
  <data key="d33">drugbank.DB09079</data>
  <data key="d34">entrez.2185</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2185" target="drugbank.DB11828">
  <data key="d31">8787</data>
  <data key="d32">43995</data>
  <data key="d25">Neratinib</data>
  <data key="d26">PTK2B</data>
  <data key="d33">drugbank.DB11828</data>
  <data key="d34">entrez.2185</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2185" target="drugbank.DB11817">
  <data key="d31">8895</data>
  <data key="d32">43995</data>
  <data key="d25">Baricitinib</data>
  <data key="d26">PTK2B</data>
  <data key="d33">drugbank.DB11817</data>
  <data key="d34">entrez.2185</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2185" target="drugbank.DB08865">
  <data key="d31">12120</data>
  <data key="d32">43995</data>
  <data key="d25">Crizotinib</data>
  <data key="d26">PTK2B</data>
  <data key="d33">drugbank.DB08865</data>
  <data key="d34">entrez.2185</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2185" target="drugbank.DB06595">
  <data key="d31">12958</data>
  <data key="d32">43995</data>
  <data key="d25">Midostaurin</data>
  <data key="d26">PTK2B</data>
  <data key="d33">drugbank.DB06595</data>
  <data key="d34">entrez.2185</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2185" target="drugbank.DB06616">
  <data key="d31">13127</data>
  <data key="d32">43995</data>
  <data key="d25">Bosutinib</data>
  <data key="d26">PTK2B</data>
  <data key="d33">drugbank.DB06616</data>
  <data key="d34">entrez.2185</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2057" target="entrez.2057">
  <data key="d23">45200</data>
  <data key="d24">45200</data>
  <data key="d25">EPOR</data>
  <data key="d26">EPOR</data>
  <data key="d27">entrez.2057</data>
  <data key="d28">entrez.2057</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp]</data>
</edge>
<edge source="entrez.2057" target="entrez.6850">
  <data key="d23">45200</data>
  <data key="d24">46818</data>
  <data key="d25">EPOR</data>
  <data key="d26">SYK</data>
  <data key="d27">entrez.2057</data>
  <data key="d28">entrez.6850</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.2057" target="entrez.1439">
  <data key="d23">45200</data>
  <data key="d24">49319</data>
  <data key="d25">EPOR</data>
  <data key="d26">CSF2RB</data>
  <data key="d27">entrez.2057</data>
  <data key="d28">entrez.1439</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.2057" target="entrez.5295">
  <data key="d23">45200</data>
  <data key="d24">54155</data>
  <data key="d25">EPOR</data>
  <data key="d26">PIK3R1</data>
  <data key="d27">entrez.2057</data>
  <data key="d28">entrez.5295</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.2057" target="entrez.5336">
  <data key="d23">45200</data>
  <data key="d24">54398</data>
  <data key="d25">EPOR</data>
  <data key="d26">PLCG2</data>
  <data key="d27">entrez.2057</data>
  <data key="d28">entrez.5336</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.2057" target="entrez.5335">
  <data key="d23">45200</data>
  <data key="d24">54399</data>
  <data key="d25">EPOR</data>
  <data key="d26">PLCG1</data>
  <data key="d27">entrez.2057</data>
  <data key="d28">entrez.5335</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.2057" target="entrez.5781">
  <data key="d23">45200</data>
  <data key="d24">59850</data>
  <data key="d25">EPOR</data>
  <data key="d26">PTPN11</data>
  <data key="d27">entrez.2057</data>
  <data key="d28">entrez.5781</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.2057" target="entrez.5777">
  <data key="d23">45200</data>
  <data key="d24">59857</data>
  <data key="d25">EPOR</data>
  <data key="d26">PTPN6</data>
  <data key="d27">entrez.2057</data>
  <data key="d28">entrez.5777</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.2064" target="entrez.2064">
  <data key="d23">45336</data>
  <data key="d24">45336</data>
  <data key="d25">ERBB2</data>
  <data key="d26">ERBB2</data>
  <data key="d27">entrez.2064</data>
  <data key="d28">entrez.2064</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.2064" target="entrez.6774">
  <data key="d23">45336</data>
  <data key="d24">46674</data>
  <data key="d25">ERBB2</data>
  <data key="d26">STAT3</data>
  <data key="d27">entrez.2064</data>
  <data key="d28">entrez.6774</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.2064" target="entrez.6850">
  <data key="d23">45336</data>
  <data key="d24">46818</data>
  <data key="d25">ERBB2</data>
  <data key="d26">SYK</data>
  <data key="d27">entrez.2064</data>
  <data key="d28">entrez.6850</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.2064" target="entrez.1956">
  <data key="d23">45336</data>
  <data key="d24">53145</data>
  <data key="d25">ERBB2</data>
  <data key="d26">EGFR</data>
  <data key="d27">entrez.2064</data>
  <data key="d28">entrez.1956</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.2064" target="entrez.5296">
  <data key="d23">45336</data>
  <data key="d24">54153</data>
  <data key="d25">ERBB2</data>
  <data key="d26">PIK3R2</data>
  <data key="d27">entrez.2064</data>
  <data key="d28">entrez.5296</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.2064" target="entrez.5295">
  <data key="d23">45336</data>
  <data key="d24">54155</data>
  <data key="d25">ERBB2</data>
  <data key="d26">PIK3R1</data>
  <data key="d27">entrez.2064</data>
  <data key="d28">entrez.5295</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.2064" target="entrez.5336">
  <data key="d23">45336</data>
  <data key="d24">54398</data>
  <data key="d25">ERBB2</data>
  <data key="d26">PLCG2</data>
  <data key="d27">entrez.2064</data>
  <data key="d28">entrez.5336</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.2064" target="entrez.5335">
  <data key="d23">45336</data>
  <data key="d24">54399</data>
  <data key="d25">ERBB2</data>
  <data key="d26">PLCG1</data>
  <data key="d27">entrez.2064</data>
  <data key="d28">entrez.5335</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.2064" target="entrez.5921">
  <data key="d23">45336</data>
  <data key="d24">58816</data>
  <data key="d25">ERBB2</data>
  <data key="d26">RASA1</data>
  <data key="d27">entrez.2064</data>
  <data key="d28">entrez.5921</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.2064" target="entrez.5781">
  <data key="d23">45336</data>
  <data key="d24">59850</data>
  <data key="d25">ERBB2</data>
  <data key="d26">PTPN11</data>
  <data key="d27">entrez.2064</data>
  <data key="d28">entrez.5781</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.2064" target="entrez.5777">
  <data key="d23">45336</data>
  <data key="d24">59857</data>
  <data key="d25">ERBB2</data>
  <data key="d26">PTPN6</data>
  <data key="d27">entrez.2064</data>
  <data key="d28">entrez.5777</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.2064" target="entrez.5747">
  <data key="d23">45336</data>
  <data key="d24">59937</data>
  <data key="d25">ERBB2</data>
  <data key="d26">PTK2</data>
  <data key="d27">entrez.2064</data>
  <data key="d28">entrez.5747</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.2064" target="drugbank.DB05944">
  <data key="d31">711</data>
  <data key="d32">45336</data>
  <data key="d25">Varlitinib</data>
  <data key="d26">ERBB2</data>
  <data key="d33">drugbank.DB05944</data>
  <data key="d34">entrez.2064</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2064" target="drugbank.DB04988">
  <data key="d31">1981</data>
  <data key="d32">45336</data>
  <data key="d25">IGN311</data>
  <data key="d26">ERBB2</data>
  <data key="d33">drugbank.DB04988</data>
  <data key="d34">entrez.2064</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2064" target="drugbank.DB01110">
  <data key="d31">2410</data>
  <data key="d32">45336</data>
  <data key="d25">Miconazole</data>
  <data key="d26">ERBB2</data>
  <data key="d33">drugbank.DB01110</data>
  <data key="d34">entrez.2064</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2064" target="drugbank.DB01118">
  <data key="d31">2440</data>
  <data key="d32">45336</data>
  <data key="d25">Amiodarone</data>
  <data key="d26">ERBB2</data>
  <data key="d33">drugbank.DB01118</data>
  <data key="d34">entrez.2064</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2064" target="drugbank.DB01127">
  <data key="d31">2486</data>
  <data key="d32">45336</data>
  <data key="d25">Econazole</data>
  <data key="d26">ERBB2</data>
  <data key="d33">drugbank.DB01127</data>
  <data key="d34">entrez.2064</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2064" target="drugbank.DB04813">
  <data key="d31">3438</data>
  <data key="d32">45336</data>
  <data key="d25">Bithionol</data>
  <data key="d26">ERBB2</data>
  <data key="d33">drugbank.DB04813</data>
  <data key="d34">entrez.2064</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2064" target="drugbank.DB00257">
  <data key="d31">4215</data>
  <data key="d32">45336</data>
  <data key="d25">Clotrimazole</data>
  <data key="d26">ERBB2</data>
  <data key="d33">drugbank.DB00257</data>
  <data key="d34">entrez.2064</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2064" target="drugbank.DB12267">
  <data key="d31">4340</data>
  <data key="d32">45336</data>
  <data key="d25">Brigatinib</data>
  <data key="d26">ERBB2</data>
  <data key="d33">drugbank.DB12267</data>
  <data key="d34">entrez.2064</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2064" target="drugbank.DB00317">
  <data key="d31">4668</data>
  <data key="d32">45336</data>
  <data key="d25">Gefitinib</data>
  <data key="d26">ERBB2</data>
  <data key="d33">drugbank.DB00317</data>
  <data key="d34">entrez.2064</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2064" target="drugbank.DB01229">
  <data key="d31">4988</data>
  <data key="d32">45336</data>
  <data key="d25">Paclitaxel</data>
  <data key="d26">ERBB2</data>
  <data key="d33">drugbank.DB01229</data>
  <data key="d34">entrez.2064</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2064" target="drugbank.DB01259">
  <data key="d31">5140</data>
  <data key="d32">45336</data>
  <data key="d25">Lapatinib</data>
  <data key="d26">ERBB2</data>
  <data key="d33">drugbank.DB01259</data>
  <data key="d34">entrez.2064</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2064" target="drugbank.DB01254">
  <data key="d31">5149</data>
  <data key="d32">45336</data>
  <data key="d25">Dasatinib</data>
  <data key="d26">ERBB2</data>
  <data key="d33">drugbank.DB01254</data>
  <data key="d34">entrez.2064</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2064" target="drugbank.DB01204">
  <data key="d31">5230</data>
  <data key="d32">45336</data>
  <data key="d25">Mitoxantrone</data>
  <data key="d26">ERBB2</data>
  <data key="d33">drugbank.DB01204</data>
  <data key="d34">entrez.2064</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2064" target="drugbank.DB00072">
  <data key="d31">5492</data>
  <data key="d32">45336</data>
  <data key="d25">Trastuzumab</data>
  <data key="d26">ERBB2</data>
  <data key="d33">drugbank.DB00072</data>
  <data key="d34">entrez.2064</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2064" target="drugbank.DB12010">
  <data key="d31">5608</data>
  <data key="d32">45336</data>
  <data key="d25">Fostamatinib</data>
  <data key="d26">ERBB2</data>
  <data key="d33">drugbank.DB12010</data>
  <data key="d34">entrez.2064</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2064" target="drugbank.DB00675">
  <data key="d31">6319</data>
  <data key="d32">45336</data>
  <data key="d25">Tamoxifen</data>
  <data key="d26">ERBB2</data>
  <data key="d33">drugbank.DB00675</data>
  <data key="d34">entrez.2064</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2064" target="drugbank.DB00623">
  <data key="d31">6443</data>
  <data key="d32">45336</data>
  <data key="d25">Fluphenazine</data>
  <data key="d26">ERBB2</data>
  <data key="d33">drugbank.DB00623</data>
  <data key="d34">entrez.2064</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2064" target="drugbank.DB00637">
  <data key="d31">6473</data>
  <data key="d32">45336</data>
  <data key="d25">Astemizole</data>
  <data key="d26">ERBB2</data>
  <data key="d33">drugbank.DB00637</data>
  <data key="d34">entrez.2064</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2064" target="drugbank.DB13919">
  <data key="d31">6603</data>
  <data key="d32">45336</data>
  <data key="d25">Candesartan</data>
  <data key="d26">ERBB2</data>
  <data key="d33">drugbank.DB13919</data>
  <data key="d34">entrez.2064</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2064" target="drugbank.DB09053">
  <data key="d31">6731</data>
  <data key="d32">45336</data>
  <data key="d25">Ibrutinib</data>
  <data key="d26">ERBB2</data>
  <data key="d33">drugbank.DB09053</data>
  <data key="d34">entrez.2064</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2064" target="drugbank.DB09115">
  <data key="d31">6783</data>
  <data key="d32">45336</data>
  <data key="d25">Diiodohydroxyquinoline</data>
  <data key="d26">ERBB2</data>
  <data key="d33">drugbank.DB09115</data>
  <data key="d34">entrez.2064</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2064" target="drugbank.DB00756">
  <data key="d31">6952</data>
  <data key="d32">45336</data>
  <data key="d25">Hexachlorophene</data>
  <data key="d26">ERBB2</data>
  <data key="d33">drugbank.DB00756</data>
  <data key="d34">entrez.2064</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2064" target="drugbank.DB00477">
  <data key="d31">7827</data>
  <data key="d32">45336</data>
  <data key="d25">Chlorpromazine</data>
  <data key="d26">ERBB2</data>
  <data key="d33">drugbank.DB00477</data>
  <data key="d34">entrez.2064</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2064" target="drugbank.DB11125">
  <data key="d31">7840</data>
  <data key="d32">45336</data>
  <data key="d25">Benzethonium</data>
  <data key="d26">ERBB2</data>
  <data key="d33">drugbank.DB11125</data>
  <data key="d34">entrez.2064</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2064" target="drugbank.DB00530">
  <data key="d31">7910</data>
  <data key="d32">45336</data>
  <data key="d25">Erlotinib</data>
  <data key="d26">ERBB2</data>
  <data key="d33">drugbank.DB00530</data>
  <data key="d34">entrez.2064</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2064" target="drugbank.DB11742">
  <data key="d31">8412</data>
  <data key="d32">45336</data>
  <data key="d25">Ebastine</data>
  <data key="d26">ERBB2</data>
  <data key="d33">drugbank.DB11742</data>
  <data key="d34">entrez.2064</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2064" target="drugbank.DB11828">
  <data key="d31">8787</data>
  <data key="d32">45336</data>
  <data key="d25">Neratinib</data>
  <data key="d26">ERBB2</data>
  <data key="d33">drugbank.DB11828</data>
  <data key="d34">entrez.2064</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2064" target="drugbank.DB00882">
  <data key="d31">9198</data>
  <data key="d32">45336</data>
  <data key="d25">Clomifene</data>
  <data key="d26">ERBB2</data>
  <data key="d33">drugbank.DB00882</data>
  <data key="d34">entrez.2064</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2064" target="drugbank.DB00803">
  <data key="d31">9289</data>
  <data key="d32">45336</data>
  <data key="d25">Colistin</data>
  <data key="d26">ERBB2</data>
  <data key="d33">drugbank.DB00803</data>
  <data key="d34">entrez.2064</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2064" target="drugbank.DB00997">
  <data key="d31">9598</data>
  <data key="d32">45336</data>
  <data key="d25">Doxorubicin</data>
  <data key="d26">ERBB2</data>
  <data key="d33">drugbank.DB00997</data>
  <data key="d34">entrez.2064</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2064" target="drugbank.DB06021">
  <data key="d31">10317</data>
  <data key="d32">45336</data>
  <data key="d25">AV-412</data>
  <data key="d26">ERBB2</data>
  <data key="d33">drugbank.DB06021</data>
  <data key="d34">entrez.2064</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2064" target="drugbank.DB08916">
  <data key="d31">11245</data>
  <data key="d32">45336</data>
  <data key="d25">Afatinib</data>
  <data key="d26">ERBB2</data>
  <data key="d33">drugbank.DB08916</data>
  <data key="d34">entrez.2064</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2064" target="drugbank.DB05294">
  <data key="d31">12890</data>
  <data key="d32">45336</data>
  <data key="d25">Vandetanib</data>
  <data key="d26">ERBB2</data>
  <data key="d33">drugbank.DB05294</data>
  <data key="d34">entrez.2064</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.2064" target="drugbank.DB06616">
  <data key="d31">13127</data>
  <data key="d32">45336</data>
  <data key="d25">Bosutinib</data>
  <data key="d26">ERBB2</data>
  <data key="d33">drugbank.DB06616</data>
  <data key="d34">entrez.2064</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.6774" target="entrez.6774">
  <data key="d23">46674</data>
  <data key="d24">46674</data>
  <data key="d25">STAT3</data>
  <data key="d26">STAT3</data>
  <data key="d27">entrez.6774</data>
  <data key="d28">entrez.6774</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho]</data>
</edge>
<edge source="entrez.6774" target="entrez.6850">
  <data key="d23">46674</data>
  <data key="d24">46818</data>
  <data key="d25">STAT3</data>
  <data key="d26">SYK</data>
  <data key="d27">entrez.6774</data>
  <data key="d28">entrez.6850</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.6774" target="entrez.1439">
  <data key="d23">46674</data>
  <data key="d24">49319</data>
  <data key="d25">STAT3</data>
  <data key="d26">CSF2RB</data>
  <data key="d27">entrez.6774</data>
  <data key="d28">entrez.1439</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.6774" target="entrez.1956">
  <data key="d23">46674</data>
  <data key="d24">53145</data>
  <data key="d25">STAT3</data>
  <data key="d26">EGFR</data>
  <data key="d27">entrez.6774</data>
  <data key="d28">entrez.1956</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.6774" target="entrez.5296">
  <data key="d23">46674</data>
  <data key="d24">54153</data>
  <data key="d25">STAT3</data>
  <data key="d26">PIK3R2</data>
  <data key="d27">entrez.6774</data>
  <data key="d28">entrez.5296</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.6774" target="entrez.5295">
  <data key="d23">46674</data>
  <data key="d24">54155</data>
  <data key="d25">STAT3</data>
  <data key="d26">PIK3R1</data>
  <data key="d27">entrez.6774</data>
  <data key="d28">entrez.5295</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.6774" target="entrez.5159">
  <data key="d23">46674</data>
  <data key="d24">55411</data>
  <data key="d25">STAT3</data>
  <data key="d26">PDGFRB</data>
  <data key="d27">entrez.6774</data>
  <data key="d28">entrez.5159</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.6774" target="entrez.5781">
  <data key="d23">46674</data>
  <data key="d24">59850</data>
  <data key="d25">STAT3</data>
  <data key="d26">PTPN11</data>
  <data key="d27">entrez.6774</data>
  <data key="d28">entrez.5781</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.6774" target="entrez.5747">
  <data key="d23">46674</data>
  <data key="d24">59937</data>
  <data key="d25">STAT3</data>
  <data key="d26">PTK2</data>
  <data key="d27">entrez.6774</data>
  <data key="d28">entrez.5747</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.6774" target="drugbank.DB06803">
  <data key="d31">12674</data>
  <data key="d32">46674</data>
  <data key="d25">Niclosamide</data>
  <data key="d26">STAT3</data>
  <data key="d33">drugbank.DB06803</data>
  <data key="d34">entrez.6774</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.6850" target="entrez.6850">
  <data key="d23">46818</data>
  <data key="d24">46818</data>
  <data key="d25">SYK</data>
  <data key="d26">SYK</data>
  <data key="d27">entrez.6850</data>
  <data key="d28">entrez.6850</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.6850" target="entrez.1439">
  <data key="d23">46818</data>
  <data key="d24">49319</data>
  <data key="d25">SYK</data>
  <data key="d26">CSF2RB</data>
  <data key="d27">entrez.6850</data>
  <data key="d28">entrez.1439</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.6850" target="entrez.1956">
  <data key="d23">46818</data>
  <data key="d24">53145</data>
  <data key="d25">SYK</data>
  <data key="d26">EGFR</data>
  <data key="d27">entrez.6850</data>
  <data key="d28">entrez.1956</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.6850" target="entrez.5296">
  <data key="d23">46818</data>
  <data key="d24">54153</data>
  <data key="d25">SYK</data>
  <data key="d26">PIK3R2</data>
  <data key="d27">entrez.6850</data>
  <data key="d28">entrez.5296</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.6850" target="entrez.5295">
  <data key="d23">46818</data>
  <data key="d24">54155</data>
  <data key="d25">SYK</data>
  <data key="d26">PIK3R1</data>
  <data key="d27">entrez.6850</data>
  <data key="d28">entrez.5295</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.6850" target="entrez.5336">
  <data key="d23">46818</data>
  <data key="d24">54398</data>
  <data key="d25">SYK</data>
  <data key="d26">PLCG2</data>
  <data key="d27">entrez.6850</data>
  <data key="d28">entrez.5336</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.6850" target="entrez.5335">
  <data key="d23">46818</data>
  <data key="d24">54399</data>
  <data key="d25">SYK</data>
  <data key="d26">PLCG1</data>
  <data key="d27">entrez.6850</data>
  <data key="d28">entrez.5335</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.6850" target="entrez.5921">
  <data key="d23">46818</data>
  <data key="d24">58816</data>
  <data key="d25">SYK</data>
  <data key="d26">RASA1</data>
  <data key="d27">entrez.6850</data>
  <data key="d28">entrez.5921</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.6850" target="entrez.5777">
  <data key="d23">46818</data>
  <data key="d24">59857</data>
  <data key="d25">SYK</data>
  <data key="d26">PTPN6</data>
  <data key="d27">entrez.6850</data>
  <data key="d28">entrez.5777</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.6850" target="entrez.5747">
  <data key="d23">46818</data>
  <data key="d24">59937</data>
  <data key="d25">SYK</data>
  <data key="d26">PTK2</data>
  <data key="d27">entrez.6850</data>
  <data key="d28">entrez.5747</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.6850" target="drugbank.DB02010">
  <data key="d31">567</data>
  <data key="d32">46818</data>
  <data key="d25">Staurosporine</data>
  <data key="d26">SYK</data>
  <data key="d33">drugbank.DB02010</data>
  <data key="d34">entrez.6850</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.6850" target="drugbank.DB01254">
  <data key="d31">5149</data>
  <data key="d32">46818</data>
  <data key="d25">Dasatinib</data>
  <data key="d26">SYK</data>
  <data key="d33">drugbank.DB01254</data>
  <data key="d34">entrez.6850</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.6850" target="drugbank.DB12010">
  <data key="d31">5608</data>
  <data key="d32">46818</data>
  <data key="d25">Fostamatinib</data>
  <data key="d26">SYK</data>
  <data key="d33">drugbank.DB12010</data>
  <data key="d34">entrez.6850</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.6850" target="drugbank.DB00619">
  <data key="d31">6404</data>
  <data key="d32">46818</data>
  <data key="d25">Imatinib</data>
  <data key="d26">SYK</data>
  <data key="d33">drugbank.DB00619</data>
  <data key="d34">entrez.6850</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.6850" target="drugbank.DB09063">
  <data key="d31">6756</data>
  <data key="d32">46818</data>
  <data key="d25">Ceritinib</data>
  <data key="d26">SYK</data>
  <data key="d33">drugbank.DB09063</data>
  <data key="d34">entrez.6850</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.6850" target="drugbank.DB11828">
  <data key="d31">8787</data>
  <data key="d32">46818</data>
  <data key="d25">Neratinib</data>
  <data key="d26">SYK</data>
  <data key="d33">drugbank.DB11828</data>
  <data key="d34">entrez.6850</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.6850" target="drugbank.DB08865">
  <data key="d31">12120</data>
  <data key="d32">46818</data>
  <data key="d25">Crizotinib</data>
  <data key="d26">SYK</data>
  <data key="d33">drugbank.DB08865</data>
  <data key="d34">entrez.6850</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.6850" target="drugbank.DB04216">
  <data key="d31">12527</data>
  <data key="d32">46818</data>
  <data key="d25">Quercetin</data>
  <data key="d26">SYK</data>
  <data key="d33">drugbank.DB04216</data>
  <data key="d34">entrez.6850</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.6850" target="drugbank.DB06595">
  <data key="d31">12958</data>
  <data key="d32">46818</data>
  <data key="d25">Midostaurin</data>
  <data key="d26">SYK</data>
  <data key="d33">drugbank.DB06595</data>
  <data key="d34">entrez.6850</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.6850" target="drugbank.DB06589">
  <data key="d31">12970</data>
  <data key="d32">46818</data>
  <data key="d25">Pazopanib</data>
  <data key="d26">SYK</data>
  <data key="d33">drugbank.DB06589</data>
  <data key="d34">entrez.6850</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.6850" target="drugbank.DB06616">
  <data key="d31">13127</data>
  <data key="d32">46818</data>
  <data key="d25">Bosutinib</data>
  <data key="d26">SYK</data>
  <data key="d33">drugbank.DB06616</data>
  <data key="d34">entrez.6850</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.1439" target="entrez.1439">
  <data key="d23">49319</data>
  <data key="d24">49319</data>
  <data key="d25">CSF2RB</data>
  <data key="d26">CSF2RB</data>
  <data key="d27">entrez.1439</data>
  <data key="d28">entrez.1439</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp]</data>
</edge>
<edge source="entrez.1439" target="entrez.5295">
  <data key="d23">49319</data>
  <data key="d24">54155</data>
  <data key="d25">CSF2RB</data>
  <data key="d26">PIK3R1</data>
  <data key="d27">entrez.1439</data>
  <data key="d28">entrez.5295</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.1439" target="entrez.5781">
  <data key="d23">49319</data>
  <data key="d24">59850</data>
  <data key="d25">CSF2RB</data>
  <data key="d26">PTPN11</data>
  <data key="d27">entrez.1439</data>
  <data key="d28">entrez.5781</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.1439" target="entrez.5777">
  <data key="d23">49319</data>
  <data key="d24">59857</data>
  <data key="d25">CSF2RB</data>
  <data key="d26">PTPN6</data>
  <data key="d27">entrez.1439</data>
  <data key="d28">entrez.5777</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.1956" target="entrez.1956">
  <data key="d23">53145</data>
  <data key="d24">53145</data>
  <data key="d25">EGFR</data>
  <data key="d26">EGFR</data>
  <data key="d27">entrez.1956</data>
  <data key="d28">entrez.1956</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho]</data>
</edge>
<edge source="entrez.1956" target="entrez.5296">
  <data key="d23">53145</data>
  <data key="d24">54153</data>
  <data key="d25">EGFR</data>
  <data key="d26">PIK3R2</data>
  <data key="d27">entrez.1956</data>
  <data key="d28">entrez.5296</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.1956" target="entrez.5295">
  <data key="d23">53145</data>
  <data key="d24">54155</data>
  <data key="d25">EGFR</data>
  <data key="d26">PIK3R1</data>
  <data key="d27">entrez.1956</data>
  <data key="d28">entrez.5295</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.1956" target="entrez.5336">
  <data key="d23">53145</data>
  <data key="d24">54398</data>
  <data key="d25">EGFR</data>
  <data key="d26">PLCG2</data>
  <data key="d27">entrez.1956</data>
  <data key="d28">entrez.5336</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.1956" target="entrez.5335">
  <data key="d23">53145</data>
  <data key="d24">54399</data>
  <data key="d25">EGFR</data>
  <data key="d26">PLCG1</data>
  <data key="d27">entrez.1956</data>
  <data key="d28">entrez.5335</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.1956" target="entrez.5159">
  <data key="d23">53145</data>
  <data key="d24">55411</data>
  <data key="d25">EGFR</data>
  <data key="d26">PDGFRB</data>
  <data key="d27">entrez.1956</data>
  <data key="d28">entrez.5159</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.1956" target="entrez.5921">
  <data key="d23">53145</data>
  <data key="d24">58816</data>
  <data key="d25">EGFR</data>
  <data key="d26">RASA1</data>
  <data key="d27">entrez.1956</data>
  <data key="d28">entrez.5921</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.1956" target="entrez.5781">
  <data key="d23">53145</data>
  <data key="d24">59850</data>
  <data key="d25">EGFR</data>
  <data key="d26">PTPN11</data>
  <data key="d27">entrez.1956</data>
  <data key="d28">entrez.5781</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.1956" target="entrez.5777">
  <data key="d23">53145</data>
  <data key="d24">59857</data>
  <data key="d25">EGFR</data>
  <data key="d26">PTPN6</data>
  <data key="d27">entrez.1956</data>
  <data key="d28">entrez.5777</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.1956" target="entrez.5747">
  <data key="d23">53145</data>
  <data key="d24">59937</data>
  <data key="d25">EGFR</data>
  <data key="d26">PTK2</data>
  <data key="d27">entrez.1956</data>
  <data key="d28">entrez.5747</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.1956" target="drugbank.DB05944">
  <data key="d31">711</data>
  <data key="d32">53145</data>
  <data key="d25">Varlitinib</data>
  <data key="d26">EGFR</data>
  <data key="d33">drugbank.DB05944</data>
  <data key="d34">entrez.1956</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.1956" target="drugbank.DB13050">
  <data key="d31">1659</data>
  <data key="d32">53145</data>
  <data key="d25">Tirilazad</data>
  <data key="d26">EGFR</data>
  <data key="d33">drugbank.DB13050</data>
  <data key="d34">entrez.1956</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.1956" target="drugbank.DB01074">
  <data key="d31">1669</data>
  <data key="d32">53145</data>
  <data key="d25">Perhexiline</data>
  <data key="d26">EGFR</data>
  <data key="d33">drugbank.DB01074</data>
  <data key="d34">entrez.1956</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.1956" target="drugbank.DB04988">
  <data key="d31">1981</data>
  <data key="d32">53145</data>
  <data key="d25">IGN311</data>
  <data key="d26">EGFR</data>
  <data key="d33">drugbank.DB04988</data>
  <data key="d34">entrez.1956</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.1956" target="drugbank.DB01110">
  <data key="d31">2410</data>
  <data key="d32">53145</data>
  <data key="d25">Miconazole</data>
  <data key="d26">EGFR</data>
  <data key="d33">drugbank.DB01110</data>
  <data key="d34">entrez.1956</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.1956" target="drugbank.DB01127">
  <data key="d31">2486</data>
  <data key="d32">53145</data>
  <data key="d25">Econazole</data>
  <data key="d26">EGFR</data>
  <data key="d33">drugbank.DB01127</data>
  <data key="d34">entrez.1956</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.1956" target="drugbank.DB04813">
  <data key="d31">3438</data>
  <data key="d32">53145</data>
  <data key="d25">Bithionol</data>
  <data key="d26">EGFR</data>
  <data key="d33">drugbank.DB04813</data>
  <data key="d34">entrez.1956</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.1956" target="drugbank.DB00257">
  <data key="d31">4215</data>
  <data key="d32">53145</data>
  <data key="d25">Clotrimazole</data>
  <data key="d26">EGFR</data>
  <data key="d33">drugbank.DB00257</data>
  <data key="d34">entrez.1956</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.1956" target="drugbank.DB12267">
  <data key="d31">4340</data>
  <data key="d32">53145</data>
  <data key="d25">Brigatinib</data>
  <data key="d26">EGFR</data>
  <data key="d33">drugbank.DB12267</data>
  <data key="d34">entrez.1956</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.1956" target="drugbank.DB00220">
  <data key="d31">4422</data>
  <data key="d32">53145</data>
  <data key="d25">Nelfinavir</data>
  <data key="d26">EGFR</data>
  <data key="d33">drugbank.DB00220</data>
  <data key="d34">entrez.1956</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.1956" target="drugbank.DB00317">
  <data key="d31">4668</data>
  <data key="d32">53145</data>
  <data key="d25">Gefitinib</data>
  <data key="d26">EGFR</data>
  <data key="d33">drugbank.DB00317</data>
  <data key="d34">entrez.1956</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.1956" target="drugbank.DB01268">
  <data key="d31">4894</data>
  <data key="d32">53145</data>
  <data key="d25">Sunitinib</data>
  <data key="d26">EGFR</data>
  <data key="d33">drugbank.DB01268</data>
  <data key="d34">entrez.1956</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.1956" target="drugbank.DB01248">
  <data key="d31">5097</data>
  <data key="d32">53145</data>
  <data key="d25">Docetaxel</data>
  <data key="d26">EGFR</data>
  <data key="d33">drugbank.DB01248</data>
  <data key="d34">entrez.1956</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.1956" target="drugbank.DB01259">
  <data key="d31">5140</data>
  <data key="d32">53145</data>
  <data key="d25">Lapatinib</data>
  <data key="d26">EGFR</data>
  <data key="d33">drugbank.DB01259</data>
  <data key="d34">entrez.1956</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.1956" target="drugbank.DB01254">
  <data key="d31">5149</data>
  <data key="d32">53145</data>
  <data key="d25">Dasatinib</data>
  <data key="d26">EGFR</data>
  <data key="d33">drugbank.DB01254</data>
  <data key="d34">entrez.1956</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.1956" target="drugbank.DB01204">
  <data key="d31">5230</data>
  <data key="d32">53145</data>
  <data key="d25">Mitoxantrone</data>
  <data key="d26">EGFR</data>
  <data key="d33">drugbank.DB01204</data>
  <data key="d34">entrez.1956</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.1956" target="drugbank.DB00072">
  <data key="d31">5492</data>
  <data key="d32">53145</data>
  <data key="d25">Trastuzumab</data>
  <data key="d26">EGFR</data>
  <data key="d33">drugbank.DB00072</data>
  <data key="d34">entrez.1956</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.1956" target="drugbank.DB12010">
  <data key="d31">5608</data>
  <data key="d32">53145</data>
  <data key="d25">Fostamatinib</data>
  <data key="d26">EGFR</data>
  <data key="d33">drugbank.DB12010</data>
  <data key="d34">entrez.1956</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.1956" target="drugbank.DB00002">
  <data key="d31">5904</data>
  <data key="d32">53145</data>
  <data key="d25">Cetuximab</data>
  <data key="d26">EGFR</data>
  <data key="d33">drugbank.DB00002</data>
  <data key="d34">entrez.1956</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.1956" target="drugbank.DB00679">
  <data key="d31">6312</data>
  <data key="d32">53145</data>
  <data key="d25">Thioridazine</data>
  <data key="d26">EGFR</data>
  <data key="d33">drugbank.DB00679</data>
  <data key="d34">entrez.1956</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.1956" target="drugbank.DB00675">
  <data key="d31">6319</data>
  <data key="d32">53145</data>
  <data key="d25">Tamoxifen</data>
  <data key="d26">EGFR</data>
  <data key="d33">drugbank.DB00675</data>
  <data key="d34">entrez.1956</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.1956" target="drugbank.DB00619">
  <data key="d31">6404</data>
  <data key="d32">53145</data>
  <data key="d25">Imatinib</data>
  <data key="d26">EGFR</data>
  <data key="d33">drugbank.DB00619</data>
  <data key="d34">entrez.1956</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.1956" target="drugbank.DB00626">
  <data key="d31">6437</data>
  <data key="d32">53145</data>
  <data key="d25">Bacitracin</data>
  <data key="d26">EGFR</data>
  <data key="d33">drugbank.DB00626</data>
  <data key="d34">entrez.1956</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.1956" target="drugbank.DB00623">
  <data key="d31">6443</data>
  <data key="d32">53145</data>
  <data key="d25">Fluphenazine</data>
  <data key="d26">EGFR</data>
  <data key="d33">drugbank.DB00623</data>
  <data key="d34">entrez.1956</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.1956" target="drugbank.DB00637">
  <data key="d31">6473</data>
  <data key="d32">53145</data>
  <data key="d25">Astemizole</data>
  <data key="d26">EGFR</data>
  <data key="d33">drugbank.DB00637</data>
  <data key="d34">entrez.1956</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.1956" target="drugbank.DB13919">
  <data key="d31">6603</data>
  <data key="d32">53145</data>
  <data key="d25">Candesartan</data>
  <data key="d26">EGFR</data>
  <data key="d33">drugbank.DB13919</data>
  <data key="d34">entrez.1956</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.1956" target="drugbank.DB09078">
  <data key="d31">6628</data>
  <data key="d32">53145</data>
  <data key="d25">Lenvatinib</data>
  <data key="d26">EGFR</data>
  <data key="d33">drugbank.DB09078</data>
  <data key="d34">entrez.1956</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.1956" target="drugbank.DB09053">
  <data key="d31">6731</data>
  <data key="d32">53145</data>
  <data key="d25">Ibrutinib</data>
  <data key="d26">EGFR</data>
  <data key="d33">drugbank.DB09053</data>
  <data key="d34">entrez.1956</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.1956" target="drugbank.DB09063">
  <data key="d31">6756</data>
  <data key="d32">53145</data>
  <data key="d25">Ceritinib</data>
  <data key="d26">EGFR</data>
  <data key="d33">drugbank.DB09063</data>
  <data key="d34">entrez.1956</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.1956" target="drugbank.DB09115">
  <data key="d31">6783</data>
  <data key="d32">53145</data>
  <data key="d25">Diiodohydroxyquinoline</data>
  <data key="d26">EGFR</data>
  <data key="d33">drugbank.DB09115</data>
  <data key="d34">entrez.1956</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.1956" target="drugbank.DB09129">
  <data key="d31">6819</data>
  <data key="d32">53145</data>
  <data key="d25">Chromic chloride</data>
  <data key="d26">EGFR</data>
  <data key="d33">drugbank.DB09129</data>
  <data key="d34">entrez.1956</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.1956" target="drugbank.DB00756">
  <data key="d31">6952</data>
  <data key="d32">53145</data>
  <data key="d25">Hexachlorophene</data>
  <data key="d26">EGFR</data>
  <data key="d33">drugbank.DB00756</data>
  <data key="d34">entrez.1956</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.1956" target="drugbank.DB00342">
  <data key="d31">7283</data>
  <data key="d32">53145</data>
  <data key="d25">Terfenadine</data>
  <data key="d26">EGFR</data>
  <data key="d33">drugbank.DB00342</data>
  <data key="d34">entrez.1956</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.1956" target="drugbank.DB00406">
  <data key="d31">7615</data>
  <data key="d32">53145</data>
  <data key="d25">Gentian violet cation</data>
  <data key="d26">EGFR</data>
  <data key="d33">drugbank.DB00406</data>
  <data key="d34">entrez.1956</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.1956" target="drugbank.DB00471">
  <data key="d31">7787</data>
  <data key="d32">53145</data>
  <data key="d25">Montelukast</data>
  <data key="d26">EGFR</data>
  <data key="d33">drugbank.DB00471</data>
  <data key="d34">entrez.1956</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.1956" target="drugbank.DB00477">
  <data key="d31">7827</data>
  <data key="d32">53145</data>
  <data key="d25">Chlorpromazine</data>
  <data key="d26">EGFR</data>
  <data key="d33">drugbank.DB00477</data>
  <data key="d34">entrez.1956</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.1956" target="drugbank.DB00530">
  <data key="d31">7910</data>
  <data key="d32">53145</data>
  <data key="d25">Erlotinib</data>
  <data key="d26">EGFR</data>
  <data key="d33">drugbank.DB00530</data>
  <data key="d34">entrez.1956</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.1956" target="drugbank.DB00549">
  <data key="d31">7932</data>
  <data key="d32">53145</data>
  <data key="d25">Zafirlukast</data>
  <data key="d26">EGFR</data>
  <data key="d33">drugbank.DB00549</data>
  <data key="d34">entrez.1956</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.1956" target="drugbank.DB00515">
  <data key="d31">8119</data>
  <data key="d32">53145</data>
  <data key="d25">Cisplatin</data>
  <data key="d26">EGFR</data>
  <data key="d33">drugbank.DB00515</data>
  <data key="d34">entrez.1956</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.1956" target="drugbank.DB11742">
  <data key="d31">8412</data>
  <data key="d32">53145</data>
  <data key="d25">Ebastine</data>
  <data key="d26">EGFR</data>
  <data key="d33">drugbank.DB11742</data>
  <data key="d34">entrez.1956</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.1956" target="drugbank.DB11828">
  <data key="d31">8787</data>
  <data key="d32">53145</data>
  <data key="d25">Neratinib</data>
  <data key="d26">EGFR</data>
  <data key="d33">drugbank.DB11828</data>
  <data key="d34">entrez.1956</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.1956" target="drugbank.DB11829">
  <data key="d31">8788</data>
  <data key="d32">53145</data>
  <data key="d25">Ruboxistaurin</data>
  <data key="d26">EGFR</data>
  <data key="d33">drugbank.DB11829</data>
  <data key="d34">entrez.1956</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.1956" target="drugbank.DB00882">
  <data key="d31">9198</data>
  <data key="d32">53145</data>
  <data key="d25">Clomifene</data>
  <data key="d26">EGFR</data>
  <data key="d33">drugbank.DB00882</data>
  <data key="d34">entrez.1956</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.1956" target="drugbank.DB00841">
  <data key="d31">9274</data>
  <data key="d32">53145</data>
  <data key="d25">Dobutamine</data>
  <data key="d26">EGFR</data>
  <data key="d33">drugbank.DB00841</data>
  <data key="d34">entrez.1956</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.1956" target="drugbank.DB00803">
  <data key="d31">9289</data>
  <data key="d32">53145</data>
  <data key="d25">Colistin</data>
  <data key="d26">EGFR</data>
  <data key="d33">drugbank.DB00803</data>
  <data key="d34">entrez.1956</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.1956" target="drugbank.DB09276">
  <data key="d31">9312</data>
  <data key="d32">53145</data>
  <data key="d25">Sodium aurothiomalate</data>
  <data key="d26">EGFR</data>
  <data key="d33">drugbank.DB09276</data>
  <data key="d34">entrez.1956</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.1956" target="drugbank.DB00988">
  <data key="d31">9553</data>
  <data key="d32">53145</data>
  <data key="d25">Dopamine</data>
  <data key="d26">EGFR</data>
  <data key="d33">drugbank.DB00988</data>
  <data key="d34">entrez.1956</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.1956" target="drugbank.DB00968">
  <data key="d31">9773</data>
  <data key="d32">53145</data>
  <data key="d25">Methyldopa</data>
  <data key="d26">EGFR</data>
  <data key="d33">drugbank.DB00968</data>
  <data key="d34">entrez.1956</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.1956" target="drugbank.DB06021">
  <data key="d31">10317</data>
  <data key="d32">53145</data>
  <data key="d25">AV-412</data>
  <data key="d26">EGFR</data>
  <data key="d33">drugbank.DB06021</data>
  <data key="d34">entrez.1956</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.1956" target="drugbank.DB10772">
  <data key="d31">10903</data>
  <data key="d32">53145</data>
  <data key="d25">Foreskin keratinocyte (neonatal)</data>
  <data key="d26">EGFR</data>
  <data key="d33">drugbank.DB10772</data>
  <data key="d34">entrez.1956</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.1956" target="drugbank.DB08916">
  <data key="d31">11245</data>
  <data key="d32">53145</data>
  <data key="d25">Afatinib</data>
  <data key="d26">EGFR</data>
  <data key="d33">drugbank.DB08916</data>
  <data key="d34">entrez.1956</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.1956" target="drugbank.DB07662">
  <data key="d31">11376</data>
  <data key="d32">53145</data>
  <data key="d25">N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE</data>
  <data key="d26">EGFR</data>
  <data key="d33">drugbank.DB07662</data>
  <data key="d34">entrez.1956</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.1956" target="drugbank.DB08865">
  <data key="d31">12120</data>
  <data key="d32">53145</data>
  <data key="d25">Crizotinib</data>
  <data key="d26">EGFR</data>
  <data key="d33">drugbank.DB08865</data>
  <data key="d34">entrez.1956</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.1956" target="drugbank.DB04216">
  <data key="d31">12527</data>
  <data key="d32">53145</data>
  <data key="d25">Quercetin</data>
  <data key="d26">EGFR</data>
  <data key="d33">drugbank.DB04216</data>
  <data key="d34">entrez.1956</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.1956" target="drugbank.DB06803">
  <data key="d31">12674</data>
  <data key="d32">53145</data>
  <data key="d25">Niclosamide</data>
  <data key="d26">EGFR</data>
  <data key="d33">drugbank.DB06803</data>
  <data key="d34">entrez.1956</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.1956" target="drugbank.DB05294">
  <data key="d31">12890</data>
  <data key="d32">53145</data>
  <data key="d25">Vandetanib</data>
  <data key="d26">EGFR</data>
  <data key="d33">drugbank.DB05294</data>
  <data key="d34">entrez.1956</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.1956" target="drugbank.DB06595">
  <data key="d31">12958</data>
  <data key="d32">53145</data>
  <data key="d25">Midostaurin</data>
  <data key="d26">EGFR</data>
  <data key="d33">drugbank.DB06595</data>
  <data key="d34">entrez.1956</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.1956" target="drugbank.DB06616">
  <data key="d31">13127</data>
  <data key="d32">53145</data>
  <data key="d25">Bosutinib</data>
  <data key="d26">EGFR</data>
  <data key="d33">drugbank.DB06616</data>
  <data key="d34">entrez.1956</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.1956" target="drugbank.DB06626">
  <data key="d31">13147</data>
  <data key="d32">53145</data>
  <data key="d25">Axitinib</data>
  <data key="d26">EGFR</data>
  <data key="d33">drugbank.DB06626</data>
  <data key="d34">entrez.1956</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.5296" target="entrez.5295">
  <data key="d23">54153</data>
  <data key="d24">54155</data>
  <data key="d25">PIK3R2</data>
  <data key="d26">PIK3R1</data>
  <data key="d27">entrez.5296</data>
  <data key="d28">entrez.5295</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.5296" target="entrez.5159">
  <data key="d23">54153</data>
  <data key="d24">55411</data>
  <data key="d25">PIK3R2</data>
  <data key="d26">PDGFRB</data>
  <data key="d27">entrez.5296</data>
  <data key="d28">entrez.5159</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.5296" target="entrez.5781">
  <data key="d23">54153</data>
  <data key="d24">59850</data>
  <data key="d25">PIK3R2</data>
  <data key="d26">PTPN11</data>
  <data key="d27">entrez.5296</data>
  <data key="d28">entrez.5781</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.5296" target="entrez.5747">
  <data key="d23">54153</data>
  <data key="d24">59937</data>
  <data key="d25">PIK3R2</data>
  <data key="d26">PTK2</data>
  <data key="d27">entrez.5296</data>
  <data key="d28">entrez.5747</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.5296" target="drugbank.DB01064">
  <data key="d31">1914</data>
  <data key="d32">54153</data>
  <data key="d25">Isoprenaline</data>
  <data key="d26">PIK3R2</data>
  <data key="d33">drugbank.DB01064</data>
  <data key="d34">entrez.5296</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.5296" target="drugbank.DB05210">
  <data key="d31">12787</data>
  <data key="d32">54153</data>
  <data key="d25">SF1126</data>
  <data key="d26">PIK3R2</data>
  <data key="d33">drugbank.DB05210</data>
  <data key="d34">entrez.5296</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.5295" target="entrez.5295">
  <data key="d23">54155</data>
  <data key="d24">54155</data>
  <data key="d25">PIK3R1</data>
  <data key="d26">PIK3R1</data>
  <data key="d27">entrez.5295</data>
  <data key="d28">entrez.5295</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.5295" target="entrez.5336">
  <data key="d23">54155</data>
  <data key="d24">54398</data>
  <data key="d25">PIK3R1</data>
  <data key="d26">PLCG2</data>
  <data key="d27">entrez.5295</data>
  <data key="d28">entrez.5336</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.5295" target="entrez.5335">
  <data key="d23">54155</data>
  <data key="d24">54399</data>
  <data key="d25">PIK3R1</data>
  <data key="d26">PLCG1</data>
  <data key="d27">entrez.5295</data>
  <data key="d28">entrez.5335</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.5295" target="entrez.5159">
  <data key="d23">54155</data>
  <data key="d24">55411</data>
  <data key="d25">PIK3R1</data>
  <data key="d26">PDGFRB</data>
  <data key="d27">entrez.5295</data>
  <data key="d28">entrez.5159</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.5295" target="entrez.5921">
  <data key="d23">54155</data>
  <data key="d24">58816</data>
  <data key="d25">PIK3R1</data>
  <data key="d26">RASA1</data>
  <data key="d27">entrez.5295</data>
  <data key="d28">entrez.5921</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.5295" target="entrez.5781">
  <data key="d23">54155</data>
  <data key="d24">59850</data>
  <data key="d25">PIK3R1</data>
  <data key="d26">PTPN11</data>
  <data key="d27">entrez.5295</data>
  <data key="d28">entrez.5781</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.5295" target="entrez.5777">
  <data key="d23">54155</data>
  <data key="d24">59857</data>
  <data key="d25">PIK3R1</data>
  <data key="d26">PTPN6</data>
  <data key="d27">entrez.5295</data>
  <data key="d28">entrez.5777</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.5295" target="entrez.5747">
  <data key="d23">54155</data>
  <data key="d24">59937</data>
  <data key="d25">PIK3R1</data>
  <data key="d26">PTK2</data>
  <data key="d27">entrez.5295</data>
  <data key="d28">entrez.5747</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.5295" target="drugbank.DB01064">
  <data key="d31">1914</data>
  <data key="d32">54155</data>
  <data key="d25">Isoprenaline</data>
  <data key="d26">PIK3R1</data>
  <data key="d33">drugbank.DB01064</data>
  <data key="d34">entrez.5295</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.5295" target="drugbank.DB08059">
  <data key="d31">9496</data>
  <data key="d32">54155</data>
  <data key="d25">Wortmannin</data>
  <data key="d26">PIK3R1</data>
  <data key="d33">drugbank.DB08059</data>
  <data key="d34">entrez.5295</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.5295" target="drugbank.DB06486">
  <data key="d31">11566</data>
  <data key="d32">54155</data>
  <data key="d25">Enzastaurin</data>
  <data key="d26">PIK3R1</data>
  <data key="d33">drugbank.DB06486</data>
  <data key="d34">entrez.5295</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.5295" target="drugbank.DB04216">
  <data key="d31">12527</data>
  <data key="d32">54155</data>
  <data key="d25">Quercetin</data>
  <data key="d26">PIK3R1</data>
  <data key="d33">drugbank.DB04216</data>
  <data key="d34">entrez.5295</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.5295" target="drugbank.DB05210">
  <data key="d31">12787</data>
  <data key="d32">54155</data>
  <data key="d25">SF1126</data>
  <data key="d26">PIK3R1</data>
  <data key="d33">drugbank.DB05210</data>
  <data key="d34">entrez.5295</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.5336" target="entrez.5336">
  <data key="d23">54398</data>
  <data key="d24">54398</data>
  <data key="d25">PLCG2</data>
  <data key="d26">PLCG2</data>
  <data key="d27">entrez.5336</data>
  <data key="d28">entrez.5336</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.5336" target="entrez.5335">
  <data key="d23">54398</data>
  <data key="d24">54399</data>
  <data key="d25">PLCG2</data>
  <data key="d26">PLCG1</data>
  <data key="d27">entrez.5336</data>
  <data key="d28">entrez.5335</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.5336" target="entrez.5781">
  <data key="d23">54398</data>
  <data key="d24">59850</data>
  <data key="d25">PLCG2</data>
  <data key="d26">PTPN11</data>
  <data key="d27">entrez.5336</data>
  <data key="d28">entrez.5781</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.5336" target="entrez.5777">
  <data key="d23">54398</data>
  <data key="d24">59857</data>
  <data key="d25">PLCG2</data>
  <data key="d26">PTPN6</data>
  <data key="d27">entrez.5336</data>
  <data key="d28">entrez.5777</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.5335" target="entrez.5335">
  <data key="d23">54399</data>
  <data key="d24">54399</data>
  <data key="d25">PLCG1</data>
  <data key="d26">PLCG1</data>
  <data key="d27">entrez.5335</data>
  <data key="d28">entrez.5335</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.5335" target="entrez.5159">
  <data key="d23">54399</data>
  <data key="d24">55411</data>
  <data key="d25">PLCG1</data>
  <data key="d26">PDGFRB</data>
  <data key="d27">entrez.5335</data>
  <data key="d28">entrez.5159</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.5335" target="entrez.5921">
  <data key="d23">54399</data>
  <data key="d24">58816</data>
  <data key="d25">PLCG1</data>
  <data key="d26">RASA1</data>
  <data key="d27">entrez.5335</data>
  <data key="d28">entrez.5921</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.5335" target="entrez.5781">
  <data key="d23">54399</data>
  <data key="d24">59850</data>
  <data key="d25">PLCG1</data>
  <data key="d26">PTPN11</data>
  <data key="d27">entrez.5335</data>
  <data key="d28">entrez.5781</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.5335" target="entrez.5777">
  <data key="d23">54399</data>
  <data key="d24">59857</data>
  <data key="d25">PLCG1</data>
  <data key="d26">PTPN6</data>
  <data key="d27">entrez.5335</data>
  <data key="d28">entrez.5777</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.5335" target="entrez.5747">
  <data key="d23">54399</data>
  <data key="d24">59937</data>
  <data key="d25">PLCG1</data>
  <data key="d26">PTK2</data>
  <data key="d27">entrez.5335</data>
  <data key="d28">entrez.5747</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.5159" target="entrez.5159">
  <data key="d23">55411</data>
  <data key="d24">55411</data>
  <data key="d25">PDGFRB</data>
  <data key="d26">PDGFRB</data>
  <data key="d27">entrez.5159</data>
  <data key="d28">entrez.5159</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.5159" target="entrez.5921">
  <data key="d23">55411</data>
  <data key="d24">58816</data>
  <data key="d25">PDGFRB</data>
  <data key="d26">RASA1</data>
  <data key="d27">entrez.5159</data>
  <data key="d28">entrez.5921</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.5159" target="entrez.5781">
  <data key="d23">55411</data>
  <data key="d24">59850</data>
  <data key="d25">PDGFRB</data>
  <data key="d26">PTPN11</data>
  <data key="d27">entrez.5159</data>
  <data key="d28">entrez.5781</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.5159" target="entrez.5777">
  <data key="d23">55411</data>
  <data key="d24">59857</data>
  <data key="d25">PDGFRB</data>
  <data key="d26">PTPN6</data>
  <data key="d27">entrez.5159</data>
  <data key="d28">entrez.5777</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.5159" target="entrez.5747">
  <data key="d23">55411</data>
  <data key="d24">59937</data>
  <data key="d25">PDGFRB</data>
  <data key="d26">PTK2</data>
  <data key="d27">entrez.5159</data>
  <data key="d28">entrez.5747</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.5159" target="drugbank.DB04868">
  <data key="d31">3359</data>
  <data key="d32">55411</data>
  <data key="d25">Nilotinib</data>
  <data key="d26">PDGFRB</data>
  <data key="d33">drugbank.DB04868</data>
  <data key="d34">entrez.5159</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.5159" target="drugbank.DB12147">
  <data key="d31">3790</data>
  <data key="d32">55411</data>
  <data key="d25">Erdafitinib</data>
  <data key="d26">PDGFRB</data>
  <data key="d33">drugbank.DB12147</data>
  <data key="d34">entrez.5159</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.5159" target="drugbank.DB01268">
  <data key="d31">4894</data>
  <data key="d32">55411</data>
  <data key="d25">Sunitinib</data>
  <data key="d26">PDGFRB</data>
  <data key="d33">drugbank.DB01268</data>
  <data key="d34">entrez.5159</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.5159" target="drugbank.DB01259">
  <data key="d31">5140</data>
  <data key="d32">55411</data>
  <data key="d25">Lapatinib</data>
  <data key="d26">PDGFRB</data>
  <data key="d33">drugbank.DB01259</data>
  <data key="d34">entrez.5159</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.5159" target="drugbank.DB01254">
  <data key="d31">5149</data>
  <data key="d32">55411</data>
  <data key="d25">Dasatinib</data>
  <data key="d26">PDGFRB</data>
  <data key="d33">drugbank.DB01254</data>
  <data key="d34">entrez.5159</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.5159" target="drugbank.DB12010">
  <data key="d31">5608</data>
  <data key="d32">55411</data>
  <data key="d25">Fostamatinib</data>
  <data key="d26">PDGFRB</data>
  <data key="d33">drugbank.DB12010</data>
  <data key="d34">entrez.5159</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.5159" target="drugbank.DB00619">
  <data key="d31">6404</data>
  <data key="d32">55411</data>
  <data key="d25">Imatinib</data>
  <data key="d26">PDGFRB</data>
  <data key="d33">drugbank.DB00619</data>
  <data key="d34">entrez.5159</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.5159" target="drugbank.DB09079">
  <data key="d31">6627</data>
  <data key="d32">55411</data>
  <data key="d25">Nintedanib</data>
  <data key="d26">PDGFRB</data>
  <data key="d33">drugbank.DB09079</data>
  <data key="d34">entrez.5159</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.5159" target="drugbank.DB09078">
  <data key="d31">6628</data>
  <data key="d32">55411</data>
  <data key="d25">Lenvatinib</data>
  <data key="d26">PDGFRB</data>
  <data key="d33">drugbank.DB09078</data>
  <data key="d34">entrez.5159</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.5159" target="drugbank.DB00398">
  <data key="d31">7170</data>
  <data key="d32">55411</data>
  <data key="d25">Sorafenib</data>
  <data key="d26">PDGFRB</data>
  <data key="d33">drugbank.DB00398</data>
  <data key="d34">entrez.5159</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.5159" target="drugbank.DB00530">
  <data key="d31">7910</data>
  <data key="d32">55411</data>
  <data key="d25">Erlotinib</data>
  <data key="d26">PDGFRB</data>
  <data key="d33">drugbank.DB00530</data>
  <data key="d34">entrez.5159</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.5159" target="drugbank.DB11829">
  <data key="d31">8788</data>
  <data key="d32">55411</data>
  <data key="d25">Ruboxistaurin</data>
  <data key="d26">PDGFRB</data>
  <data key="d33">drugbank.DB11829</data>
  <data key="d34">entrez.5159</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.5159" target="drugbank.DB11800">
  <data key="d31">8890</data>
  <data key="d32">55411</data>
  <data key="d25">Tivozanib</data>
  <data key="d26">PDGFRB</data>
  <data key="d33">drugbank.DB11800</data>
  <data key="d34">entrez.5159</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.5159" target="drugbank.DB09221">
  <data key="d31">9195</data>
  <data key="d32">55411</data>
  <data key="d25">Polaprezinc</data>
  <data key="d26">PDGFRB</data>
  <data key="d33">drugbank.DB09221</data>
  <data key="d34">entrez.5159</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.5159" target="drugbank.DB05146">
  <data key="d31">11711</data>
  <data key="d32">55411</data>
  <data key="d25">XL820</data>
  <data key="d26">PDGFRB</data>
  <data key="d33">drugbank.DB05146</data>
  <data key="d34">entrez.5159</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.5159" target="drugbank.DB08896">
  <data key="d31">12215</data>
  <data key="d32">55411</data>
  <data key="d25">Regorafenib</data>
  <data key="d26">PDGFRB</data>
  <data key="d33">drugbank.DB08896</data>
  <data key="d34">entrez.5159</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.5159" target="drugbank.DB05294">
  <data key="d31">12890</data>
  <data key="d32">55411</data>
  <data key="d25">Vandetanib</data>
  <data key="d26">PDGFRB</data>
  <data key="d33">drugbank.DB05294</data>
  <data key="d34">entrez.5159</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.5159" target="drugbank.DB06595">
  <data key="d31">12958</data>
  <data key="d32">55411</data>
  <data key="d25">Midostaurin</data>
  <data key="d26">PDGFRB</data>
  <data key="d33">drugbank.DB06595</data>
  <data key="d34">entrez.5159</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.5159" target="drugbank.DB06589">
  <data key="d31">12970</data>
  <data key="d32">55411</data>
  <data key="d25">Pazopanib</data>
  <data key="d26">PDGFRB</data>
  <data key="d33">drugbank.DB06589</data>
  <data key="d34">entrez.5159</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.5159" target="drugbank.DB06616">
  <data key="d31">13127</data>
  <data key="d32">55411</data>
  <data key="d25">Bosutinib</data>
  <data key="d26">PDGFRB</data>
  <data key="d33">drugbank.DB06616</data>
  <data key="d34">entrez.5159</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.5159" target="drugbank.DB06626">
  <data key="d31">13147</data>
  <data key="d32">55411</data>
  <data key="d25">Axitinib</data>
  <data key="d26">PDGFRB</data>
  <data key="d33">drugbank.DB06626</data>
  <data key="d34">entrez.5159</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.5921" target="entrez.5921">
  <data key="d23">58816</data>
  <data key="d24">58816</data>
  <data key="d25">RASA1</data>
  <data key="d26">RASA1</data>
  <data key="d27">entrez.5921</data>
  <data key="d28">entrez.5921</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.5781" target="entrez.5781">
  <data key="d23">59850</data>
  <data key="d24">59850</data>
  <data key="d25">PTPN11</data>
  <data key="d26">PTPN11</data>
  <data key="d27">entrez.5781</data>
  <data key="d28">entrez.5781</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho]</data>
</edge>
<edge source="entrez.5781" target="entrez.5777">
  <data key="d23">59850</data>
  <data key="d24">59857</data>
  <data key="d25">PTPN11</data>
  <data key="d26">PTPN6</data>
  <data key="d27">entrez.5781</data>
  <data key="d28">entrez.5777</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.5781" target="entrez.5747">
  <data key="d23">59850</data>
  <data key="d24">59937</data>
  <data key="d25">PTPN11</data>
  <data key="d26">PTK2</data>
  <data key="d27">entrez.5781</data>
  <data key="d28">entrez.5747</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.5781" target="drugbank.DB13089">
  <data key="d31">1738</data>
  <data key="d32">59850</data>
  <data key="d25">Enoxolone</data>
  <data key="d26">PTPN11</data>
  <data key="d33">drugbank.DB13089</data>
  <data key="d34">entrez.5781</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.5781" target="drugbank.DB01196">
  <data key="d31">2214</data>
  <data key="d32">59850</data>
  <data key="d25">Estramustine</data>
  <data key="d26">PTPN11</data>
  <data key="d33">drugbank.DB01196</data>
  <data key="d34">entrez.5781</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.5777" target="entrez.5777">
  <data key="d23">59857</data>
  <data key="d24">59857</data>
  <data key="d25">PTPN6</data>
  <data key="d26">PTPN6</data>
  <data key="d27">entrez.5777</data>
  <data key="d28">entrez.5777</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp]</data>
</edge>
<edge source="entrez.5777" target="entrez.5747">
  <data key="d23">59857</data>
  <data key="d24">59937</data>
  <data key="d25">PTPN6</data>
  <data key="d26">PTK2</data>
  <data key="d27">entrez.5777</data>
  <data key="d28">entrez.5747</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, pred]</data>
</edge>
<edge source="entrez.5777" target="drugbank.DB13089">
  <data key="d31">1738</data>
  <data key="d32">59857</data>
  <data key="d25">Enoxolone</data>
  <data key="d26">PTPN6</data>
  <data key="d33">drugbank.DB13089</data>
  <data key="d34">entrez.5777</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.5777" target="drugbank.DB01196">
  <data key="d31">2214</data>
  <data key="d32">59857</data>
  <data key="d25">Estramustine</data>
  <data key="d26">PTPN6</data>
  <data key="d33">drugbank.DB01196</data>
  <data key="d34">entrez.5777</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.5747" target="entrez.5747">
  <data key="d23">59937</data>
  <data key="d24">59937</data>
  <data key="d25">PTK2</data>
  <data key="d26">PTK2</data>
  <data key="d27">entrez.5747</data>
  <data key="d28">entrez.5747</data>
  <data key="d29">GeneGeneInteraction</data>
  <data key="d30">[exp, ortho, pred]</data>
</edge>
<edge source="entrez.5747" target="drugbank.DB01268">
  <data key="d31">4894</data>
  <data key="d32">59937</data>
  <data key="d25">Sunitinib</data>
  <data key="d26">PTK2</data>
  <data key="d33">drugbank.DB01268</data>
  <data key="d34">entrez.5747</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.5747" target="drugbank.DB12010">
  <data key="d31">5608</data>
  <data key="d32">59937</data>
  <data key="d25">Fostamatinib</data>
  <data key="d26">PTK2</data>
  <data key="d33">drugbank.DB12010</data>
  <data key="d34">entrez.5747</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.5747" target="drugbank.DB09079">
  <data key="d31">6627</data>
  <data key="d32">59937</data>
  <data key="d25">Nintedanib</data>
  <data key="d26">PTK2</data>
  <data key="d33">drugbank.DB09079</data>
  <data key="d34">entrez.5747</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.5747" target="drugbank.DB11828">
  <data key="d31">8787</data>
  <data key="d32">59937</data>
  <data key="d25">Neratinib</data>
  <data key="d26">PTK2</data>
  <data key="d33">drugbank.DB11828</data>
  <data key="d34">entrez.5747</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.5747" target="drugbank.DB08865">
  <data key="d31">12120</data>
  <data key="d32">59937</data>
  <data key="d25">Crizotinib</data>
  <data key="d26">PTK2</data>
  <data key="d33">drugbank.DB08865</data>
  <data key="d34">entrez.5747</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.5747" target="drugbank.DB04216">
  <data key="d31">12527</data>
  <data key="d32">59937</data>
  <data key="d25">Quercetin</data>
  <data key="d26">PTK2</data>
  <data key="d33">drugbank.DB04216</data>
  <data key="d34">entrez.5747</data>
  <data key="d29">DrugTargetGene</data>
</edge>
<edge source="entrez.5747" target="drugbank.DB06616">
  <data key="d31">13127</data>
  <data key="d32">59937</data>
  <data key="d25">Bosutinib</data>
  <data key="d26">PTK2</data>
  <data key="d33">drugbank.DB06616</data>
  <data key="d34">entrez.5747</data>
  <data key="d29">DrugTargetGene</data>
</edge>
</graph></graphml>